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Summary 
The extracellular-Ca2+ sensing receptor (CaSR) is a G protein-coupled receptor which is 
essential for Ca2+ homeostasis in the body. The best studied function of the CaSR lies in the 
parathyroid gland, where hypercalcaemia activates the receptor which in consequence inhibits 
parathyroid hormone secretion. However, for other tissues like the vasculature the 
physiological and pathophysiological roles of the CaSR are a lot less well defined. 
The CaSR is expressed in all layers of blood vessels, the endothelium, the vascular smooth 
muscle cells (VSMC) and the tunica adventitia. Previous studies have suggested roles for the 
vascular CaSR in protection against vascular calcification and in blood pressure regulation. In 
the course of my thesis, I have investigated the specific roles of the vascular CaSR by 
characterising the phenotype of a transgenic mouse model of targeted CaSR deletion from 
VSMC (SM22α-Cre x LoxP-CaSR). In characterising this mouse model, I have made three 
principal discoveries: 
1) The VSMC CaSR protects against vascular calcification induced by high Ca2+ and Pi 
in vitro. No calcification was discovered in mice lacking the VSMC CaSR in vivo, 
suggesting that this protective effect of the CaSR might only assert itself in 
pathological disease. 
2) The VSMC CaSR contributes to blood pressure regulation. Mice lacking the VSMC 
CaSR exhibit hypotension which is due to impaired vascular contractility and 
therefore reduced total peripheral resistance. I propose a role for the VSMC CaSR as 
auto- / paracrine amplifier of VSMC contraction. Furthermore, knock-out mice exhibit 
bradycardia and sporadic cardiac remodelling. 
3) Mice lacking the VSMC CaSR exhibit profound changes in mineral ion metabolism, 
together with severe hypercalcaemia, hypercalciuria, hyperphosphaturia and increased 
1,25-(OH)2-Vitamin D3 and phosphaturic FGF23 levels, and decreased bone mineral 
density, consistent with a phenotype resembling primary hyperparathyroidism. The 
mechanisms behind this influence remain yet to be fully understood. 
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1 Introduction 
In the course of this introduction, I want to give brief overviews of the calcium-sensing 
receptor (CaSR), its main actions in mineral ion metabolism and CaSR associated disorders. 
Furthermore, I will describe the discovered roles of the CaSR its role in the vasculature and in 
vascular calcification, thereby explaining the rationale behind this thesis and finally introduce 
models of CaSR deletion which are used to study CaSR function in vivo to set the stage for 
the investigations undertaken in the course of my thesis. 
 
1.1 The extracellular Calcium-Sensing Receptor 
1.1.1 General 
In 1993, Brown et al. discovered a previously unknown G protein-coupled receptor in bovine 
parathyroid glands (Brown et al. 1993). The main physiological ligand of this receptor is 
extracellular free ionised calcium (Ca2+o), which consequently led to its name, extracellular 
calcium-sensing receptor (CaSR). The main function of this CaSR was discovered to be the 
regulation of free plasma Ca2+ levels via suppression of parathyroid hormone (PTH) synthesis 
and secretion in the parathyroid gland (Brown et al. 1993). In the years following the cloning 
of this receptor, CaSR expression was found not only in the parathyroid glands, but also in a 
multitude of organs including kidney (Riccardi et al. 1998), bone and cartilage (Chang et al. 
2008), placenta (Bradbury et al. 1998), intestine (Chattopadhyay et al. 1998), pancreas (Bruce 
et al. 1999; Rasschaert and Malaisse 1999), skin (Komuves et al. 2002), brain (Ruat et al. 
1995), liver (Canaff et al. 2001) and the vasculature (Bukoski et al. 1997; Weston et al. 2005; 
Ziegelstein et al. 2006). However, in many of these organs the roles of this protein are not yet 
fully understood. 
The CaSR is a member of family C of the G protein-coupled receptors (GPCRs). This family 
comprises three subfamilies of receptors with group 1 containing metabotropic glutamate 
receptors (mGluRs), group 2 containing the CaSR and vomeronasal organ receptors and 
group 3 comprising of the γ-amino-butyric acid receptor family B (GABAB) receptor 
subfamily (Brown and MacLeod 2001). Receptors belonging to family C GPCRs share a 
common topology which consists of a very large extracellular domain which forms a so called 
Venus-fly trap domain, which is an evolutionary old protein feature is involved in invertebrate 
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ligand sensing (Felder et al. 1999) and which contains Ca2+ binding sites (Silve et al. 2005). 
The human CaSR consists of 1085 amino acids and is encoded by a gene organized in 7 
exons, with exon 2-6 encoding the extracellular domain (613 amino acids) and exon 7 
encoding the transmembrane and intracellular domains (250 and 222 amino acids respectively 
(Brown et al. 1993); Figure 1). The CaSR is expressed at the cell surface in the form of 
homodimers (Bai et al. 1998; Ward et al. 1998), held together via disulphide bonds at cysteine 
residues 129 and 131 (Ray et al. 1999) as well as non-covalent interactions (Zhang et al. 
2001b). The CaSR sequence shows high homology across different species, e.g. ~ 90 % for 
rat and mouse (Riccardi et al. 1995; Pi et al. 2000) compared to the initially identified bovine 
receptor, and it is highly evolutionary conserved across vertebrates in general (Herberger and 
Loretz 2013). 
 
 
Figure 1: Topology of the human CaSR showing the large extracellular domain typical for family C 
type GPCRs. The rectangle indicates the plasma membrane region (Smajilovic and Tfelt-Hansen 
2007). Image used under license from Oxford University Press. 
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1.1.2 Ligands of the CaSR 
Compared to other GPCRs, the EC50 of the CaSR for Ca2+ in parathyroid cells is rather high 
(ca. 1.2 mM) (Brown and MacLeod 2001), but such a feature is compatible with the role for 
the receptor in the control free ionised blood plasma Ca2+ levels within a very narrow 
concentration frame (1.1 – 1.3 mM Ca2+). This tight control is possible through a very high 
cooperativity of the receptor, which results in a very steep inverse dependence for PTH 
secretion of Ca2+ levels (Figure 2). It has been show that this steep control of receptor 
activation is facilitated by a mechanism named agonist-driven insertion signalling (ADIS) 
which appears to be a unique feature of the CaSR. In ADIS, activation of the receptor leads to 
maturation and insertion of more receptors into the plasma membrane (Grant et al. 2011) from 
its main reservoir the endoplasmic reticulum (Cavanaugh et al. 2010). 
 
  
Figure 2: Ca2+ dose dependent suppression of PTH release. The “Set point” indicates the 
physiological free ionised blood plasma Ca2+ level. Zero to maximal effect (suppression of PTH 
secretion) is achieved over a very narrow concentration range, resulting in a steep PTH / Ca2+ 
relationship (Brown 2013). Image used under license from Elsevier. 
 
CaSR activation can effect a variety of intracellular signalling cascades, largely involving 
activation of Gq/11, but also including Gi/o, G12/13 and β-arrestin. The preference for one of 
these pathways has recently been shown to be influenced by the type of agonist activating the 
CaSR, orthosteric and allosteric alike (Davey et al. 2012; Thomsen et al. 2012). More 
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information on CaSR signalling which would go beyond the scope of this thesis can be found 
in the aforementioned literature as well as in many pertinent reviews (Brown and MacLeod 
2001; Hofer and Brown 2003; Magno et al. 2011). 
Orthosteric agonists achieve direct activation of the CaSR. As already indicated, in addition to 
Ca2+o, the CaSR also binds a variety of other ligands. Orthosteric and allosteric agonists, as 
well as antagonists have been identified. 
Orthosteric agonists, which are able to activate the receptor directly in the absence of Ca2+, 
include di- and trivalent cations (such as Ca2+, Sr2+, Mg2+, Gd3+ or La3+) (Brown and 
MacLeod 2001) polyamines (spermine, spermidine) (Quinn et al. 1997) and aminoglycoside 
antibiotics (e.g. neomycin, gentamicin) (McLarnon et al. 2002).  
Amino acids like L-Phe, L-Trp, L-Tyr and L-His act as natural allosteric agonists of the CaSR 
(Conigrave et al. 2007). Synthetic allosteric agonists of the CaSR are the so called 
calcimimetics (including compounds such as Cinacalcet, Calindol or R-568). Cinacalcet has 
been approved as medication for treating severe hyperparathyroidism caused by chronic 
kidney disease (CKD), so called secondary hyperparathyroidism (see below) (Cunningham et 
al. 2011). However, cinacalcet also sees off-label use for therapy of primary 
hyperparathyroidism (e.g. by adenoma of the parathyroid gland) or phosphate wasting 
(Shoback et al. 2003; Brown 2010).  
Calcilytics are allosteric antagonists of the CaSR show therapeutic potential, as exemplified 
by their possible use for the treatment of hypoparathyroidism (Saidak et al. 2009) or 
Alzheimer’s disease (Armato et al. 2013). Because of their potential to evoke rapid 
fluctuations in PTH levels, some compounds of this class were initially developed for the 
treatment of osteoporosis (John et al. 2011). On the other hand, the profile of PTH release was 
recently found to be unfavourable for treatment of osteoporosis at least for the calcilytic 
ronacaleret (Caltabiano et al. 2013). 
In contrast to the orthosteric agonists, these allosteric-acting compounds require the presence 
of an orthosteric ligand like Ca2+ to affect the receptor and thus can only modulate the 
potency of orthosteric compounds by shifting the half-maximal effective concentration (EC50) 
for Ca2+ to the left (calcimimetics) or right (calcilytics). Figure 3 illustrates these effects. 
Interestingly, neither natural / nor synthetic endogenous orthosteric antagonists of the CaSR 
have been found (Saidak et al. 2009). 
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Figure 3: Blood Ca2+ set point for PTH secretion. Increasing blood Ca2+ concentrations reduce PTH 
secretion caused by the CaSR. The allosteric CaSR agonists calcimimetics, as well as activating 
mutations of the CaSR (autosomal dominant hypocalcaemia, ADH) cause left shifts of the curve, 
indicative of the greater activation of the CaSR in response to blood Ca2+, while the allosteric CaSR 
antagonists calcilytics as well as heterozygous inactivating mutations (familial hypercalcaemic 
hypercalciuria, FHH) cause rightward shifts, indicative of attenuated CaSR activation. (Christensen et 
al. 2011). Image used under license from Wolters Kluwer Health. 
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1.2 The role of the CaSR in Ca2+ homeostasis  
1.2.1 Ca2+ homeostasis and the CaSR 
Ca2+ homeostasis is a highly controlled process and involves a variety of hormones which are 
interconnected by multiple feedback loops. Figure 4 shows an overview of these complex 
interactions. The CaSR plays a major role in this homeostasis by directly or indirectly 
controlling the various factors that contribute to absorption, reabsorption, resorption and 
excretion of Ca2+ thus keeping blood Ca2+ levels in their physiological range, which is about 
1.1 – 1.3 mM free ionised Ca2+. The largest reservoir for Ca2+ is the bone, which contains 85 
% of the bodies Ca2+ in the form of hydroxyapatite (Ca10(PO4)6(OH)2) (Guyton and Hall 
2006). 
 
 
Figure 4: Ca2+ and Pi homeostasis. (1) Ca2+ suppresses PTH release via the CaSR. (2) PTH 
stimulates 1,25-D3 synthesis in the kidney which is in turn inhibiting PTH release via negative 
feedback. (3) 1,25-D3 stimulates Ca2+ and Pi (re-) absorption from kidney and intestine. (4) PTH also 
has a direct effect on the kidney where it increases Ca2+ reabsorption and (5) increases bone turnover 
which can act, dependent on the secretion kinetics, either act net anabolic (transient spikes) or 
catabolic (continuous elevation). (8) In bone, PTH also stimulates the production of FGF23, which 
decreases renal Pi reabsorption and leads to (9) phosphaturia via downregulation of NaPi2A and 
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NaPi2C Na+-Pi cotransporters (Gattineni et al. 2009). (7, 10) FGF23 has an inhibiting effect on 1,25-
D3 production, which in turn upregulates FGF23 production. (11) FGF23 also inhibits PTH production, 
although this effect seems to be lost under uremic conditions (Canalejo et al. 2010). Modified after (Hu 
et al. 2013). Image used with permission from Annual Reviews. 
 
1.2.1.1 Systemic effects of the CaSR 
As mentioned, the most prominent and first discovered role of the CaSR is regulation of PTH 
production in the parathyroid gland (Brown et al. 1993). PTH is a key regulator of Ca2+ 
provision in case of hypocalcaemia sensed by the CaSR. The main function of PTH is to 
increase blood Ca2+ levels. PTH is secreted from chief cells of the parathyroid gland and acts 
on the kidney, by increasing renal Ca2+ reabsorption, by increasing Pi excretion, and by 
upregulating 1α-hydroxylase thus increasing production of the hormone 1,25-(OH)2-Vitamin 
D3 (calcitriol, 1,25-D3). Furthermore, PTH, as well as 1,25-D3, stimulate bone resorption by 
acting on osteoblasts upregulating receptor activator of nuclear factor κB ligand (RANKL) 
production and thereby bone-resorption through osteoclasts (Brown 2013).  
With regard to Figure 2 it was already mentioned that the CaSR keeps a tight control over 
PTH secretion with a very steep relation between Ca2+o and PTH production. This control 
does not end at increased PTH secretion though. In case of high PTH demand, like in some of 
the disorders mentioned in section 1.2.2, continuous hypocalcaemia leads to upregulation of 
PTH gene expression and finally increased proliferation of parathyroid cells, leading to 
parathyroid hyperplasia (Naveh-Many et al. 1995) which is associated with a loss of CaSR 
expression (Yano et al. 2000, 2003). Importantly, calcimimetics can upregulate CaSR 
expression in hyperplastic parathyroid glands, contributing to the therapeutic effect of 
enhanced CaSR activation in hyperparathyroidism (Mendoza et al. 2009). 
Activation of the parathyroid CaSR not only reduces PTH secretion, but also enhances 
vitamin D receptor (VDR) expression (Rodriguez et al. 2007; Mendoza et al. 2009). 1,25-D3 
acting on the parathyroid VDR inhibits PTH secretion, thus acting together with the CaSR to 
defend against hypercalcaemia. Finally 1,25-D3 also inhibits its own production via VDR, 
thus acting as a negative feedback loop. 
1,25-D3 production by the rate-limiting enzyme 1-α-hydroxylase in the renal proximal tubules 
is stimulated by PTH and stimulates Ca2+ and Pi absorption from the gastrointestinal tract as 
well as reabsorption from the kidney (Guyton and Hall 2006). 1,25-D3, which is upregulated 
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by PTH, not only promotes increased Ca2+ but also Pi absorption. As a negative feedback 
mechanism, both 1,25-D3 as well as Pi stimulate upregulation of fibroblast growth factor 23 
(FGF23).  
FGF23 is a 251 amino acid factor (Yamashita et al. 2000) which is synthesized chiefly in 
osteocytes, and together with its co-factor Klotho, inhibits Pi reabsorption in the kidney by 
inhibiting insertion of phosphate transporters in the proximal tubule (Razzaque 2009) but also 
inhibits PTH release and 1,25-D3 synthesis (Krajisnik et al. 2007), thus contributing to 
maintaining blood Pi levels. This feedback mechanism is important, as increased 1,25-D3 
stimulates both Ca2+ and Pi absorption. To avoid an inappropriate increase in the Ca2+o x Pi 
product, FGF23 in turn lowers Pi concentration by inhibiting Pi reabsorption (Quinn et al. 
2013b). Finally, FGF23 also exerts an inhibiting influence on PTH as well as 1,25-D3 
production, again closing a negative feedback loop, as reviewed in (Brown 2013).. 
Apart from these systemic effects on Ca2+ homeostasis, the CaSR also has very specific local 
effects that contribute to maintenance of Ca2+ homeostasis, which include roles in the kidney 
and in bone. 
 
1.2.1.2 Local effects of the CaSR 
In the kidney, the CaSR acts independently of PTH to predominantly decrease blood Ca2+ 
levels by preventing further reabsorption of Ca2+ from the filtrate. The best documented 
action of the CaSR in the kidney is its action in the thick ascending limb, where Ca2+ (and 
Mg2+) reabsorption passively follows a gradient in potential difference between positively 
charged luminal side and negatively charged intracellular side. Apical NKCC2 transports 1 
Na+, 1 K+ and 2 Cl- into the cells of the thick ascending limb. K+ is brought back into the 
lumen by ROMK K+ channels. Na+ and Cl- are transported into the blood by the 3Na+/2K+-
ATPase and Cl- channels. Therefore, the effusing K+ creates a potential difference which in 
turn leads to increased passive (paracellular) reabsorption of Ca2+ an Mg2+. Fitting with its 
main function to control Ca2+ homeostasis in the blood, increased serum Ca2+ levels activate 
the CaSR on the basolateral side of the thick ascending limb which inhibits ROMK channels. 
Therefore, less K+ can be recycled into the lumen, leading to a reduction in NKCC2 activity 
and potential difference and therefore reduced reabsorption of Ca2+, Mg2+ and Na+ from the 
urine back into the blood, as reviewed in (Riccardi and Brown 2010). PTH induced 
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transcellular Ca2+ reabsorption is also inhibited by the CaSR (Motoyama and Friedman 2002). 
Apart from these actions in the thick ascending limbs, the CaSR also has roles in other parts 
of the nephron. In the proximal tubule, the luminal CaSR supresses the PTH-induced 
inhibition of phosphate reabsorption (Ba et al. 2003) and is probably involved in inhibition of 
1,25-D3 synthesis (Bland et al. 1999). In the distal tubule, the CaSR probably promotes Ca2+-
channel dependent transcellular Ca2+ reabsorption, as compensation for reduced Ca2+ 
reabsorption  in case of renal Na+ wasting (Topala et al. 2009). Finally, in the collecting ducts, 
the CaSR in involved in the upregulation of the Na+/H+ pump in the collecting ducts, which 
acidifies the urine in case of hypercalciuria to prevent formation of kidney stones (Renkema 
et al. 2009). 
It was already mentioned that CaSR regulated PTH induces bone resorption by stimulation of 
RANKL production on osteoblasts. However, the CaSR is also expressed in the bone where it 
regulates mineralisation, but these functions are still poorly understood. Using their mouse 
model of targeted gene deletion (see 1.5.2), Chang and colleagues demonstrated that the 
osteoblast CaSR is directly responsible for regulation of osteoblast function as well as 
indirectly by inhibiting RANKL production (Chang et al. 2008; Dvorak-Ewell et al. 2011).  
 
1.2.2 Genetic and acquired conditions relating to the CaSR 
Because of its prominent role in regulation of Ca2+ homeostasis, it should not come as a 
surprise that disorders in mineral ion metabolism frequently involve the CaSR. Genetic 
conditions relating to the CaSR include familial hypocalciuric hypercalcaemia (FHH), 
neonatal severe hyperparathyroidism (NSHPT) and autosomal dominant hypocalcaemia 
(ADH). Acquired conditions include primary and secondary hyperparathyroidism.  
 
1.2.2.1 Familial hypocalciuric hypercalcaemia 
FHH is caused by heterozygous autosomal dominant inactivating mutations of the CaSR, 
causing a rightwards shift in the set point for blood Ca2+ levels. This change in set point 
means that patients suffering from FHH have higher PTH levels and increased Ca2+ 
reabsorption by the kidney, resulting in hypercalcaemia and hypocalciuria, thus the name. 
However, this change in blood Ca2+ levels is very often asymptomatic (Pollak et al. 1996; 
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Ward et al. 2012). 1,25-D3 levels are often normal in FHH. Since parathyroidectomy 
normally does not resolve FHH, it is important to discriminate between primary 
hyperparathyroidism (see below) and FHH. The best diagnostic criterion for this (apart from 
the detection of a known CaSR mutation) is the hypocalciuria associated with the reduced 
CaSR activation in the kidney. Reviewed in (Egbuna and Brown 2008; Christensen et al. 
2011). 
 
1.2.2.2 Neonatal severe hyperparathyroidism 
Similar to FHH, NSHPT is caused by inactivating mutations of the CaSR, but in contrast to 
the former, both CaSR alleles are affected in NSHPT. In contrast to the mostly benign form of 
FHH, the loss of a functional CaSR in NSHPT leads to a life threatening condition which is 
associated with extreme hyperparathyroidism, hypercalcaemia and elevated 1,25-D3 levels, 
polyuria, reduced blood pressure, dehydration and failure to thrive, possible leading to 
premature death. In severe cases, parathyroidectomy is the only option for treatment. 
Reviewed in (Pollak et al. 1996; Egbuna and Brown 2008). 
 
1.2.2.3 Autosomal dominant hypocalcaemia 
In contrast to FHH and NSHPT where inactivating mutations of the CaSR were right-shifting 
the blood Ca2+ set-point, activating mutations of the CaSR cause a left-shift of this set-point, 
thus leading to pathologically enhanced suppression of PTH release by the CaSR. The clinical 
presentation of this disorder can range from asymptomatic to severe, with low PTH levels, 
hypocalcaemia and hypercalciuria. Because of the latter, curative intervention with Vitamin D 
therapy can lead to formation of kidney stones. Reviewed in (Pollak et al. 1994; Egbuna and 
Brown 2008). 
 
1.2.2.4 Bartter-like syndrome 
Bartter syndrome, classified in types I-V are characterised by defective electrolyte 
reabsorption in the TAL of the kidney. Types I-IV are not related to the CaSR but mutations 
in the genes for certain ion channels and transporters. Bartter syndrome type V, also called 
Bartter-like syndrome is caused by severe gain-of-function mutations of the CaSR (Hebert 
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2003). As described, activity of NKCC2 is indirectly controlled by the inhibiting action of the 
CaSR on ROMK channels. Activating mutations in the renal CaSR (Vargas-Poussou et al. 
2002) therefore lead to increased inhibition of ROMK channels, reduced activity of NKCC2, 
loss of the potential gradient in the loop of Henle and therefore reduces Ca2+ and Mg2+ 
reabsorption. The net effect is therefore renal salt, potassium, Ca2+ and Mg2+ wasting, going 
along with insufficient urine concentration, activation of the RAAS, polyuria and dehydration. 
The main criteria to discriminate Bartter-like syndrome from “classical” Bartter syndrome 
caused by mutations of ion channels and transporters (e.g. NKCC2 for Bartter syndrome type 
I) is the associated hypocalcaemia. Reviewed in (Hebert 2003; Egbuna et al. 2009; Ward et al. 
2012). 
 
1.2.2.5 Primary hyperparathyroidism 
In primary hyperparathyroidism, PTH secretion is elevated despite high circulating blood 
Ca2+ levels. As the disorder originates only from the parathyroid gland, urinary Ca2+ excretion 
is not affected and primary hyperparathyroidism is therefore associated with hypercalciuria 
(in contrast to FHH, where the loss-of-function mutation in the renal CaSR leads to 
hypocalciuria). Primary hyperparathyroidism can be associated with hypertension, cardiac 
remodelling or blood vessel stiffness, although the data on this are conflicting, as these 
changes do not affect all patients (Silverberg 2000; Walker et al. 2010). Primary 
hyperparathyroidism is normally caused by parathyroid adenoma, in which expression of the 
CaSR is lost. It has also been shown that reduction of CaSR expression in parathyroid chief 
cells is associated with increased proliferation of these cells, explaining the parathyroid 
hyperplasia associated with this disorder (Naveh-Many et al. 1995; Yano et al. 2003). 
Reviewed in (Habib and Camacho 2010; Ward et al. 2012).  
 
1.2.2.6 Secondary hyperparathyroidism 
Secondary hyperparathyroidism, as the name implies, is not principally caused by changes in 
the parathyroid gland, but is instead a feature developing during progression of CKD. In this 
disease state, the progressive loss of renal function leads to decreased 1,25-D3 production and 
Pi excretion. The reduced 1,25-D3 levels lead to reduced absorption and reabsorption of Ca2+, 
culminating in hypocalcaemia. The reduced blood Ca2+ levels lead to reduced suppression of 
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PTH release via the CaSR. Continuous stimulation of the parathyroid gland leads to 
hyperplasia in which CaSR expression is diminished (Lee et al. 2013). Reduced 1,25-D3 
levels, as a feature of secondary hyperparathyroidism, again decreases the direct inhibitory 
effect of 1,25-D3 on PTH secretion. Parathyroid hyperplasia, together with reduced CaSR 
expression then leads to severe hyperparathyroidism which initiates bone catabolism and 
together with the impaired renal function, leads to hypercalcaemia in combination with 
hyperphosphataemia. Reviewed in (Cunningham et al. 2011). This increase in blood Pi and 
Ca2+ levels then can then induce vascular calcification, as described below. 
 
1.3 Role of the CaSR in the vasculature 
1.3.1 The vasculature and blood pressure regulation 
Mammalian blood vessels consist of three layers, from the lumen outwards, these layers are 
the tunica intima, which is composed of a single layer of endothelial cells and forms the 
barrier to the blood. The tunica intima is separated by the innermost (internal) elastic lamina 
from the tunica media, which is composed of a varying number alternating layers of vascular 
smooth muscle cells (VSMC), and elastic laminae, depending on the size of the blood vessel.  
The main physiological role of VSMC is to provide the means for contraction and 
maintenance of the blood vessel tone and therefore regulating blood supply (and pressure) in 
the organs of the body (Guyton and Hall 2006). VSMC are of mesenchymal origin (Shroff et 
al. 2013) which is important in the context of their transdifferentiation into cell types of the 
same origin, specifically osteoblast-like cells (see below). 
The outermost (external) elastic lamina finally marks the beginning of the tunica adventitia, 
which anchors the blood vessel to the surrounding tissue. The tunica adventitia is made up of 
connective tissue, fibroblasts, bordering fatty tissue and perivascular nerves (and in case of 
very large arteries such as the aorta also vasa vasorum, i.e. supporting blood vessels to supply 
oxygen to the thick layers of cells in these arteries). See Figure 5 for a microphotograph of a 
murine aorta. 
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Figure 5: Histology of blood vessels. Microphotograph shows murine aorta cross-section in low (upper 
panel) and high (lower panel) magnification. Tunica adventitia (TA), tunica media (TM), tunica intima 
(TI), the lumen and elastic laminae (arrows) are indicated. 
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Arteries can be categorised into large conductance arteries, such as the aorta or the femoral 
artery, small resistance arteries, which are responsible for control of peripheral resistance and 
capillaries, where the gas exchange takes place and which form the last part of the blood 
vessel tree. Large conductance arteries act as a pressure reservoir by expanding during systole 
and contracting during diastole, keeping the blood flow constant during the cardiac cycle, the 
so called “Windkessel” effect (Belz 1995). A loss of elasticity, as associated with vascular 
calcification and arteriosclerosis, leads to increase stiffness of these large conductance arteries 
and a subsequent increase in pulse wave velocity and pulse height (PH, difference between 
systolic and diastolic blood pressure) with especially prominent increases in systolic blood 
pressure because the pressure reservoir effect is lost, as reviewed in (Amann and Ritz 1998; 
Dao et al. 2005). On the other hand, small resistance arteries serve as one of the main factors 
in blood pressure regulation by providing resistance (total peripheral resistance, TPR) against 
the blood flow. 
Contraction of VSMC is regulated by the sympathetic nervous system through α1-adrenergic 
receptors. Relaxation of VSMC is elicited indirectly by the action of endothelial cells by 
producing gaseous nitric oxide (NO), which acts in large conductance as well as small 
resistance arteries and the endothelial derived hyperpolarization (EDH) (Nagao et al. 1992), 
which is mostly active in the small resistance arteries (Shimokawa et al. 1996) and is a 
summary name for a variety of different factors including K+, reactive oxygen species or 
prostacyclin (Edwards et al. 2010) as well as charge transfer via myo-endothelial gap 
junctions (Sandow et al. 2002).  
In addition to TPR, blood pressure is also dependent on blood volume, in that an increased 
blood volume, e.g. through osmotic causes like increased Na+ ingestion, causes elevations in 
pressure while loss of blood volume, e.g. in hypovolemic shock goes along with reduced 
blood pressure. Blood volume and TPR are tightly controlled by the renin angiotensin 
aldosterone system (RAAS). In brief, the RAAS works be secretion of renin from the 
juxtaglomerular cells of the kidney following stimulation through various stimuli, the most 
important being reduction in urine compared to plasma osmolarity, and reduction in renal 
perfusion pressure. Renin cleaves angiotensinogen into angiotensin I which is metabolised in 
the lung by the angiotensin converting enzyme (ACE) into angiotensin II, the physiologically 
active form. Angiotensin II directly contracts resistance arteries thus increasing TPR and 
blood pressure by acting on AT1 receptors on VSMC effecting vasoconstriction through Gq/11 
and intracellular (Ca2+i) signalling. Furthermore, angiotensin II induces production and 
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secretion of aldosterone, a mineralocorticoid hormone, which acts on the collecting duct of 
the kidney promoting upregulation of the Na+/K+ ATPase on the basolateral side of the 
collecting duct cells, as well as the amiloride sensitive Na+ channel ENaC on the apical side, 
thus increasing reabsorption of water and Na+ as well as excretion of K+. The net effect of 
RAAS activation is therefore an increase in blood pressure through increased TPR and blood 
volume (Guyton and Hall 2006; Kobori et al. 2007). See Figure 6 for a graphical 
representation of the RAAS. 
 
 
Figure 6: The renin-angiotensin-aldosterone system (RAAS). Renin which is secreted by the 
juxtaglomerular apparatus in response to decreased renal perfusion pressure and changes in filtrate 
osmolality cleaves liver-produced angiotensinogen into angiotensin I which in turn is cleaved into 
angiotensin II by the angiotensin converting enzyme (ACE). Angiotensin II then has a variety of 
effects, including increase of sympathetic activity, stimulation of aldosterone production and therefore 
tubular water and salt reabsorption, direct vasoconstrictive effects on blood vessels and antidiuretic 
hormone (ADH, vasopressin) secretion. The sum of these effects leads to an increase in blood 
pressure and circulating volume which in turn exhibits a negative feedback on the RAAS: Modified 
after A. Rad [licensed under GFDL (http://www.gnu.org/copyleft/fdl.html) or CC-BY-SA-3.0 
(http://creativecommons.org/licenses/by-sa/3.0/)], via Wikimedia Commons. 
 
Finally, blood pressure depends on heart rate or, more specifically, cardiac output (CO), 
which is defined as stroke volume x heart rate, thus indicating the amount of blood ejected by 
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the heart per time interval. Increases in CO increase predominantly systolic pressure 
(Klabunde 2005). Heart rate and blood pressure are closely regulated in physiology, with an 
increase in the one resulting in a compensating decrease in the other (baroreflex) thus keeping 
systemic blood pressure constant (Wang et al. 2004). Figure 7 shows an overview of factors 
contributing to blood pressure homeostasis. 
 
 
Figure 7: Simplified overview of factors contributing to blood pressure homeostasis. The autonomic 
nervous system (lilac) contributes to control of cardiac output and TPR via sympathetic and 
parasympathetic innervation. The RAAS (light blue) contributes to regulation of blood volume and 
TPR. Shear stress and other factors contribute to local autoregulation of TPR by the blood vessels 
themselves, e.g. by NO production or EDH (orange). 
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1.3.2 Direct effects of the CaSR on vascular tone 
The CaSR has been found to be expressed in all three layers of blood vessels, the tunica 
intima, the tunica media as well as the tunica adventitia (Bukoski et al. 1997; Wonneberger et 
al. 2000; Ohanian et al. 2005; Weston et al. 2005). The functional role of the CaSR in these 
three layers of blood vessels has initially been related to vascular tone regulation. 
The earliest discovery of CaSR in the vasculature was in 1997, when Bukoski at al. (Bukoski 
et al. 1997) found the CaSR to be expressed in the perivascular nerves of mesenteric arteries 
where it was believed to cause perivascular mediated vasodilation, a hypothesis which is now 
controversial (Weston et al. 2005). 
CaSR in VSMC was identified first in the gerbilline spiral modiolar artery where CaSR 
activation was associated with a biphasic increase in Ca2+i induced vasoconstriction 
(Wonneberger et al. 2000). Ohanian and colleagues found the CaSR to be expressed in rat 
subcutaneous small arteries, where Ca2+o evoked a biphasic response of initial contraction in 
concentrations of up to 2 mM and dilation at higher concentrations (Ohanian et al. 2005). The 
CaSR has subsequently been found in cultured rat (Smajilovic et al. 2006), bovine and human 
VSMC, and in human (Alam et al. 2009) and murine aortae (Loot et al. 2013). Finally, the 
CaSR was found to be expressed in the vascular endothelium where activation of the receptor 
by the calcimimetic calindol produced endothelium-dependent relaxation of rat mesenteric 
arteries, which was mediated by VSMC hyperpolarization (Weston et al. 2005). In contrast to 
the described findings by Bukoski and colleagues (Bukoski et al. 1997), perivascular nerves 
did not seem to be involved in this effect. In the study by Weston et al. the authors concluded 
that this hyperpolarizing effect is the result of opening of the endothelial intermediate 
conductance Ca2+ sensitive K+ channel (IKCa) by the CaSR, leading to endothelial 
hyperpolarisation which is transferred to the VSMC by gap-junctions or the increased 
interstitial K+ concentrations resulting from IKCa activation (Weston et al. 2005). Another 
study performed on isolated human aortic endothelial cells (HAEC), provided evidence, 
through absence of the observed effects in CaSR siRNA treated cells, for a CaSR-dependent 
Gq modulated Ca2+i increase leading to stimulation of NO production (Ziegelstein et al. 2006), 
pointing towards an NO-mediated mode of VSMC relaxation for the endothelial CaSR. 
Similar observations were made in other studies, e.g. in a recent study on aortic rings of 
healthy and diabetic mice where the authors detected the CaSR in the endothelium as well as 
in VSMC (Loot et al. 2013). The endothelial CaSR evoked NO production and vasorelaxation 
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was reversible by calcilytics. The VSMC CaSR was described to have a potentiating effect on 
VSMC contraction induced by Ca2+i-dependent contracting agonists like the α1-
adrenoreceptor agonist phenylephrine. In essence, Ca2+i removed from the VSMC into the 
interstitium activates the CaSR which in turn potentiates the initial contraction. Inexplicably, 
calcimimetics evoked a CaSR dependent, endothelium independent relaxation (Loot et al. 
2013). One can speculate that this highly surprising result could be indicative of different 
signalling pathways by orthosteric and allosteric agonists (Davey et al. 2012) but further 
investigation in this phenomenon will clearly be necessary. 
In addition, a recent study suggested that this endothelium-mediated effect on blood pressure 
regulation might not exclusively be CaSR regulated. On cultured HUVEC and HAEC, both 
the active R-enantiomer of the calcimimetic 568 (R-568) as well as the inactive S-enantiomer 
both evoked a response of increased Ca2+i mobilization and subsequent eNOS activation, in 
the absence or presence of the calcilytic calhex-231 (Bonomini et al. 2012). The authors 
speculate that GPRC6A, a structurally very similar “orphan” GPCR to CaSR which has been 
implicated in amino-acid as well as osteocalcin sensing (Clemmensen et al. 2014), could be 
the effector of the observed effect of R- and S-568 on eNOS activation in their study. It has to 
be noted however, that the concentrations of R- and S-568 used in these experiments were 
high (1–100 µM) which suggests that off-target effects of the compounds could have been 
responsible for the observed results. These target non-specific effects of (some) calcimimetics 
are related to their chemical structure, as they were originally derived from 
phenylalkylamines, inhibitors of L-type (voltage gated) Ca2+ channels (Nemeth et al. 1998). 
In another study calcimimetic-induced vasorelaxation has been attributed to the inhibition of 
Ca2+o influx into VSMC through inhibition of L-type Ca2+ channels, rather than activation of 
CaSR (or GPRC6A) (Thakore and Ho 2011).  
These complex interactions and different observations of CaSR actions on endothelium and 
VSMC highlight the importance of our study of targeted gene deletion of the CaSR from 
VSMC. 
 
1.3.3 In vivo effects of the CaSR on blood pressure 
A calcium rich diet is generally recognized as reducing blood pressure (Ayachi 1979) while 
reduced Ca2+ intake is associated with an increase in blood pressure (McCarron et al. 1982). 
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The mechanism behind this blood pressure lowering effect of Ca2+ has been attributed to 
elevated diuresis (Ayachi 1979), reduction in sympathetic drive (Peuler et al. 1987) or direct 
dilatory effects on the vasculature thereby causing a reduction in TPR (Bukoski et al. 1997; 
Bukoski 2001). As implied by the multitude of in vitro results of the vascular CaSR on blood 
vessel contractility described above, some of these effects might be CaSR mediated.  
Despite this possibly blood pressure lowering effect of a Ca2+ rich diet, patients suffering 
from hypercalcaemic hyperparathyroidism in CKD after renal transplantation are often 
hypertensive. Parathyroidectomy has been shown to reduce this hypertension in humans 
(Rostaing et al. 1997) and animals (Ogata et al. 2003). A similar reduction of blood pressure 
can be seen by calcimimetic treatment in humans (Zitt et al. 2011) as well as uremic animal 
models (Ogata et al. 2003; Odenwald et al. 2006). Indeed, calcimimetics have been shown to 
have a profound influence on blood pressure in vivo. In a study on healthy and uremic rats, R-
568 showed a distinctive biphasic influence on blood pressure, leading to a short-term 
increase in blood pressure in both healthy and uremic animals which went back to normal in 
healthy animals but was succeeded by a pronounced antihypertensive long-term effect in 
uremic rats (Odenwald et al. 2006). A study by Fryer and colleagues suggested that this short-
term increase in blood pressure might be attributed to reduced blood Ca2+ levels, leading to 
reduced activation of endothelial NO production (Fryer et al. 2007). Since Fryer and 
colleagues only studied the rats for 90 minutes following cinacalcet treatment, it is possible 
that they might have missed the beneficial long term blood pressure lowering effects of 
cinacalcet observed in the previously described studies.  
Apart from the mentioned direct effects of the CaSR and calcimimetics on vascular tone, 
these blood pressure lowering effects on uremic animals could be related to other, more direct 
actions of the CaSR. 
One of these could be the general protective effect the CaSR exerts against complications 
associated with CKD, such as arterial and cardiac remodelling (Ogata et al. 2003). Loss of 
blood vessel elasticity is associated with increased blood pressure (Dao et al. 2005). The 
CaSR has been implicated in protection against vascular calcification (see chapter 1.4) and 
one modus operandi of blood pressure reduction by calcimimetics could be via reduction, or 
prevention, of vascular remodelling. In their pertinent review on CaSR in blood pressure, 
Smajilovic and colleagues have however pointed out that this protection from calcification 
would be a very long-term effect which could hardly account for the blood pressure reducing 
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effects observed in studies over a course of days (Smajilovic et al. 2011). Indeed a large 
clinical trial, investigating the effects of cinacalcet on the prevention of cardiovascular 
diseases like myocardial infarction or heart failure failed to detect a protective influence of the 
calcimimetic on cardiovascular events. However, as described below, this study was riddled 
with major limitations, such as patients in the placebo group buying over-the-counter 
calcimimetics (Chertow et al. 2012). 
Other possibilities of CaSR action on blood pressure regulation include interaction of the 
CaSR with sympathetic drive. An older study suggested an impaired sympathetic drive and 
baroreflex as the causes for Ca2+ induced hypotension (Peuler et al. 1987). Our own group 
have detected CaSR expression in sympathetic neurons (Vizard et al. 2008). The mechanisms 
of CaSR influence on sympathetic tone remain yet to be determined.  
Other studies suggested that the blood pressure lowering action of calcimimetics might not at 
all be entirely CaSR mediated: intravenous administration of the calcimimetic R-568 and its 
non-CaSR selective enantiomer S-568 did not alter blood pressure in rats when applied in 
concentrations sufficient to induce suppression of PTH via CaSR activation. In higher 
concentrations, both R-568 and its non-CaSR sensitive enantiomer S-568 reduced blood 
pressure (Nakagawa et al. 2009), which might be attributed to non-specific effects on L-type 
Ca2+ channels (Smajilovic et al. 2007; Thakore and Ho 2011). These results were in line with 
the already described unspecific effects of R- and S-568 in HUVEC and HAEC in vitro, 
where both R- and S-568 enantiomers induced endothelial NO production (Bonomini et al. 
2012). In support of the idea of non-CaSR mediated effects of calcimimetics on blood 
pressure reduction has been suggested in a recent study where R-568 was shown to inhibit the 
endothelin-converting-enzyme 1 in human endothelial cells (Martinez-Miguel et al. 2013). 
Importantly, the CaSR has also been shown to be involved in renal renin production. 
Stimulation of the receptor with the calcimimetic cinacalcet directly inhibits renin production 
in vivo (Maillard et al. 2009; Atchison et al. 2010) and in vitro (Ortiz-Capisano et al. 2007) 
again emphasising the major role of the receptor in regulation of mineral ion homeostasis. 
However, the decrease in renin production did not go along with a decrease in blood pressure 
in rats treated with cinacalcet: low doses of the calcimimetic had no effect on blood pressure, 
while renin production was still reduced (Atchison et al. 2010). Another study found that the 
calcilytic NPS 2143 increased blood pressure in rats which was attenuated by losartan, an 
inhibitor of the angiotensin II AT1 receptor and potent anti-hypertensive drug, highlighting 
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the involvement of the CaSR, or allosteric modulators of the CaSR, in regulation of the 
RAAS (Rybczynska et al. 2010). In addition, Bartter V patients, in which there are activating 
CaSR mutations, exhibit hypokalaemia, hyperreninaemia and hyperaldosteronaemia (Vargas-
Poussou et al. 2002). 
 
1.4 Role of the CaSR in vascular calcification 
1.4.1 Vascular calcification 
It is important to differentiate between the different types of calcifications that can occur in 
blood vessels. When talking about vascular calcification, this generally means medial 
calcification (or Mönckeberg’s sclerosis), which is predominantly associated with the mineral 
ion imbalance present in CKD, namely hyperphosphataemia and hypercalcaemia. Vascular 
calcification is the active process of mineral deposition in VSMC and is a major complication 
and one of the main causes of death in CKD and end-stage renal disease (ESRD) (Blacher et 
al. 2001; London et al. 2005). It has been shown that vascular calcification is directly 
associated with accelerated arterial aging and remodelling (Gauthier-Bastien et al. 2013; 
London et al. 2013) in CKD and ESRD patients and that Ca2+ load is a major factor in 
determining risk for aortic aging (London et al. 2008), resulting in blood vessel stiffening, 
subsequent rise in pulse wave velocity, hypertension and cardiac hypertrophy (Blacher et al. 
1999). This should not be confused with calcific atherosclerosis, or intimal calcification, 
which is primarily caused by ossification of atherosclerotic plaques and is associated with 
inflammation, hypertension and dyslipidaemia and ischemic heart disease. Importantly, in 
contrast to atherosclerosis, vascular calcification is probably at least not initially associated 
with inflammation, although in advanced stages of CKD, atherosclerosis might occur together 
with medial calcification because of a high prevalence of risk factors for the former in such 
patients (Shroff et al. 2013). Finally, calcification of small peripheral arterioles, calcific 
uremic arteriolopathy, also called calciphylaxis, is a form of medial calcification which 
predominantly affects small arterioles, eventually causing occlusion and ischemia 
(Karwowski et al. 2012).  
The arterial remodelling and calcification of blood vessels was shown to be caused by a 
transdifferentiation of medial VSMC into an osteoblast-like phenotype, going along with 
upregulation of typical bone-associated biomarkers such as alkaline phosphatase, osterix, or 
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runt-related transcription factor 2 (runx2) (Shanahan et al. 1999; Tyson et al. 2003). The 
importance of runx2 and osteogenic differentiation in the process of vascular calcification has 
recently been demonstrated by a mouse model of targeted deletion of runx2 from VSMC 
where the KO mice developed markedly less vascular calcification on a high fat diet than 
control mice (Sun et al. 2012). Indeed, the calcified deposits in calcified VSMC are 
chemically identical to the structure mineral of bone, namely hydroxyapatite (Duer et al. 
2008).  
It has been demonstrated that matrix vesicles originating from VSMC are initial sites of 
hydroxyapatite formation. These vesicles are a mechanism by which the cell rids itself from 
high Ca2+i levels and which under physiological conditions contain inhibitors of calcification 
such as fetuin A, pyrophosphate (PPi) and matrix gla protein (MGP) to prevent calcification. 
Fetuin A is produced in the liver accumulates at sites of calcification and binds Ca2+ and Pi 
complexes (Reynolds et al. 2005). PPi similarly is produced directly by VSMC and disrupts 
hydroxyapatite deposition, thus also protecting against vascular calcification (Prosdocimo et 
al. 2010). MGP protects against vascular calcification (Luo et al. 1997) by inhibiting crystal 
formation and scavenging bone morphogenic protein 2 (BMP-2), an inducer of osteogenic 
(trans)differentiation (Proudfoot and Shanahan 2006).In uraemia, these calcification inhibitors 
are depleted, leading to formation of hydroxyapatite in those vesicles (Reynolds et al. 2004; 
Reynolds et al. 2005). However, clinically, the levels of not all of these calcification inhibitors 
seem to be correlated with vascular stiffness in patients suffering from CKD. A relatively 
small correlation was only found for MGP but not fetuin A (Liabeuf et al. 2013), It possible 
that the missing correlation of vascular calcification with circulating levels of fetuin A can be 
explained by the aforementioned accumulation of fetuin A at sites of calcification (Reynolds 
et al. 2005). Figure 7 provides a graphical overview of VSMC transdifferentiation into an 
osteogenic phenotype. 
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Figure 8: Overview of osteogenic VSMC transdifferentiation and calcification. Transdifferentiation of 
VSMC into an osteogenic phenotype goes along with a loss of calcification inhibitors and calcifying 
matrix vesicle release as well as changes in gene expression including upregulation of osteogenic 
marker genes like runx2 or alkaline phosphatase (ALP) and downregulation of smooth muscle 
markers like SM22. ECM = extracellular matrix (Shanahan et al. 2011). Image used under license from 
Wolters Kluwer Health.  
 
Indeed, calcification of blood vessels is highly dependent on their environment. Ex vivo 
experiments on human blood vessels showed that, under the same conditions of high Ca2+o 
and Pi, blood vessels from dialysis patients exhibited a marked increase in calcification 
compared to blood vessels from healthy controls. This indicates that long term predisposition 
in an uremic environment is required for the onset of calcification and is believed to be 
associated with increased levels of apoptosis occurring in uremic blood vessels, which in turn 
form nucleation sited for beginning vascular calcification (Shroff et al. 2008). 
The exact mechanism behind this phenotypic change and onset of vascular calcification is still 
unclear but seems to be a response to the altered environment of the cells in uremic 
conditions, that is elevated Pi and blood Ca2+ levels (Block et al. 1998). High Pi and Ca2+o 
levels were demonstrated to induce the upregulation of bone biomarkers in VSMC. Animal 
studies on uremic rats suggested that high phosphate levels induce the phenotypic 
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transdifferentiation of VSMC leading to vascular calcification (Pai et al. 2011). In vitro 
experiments also suggested that (passive) hydroxyapatite formation may precede the onset of 
vascular calcification and drives the transdifferentiation into an osteoblastic phenotype (Sage 
et al. 2011; Villa-Bellosta et al. 2011). It is very possibly that a combination of different 
effects occurs at the same time in vivo. The CaSR is believed to play a key role in preventing 
this transdifferentiation of VSMC into an osteoblastic phenotype which is described below. 
As already hinted at, vascular calcification is very often associated with other cardiovascular 
complications such as hypertension and cardiac hypertrophy. Increased stiffness of large 
conductance arteries associated with vascular calcification results in a loss of the ability of the 
blood vessel to dilate in response to the systolic pressure, resulting in increased pulse wave 
velocity and pulse wave reflection leading to systolic hypertension. This results in an increase 
in cardiac afterload and consequently left ventricular hypertrophy (Blacher et al. 1999; 
Amann and Tyralla 2002; Dao et al. 2005). 
 
1.4.2 Protection against vascular calcification by the CaSR 
Recently, evidence has been accumulating that one of the roles of the vascular CaSR could be 
in the protection from vascular calcification.  
Calcimimetics lower PTH – and consequentially extracellular Ca2+ levels – via activation of 
the CaSR in the parathyroid glands. In uremic animal models, administration of calcimimetics 
has been shown to be protective against vascular calcification and other complications. 
Consequently, an indirect protective effect of the CaSR against vascular calcification, 
mediated by normalising Ca2+ and phosphate homeostasis has been proposed (Ogata et al. 
2003; de Francisco et al. 2006; Kawata et al. 2008).  
However, the abundant expression of the CaSR in blood vessels suggests that the CaSR might 
also have a direct protective role on the vasculature itself, in addition to its indirect effects via 
the parathyroid glands. Our group has demonstrated that over-expression of a dominant 
negative mutation of CaSR (R392X) increases calcification of isolated VSMC in vitro, and 
that treatment of the VSMC with calcimimetics reduces vascular calcification (Alam et al. 
2009). These findings have been confirmed by later studies (Mendoza et al. 2011; Ciceri et al. 
2013).  
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However, direct stimulation of the CaSR by agonists alone cannot be the driving force behind 
the protective action of the CaSR as Ca2+, the main agonist of the CaSR, is available in 
abundance in pathophysiological states or experimental conditions leading to vascular 
calcification, i.e. high Ca2+o levels. It is well established that in vitro calcified cultured VSMC 
as well as calcified arteries (Molostvov et al. 2007; Alam et al. 2009) lose CaSR expression, 
which points towards a different mechanism behind the protective effect of calcimimetic 
treatment against vascular calcification. This mechanism seems to be associated with 
prevention of CaSR downregulation. Indeed, in human VSMC increasing Ca2+o from 1.8 mM 
to 5 mM led to a reduction of CaSR expression. Under these conditions, calcimimetics 
increased CaSR surface and total expression levels in VSMC (Henaut et al. 2014). Similarly, 
calcification of cultured rat VSMC was reduced by the calcimimetic calindol (Ciceri et al. 
2012b). The protective action of the CaSR against vascular calcification could therefore be 
interpreted as a direct effect of the calcimimetics on preventing CaSR downregulation and 
therefore the preservation of its function in blood vessels. This upregulating action of the 
calcimimetics on CaSR is well known also in other model systems of CaSR transfected 
human embryonic kidney (HEK) 293 cells (Davies et al. 2006; Cavanaugh et al. 2010) or in 
vivo, in the parathyroid gland (Mendoza et al. 2009).  
The signalling pathways downstream of CaSR stimulation leading to this protective effect 
against VSMC calcification are still unclear. It is long since known that, when VSMC begin 
to mineralise, their phenotype changes from a smooth muscle to an osteoblastic one (Jakoby 
and Semenkovich 2000; Tyson et al. 2003), a process which goes along with increased arterial 
stiffness and blood pressure (Gauthier-Bastien et al. 2013). Calcimimetics, and therefore 
CaSR activation and upregulation, appear to delay this transdifferentiation, as shown in 
animal models of CKD where increased osteoblastic gene expression in aortic VSMC was 
inhibited by calcimimetic treatment while the endogenous calcification inhibitor matrix-gla-
protein (MGP) was upregulated in vivo (Koleganova et al. 2009) as well as in vitro (Mendoza 
et al. 2011; Ciceri et al. 2013). Whether the two events appear sequentially remains to be 
investigated. 
Taken together, these results from pre-clinical studies supported the idea that calcimimetics 
might prove beneficial at reducing vascular calcification in patients suffering from CKD both 
indirectly, by reducing circulating parathyroid hormone and therefore Ca2+ levels, but also 
directly, by targeting the vascular CaSR. 
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1.4.3 Clinical use of calcimimetics 
Yet, clinical trials aimed at testing the efficacy of calcimimetic (Cinacalcet hydrochloride) 
treatment in preventing vascular calcification are ambiguous at best. In a retrospective study, 
patients treated with Cinacalcet exhibited significantly reduced risks of cardiovascular 
associated mortality (Block et al. 2010), although the mechanism behind this is still not 
understood. In contrast, a medium scale (360 patients) clinical trial (ADVANCE) to 
investigate the effects of cinacalcet + vitamin D on vascular calcification in patients 
undergoing haemodialysis suggested a slightly slower progression of vascular calcification 
(coronary artery calcification) in patients treated with cinacalcet + vitamin D compared to 
vitamin D alone (Raggi et al. 2011; Urena-Torres et al. 2013) but could not prove a significant 
benefit in patients treated with cinacalcet alone. The study had some significant design flaws, 
including an open-label design, lack of control of other medication of the patients and a 
follow up period of only 12 months. The latter issue has been addressed in the large scale, 
multicentre EVOLVE study (3883 patients) which recruited patients suffering from stage 5 
chronic kidney disease with concomitant secondary hyperparathyroidism and undergoing 
dialysis (Chertow et al. 2007). The primary endpoints of this study were time until death or 
appearance of a severe cardiovascular event (such as, for instance, myocardial infarction or 
unstable angina pectoris). In this study cinacalcet treatment only showed a relative risk 
reduction of 7 % for these events, which was not significantly different from conventional 
treatment alone (Vitamin D, phosphate binders) (Chertow et al. 2012). Unfortunately, 
similarly to the ADVANCE study, the EVOLVE study was riddled by many shortcomings. A 
large difference in baseline characteristics, a high rate of treatment discontinuation in 1/3 of 
the patients recruited in the cinacalcet group and the availability and of self-medication with 
over the counter available cinacalcet in the placebo group probably played a large role in 
these questionable outcomes (Carney 2013).  
These difficult to interpret clinical results highlight the importance to clarify the physiological 
role of the CaSR in the vasculature, and its putative protective role against vascular 
calcification. Producing a tissue-specific CaSR ablation from VSMC should enable us to 
evaluate the physiological significance of the VSMC CaSR in protection against vascular 
calcification. This was the rationale for the generation and phenotypic characterisation of the 
SM22α-Cre x LoxP-CaSR mouse when devising this study. 
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1.5 Models of CaSR deletion 
1.5.1 Models of constitutive CaSR deletion 
Transgenic animals are the preferred model system to address the specific function of a 
protein in physiology and pathophysiology as they allow a holistic study of a genes function 
in the context of the whole organism (Austin et al. 2004), and indeed a great multitude of 
studies using transgenic models of CaSR deletion have been performed to determine the role 
of the receptor in various tissues and regulating systems. The first model of constitutive CaSR 
deletion was developed by Ho and colleagues in 1995, 2 years after the identification of the 
CaSR (Ho et al. 1995). The constitutive CaSR knock-out mouse (CaSR-/-) shows a phenotype 
of severe hypercalcaemia, growth retardation and impaired bone structure and rarely lives 
longer than a few weeks resembling NSHPT, while the heterozygous CaSR knock-out mouse 
(CaSR+/-) only shows a mild phenotype resembling FHH. To allow for investigation of CaSR 
function in adults, different mouse models for constitutive knock-out of the CaSR have been 
developed where the phenotype of the CaSR-/- mouse was (partly) rescued: In Gcm2-/--CaSR-/- 
mice, where the CaSR is knocked out in mice of a background of deleted glial cells missing-2 
(Gcm2), a master regulator for parathyroid gland development (thus leading to parathyroid 
gland ablation), the severe phenotype of the CaSR-/- mouse is rescued except for persisting 
hypocalciuria (Tu et al. 2003). A very similar rescue was observed when knock-out of the 
CaSR was combined with knock out of PTH gene. The resulting CaSR-/--PTH-/- mice are not 
different in size and lifespan from control mice but have imbalanced Ca2+ levels in blood and 
urine due to the missing action of the CaSR in the kidney (Kos et al. 2003).  
Finally, deletion of 1,25-D3 in with mice lacking the CaSR (1,25-D3-/--CaSR-/-) improved 
lifespan, growth, bone status and serum Ca2+ levels compared to those observed in CaSR-/- 
mice, but also exacerbated hypophosphataemia and hyperparathyroidism (Liu et al. 2011). 
Table 1 shows an overview of all studies on CaSR function performed with transgenic models 
of CaSR deletion (including those of targeted gene deletion, see below). 
Importantly, the constitutive CaSR-/- mouse is not a complete knockout. When investigating 
specific effects of CaSR deletion in some tissues, an alternative splice variant of the CaSR, 
lacking the 77 amino acid exon 5 (which is targeted by the gene deletion strategy in the CaSR-
/- mouse) was discovered (Oda et al. 2000). In some tissues, this exon 5-less splice variant was 
non-functional (Oda et al. 2000) while it functionally replaced full-length CaSR function in 
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others (Rodriguez et al. 2005; Finney et al. 2011), making investigation of tissue specific 
effects of CaSR KO difficult. 
 
1.5.2 Models of targeted CaSR deletion via the Cre-LoxP system 
To overcome these problems and allow studying of CaSR roles in specific tissues, the Cre- 
(cyclization recombinase) LoxP (locus of X-over P1) system of targeted gene deletion was 
used to generate mice lacking the CaSR only in certain tissues (Chang et al. 2008). 
The Cre-LoxP system facilitates deletion of specific genes from specific tissue by breeding 
two types of genetically modified mice: the first mouse carries LoxP-sites flanking a portion 
of a gene which is to be deleted in the final knock-out mouse model. The LoxP-sites are 
originally a feature of bacteriophage P1 consisting of 34 base pairs; bp (Sternberg and 
Hamilton 1981). This sequence is recognised by the 38 kDa enzyme Cre recombinase, which 
is introduced under the control of a tissue- and/or age-specific promoter into the second 
transgenic mouse (Orban et al. 1992) When these two mice are bred, the Cre-recombinase, 
which is only expressed in cells where the promoter which controls Cre expression is active, 
will cleave the gene flanked by the LoxP-sites, resulting in tissue, or rather promoter-specific 
deletion of the target gene.  
Using this system, Chang et al. have developed a tissue selective CaSR knock-out mouse 
(CaSR-LoxP, Δexon7) in which ablation of the CaSR from chondrocytes, osteoblasts and the 
parathyroid cells was successfully established by using three specific Cre driving promoters. 
Using these models, they showed that the osteoblastic, parathyroid and chondrocyte CaSR are 
essential for regulation of osteoblastic activity, with KO mice showing severe growth 
retardation and impaired bone structure (Chang et al. 2008). Recently, the same CaSR-LoxP 
mouse has also been used to generate an intestinal epithelium-specific CaSR knock-out mouse 
which presented a marked phenotype of altered colonic crypt structure and colonic epithelial 
cell hyperproliferation (Rey et al. 2012).  
 
1.5.3 The SM22α-Cre x LoxP-CaSR mouse 
The aim of my study was to determine the role of the vascular CaSR. Targeted deletion of the 
CaSR from VSMC was achieved by breeding the CaSR-LoxP (Δexon7) mouse with an 
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SM22α (smooth muscle protein of 22 kDa isoform alpha (Lees-Miller et al. 1987)) promoter 
driven Cre mouse (Li et al. 1996b; Holtwick et al. 2002), thus creating the SM22α-Cre x 
LoxP-CaSR mouse. Mice were bred by our Dr. Wenhan Chang as part of a collaborative 
study. Two heterozygous breeding pairs were sent to Cardiff for phenotypic characterisation.  
The transgenic strategy used in the CaSR-LoxP mouse model consists of LoxP sites flanking 
exon 7 of the murine CaSR (CaSR-LoxP), leading to deletion of exon 7 and thus the 
production of a truncated (Δexon7) CaSR protein in Cre expressing tissues. Exon 7 encodes 
the whole intracellular and transmembrane domain of the CaSR (REF here). The truncated 
product therefore consists of the extracellular domain only which, due to lack of its 
transmembrane domain, cannot anchor to plasmamembrane and is therefore trapped in the 
cell. Δexon7-CaSR in human embryonic kidney (HEK) 293 cells show absence of CaSR 
activation when exposed to extracellular Ca2+ compared to HEK 293 transfected with the full 
length CaSR, proving that the truncated product is indeed non-functional. For PTH-Cre x 
LoxP-CaSR mice, a reduction of about 90 % in CaSR mRNA was found in Cre expressing 
parathyroid glands. In comparison, mRNA levels for the Δexon7-CaSR were increased about 
2-fold was found, indicating an increased rate of CaSR transcription possibly in response to 
lost CaSR function. Protein levels of the full length CaSR were reduced by > 95 % while 
truncated CaSR protein expression levels were about 10 % compared to WT control. The 
latter result indicates that the Δexon7-CaSR protein is more unstable and subject to rapid 
degradation despite the increased mRNA levels (Chang et al. 2008). 
The promoter driving Cre was SM22α, a mainly smooth muscle cell associated protein which 
locates to the cytoskeleton of these cells (Zhang et al. 2001a). The function of SM22α has yet 
to be fully understood but seems to be connected to cell contraction, migration and tumour 
suppression (Assinder et al. 2009). Expression patterns or SM22α proteins are different from 
the promoter construct and are highly variable depending on gene length (Xu et al. 2003). 
Specificity of the SM22α-Cre promoter construct for murine VSMC is debated, but probably 
not complete. While earlier studies indicated sole VSMC specificity in adult mice (Li et al. 
1996b; Moessler et al. 1996; Holtwick et al. 2002) and transient expression of SM22α in the 
embryonic heart (Li et al. 1996a), more recent studies indicated expression of SM22α-Cre in 
adult visceral and cardiac smooth muscle cells (Lepore et al. 2005) as well as myeloid and 
lymphoid cells (Shen et al. 2012). 
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Table 1: Studies performed on transgenic mouse models of CaSR deletion. Studies are ordered 
chronologically. Equal models are highlighted with the same colour. Studies using models of target 
specific gene deletion are highlighted in grey.  
Model 
Investigated 
system / deletion 
from 
Observed effects Reference 
CaSR-/- (Δexon5) 
Phenotypic 
characterisation, 
model generation 
CaSR+/- mice show phenotype 
similar to FHH (elevated serum 
Ca2+ and PTH levels), CaSR-/- 
mice show phenotype similar to 
NSHPT and have a lifespan < 1 
month  
(Ho et al. 
1995) 
CaSR-/- (Δexon5) Keratinocytes 
Δexon5-less splice variant 
described unable to sense Ca2+ in 
keratinocytes 
(Oda et al. 
2000) 
CaSR-/--PTH-/- 
(Δexon5) 
Phenotypic 
characterisation, 
model generation 
PTH deficient background rescues 
phenotype of CaSR-/- mice by 
reducing PTH levels 
(Kos et al. 
2003) 
CaSR-/--Gcm2-/- 
(Δexon5) 
Phenotypic 
characterisation, 
model generation 
Gcm2-deficient background 
rescues phenotype of CaSR-/- 
mice by reducing PTH levels 
(Tu et al. 
2003) 
CaSR-/- (Δexon5) Growth plate chondrocytes 
Δexon5-less splice variant 
compensated for loss of full length 
CaSR in growth plate 
chondrocytes 
(Rodriguez 
et al. 2005) 
PTH-Cre x LoxP-
CaSR (Δexon7) 
Skeletal phenotype 
/ Parathyroid 
 
Growth retardation, inhibited bone 
formation, elevated PTH, serum 
and urine Ca2+ 
(Chang et 
al. 2008) 
 
2.3Col(I)-Cre x 
LoxP-CaSR 
(Δexon7) 
Skeletal phenotype 
/ Osteoblasts 
Growth retardation, inhibited bone 
formation, early death 
Osx-Cre x LoxP-
CaSR (Δexon7) 
Skeletal phenotype 
/ Osteoblasts 
Growth retardation, inhibited bone 
formation, early death 
ColII-Cre x LoxP-
CaSR (Δexon7) 
Skeletal phenotype 
/ Chondrocytes 
Embryonically lethal, delayed 
growth plate development 
CaSR-/--PTH-/- 
(Δexon5) 
PTH independent 
role of the CaSR in 
Ca2+ homeostasis 
1,25-D3 mediated elevated Ca2+ 
levels, reduced renal Ca2+ 
excretion, increased intestinal 
Ca2+  
(Egbuna et 
al. 2009) 
CaSR-/--PTH-/- 
(Δexon5) 
PTH independent 
role of the CaSR in 
Ca2+ homeostasis 
PTH independent hypercalcaemia 
on Ca2+ rich or Pi deplete diet 
through reduced renal excretion 
and calcitonin levels 
(Kantham 
et al. 2009) 
CaSR-/--PTH-/- 
(Δexon5) Stomach 
No gastrin and acid secretion in 
CaSR-/--PTH-/- mice. CaSR acts as 
nutrient sensor in the stomach 
(Feng et al. 
2010) 
CaSR-/--1α-
Hydroxylase-/- 
(Δexon5) 
Skeletal phenotype 
Rescue diet (high Ca2+) 
normalises phenotype of 1α-
Hydroxylase-/- but leads to 
hypercalcaemia in double KO. 
Reduced osteoclastic activity 
(Richard et 
al. 2010) 
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CaSR-/--PTH-/-, 
CaSR-/--1α-
Hydroxylase-/- 
(Δexon5) 
Teeth 
PTH deficient background rescues 
phenotype of CaSR-/- mice; 1,25-
D3 deficient background reduces 
phenotype 
(Sun et al. 
2010) 
Co3.6-Cre x 
LoxP-CaSR 
(Δexon7) 
Skeletal phenotype 
/ Osteoblasts 
Growth retardation, reduced 
osteoblast differentiation, 
increased RANKL expression 
(Dvorak-
Ewell et al. 
2011) 
CaSR-/- (Δexon5) Foetal lung development 
Δexon5-less splice variant 
compensated for loss of full length 
receptor in foetal lungs 
(Finney et 
al. 2011) 
CaSR-/--PTH-/-, 
CaSR-/--1α-
Hydroxylase-/- 
(Δexon5) 
Interaction of CaSR 
with PTH and 1,25-
D3 in skeletal 
phenotype 
PTH deficient background rescues 
phenotype of CaSR-/- mice; 1,25-
D3 deficient background reduces 
phenotype, hypercalcaemia and 
PTHrP identified as major factor 
for CaSR-/- lethality 
(Liu et al. 
2011) 
CaSR-/--PTH-/- 
(Δexon5) 
Bone turnover in 
neonates 
Dietary high Ca2+ promotes bone 
formation in PTH-/- but not CaSR-/-
-PTH-/- mice. CaSR mediates 
dietary Ca2+ induced bone 
turnover 
(Shu et al. 
2011) 
Six2-Cre x LoxP-
CaSR (Δexon3) Kidney 
No effect unchallenged, increased 
activation of NKCC2, reduced 
Ca2+ excretion on high Ca2+ diet 
(Toka et al. 
2012) 
Vil-Cre x LoxP-
CaSR (Δexon7) 
Intestinal epithelial 
cells 
Increased epithelial proliferation, 
changes in crypt structure and β-
catenin signalling 
(Rey et al. 
2012) 
CaSR-/--PTH-/- 
(Δexon5) 
Influence of PTH on 
bone in absence of 
CaSR 
Attenuated PTH induced increase 
in bone turnover compared to 
PTH-/- single KO 
(Xue et al. 
2012) 
PTH-Cre x LoxP-
CaSR+/- (Δexon7) 
Influence of age 
and sex on 
development of 
hyperparathyroidism 
Elevated PTH protects trabecular 
bone in male mice > 3 months, 
reduces trabecular bone in 3 
month females which is revers in 
12 month females 
(Cheng et 
al. 2013) 
CaSR-/--PTH-/- 
(Δexon5) Colon 
Increased inflammation and Wnt 
signalling, increased susceptibility 
for colonic aberrations 
(MacLeod 
2013) 
CaSR-/--PTH-/- 
(Δexon5) Erythrocytes 
CaSR deletion rescues impaired 
erythrocyte phenotype caused by 
PTH deletion 
(Romero et 
al. 2013) 
CaSR-/--PTH-/- 
(Δexon5) 
Interactions 
between Ca2+ and 
Mg2+ homeostasis 
Reduced Mg2+ levels in PTH-/- and 
CaSR-/--PTH-/- mice which are 
normalised by dietary Ca2+, 
exacerbated hypercalcaemia with 
dietary Mg2+  
(Quinn et 
al. 2013a) 
CaSR-/--PTH-/- 
(Δexon5) 
Ca2+ and Pi 
mediated regulation 
of FGF23 
FGF23 production is activated by 
Ca2+ and Pi independently of 
CaSR and PTH 
(Quinn et 
al. 2013b) 
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1.6 Scope and objectives of the thesis 
As I have introduced in the previous sections, multiple studies on the involvement of the 
vascular CaSR in control of vascular tone and vascular calcification have already been 
performed, but definitive answers explaining the actual physiological and pathophysiological 
role of the vascular CaSR are still missing.  A thorough and systematic investigation of the 
specific functions of the VSMC CaSR, with emphasis on possible different roles in vascular 
tone regulation and protection from calcification, is therefore essential. To address these 
issues I characterised a mouse model of targeted deletion of the CaSR from VSMC (SM22α-
Cre x LoxP-CaSR) to elucidate the physiological and pathophysiological roles of the CaSR in 
VSMC. To achieve these goals, a variety of objectives were set for the thesis which I address 
in chapters 3-9: 
1) Optimisation of experimental protocols for in vitro and in vivo investigation of the role 
of the CaSR in VSMC. 
2) Gross description of the phenotype of the SM22α-Cre x LoxP-CaSR mouse, including 
body weights, reproductive capabilities and overt phenotypic difference between WT 
and KO animals. 
3) Investigation of the in vitro phenotype of cultured VSMC to study principal 
differences in CaSR expression and intracellular distribution as well as proliferation / 
apoptosis of VSMC isolated from control as well as WT and KO mice. 
4) Characterisation of the effect of absence of the VSMC CaSR in the propensity for 
vascular calcification in vivo, ex vivo and in vitro and therefore the contribution of the 
VSMC CaSR on protection against vascular calcification. 
5) In vivo characterisation of the cardiovascular system of the SM22α-Cre x CaSR-LoxP 
mouse to determine the contribution of the VSMC CaSR to blood pressure regulation 
in vivo. This is of great importance as the specific role of the VSMC CaSR in blood 
pressure regulation is still unclear. Targeted deletion of the CaSR from VSMC allows 
for dissection of the effect of the VSMC CaSR independently of the effects of the 
perivascular and endothelial CaSR. 
The best characterised role of the CaSR lies in maintenance of Ca2+ homeostasis. 
Therefore, the mineral ion metabolism of the SM22α-Cre x LoxP mousse was studied 
in vivo, specifically by investigating the metabolism, bone and clinical chemistry of 
blood and urine of the animals. 
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2 Materials and Methods 
2.1 Chemicals and substances  
All chemicals were acquired from Sigma-Aldrich (Dorset, UK) unless otherwise stated. The 
calcimimetic R-568 was kindly provided by Amgen (Thousand Oaks, CA, USA).  
 
2.2 Experimental animals 
All experiments and animal procedures were performed adhering to UK Home Office 
guidelines. Founder animals for the smooth muscle cell specific CaSR knock-out were 
produced by W. Chang, Endocrine Research Unit, Department of Medicine, University of 
California, USA by breeding SM22α-Cre+ mice (Li et al. 1996b; Holtwick et al. 2002) with 
mice containing LoxP sites flanking exon 7 of the murine CaSR gene (Chang et al. 2008) of 
mixed 129S1/SvImJ and C57/Bl6 background. C57/BL6 mice were used as control animals 
where applicable. For the excision performance of the Cre-enzyme, homo- and hemizygous 
Cre presentation is considered equivalent. Mice of the following genotypes were considered 
“wild type” (WT): Cre+/flox-/-, Cre-/flox+/+, Cre-/flox+/-, Cre-/flox-/-. Mice of the following 
genotypes were considered “heterozygous” (HET): Cre+/flox+/-, Cre+/flox-/+. Mice of the 
following genotype were considered “knock-out” (KO): Cre+/flox+/+ (Table 2).  
Mice were housed in standard cages housing a maximum of five animals in one cage and fed 
Rat and Mouse No. 3 Breeding diet, henceforth called “standard diet” (Special Diet Service, 
Essex, UK) and tap water ad libitum.  
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Table 2: Control, WT, HET and KO genotype depending on Sm22α-Cre and CaSR-LoxP expression. 
++ = two positive alleles, +-, -+ = one positive allele, -- = no positive alleles. Green = WT, dark green = 
control, yellow = HET, red = KO 
  CaSR-LoxP 
  ++ +- -+ -- 
S
M
22
α-
C
re
 
++ 
++ 
++ KO 
+- 
++ HET 
-+ 
++ HET 
-- 
++ WT 
+- 
++ 
+- KO 
+- 
+- HET 
-+ 
+- HET 
-- 
+- WT 
-+ 
++ 
-+ KO 
+- 
-+ HET 
-+ 
-+ HET 
-- 
-+ WT 
-- 
++ 
-- WT 
+- 
-- WT 
-+ 
-- WT 
-- 
-- CTRL 
 
 
Since HET mice were not extensively used in this study, the breeding strategy employed 
focused on producing a maximum number of WT and KO animals only. KO x KO breedings 
and WT x KO breedings, both resulting in WT and KO offspring as well as WT x WT 
breedings, resulting in WT offspring only, were employed. 
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2.3 Genotyping of SM22α-Cre x loxP-CaSR mice 
Deoxyribo nucleic acid (DNA) was extracted from ear biopsies using DirectPCR® Ear DNA 
Extraction system (Viagen, Los Angeles, CA, USA) with proteinase K (Bioline, London, UK) 
by adding 100 µl “Direct PCR ® Ear + 4µl proteinase K 10 mg / ml per reaction to each 
biopsy and incubating overnight at 55 °C. Enzymatic digestion was then stopped by 
incubation at 85 °C for 45 min and samples were stored at -20 °C. 
Genotype was determined using the SM22α promoter and Cre coding region primers from 
(Holtwick et al. 2002) and the LoxP primers described in (Chang et al. 2008). See Table 3 for 
sequences and product sizes.  
 
Table 3: Primer sequences and expected product sizes (Holtwick et al. 2002; Chang et al. 2008) for 
genotyping of SM22α-Cre x LoxP-CaSR mice. 
Primer Sequence Product size 
SM22-Pro 5’-CAG ACA CCG AAG CTA CTC TCC TTC C-3’ 500 bp for Cre 
containing allele(s) 
no product for WT SM22-Cre 5’-CGC ATA ACC AGT GAA ACA GCA TTG C-3’ 
CaSR fl Up 5’-GTG ACG GAA AAC ATA CTG C-3’ 167 bp for floxed 
CaSR allele 
133 bp for WT allele CaSR fl Low 5’-CGA GTA CAG GCT TTG ATG C-3’ 
 
Polymerase chain reactions (PCRs) were performed in 200 µl individual nuclease free reaction tubes 
using deoxy-nucleotide triphosphates (dNTPs) and Biotaq® DNA Polymerase Kit (both Bioline). See 
Table 4 and Table 5 for the mastermix and thermocycler program for Sm22α-Cre and Table 7 for the 
mastermix and temperature protocol for CaSR-LoxP. 
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Table 4: Mastermix for SM22α-Cre PCR. 
Reagent 1x Reaction Concentration 
10X Buffer (Bioline) 2.500 µl  
BIOTaq DNA Polymerase 0.250 µl 2 U 
Sm22 Pro Primer 0.125 µl 100 nM 
Sm22 Cre Primer 0.125 µl 100 nM 
100 mM dNTPs (Bioline) 0.250 µl 1 mM 
50 mM MgCl2 2.000 µl 4 mM 
H2O 18.250 µl  
DNA sample 1.500 µl  
Reaction volume 25.000 µl  
 
Table 5: Thermocycler program for SM22α-Cre PCR. 
Step Cycles Time Temperature 
Initial denaturation 1  5 Min 95 °C 
Denaturation 
40 
30 Sec 95 °C 
Annealing 1 Min 50 °C 
Extension 2 Min 72 °C 
Final Extension 1  10 Min 72 °C 
Hold    4 °C 
 
Table 6: Mastermix for CaSR-LoxP PCR. 
Reagent 1x Reaction Concentration 
10X Buffer (Bioline) 2.500 µl  
BIOTaq DNA Polymerase 0.250 µl 2 U 
CaSR fl Up Primer 0.125 µl 100 nM 
CaSR fl Low Primer 0.125 µl 100 nM 
100 mM dNTPs (Bioline) 0.250 µl 1 mM 
50 mM MgCl2 2.000 µl 4 mM 
H2O 18.250 µl  
DNA sample 1.500 µl  
Reaction volume 25.000 µl  
 
Table 7: Thermocycler program for CaSR-LoxP PCR. 
Step Cycles Time Temperature 
Initial denaturation 1  5 Min 95 °C 
Denaturation 
40 
30 Sec 95 °C 
Annealing 1 Min 47 °C 
Extension 2 Min 72 °C 
Final Extension 1  10 Min 72 °C 
Hold    4 °C 
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2.4 In vitro assays 
2.4.1 Culture media 
2.4.1.1 Growth medium 
Dulbecco’s modified Eagle medium (DMEM) without CaCl2 (Life Technologies, Grand 
Island, NY, USA), supplemented with 1.2 mM CaCl2, 50 U / ml penicillin-streptomycin, 2 
mM L-glutamine, 10 % (v/v) foetal bovine serum (FBS), 1 mM Na-pyruvate and 1 % (v/v) 
amphotericin B solution (all Life Technologies). This medium is henceforth referred to as 
“growth medium”. 
 
2.4.1.2 VSMC culture medium 
Growth medium without amphotericin B. 
 
2.4.1.3 Supplemented media 
Ca2+ and inorganic phosphate (Pi) concentrations of media were adapted to experimental 
requirements by the addition of sterile 1M CaCl2 solution and inorganic 1M phosphate buffer 
(NaH2PO4 / Na2HPO4) pH 7.4. 
 
2.4.2 HEK-CaSR cells 
Frozen stocks of stably transfected CaSR overexpressing HEK 293 cells (HEK-CaSR cells) 
were available in house from a previous study (Maldonado-Perez et al. 2003) and were 
maintained by Dr. Sarah Brennan. HEK-CaSR cells were cultured in DMEM containing 1.8 
mM Ca2+ 50 U / ml penicillin-streptomycin, 2 mM L-glutamine, 10 % (v/v) FBS and 1 mM 
Na-pyruvate. 
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2.4.3 pH assays 
Growth medium containing 0.8, 1.2, 1.8 or 2.5 mM CaCl2 or 1, 2 or 3 mM Pi was titrated for 
Pi (phosphate buffer) or CaCl2 influence on medium pH. The medium was gassed with 5% 
CO2 in air to simulate conditions in a tissue culture incubator. After equilibration of the pH, Pi 
or CaCl2 were added to the media in 0.2 mM increments and the pH noted after equilibration. 
 
2.4.4 Primary VSMC culture from explants 
VSMC were prepared according to published procedure (Sage et al. 2011) with modifications. 
In brief, mice were killed by cervical dislocation and the thoracic aorta was dissected. Aortae 
of 2-5 mice of the same genotype were pooled for one cell batch and placed in growth 
medium and cleaned from the tunica adventitia and connective tissue. Segments of aorta ca. 1 
mm in length were transferred to a culture flask and, after 10 minutes of drying in a tissue 
culture incubator, covered with growth medium and incubated at 37 °C / 95 % relative 
humidity / 5 % CO2 until cells had grown out of the explants (ca. 2-4 weeks). The explants 
were the removed by aspiration and the cells were passaged using 0.05 % (v/v) trypsin-
ethylenediaminetetraacetic (EDTA) solution in sterile phosphate-buffered saline, pH 7.4 
(PBS) without calcium chloride and magnesium chloride (all Life Technologies). Beginning 
with this passage VSMC culture medium was used instead of growth medium. Medium was 
changed every 3-4 days; see Figure 9 for a photo series of the process. Cells were used at 
passages 2-6 for experiments. 
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Figure 9: Generation of explant-derived aortic VSMC. The thoracic aorta is dissected from the spine 
(A) and removed to a Petri dish filled with sterile isolation medium (B) where the vessel is cleared from 
all tunica adventitia by gently pulling / scraping the connective tissue (C and D) until only the semi-
translucent tunica media remains (E). The vessel is then cut into small (ca. 1 mm) pieces (F) which are 
then transferred into a T-25 cell culture flask by the use of a hypodermic needle (G). The flask is kept 
in an upright position at 37 °C for 10–15 minutes so that the explants are not in contact with medium 
and can attach firmly to the surface of the flask (H). 5 ml isolation medium is added and the explants 
are kept at 37 °C / 95 % relative humidity (rh) / 5 % CO2 for ca. 7 days after which the medium is 
changed. VSMC will start to grow out of the explants (I). After ca. 2-3 weeks, the explants are removed 
and the VSMC passaged to generate a monolayer of cells (J). Cells at this point are considered to be 
at passage 1. From this step onwards, the cells are kept in growth medium (see definition in 2.4.2). 
Pictures A, B, E and F kindly provided by Dr. Thomas Davies. 
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2.4.5 Acute isolation of VSMC 
VSMC from aortae were acutely isolated for immunostaining and calcium imaging following 
published protocol in (Moskalenko et al. 2010) by Dr. Polina Yarova. In brief, aortae were 
harvested and processed into 2 mm segments as described for the explant cultures, and the 
lumen was flushed with cold isolation medium. The segments were incubated in a 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.4 buffered solution containing 
1 mg / ml bovine serum albumin (BSA), 1 mg / ml papain, 1 mg / ml dithiothreitol, 2 mg / ml 
collagenase and 0.5 mg / ml soybean trypsin inhibitor at 37 °C for 30 minutes with stirring 
every 5-10 minutes. Following a quick wash in ice-cold HEPES pH 7.4 buffer, the segments 
were finally disaggregated into single cells in HEPES buffer pH 7.4 containing 1 mg / ml 
BSA by pipetting up and down. The supernatant then was centrifuged at 400 x g for 5 minutes 
and the cell pellet suspended in isolation medium for subsequent fixation and IF. 
 
2.4.6 Double immunostaining of VSMC and HEK-CaSR cells 
Cells were grown on sterilized glass coverslips of 13 mm diameter in 24 well plates as 
described in 2.4.2, 2.4.4 or 2.4.5. The culture medium was removed and the cells were fixed 
in 4 % (w/v) PFA in PBS for 15 minutes after which the cells were washed in 50 mM NH4Cl 
in PBS to quench free aldehyde groups remaining from the fixation step. Permeabilisation and 
blocking of unspecific antibody binding was performed in a single step by incubating the 
fixed cells using 0.05 % (v/v) Triton X 100 + 1 % (w/v) BSA in PBS for 60 minutes (blocking 
buffer). For staining of the CaSR, a rabbit-derived polyclonal antibody, raised against the N-
terminal domain of the human CaSR with 100% sequence homology with mouse was used 
(AnaSpec, 53286, Fremont, CA, USA). Staining of SM22α was performed using a goat 
derived polyclonal antibody (Abcam, AB10135, Cambridge, UK). Cells were incubated 
overnight at 4 °C with both primary antibodies. Negative controls were performed by 
omission of the primary antibodies or replacement with an isotype control of rabbit IgG 
(Abcam). After washing in PBS, primary antibody binding was visualized using appropriate 
Alexa Fluor 488 and Alexa Fluor 594 fluorescence-dye coupled secondary anti IgG antibodies 
in a dilution of 1:500 in blocking buffer. Nuclei were counterstained with Hoechst 34580. 
Coverslips with adhering cells were then mounted on standard glass slides using ProLong 
Gold® (all Life Technologies). 
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Slides were visualized using a Leica DMRB microscope (Leica Microsystems). 
Epifluorescence images of immunostained tissues and cells were analysed and photographed 
with an Olympus BX61 automated microscope equipped with a 100 W high pressure mercury 
lamp, using AnalySIS software (Olympus Microscopy, Essex, UK). Confocal images were 
acquired using a Leica TCS SP2 AOBS spectral confocal laser-scanning microscope using 
Leica Confocal Software (Leica Microsystems). For subsequent quantitative analysis, slides 
were imaged using an automated immunofluorescence slide scanner (see 2.4.8). 
Additional commercial anti-CaSR primary antibodies were tested on HEK-CaSR cells and 
kidney sections: rabbit derived polyclonal antibody against the C-terminal domain of the 
human CaSR with 100 % sequence homology with mouse (LifeSpan Biosciences, LS-
C117834, Seattle, WA, USA), mouse-derived polyclonal antibody against the synthetic full 
length protein of the CaSR (Novus Biologicals, H00000846-B01P, Cambridge, UK), mouse 
derived monoclonal antibody against the N-terminal domain (ADD epitope) of the human 
CaSR, clone 5C10 (Abcam, AB19347). Furthermore, two in house available custom 
antibodies were tested: a previously produced rabbit antiserum raised against the N-terminal 
domain (ADD epitope) of the CaSR, titled 733 as well as a rabbit polyclonal affinity purified 
antibody raised against the N-terminal domain (ADD epitope), titled Shob, kindly donated by 
D. Shoback, University of California San Francisco, San Francisco, CF, USA). 
 
2.4.7 Staining of apoptotic cells (TUNEL assay) 
Batches of VSMC grown from WT and KO aortae were stained for apoptosis using the 
terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) method. The 
staining was performed by Dr Thomas Davies as described in (Davies 2013). In brief, near 
confluent VSMC were cultured in the presence of 1.2, 1.8 or 2.5 mM Ca2+ and either 1 mM or 
3 mM Pi for 48 h after which they were fixed in 4 % (w/v) PFA in PBS. Apoptotic cells were 
labelled using terminal transferase with Biotin-16-dUTP (Roche Diagnostics, Burgess Hill, 
UK) as substrate which was stained using FITC-Avidin (Abcam). Nuclei were counterstained 
with Höchst 33258. VSMC were then stained for CaSR and SM22α expression as described 
(see above) with the SM22α primary antibody stained using a AlexaFluor 647 conjugated 
anti-goat IgG secondary antibody (Life Technologies) replacing the AlexaFluor 488 
conjugated antibody used in VSMC immunofluorescence staining experiments without 
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apoptosis staining. Quantitative immunofluorescence was used to quantify the percentage of 
apoptotic cells (see 2.4.8). 
 
2.4.8 Quantitative immunofluorescence 
Quantitative immunofluorescence microscopy (e.g. (Bogusz et al. 2012)) to evaluate CaSR 
expression as well as apoptosis and cell density was performed by scanning slides with 
VSMC stained for apoptosis or SM22α and CaSR using TissueFAXS® automated 
immunofluorescence microscopy hard- and software (TissueGnostics GmbH, Vienna, 
Austria) at the Institute for Pathophysiology and Allergy Research, General Hospital Vienna, 
Austria. Acquisition of the different slides were performed keeping the settings of exposure, 
contrast and camera gain exactly the same between the different slides, containing different 
batches of VSMC cells from either WT or KO mice. The acquired multispectral images 
(fields of view) were then fused into large images encompassing the total scanned region 
using an automated image stitching algorithm available in the TissueFAXS software. The 
obtained images of a whole region varied in size depending on the cell distribution on the 
individual coverslip, but generally consisted of 9x9 – 12x12 fields of view using a 40x 
objective. These regions were then analysed using TissueQuest® (TQ) software 
(TissueGnostics), yielding quantification of the expression levels of the different staining as 
well as percentages of cells positive or negative for the expression of a certain staining (e.g. 
positive for expression of SM22α) enabling the sorting of the analysed cells into different 
categories (e.g. VSMC and non-VSMC). The detailed analysis procedure was as follows: All 
images of one batch of slides were loaded into the same TissueQuest project file. Every single 
image was then scrutinized manually and regions of interest (ROI) were defined for each 
image. The ROIs define the area of the images the software will analyse in the subsequent 
steps. Generally, the ROIs were selected to equal the entirety of the acquired image area 
included in the analyses. However, areas of extremely high cell density or areas of the images 
containing artefacts like dust or air bubbles (enclosed in the mounting medium of the 
coverslip) were manually removed from the ROIs to prevent generation of false results. In 
addition to these large ROIs for subsequent analysis, a number of smaller ROIs were 
manually drawn to allow for optimization of detection and analysis parameter settings before 
the actual analysis of the series of images. The TissueQuest software uses nuclei to detect 
single cells. The nuclei are detected by use of automatic and manual background thresholding 
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where positive objects (= nuclei) are discriminated from the background of the image using 
the image channel (colour) for the nuclear staining (Höchst). Settings for optimal detection of 
these nuclei (expected nuclear area, background threshold etc.) were optimized using the 
aforementioned small ROIs. Optimization of these parameters is highly important as wrong 
settings can lead to completely wrong image segmentation and therefore cell detection. 
Examples of false and correct nuclear detection parameters are shown in Figure 10.  
 
 
Figure 10: Examples for incorrect and correct segmentation of nuclei for cell detection in quantitative 
immunofluorescence measurements. The images show the nuclear channel of multispectral images 
from VSMC stained with Höchst nuclear die for nuclei visualization. Green boundaries indicate 
detected nuclei by the TissueQuest software. In the first image from the left (Oversegmentation), a too 
low setting for background threshold resulted in the complete oversegmentation of the image, i.e. the 
false detection of too many nuclei in the image. In the second image from the left (Wrong border), the 
falsely detected small nuclei from the first image were removed by excluding nuclei below a certain 
area threshold. However, the too-low background threshold still resulted in wrongly shaped detection 
borders for the nuclei. In the third image (False negatives), the background threshold was set too high, 
resulting in undersegmentation and therefore false negatives. In the fourth image (Correct 
segmentation), the chosen parameters resulted in correct nuclear detection. Image contrast enhanced 
for better visualization. 
 
After settings were optimised to allow the best possible nuclear detection results, these setting 
were used to analyse all ROIs containing VSMC from WT and KO cells. Evaluation of 
expression levels (= staining intensities) in the channels other than the nuclear channel (i.e. 
green fluorescence and red fluorescence) was performed in a ring-shaped area around the 
detected nuclei (= ring mask, Figure 11) with a diameter of 8 µm for stained targets located in 
the cytosol and membrane of the VSMC (SM22α and CaSR) or in the area of the nuclei 
themselves for TUNEL stained cells (nuclear mask, Figure 12). 
Oversegmentation Wrong border False negatives Correct segmentation 
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Figure 11: Example of ring masks for quantification of SM22α and CaSR staining intensities. Mean 
and maximum pixel intensities are measured in the 8 µm measuring ring bordering the blue nuclei. 
Green borders indicate CaSR- cells, red borders indicate CaSR+ cells. Image contrast enhanced for 
better visualisation. 
 
 
Figure 12: Example of a nuclear mask for detection of apoptotic cells visualized using TUNEL staining. 
Nuclear staining (Höchst) is used to detect all nuclei (cells) in the image (left image). Nuclei which also 
stain positively in the TUNEL assay are being detected by the software (right image, red borders). Red 
arrows indicate apoptotic cells. 
 
During the analysis, mean and maximum pixel intensity values, (intensity resolution 8 bits, 
ranging from 0 to 255) for all detected cells are calculated. These values are then plotted by 
the software into scattergrams, allowing for gating of different populations of cells, similar to 
the analysis of flow cytometry data. Gates were then manually set to select only true positive 
detected cells (e.g. by removal of false positively detected nuclei, based on nuclear size). The 
mean intensity values for CaSR and SM22α were then gated to divide the detected cells into 
Nuclear staining TUNEL staining 
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four populations: CaSR+/SM22α+, CaSR+/SM22α-, CaSR-/SM22α+ and CaSR-/SM22α- 
(Figure 13).  
 
 
Figure 13: Example scattergram from TissueQuest® showing mean green fluorescence intensity 
(SM22α) on the x axis (GFP – Mean Intensity) and mean red fluorescence intensity (CaSR) on the y 
axis (Texa – Mean Intensity). Gates were being set by visual observation and being kept constant for 
all batches of cells resulting in four populations of cells: CaSR+/SM22α+ (upper right quadrant), 
CaSR+/SM22α- (upper left quadrant), CaSR-/SM22α+ (lower right quadrant) and CaSR-/SM22α- 
(lower left quadrant). 
 
To evaluate the different CaSR expression levels in VSMC isolated from WT and KO mice, 
the mean CaSR staining intensity values of only the VSMC in the total cell population 
(SM22α+ cells, thereby excluding all non-VSMC in the image) were normalised to their 
respective staining intensities for SM22α. This step was performed to allow comparison of the 
various analysed VSMC batches as absolute staining intensities varied between VSMC 
batches. CaSR expression is therefore reported as CaSR intensity / SM22α intensity for 
SM22α+ cells. To account for the different number of cells analysed in each image, the results 
were weighed with respect to the evaluated number of SM22α+ cells per batch (e.g. CaSR 
intensity from a ROI containing 100 cells would contribute 10 % to the total mean when 
pooled with a ROI containing 900 cells which contributes 90 %). Finally, the obtained values 
for relative CaSR expression of VSMC from KO mice was normalised to their respective WT 
controls from the same experiment (to allow comparability between the separately performed 
experiments which were stained, scanned and analysed at different dates). It has to be noted 
that the determination of the green fluorescence gate (SM22α) and therefore the decision from 
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which staining intensity onwards a cell qualifies as positive for SM22α had to be performed 
manually. However, since the same value for the green fluorescence gate was used for all 
investigated regions, comparisons between different batches of WT and KO cells are possible. 
Apoptotic cells (TUNEL+) are reported as % of VSMC (SM22α+) cells.  
 
2.4.9 VSMC numbers / proliferation 
Cells were seeded at 7,500 cells per cm² in a 12-well plate and allowed to adhere to the 
bottom of the plate for 24 h. The medium was then changed to growth medium containing 1 
% FBS for 24 h to synchronize cell cycles. Cells were then left in growth medium containing 
10 % FBS supplemented with various CaCl2 concentrations and then counted manually using 
a haemocytometer at the end of 5 and / or 10 days incubation. The medium was changed 
every 2-3 days. 
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2.5 Histomorphometry and immunofluorescence studies 
2.5.1 Organ fixation and sectioning 
Dissected organs were fixed by immersion fixation in 4 % (w/v) PFA in PBS for 4 hours and 
then washed in PBS and stored in 30 % (w/v) sucrose in PBS at 4 °C for cryoprotection. 
Tissues were embedded in optimal cutting temperature compound (TissueTek OCT, Sakura-
Finetek, Alphen aan den Rijn, NL) on dry ice and 8-10 µm sections were prepared using a 
cryo-microtome (Leica 2300L, Leica microsystems, Milton Keynes, UK).  
 
2.5.2 Immunofluorescence staining of tissues 
For immunofluorescence, sections were rehydrated in PBS followed by incubation for 10 
minutes in 50 mM NH4Cl in PBS and then were antigen retrieved in steaming hot 10 mM 
citrate buffer pH 6 for 15 minutes followed by 5 minutes in 1 % sodium dodecyl sulphate 
(SDS) in PBS. Non-specific antibody binding was prevented using 1 % (w/v) BSA + 0.1 % 
(v/v) Tween 20 in PBS (blocking buffer) for 1 hour. Immunostainings and microscopic 
imaging were then performed as already described for cells (2.4.6). 
For kidney sections, high autofluorescent background was quenched by incubation of the 
sections in 0.2 mM Sudan Black B in 70 % ethanol for 10 minutes in between the second 
secondary antibody and the nuclear counterstain (Sun et al. 2011).  
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2.6 Calcification assays 
2.6.1 In vitro VSMC calcification 
Cells were seeded in 24-well plates and were grown to 100 % confluency. The medium was 
then changed to growth medium supplemented with various CaCl2 concentrations as specified 
in the results section. For induction of calcification, beta-glycero-phosphate (BGP) ± alkaline 
phosphatase or inorganic Pi were added to the culture medium. Cells were left in culture for 
10 days at the end of which they were fixed for 15 minutes in 4 % (w/v) PFA at room 
temperature and the amount of calcification was visualized by staining with 2 % alizarin red S 
(w/v) in water, pH 4.2 (Puchtler et al. 1969).  
 
2.6.2 Staining for calcification on blood vessel sections 
Cryosections of 4% (w/v) PFA fixed WT and KO aortae were stained for calcifications using 
Alizarin Red S as described in 2.6.1. 
 
2.6.3 Ex vivo calcification of aortic explants 
The assay was performed as described previously (Leroux-Berger et al. 2011). In brief, aortae 
were dissected as described for the primary VSMC isolation (see 2.4.2). After cleaning of the 
aortae from the tunica adventitia, the endothelial layer was destroyed by stretching the tissue 
over the whole length. The vessel was then cut into 3-4 pieces of approximately equal length 
(5–8 mm). The pieces were then incubated for 5 days in growth medium (see 2.4.2) 
supplemented with varying of CaCl2 concentrations (1.2–2.5 mM) and 3 mM Pi, similarly to 
the VSMC calcification assays (see 2.6.1). After the incubation period, the explants were 
washed twice in PBS for 2 hours and deposited calcium was extracted by decalcifying the 
explants overnight in 0.6 N HCl at 37 °C. Eluted Ca2+ concentration in the supernatant was 
measured using the o-cresolphthalein complexone method (Moorehead and Biggs 1974; Jono 
et al. 1997). Ca2+ concentrations were normalised against the weight of the explants. Typical 
explant weights varied between 1.0 and 5.0 mg (measured on an analytical balance). 
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2.7 Cardiovascular analysis 
2.7.1 Blood pressure measurement by tail cuff 
Blood pressure of age- and sex-matched WT and KO mice were measured by tail cuff (Feng 
et al. 2008) using a 2-channel CODA system (Kent Scientific, Torrington, CT, USA) 
instruments and software, following the manufacturer’s instructions. Mice were accustomed 
with the procedure by being restrained in either the supplied CODA restrainers or self-made 
restraining devices made from 50 ml syringes (Figure 14). 
 
 
Figure 14: Mouse restrainers. Left: Restrainer made out of a 50 ml syringe. Middle: Large restrainer for 
mice up to 50 g. Right: Small restrainer for mice up to 25 g. 
 
During the restraint and the actual procedure, the mice were warmed using an infrared lamp 
and temperature was monitored using an infrared thermometer, which was also used to 
measure the paw temperature of scruffed mice. For the final measurements, 15 
acclimatization cycles of inflating and deflating of the cuff were granted to the animal to 
become accustomed to the sensation and to reduce struggling inside the restrainer. Blood 
pressure was then averaged from 10 successive measurement cycles and only measurements 
which were flagged as “OK” by the software were used for the averages. Measurements were 
performed in batches of age groups, alternating KO and WT mice. Measurements were 
performed over the course of two days at approximately the same time of day, either in the 
morning or during the night, to account for circadian variations in blood pressure (Li et al. 
1999).  
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2.7.2 Blood pressure measurement by radiotelemetry 
Blood pressure, heart rate and derived parameters (see Table 8) were measured by 
radiotelemetry (Boedtkjer et al. 2011) in collaboration with Professor Robert Fenton and Dr. 
Vladimir Matchkov (both Aarhus University, Denmark). HD-X11 radiotelemetry transmitters 
(Data Sciences International, USA) were implanted under general anaesthesia using a 
combination of fluanisone (10 mg / kg body weight), fentanyl (0.3 mg / kg body weight) and 
midazolam (1 mg / kg body weight). The transmitters were implanted in the aortic arch via the 
left carotid of 3 month old male animals (Figure 15) while the transmitter and power source 
were placed sub dermally in the abdominal region of the animal. Operations were performed 
by Dr. Vladimir Matchkov. 
 
 
Figure 15: Implantation of radiotelemetry probes. The probes were implanted in the left carotid artery 
of the anaesthetized mouse and pushed forward into the aortic arch. 
 
Mice were allowed to recover for 2 days before housing them in metabolic cages where they 
were kept on standard diet (see 2.2) for 4 days. Diet was then changed to a high salt diet (4% 
NaCl) for a period of 4 days. See chapter 2.8.1 for details on metabolic cage studies. For 
reasons of animal welfare, mice were then transferred back in normal housing cages and put 
back on standard diet. After a 3 days, drinking water of the mice was supplemented with 0.5 
mg / l L-nitro-arginine-methyl-ester (L-NAME) for 2 days. See Figure 16 for an overview of 
the timeline of the telemetry experiment.  
 
 
 
Carotid artery 
Sling used to 
fasten telemetry 
probe 
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Figure 16: Timeline of telemetry experiments. 
 
Telemetry signals from the probes were recorded for the whole duration of the experiment in 
intervals of 5 minutes in quintuplicates resulting in 60 measurements per hour. Parameters 
measured are given in Table 8. Raw data traces were generated with Ponemah analysis 
software 5.00 (Data Sciences International). Raw values were concentrated by combining all 
measurements for one hour. For smoothing of the traces, a rolling average (a new value is 
calculated for every hour based on the average of its adjacent hours) over 4 hours (data 
points) was applied (Figure 17) (Odenwald et al. 2006). Because of the different housing 
conditions, the standard diet vs. high salt diet and standard diet vs. 0.5 mg / l L-NAME diet 
phases were treated as two separate and incomparable experiments during analysis. 
 
Table 8: Parameters obtained from radiotelemetry. Abbr. = Abbreviation 
Parameter Abbr. Unit 
Systolic blood pressure Sys mm Hg 
Diastolic blood pressure Dia mm Hg 
Mean arterial blood pressure MAP mm Hg 
Heart Rate HR bpm 
Pulse height 
(pulse pressure) PH mm Hg 
positive 1st derivative of the 
pressure curve dp/dt mm Hg / ms 
 
 
Days 
Surgery 
Recovery 
Standard diet (1) 
4 % NaCl diet 
Standard diet (2) 
0.5 mg / l 
L-NAME 
Metabolic cages Standard cages 
Telemetry recorded 
-2 -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
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Raw
Rolling Average
over 4 values
 
Figure 17: Example for use of a rolling average over 4 adjacent values for curve smoothing. The 
averaged curve follows the general trend while eliminating the large scatter of the raw data. 
 
For statistical comparison of the different parameters between WT and KO mice, fixed three 
hour periods, one during the mice’s active period and one during their resting period, on the 
last day of a diet regimen (e.g. standard diet, high salt diet, L-NAME) were selected on the 
basis of the average MAP curve for all mice (Figure 18). For the calculations, the raw values 
(not smoothed by rolling average) were used. An additional, new method of analysis is 
described in appendix B, 12.2. 
The averaged values of the periods (specific three hour intervals which were the same for all 
mice) were averaged and compared using by two-way ANOVA for comparisons between WT 
and KO mice on different diets and individually during their active and resting period. 
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2.7.3 Cardiac magnetic resonance imaging (MRI) 
Cardiac cine-MRI scans were acquired using a Bruker Biospec 94/20 9.4 Tesla magnetic 
resonance imaging (MRI) system at the Experimental MRI centre (EMRIC) at Cardiff 
University. Details on the imaging system and preparation of the animals have been described 
previously (Kalogerou et al. 2011). In brief, the mice were anaesthetized using 1-5% (v/v) 
isoflurane in oxygen to achieve a breathing rate between 30-80 times per minute, as 
determined by pressure plate. Temperature of the animal was monitored by rectal probe and 
controlled by heated / cooled water tubing. 3-way electrocardiography (ECG) was applied. 
All measurements were performed using the Small Animal Monitor software and monitoring 
equipment (SA Instruments, Stony Brook, NY, USA). Bruker Paravision 5.0 was used to 
control the instrument. Details on cardiac analysis in rodents can be found in (Johnson 2008) 
and on cardiac cine-MRI specifically in (Schneider et al. 2006). Cardiac analysis in brief: the 
heart can be divided into two two-dimensional planes: The long axis, with the image plane 
going from the apex to the base of the heart, and the short axis which is oriented orthogonal to 
the long axis and therefore shows the diameter of the ventricles See Figure 19 for a graphical 
representation and example MRI images of the axes. 
 
 
Figure 19: Short and long axes of the heart. Left panel: graphical representation of the heart with a 
blue broken line indicating the long axis and a red broken line indicating the short axis (image public 
domain). Right panel: Example long and short axis MRI images. Broken orange arrows indicate 
anatomical features. LV = left ventricle, RV = right ventricle. 
 
To visualize the whole heart for analysis, it has to be analysed in all four dimensions. Multiple 
z-aligned 2D images of planes in the heart allow for a 3D reconstruction of the heart while 
Long axis Short axis Aortic arch 
Base 
Apex LV RV 
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timed frames for all slices allow the tracking of the hearts movements during the heartbeat, 
which results in a “movie” of the beating heart (cine-MRI). To achieve this, the scanning 
sequence for all scans was coupled to ECG trace: every 5 ms following the R-wave, one 
frame for the final movie of a particular z-slice was recorded until the next R-wave was 
reached (Figure 20). During respiration, scanning was stopped to avoid the introduction of 
artefacts due to chest-motion. 
 
 
Figure 20: ECG-gated cardiac MRI. Left panel: idealised representation of an ECG trace showing MRI 
scans (orange broken lines) synchronized to the R-wave (image public domain). Right panel: 
Exemplary ECG trace of a mouse during MRI scan, showing clearly detectable R-waves which are 
detected by the monitoring software. Waves are indicated by their representative letters. The period (R 
to R) of this particular trace was 164 ms equating to a heart rate of approximately 365 bpm.: Modified 
cropped screenshot from Snapview 2.00 (SA Instruments). 
 
Each mouse was scanned with a specific set of scans: One tri-axial pilot cine scan to 
determine the orientation of the heart followed by one long axis pilot cine scan with three 
slices depth to determine the geometry setup for the short axis scans. A high quality long axis 
scan with the image plane approximately going through the centre of the heart (for 
visualization and length measurement purposes) was then followed by eight high quality short 
axis scans ranging from above the base (ca. at the top of the aortic arch) to below the apex of 
the heart (so that the left ventricular cavity was no longer visible) for cardiac analysis. The 
mice were positioned and aligned and the scans performed by Mr Andrew Stewart, technician 
at the Cardiff EMRIC. The scanning sequence was programmed and optimized by Dr Pawel 
Tokarczuk, at Cardiff EMRIC. The completed scan cycle was then exported from the Bruker 
proprietary file format into files of the Digital Imaging and Communications in Medicine 
(DICOM) open standard and analysed using the academic version of Segment 1.9 (Medviso, 
Lund, Sweden). To exclude bias during the manual segmentation process, all DICOM files 
50 ms 
500 mV P 
Q 
R 
S 
T P 
Q 
R 
S 
T 
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were blinded by a third person prior to analysis (Dr. Isabella Ellinger, Medical University of 
Vienna, Austria). 
The analysis was performed in a combined manual-automatic way. Left ventricular epicard 
and endocard of all slices and timeframes were manually marked up using the respective epi- 
and endo-cardium tools of Segment. This resulted in about 240 markups (average 20 frames x 
6 slices with visible endocardium x 2 for epicardium and endocardium) per mouse. To 
preserve epicard continuity between the markups of the different slices and timeframes, the 
following procedure was observed (Figure 21): markups for endo- as well as epicard of the 
first timeframe of the most apical slice were drawn freehand. Both contours were then 
automatically refined using the respective software tool. These markups were then propagated 
one frame forward in time and adjusted manually or refined by the respective software tool. 
After finishing marking up the slice for all timeframes, the markups were propagated upward 
to the next slice in basal direction, where the manual and automatic refinement of the contours 
started anew at the first timeframe. Papillary muscles were excluded from the contour, i.e. 
they were included in the left ventricular volume. To avoid errors based on bias or experience, 
a re-iterative approach was chosen for the manual analysis. After all markups were complete 
and passed visual inspection, systole (= minimum LV volume) and diastole (= maximum LV 
volume) were auto-detected by the program using the respective tool. Right ventricle was 
marked up at the timeframes for systole and diastole as calculated by the LV markup and 
analysed in the same fashion. High quality long axis scans were used to measure heart length 
and diameter using the “ruler” tool in segment. All measured and calculated parameters are 
listed in Table 9. 
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Figure 21: Workflow of the manual MRI analysis. Full arrows indicate normal workflow from first to last 
step. Broken arrows indicate iterations and re-evaluations. All samples were blinded to avoid bias 
during the segmentation process. 
 
  
Manual epi- and 
endocardium 
segmentation of first 
timeframe 
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segmentation by one 
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timeframe 
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segmentation of 
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segmentation to the 
next slice 
All slices segmented 
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segmentation with 
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Table 9: Parameters obtained from cardiac cine MRI analysis. Abbr. = Abbreviation, LV = Left 
ventricle/ventricular, RV = Right ventricle/ventricular. 
Parameter Abbr. Calculation Notes 
Total body weight TBW   
LV-Mass LVM  
Volume of epicard as 
determined by markup. 
Density of heart tissue ~ 
1.05 g / ml 
LV-End diastolic volume LV-EDV   
LV-End systolic volume LV-ESV   
LV Stroke volume LV-SV LV-EDV - LV-ESV  
LV Ejection fraction LV-EF (SV/EDV) * 100  
Cardiac output CO LV-EF * heart rate 
Heart rate measurements 
not comparable because of 
general anaesthesia. Not 
used for analyses. 
LV Peak ejection rate LV-PER   
LV-Peak fill rate LF-PFR   
Diastolic remodelling 
index DRI LVM / LV-EDV  
Systolic remodelling index SRI LVM / LV-ESV  
End systolic length ESL  Measured from long axis 
End diastolic length EDL  Measured from long axis 
End systolic diameter ESD  Measured from long axis 
End diastolic diameter EDD  Measured from long axis 
LV average wall thickness LV-WT  Average of second and third apical slices 
RV end-diastolic volume RV-EDV   
RV end-systolic volume RV-ESV   
RV stroke volume RV-SV RV-EDV - RV-ESV  
RV ejection fraction RV-EF (RV-SV / RV-EDV) * 100  
 
  
59 
 
2.8 Metabolism, clinical chemistry and bone 
2.8.1 Metabolic cage studies 
Mice were weighed and transferred to metabolic cages (Tecniplast, Buguggiate, IT) and then 
left for 48 hours to allow them to acclimatize to the new environment. Over the course of the 
following 24 hours, food and water intake, as well as faeces and urine production, were 
measured gravimetrically.  
Additional metabolic cage studies were performed in collaboration with Professor Robert 
Fenton and Dr. Vladimir Matchkov (Aarhus University, Denmark). In these studies, mouse 
weight, food and water intake, as well as faeces and urine production were recorded over a 
period of 8 days where the mice were fed standard diet (see 2.2) for 4 days followed by a high 
salt diet (standard diet supplemented with 4 % w/w NaCl) for an additional 4 days. 
Urine and faeces of all metabolic cage studies were stored at -80 °C for further analysis.  
 
2.8.2 Clinical chemistry 
Post-mortem blood collection from animals after neck dislocation was performed by quickly 
opening of the chest cavity and drawing blood directly from the heart using a 26 G needle. 
For serum collection, the blood was transferred into uncoated sterile tubes, for plasma 
collection, the blood was transferred into EDTA-coated collection tubes (BD Biosciences, 
Oxford, UK) and mixed by manual shaking. Blood was then left standing at room temperature 
for 30 minutes. The blood was centrifuged at 2,000 x g for 10 minutes and the supernatant 
transferred to a fresh tube and stored at -80 °C. 
Blood collection from live animals was performed via tail nick, as described in (Sadler and 
Bailey 2013). In brief, animals were restrained as described in 2.7.1.The tail of the mouse was 
then cut at the position of one of the tail veins perpendicularly about 2 cm from the tip and 
about 0.5 mm deep using a razor blade. Blood was then collected in capillary haematocrit 
tubes coated with either Potassium-EDTA or sodium-heparin for plasma and uncoated 
haematocrit capillary tubes for serum. The collected blood was transferred to sterile un-treated 
tubes and left standing at RT for 30 minutes. The blood was then centrifuged at 2,000 x g for 
10 minutes and the supernatant transferred to a fresh tube and stored at -80 °C. 
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Concentrations of electrolytes Na+, K+, Mg2+, Ca2+, Cl-, and FGF 23 in serum as well as Na+, 
K+, Mg2+, Ca2+, Cl-, Pi and Urea in urine were analysed by Mr Joao Graca and Dr Sally Price 
(Astra Zeneca, Macclesfield, UK) using a Roche modular P analyser (Roche diagnostics, and 
a commercially available ELISA kit for FGF 23 (Kainos Laboratories, Tokyo, Japan). 
Concentration of 1–84 PTH of plasma samples was analysed by Dr Donald Ward (University 
of Manchester, UK) using a commercially available ELISA kit (Immunotopics, San 
Clemente, USA). Concentration of 1,25-OH-Vitamin D3 (1,25-D3) of plasma samples were 
measured by Prof. Wenhan Chang (UCSF, CA, USA). Commercially available assays were 
used to measure concentrations of renin, aldosterone (both Abcam) and Fetuin A (R&D 
Systems, Abingdon, UK) according to the manufacturers’ instructions. Clinical chemistry 
analyses of plasma and urine samples collected post-mortem in the course of the metabolic 
cage studies (see 2.8.1) were performed by a commercially available clinical pathology 
service (MRC Harwell, Oxford, UK). 
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2.8.3 Bone morphology 
Femura of mice were analysed by micro X-Ray computed tomography (µCT) analysis by Dr 
Wenhan Chang, UCSF, USA (Chang et al. 2008). Measured parameters are listed in Table 10. 
Table 10: Bone structure parameters measured by µCT (performed by Dr W. Chan, UCSF, USA). 
Abbr. = Abbreviation 
Parameter Abbr. Calculation 
Distal Femur  
(trabecular bone)   
Total volume Tb.TV  
Bone volume Tb.BV  
Bone volume fraction Tb.BV/TV Tb.BV / Tb.TV 
Connectivity density Tb.CD  
Structure model index  
(Measure of trabecular shape) Tb.SMI  
Number of trabeculae Tb.N  
Trabecular thickness Tb.Th  
Intratrabecular space Tb.Sp  
Bone Mineral Density Tb.BMD  
   
Tibio-fibular junction 
(cortical bone)   
Total volume Ct.TV  
Bone volume Ct.BV  
Bone volume fraction Ct.BV/TV Ct.BV / Ct.TV 
Bone mineral density Ct.BMD  
Cortical thickness Ct.Th  
 
 
2.9 Statistical analysis 
Data were organised using Microsoft Excel 2010 (Microsoft, Redmond, WA, USA). All 
statistics were performed using GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). 
GraphPad Prism 5 does not report exact p-values for ANOVA post-tests. Where these tests 
were used, approximations (> 0.05, < 0.05, < 0.01, and < 0.001) are listed in the respective 
results tables. Statistical sample size is reported as N (number of separate experiments / 
biological repeats) over n (technical repeats per sample, where applicable). The employed 
statistical tests and significance levels are specified in the respective results sections or in the 
figure legends. 
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3 Method development and optimisation 
3.1 Introduction 
Before the experiments to characterise the SM22α-Cre x LoxP-CaSR mouse could 
commence, various protocols and assays had to be optimized. As loss of CaSR expression is 
accompanied by increased mineralization in bovine VSMC and human arteries (Alam et al. 
2009), the ability of WT and KO derived VSMC to mineralize in vitro was to be investigated. 
Because of substantial discrepancy in the literature, e.g. (Son et al. 2006; Wang et al. 2007; 
Alam et al. 2009; Panizo et al. 2009; Prosdocimo et al. 2010; Sage et al. 2011; Villa-Bellosta 
and Sorribas 2011; Zhu et al. 2011; Ciceri et al. 2012a) in protocols for induction of 
calcification of VSMC, initial experiments to find the best conditions for calcification of 
murine VSMC had to be conducted using VSMC from control mice. 
The potency of the CaSR is influenced by extracellular pH (Quinn et al. 2004) (Figure 23). 
Therefore, the influence of the used medium additives (namely different concentrations of 
Ca2+ and Pi) on medium pH had to be investigated in control experiments to ensure that 
potential observed Ca2+ mediated effects are ligand mediated and not the result of a change in 
pH, which ultimately would affect CaSR EC50 values for Ca2+. To my knowledge, this is the 
first time that the effects of possible pH changes in culture medium effected by experimental 
conditions is investigated when studying CaSR-mediated responses. 
 
 
Figure 22: Influence of external pH on EC50 for CaSR activation by Ca2+ and Mg2+ (Quinn et al. 2004). 
Image used with permission of The American Society for Biochemistry and Molecular Biology. 
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For investigation of CaSR expression in tissues and VSMC preparations, it is important to use 
a well characterised antibody. One of the best characterised antibodies for the CaSR is a 
mouse monoclonal antibody, clone 5C10, directed against an antigenic region in the amino-
terminus of the CaSR (residue 215-235, termed “ADD”). This antibody recognizes the non-
glycosylated (120 kDa), high-mannose (130-140 kDa) and fully glycosylated forms (150-160 
kDa) of the CaSR as well as dimers and oligomers (250–300 kDa) of the receptor in western 
blot analysis (Weston et al. 2005; Alam et al. 2009; Magno et al. 2011) and is also widely 
used in immunohistochemical analyses (Weston et al. 2005; Alam et al. 2009). However, 
since the host species of this particular antibody is mouse, it is not ideally indicated for use on 
mouse tissue or cells as required in this study. Other in-house available antibodies as well as 
other available commercial antibodies were therefore compared to the “ADD” antibody using 
HEK cells stably transfected to express the (human) CaSR (Maldonado-Perez et al. 2003). 
Frozen sectioned murine kidney tissue, which acts as a positive control for CaSR expression 
and which in the course of the holistic characterisation approach of the SM22α-Cre x LoxP-
CaSR mouse will be widely used for immunohistochemistry studies, is especially known for 
high autofluorescence (Viegas et al. 2007; Sun et al. 2011). Therefore, this tissue was widely 
used for optimisation protocols for antibody staining and specific autofluorescence quenching. 
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3.2 Results 
3.2.1 Influence of addition of different concentrations of Ca2+ and 
Pi on the pH of the culture medium 
pH is known to modulate CaSR affinity for Ca2+o with alkalinisation enhancing it while 
acidification inhibiting it (Quinn et al. 2004). As an initial control for my experiments, the 
impact of the experimental additives Ca2+ and Pi on medium pH was tested to ensure 
observed functional changes in in vitro assays are the result of changes in ion concentration 
and not a shift in medium pH, which would ultimately influence CaSR affinity for its 
agonists. Addition of Pi did not change medium pH in the range of the used Pi concentrations 
(1–3 mM Pi). Addition of CaCl2 decreased medium pH by approximately -0.1 over the range 
of the investigated conditions (0.8–2.5 mM CaCl2) (Figure 23). Since the shift of CaSR EC50 
for Ca2+ caused by a pH shift of -0.1 would be expected to be in the micromolar range (Quinn 
et al. 2004) (c.f. Figure 22), the effect of addition of Ca2+ (in the form of a 1M solution of 
CaCl2) and / or Pi (in the form of a 1 M phosphate buffer pH 7.4, composed of NaH2PO4 and 
Na2HPO4) on medium pH was considered small. 
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Figure 23: Influence of addition of different concentration of Pi (phosphate buffer pH 7.4, composed of 
NaH2PO4 and Na2HPO4) or CaCl2 on medium pH. Growth medium was bubbled with a mixture of 5 % 
CO2 in air. The figure shows that pH did not drop below pH 7.6 irrespective of equilibration time. Grey 
areas indicate concentrations used in this study (0.8–2.5 mM CaCl2, 1–3 mM Pi). Increasing CaCl2 
concentrations lead to a small drop in medium pH in the concentrations used in this study (A). 
Increasing Pi concentrations did not influence pH in the concentration range used in this study but a 
definite drop in medium pH was observed between the lower (0.8 and 1.2 mM) and higher (1.8 and 2.5 
mM) CaCl2 concentrations (B) as expected from the results in (A). N = 1 
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3.2.2 In vitro VSMC calcification protocol development 
Initial mineralization assays were carried out using BGP as a phosphate source for the 
mineralization process, as described previously (Alam et al. 2009; Panizo et al. 2009; Zhu et 
al. 2011). However, in our study, calcification could not be observed either in the presence of 
5 mM BGP after 6 weeks of incubation (data not shown) or with 10 mM BGP after an 
incubation period of 2 weeks (albeit moderate calcification was observed after 4 weeks) 
(Figure 24, left panels). It is possible that these negative results were caused by a lower 
endogenous alkaline phosphatase (ALP) activity (A. Sage, University of California Los 
Angeles, CA, USA, personal communication) in murine VSMC in contrast to bovine or 
human derived VSMC. Experiments carried out with medium supplemented with 6 U / ml 
ALP resulted in abundant calcification of all VSMC regardless of extracellular Ca2+ 
concentration (Figure 24, middle panels). Finally, a Pi buffer (pH 7.4, composed of NaH2PO4 
and Na2HPO4), as described in (Sage et al. 2011), was used and resulted in time- , Ca2+- and 
Pi-dependent calcification of murine VSMC (Figure 24, right panels).  
 
 
Figure 24: Optimization of in vitro mouse primary VSMC calcification assay. Alizarin red S staining of 
confluent VSMC derived from aortic explants from control mice. In the presence of medium containing 
2.5 mM Ca2+, treatment with 10 mM β-glycerol phosphate (BGP) did not induce calcification in cells 
cultured for two weeks and induced only moderate calcification after four weeks. 6 U alkaline 
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phosphatase (ALP) / ml medium + 5 mM BGP resulted in weak calcification after two weeks in culture 
and high levels of calcification after four weeks irrespective of Ca2+ concentrations in the culture 
medium. Addition of 3 mM phosphate to the culture medium, supplied as Pi buffer pH 7.4 (Pi), resulted 
in moderate calcification after two weeks in the presence of medium containing either 1.8 or 2.5 mM 
Ca2+. Treatment for 4 continuous weeks resulted in mild calcification in the presence of 1.2 mM Ca2+ 
and high levels of calcification in the presence of 1.8 and 2.5 mM Ca2+. Because of the concentration 
and time dependant calcification response to Pi, this phosphate source was chosen as additive for 
subsequent calcification experiments. 
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3.2.3 Immunofluorescence staining optimisation 
3.2.3.1 Anti-CaSR antibody comparison in HEK293 cells stably transfected with 
the human CaSR (HEK-CaSR)  
The ability of several commercially and non-commercially available antibodies to perform 
against a “gold-standard” commercially available 5C10 antibody (Abcam ADD, which detects 
amino acid 214-230 of the human CaSR) was tested in immunofluorescence double staining 
experiments on stably transfected HEK-CaSR cells (Maldonado-Perez et al. 2003). Two in-
house available custom antibodies from previous studies, “733”, provided by Prof. Daniela 
Riccardi (Cardiff University) and “Shob”, kindly provided to us by Dr Dolores Shoback 
(UCSF, USA) and two commercially available rabbit polyclonal antibodies, as well as a 
mouse polyclonal antibody raised against the synthetic human full length protein were tested 
in comparison. Figure 25 shows that both the Shob and the AnaSpec antibodies gave results 
comparable to the Abcam ADD antibody. The 733 antibody produced no staining while the 
LifeSpan C-terminal directed antibody stained exclusively the nucleus (Figure 25). The 
antibodies were also tested for specificity and comparability in western blot analysis of CaSR-
HEK cell lysates and the AnaSpec antibody produced comparable results as the 5C10 
antibody (S. Brennan, personal communication). See Table 11 for a list of the tested 
antibodies. 
Thus, given that the commercial AnaSpec antibody is readily available and detects CaSR 
immunoreactivity of the predicted size in HEK-CaSR cells, it was chosen as antibody for 
future CaSR detection and immunolocalization studies in cells and tissue. 
 
Table 11: List of tested anti-CaSR antibodies. N-term = N-terminal, C-term = C-terminal, N/D = not 
disclosed 
Antibody Supplier Type Source Antigenic region 
ADD Abcam Monoclonal IgG Mouse N-term 214-235 
Anaspec Anaspec Polyclonal IgG Rabbit N-term, N/D 
Lifespan C-term Lifespan Polyclonal IgG Rabbit C-term aa 854-903 
733 In house Polyclonal IgG Rabbit N-term 214-235 
Shob In house Polyclonal IgG Rabbit N-term 214-235 
Full Length Novus Biologicals Polyclonal IgG Mouse 1 – 1078 aa 
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Figure 25: Test of anti CaSR antibodies on HEK293 cells stably transfected with human CaSR (HEK-
CaSR). Confocal images of PFA fixed HEK-CaSR cells shown with (row 1) or without (rows 2 and 3) 
overlay of all channels and Hoechst 34580 nuclear counterstaining, shown on its own in (row 4). Cells 
were double stained with the reference mouse monoclonal anti-CaSR antibody, clone 5C10 (Abcam 
ADD) and one out of four rabbit polyclonal anti-CaSR antibodies. Of the two tested commercial 
antibodies, the AnaSpec antibody, which is directed against the N-terminal domain of the CaSR 
showed a very similar staining pattern (A2) as the Abcam ADD staining (A3), although the latter 
produced more pronounced nuclear staining. The LifeSpan antibody, directed against the C-terminal 
domain, directed produced exclusive nuclear staining (B2) which was in stark contrast to the ADD 
staining pattern (B3). The 733 antibody, which was produced in house for a previous study, failed to 
produce any staining (C2) while the Shob antibody, donated by D. Shoback (University of California 
San Francisco, San Francisco, CA, USA) produced similar staining results (D2) as the Abcam ADD 
(D3) antibody. A mouse polyclonal antibody, raised against the synthetic full-length peptide of the 
CaSR, produced staining of similar appearance (E) to the previously observed Abcam ADD stainings. 
Negative controls, shown as overlay of all channels and Hoechst 34580 nuclear staining, included 
goat anti mouse (F) or goat anti rabbit (G) secondary antibodies and no primary antibodies and 
showed no staining. N/A: not available (only single stainings were performed using this antibody). 
Scale bars represent 30 µm. 
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3.2.3.2 Optimization of immunofluorescence kidney stainings 
The different antibodies were tested on kidney tissue by immunostaining. However, this 
approach proved difficult because of very high background autofluorescence of the tissue,. 
Common quenching methods, which included the use of NH4Cl and glycine incubation, 
proved ineffective, as only signals from pecam-1 or sm22α positive tissue, but no CaSR 
staining were detectable (Figure 26).  
 
Figure 26: Antibody staining trial on control kidney sections. Four different rabbit polyclonal antibodies 
against the CaSR were tested for their ability to detect CaSR expression in PFA-fixed murine 
cryosections from kidneys of two C57/Bl6 animals (K1 and K2). Pictures show a renal blood vessel 
(BV), the medulla and the cortex of the kidneys as overlay of the antibody’s respective channel (red) 
with Hoechst 34580 nuclear counterstain. The column “green AF” shows pictures of the 
autofluorescence present in the tissue at 488 nM emission wavelength. The commercially available 
(Anaspec and LifeSpan) C-terminal, the in house 733 and Shob antibodies were tested. As a control 
for the staining procedure, the endothelium- and VSMC-specific markers pecam-1 and sm22α were 
used, respectively. The latter two stainings worked in both kidneys, while no staining for the CaSR 
was observed regardless of the antibody used. Autofluorescence of the tissue was very high in both 
488 and 594 channels and especially prominent in the cortex of the kidneys. N/A: not available due to 
tissue loss. Scale bar = 100 µm in all pictures. 
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To overcome this problem, a protocol using Sudan Black B, as described in (Sun et al. 2011), 
was developed and optimized to quench autofluorescence effectively in all channels (Figure 
27), although at the cost of lower contrast due to reduced black-levels in the embedding 
medium, but with a marked increase in staining visibility, as demonstrated by CaSR staining 
on cryosections of the same mouse kidney once non-quenched and Sudan Black B quenched 
respectively. In the non-quenched section specific staining was very hardly distinguishable 
from autofluorescence (negative control by omission of primary antibody) while specific, 
high contrast staining was observed when the section was quenched using Sudan Black B 
with background fluorescence almost reduced to zero (Figure 28).  
Immunostainings and investigation of the kidneys of WT and KO mice will be performed in 
the future. 
 
 
Figure 27: Quenching of high autofluorescence in the kidney using Sudan Black B. Epifluorescence 
images of PFA fixed 8 µm cryosections of mouse kidney tissue without staining. Without quenching 
(top row) no background was visible in the blue channel, but very high autofluorescence remained in 
both the green and red channels. Autofluorescence quenching with 0.2 % Sudan Black B in 70 % 
ethanol (bottom row) reduced background fluorescence significantly in all channels. Scale bars = 100 
µm 
. 
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Figure 28: Effect of autofluorescence quenching using 0.2 % Sudan Black B in 70 % ethanol on PFA 
fixed 8 µm cryosections of mouse kidney stained for the CaSR. All images were acquired using the 
same exposure. Negatives (no primary antibody) in top right corners. Scale bars = 100 µm 
 
  
 
Sudan Black No quenching 
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3.3 Discussion 
In this chapter I optimized and developed protocols which were I then used during my PhD 
(influence of pH on culture conditions, calcification conditions, determination of CaSR 
antibodies for VSMC stainings) and future use (immunofluorescence staining protocol for 
kidney sections).  
In addition to Ca2+, a variety of Pi sources were investigated as potential mineralisation 
inducers. Pi was selected as phosphate source for the experiments. I determined that in the 
presence of various Ca2+ concentrations, the best phosphate source for an in vitro calcification 
assay of murine cultured VSMC is free ionised Pi in the form of a Na2HPO3 / NaH2PO3 
buffer. Even though higher Pi concentrations have been used in other studies (Prosdocimo et 
al. 2010; Leroux-Berger et al. 2011), I chose to use concentrations of 1.4, 2.0 and 3.0 mM Pi 
to mimic control normo-, and hyper-phosphataemic conditions in which calcification of 
VSMC has been demonstrated to occur (Villa-Bellosta and Sorribas 2011). I also determined 
that this Ca2+ and Pi supplementation of the culture medium does not influence medium pH 
sufficiently to induce changes in CaSR EC50 for Ca2+. Furthermore, an anti-CaSR antibody 
was selected for immunostainings and an immunofluorescence protocol was developed which 
allows high-contrast staining and suppression of the endogenous autofluorescence in murine 
kidney tissue. This method will be used in the future (not in the course of this thesis) to 
investigate the renal phenotype of the SM22α-Cre x LoxP-CaSR mouse.  
 
3.4 Conclusions 
• Optimal experimental protocols were developed for in vitro murine VSCM 
calcification. 
• Addition of Pi and Ca2+ to culture medium of murine VSMC in vitro does not 
significantly alter medium pH, ruling out an effect of pH on CaSR function. 
• The best possible antibody was selected for immune-staining of the CaSR. 
• Immunofluorescence staining protocols for murine kidney sections were optimized. 
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4 General phenotype of the CaSR-LoxP x SM22α-
Cre mouse 
4.1 Introduction 
The very first step towards investigating the phenotype of the SM22α-Cre x LoxP-CaSR 
mouse was to establish a method for accurate determination of the mice’s genotype. Tissue 
specificity of the SM22α-Cre promoter had been demonstrated previously (Moessler et al. 
1996; Holtwick et al. 2002). Within this project, it was investigated if the mice showed any 
obvious differences in behaviour, reproductive capabilities, lifespan or body weights to 
explore any immediate effects of deleting the CaSR from the vasculature. Due to the large 
animal numbers used during this project overall, this part of the work was performed in 
collaboration with Dr Thomas Davies, see also (Davies 2013). Finally, expression of the 
CaSR in murine blood vessels was confirmed in this chapter. 
 
 
75 
 
4.2 Results 
4.2.1 Genotyping and cursory phenotypic differences 
Genotyping of the mice performed on ear biopsies showed expression of SM22α driven Cre 
expression as well as floxed CaSR alleles in wild-type (WT), heterozygous (HET) and knock-
out (KO) mice as expected (Figure 29).  
 
 
Figure 29: Exemplary genotyping results from mice of genotypes used in this study. Following PCR 
amplification, samples were electrophoretic separated using a 15 % (v/v) acrylamide gel for LoxP-
CaSR and a 2 % (w/v) agarose gel for Cre, Upper panels: a 167 bp band is expected for a floxed 
CaSR allele and a 133 bp band for the WT allele. Lower panels: presence of the sm22α-Cre construct 
is shown by a 500 bp band. Mice expressing two floxed CaSR alleles (LoxP-CaSR+/+) but no Cre-
recombinase (Cre-) are defined as WT (left panel, WT), mice expressing one floxed CaSR allele 
(LoxP-CaSR+/-), one WT-CaSR allele and Cre-recombinase (Cre+) are defined as HET (middle panel, 
HET), mice expressing two floxed CaSR alleles and Cre-recombinase (Cre+) are defined as KO (right 
panel, KO). Bands are shown for illustrative purposes and do not correspond to particular mice used in 
this study. Image contrast has been enhanced for better visibility. 
 
In terms of overall appearance, no phenotypic differences could be found between wild type 
(WT), heterozygous (HET) and KO genotypes (Figure 30) as mice of all three genotypes 
appeared healthy, well groomed, alert and inquisitive and lived out normal lifespans, at least 
beyond 18 months (see also Figure 31), but also beyond 24 months by observation. 
 
133 bp CaSR 
167 bp CaSR-LoxP 
500 bp SM22α-Cre 
WT HET KO 
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Figure 30: Photographs of exemplary WT, HET and KO mice. Image modified after (Davies 2013). 
 
4.2.2 Body weight 
Body weights of the mice over time showed a significant difference only for female mice 1 
month after birth, with a mean weight of 14.87 g ± 0.40 (N = 35) for WT and 12.27 g ± 0.75 
(N = 21) for KO animals (p < 0.01, mean ± SEM, two-way analysis of variance (ANOVA), 
Bonferroni post-test) but this difference was lost as the mice grew older (Figure 31). No 
difference was seen in WT and KO male mice up to 18 months of age. All values for the 
weights are reported in Appendix A, Table 14. 
 
WT HET KO 
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Figure 31: Body weight of male and female WT, HET and KO mice over the course of 18 (male) or 6 
(female) months of age. A significant difference was observed between one month old female mice 
WT and KO. N = 3–65 (details in ), mean ± SEM. ** P < 0.01 vs. WT, Two-way ANOVA with 
Bonferroni post-test. 1–6 month by Dr. Thomas Davies (Davies 2013), 12 and 18 month data by MS. 
 
4.2.3 Reproductive capabilities 
Reproductive capability of WT, HET and KO mice was comparable and did not show any 
significant differences (Figure 32). See (Davies 2013) for detailed analysis of Mendelian 
ratios and breeding ratios. 
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Figure 32: Reproductive capabilities of WT, KO and HET mice. Litter sizes were comparable 
irrespectively of the genetic background of the parents. N = 7-9 litters, mean + SEM, ANOVA. Data 
collected by Dr Thomas Davies (Davies 2013). 
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4.2.4 Expression of the CaSR in the vasculature 
In a pilot study on a mesenteric artery of a control (C57/Bl6) mouse, CaSR expression was 
found in all three layers of the blood vessel by immunofluorescence staining, as shown by co-
localisation of CaSR immunoreactivity with pecam-1 (endothelial marker, which showed the 
strongest signal), SM22α (VSMC) and cells of the tunica adventitia (Figure 33). These results 
are consistent with previous publications in mouse/rat/human (Bukoski et al. 1997; Weston et 
al. 2005; Molostvov et al. 2007; Loot et al. 2013). 
Trial immunostaining for CaSR on sections of WT and KO aortae showed only a very weak 
signal in the tunica media, consisting of SM22α+ VSMC, while high levels of staining for the 
CaSR was observed in the tunica intima, i.e. the pecam-1 positive endothelium of the blood 
vessels. The observed background in the negative controls was, however, very high, which 
could have accounted for the weak CaSR staining in the VSMC (Figure 34). Several 
optimisation protocols were tested to improve upon CaSR detection in mouse aortae and 
mesenteric arteries from WT and KO animals, but did not yield better results (not shown). 
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Figure 33: Immunolocalization of the CaSR, pecam-1 and SM22α in transverse sections of mesenteric 
arteries from control mice. Epifluorescence images (A and C-E) and confocal images (B) from the area 
marked by the squares in (A) of PFS fixed 7 µm cryosections. Staining for CaSR (red) with (A1 and 
B1) and without (A2 and B2) overlay of Hoechst 34580 counterstaining for nuclei (blue) and elastin 
autofluorescence (green). Expression of the CaSR was observed in the endothelial layer as well as in 
some smooth muscle cells. Staining for endothelial marker pecam-1 (red) in a consecutive section of 
the same mesenteric artery shown with (C1) and without (C2) Hoechst 34580 and elastin overlay 
demonstrates that the endothelium is intact throughout the vessel ring and localized in the same 
region of the tissue as the observed CaSR staining. Staining for SM22α (red) with (D1) and without 
(D2) overlay of Hoechst 34580 and elastin overlay shows high expression of SM22α in the smooth 
muscle cell layer of the artery. A negative control, performed by omitting the primary antibody, shown 
with (E1) and without (E2) Hoechst 34580 and elastin overlay, displayed no staining. Scale bar 
represents 50 µm for (A and C-E) and 10 µm for (B). 
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Figure 34: Immunolocalization of the CaSR, Pecam-1 and SM22α in transverse section of aortae from 
WT and KO mice. Epifluorescence images of PFA-fixed 7 µm cryosections. CaSR staining (red) in 
aortae from WT (A) and KO (D) mice shown with (A1 and D1) and without (A2 and D2) overlay of 
Hoechst 34580 nuclear counterstain (blue) and elastin autofluorescence (green) showing expression 
of the CaSR in the endothelium and, to a lesser extent, in the VSMC. Pecam-1 staining (red) shown 
with (B1) and without (B2) Hoechst 34580 and elastin overlay illustrates the localization of the 
endothelium. Staining for SM22α (red) shown with (C1) and without (C2) Hoechst 34580 and elastin 
overlay illustrates the localization of VSMC. In (A-C), the tunica adventitia exhibits high 
autofluorescence. Negative controls, realised through omission of the respective primary antibodies, 
using anti-rabbit secondary antibody only shown with (G1, I1) and without (G2, I2) Höchst 34580 and 
elastin overlay as well as anti-goat secondary antibody only shown with (H1, H1) and without (H2, J2) 
Höchst 34580 and elastin overlay show high background fluorescence in the tissue but no specific 
staining. The lumen is located at the bottom right corners of the images. Scale bars = 50 µm. 
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4.3 Discussion 
Δexon 7 CaSR KO mice appeared grossly undistinguishable from the WT controls in that no 
differences in appearance, body weight, reproductive capabilities or survival rates were found. 
It was therefore decided to concentrate the in-depth phenotypic characterisation of WT and 
KO animals, setting aside that of HET mice at this stage. The fact that KO mice live out a full 
lifespan compared to WT control furthermore indicates that targeted deletion was at least 
insofar successful as a more generalized knock-out of the CaSR would have led to a much 
more severe and lethal (Ho et al. 1995), or at the very least obvious, phenotype (Chang et al. 
2008). CaSR expression was observed in all three layers of mesenteric arteries vessels from 
control C57/Bl6 mice, thus combining the previously separately observed localisations of the 
CaSR in the vasculature (Bukoski et al. 1997; Wonneberger et al. 2000; Weston et al. 2005; 
Molostvov et al. 2007; Loot et al. 2013). Using an antibody directed against the amino-
terminus of the CaSR, the immunostaining patterns in aortae from WT as well as KO mice 
were comparable, and no obvious difference in staining intensities was observed between 
blood vessels from the two genotypes. This result could be explained by the remaining 
presence of the Δexon7 fragment of the CaSR which, albeit not functional, is still produced by 
KO cells (Chang et al. 2008) and should remain antigenic to antibodies directed against the N-
terminus of the CaSR, like the ones used in this study (c.f. the discussion of the next chapter 
and Figure 44). Unfortunately a reliable antibody directed against the C-terminal end of the 
receptor, which should not bind to the truncated remaining fragment present in KO cells, is to 
date, not available (c.f. Figure 25). Additional studies on immunofluorescence stained VSMC 
isolated from WT and KO mice were performed and are described in 5.2.1. The effects of 
CaSR deletion from VSMC on specific cytological and physiological systems were 
investigated and described in the following chapters. 
 
4.4 Conclusions 
• SM22α-Cre x LoxP-CaSR mice do not present an immediately apparent 
phenotype. 
• CaSR expression was confirmed in all three layers of arteries. 
• Reliable tissue immunostaining for determination of CaSR expression in Δexon7 
CaSR KO mice requires a not yet available C-terminal anti-CaSR antibody. 
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5 Effect of CaSR deletion on cultured VSMC  
5.1 Introduction 
Blood pressure regulation in vivo is extremely complex and encompasses a variety of 
regulatory and compensatory mechanisms of e.g. endothelium-VSMC crosstalk, circulatory 
factors, etc., all of which are very difficult to control. Because the CaSR is expressed in all 
three layers of the vasculature, the complexity of this system makes it challenging to dissect 
the function of the VSMC CaSR independently of that of the endothelium. To discern these 
cell-type specific roles of the CaSR, in the first instance, I investigated the role of the VSMC 
CaSR in an isolated and controlled in vitro system.  
In this chapter, the effects of targeted CaSR deletion from VSMC were investigated. The first 
step was to validate the culture system and the effectiveness of the genetic manipulation at 
producing tissue-specific CaSR ablation by investigating the expression of a VSMC-specific 
marker, namely SM22α, as well as CaSR protein and their expression patterns using 
immunolocalization experiments. Quantitative immunofluorescence was used to measure the 
amount of expression of CaSR in VSMC isolated from WT and KO mice. Furthermore, the 
CaSR has been implicated in control of VSMC proliferation. Rat aortic VSMC were shown to 
react with increased proliferation to rising concentrations of Ca2+ in the culture medium, 
although it was unclear whether this response was purely CaSR mediated (Smajilovic et al. 
2006). In human aortic smooth muscle cells, neomycin led to increased proliferation while 
knock-down of the receptor (using siRNA) resulted in reduced proliferation (Molostvov et al. 
2008). Studies on VSMC lacking the CaSR cultured from KO mice will allow us to confirm 
whether these effects are CaSR mediated. 
Importantly, VSMC were cultured in the presence of physiologically relevant 1.2 mM Ca2+ in 
the culture medium, in contrast to the 1.8 mM Ca2+ present in most media, as previous studies 
have shown that 1.8 mM Ca2+ leads to loss of CaSR expression by downregulation (Alam et 
al. 2009). 
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5.2 Results 
5.2.1 CaSR expression in VSMC 
Cultured VSMC were immunostained for CaSR expression to determine the abundance of the 
wild-type CaSR by co-localizing the CaSR with a smooth muscle marker, SM22α. Four 
populations were identified in the colonies: CaSR+/SM22α+, CaSR+/SM22α-, CaSR-
/SM22α+ and CaSR-/SM22α- (see Figure 35 for a representative picture from VSMC isolated 
from C57/BL6 mice). Quantitative immunofluorescence microscopy showed that 
approximately half of the cells present in all investigated batches of cells from both WT and 
KO mice could be classified as VSMC (staining positively for SM22α), with some degree of 
variation between batches (54.0 ± 8.7 % for WT and 58.3 ± 10.4 % for KO, N = 9) (Figure 
36). 
 
 
Figure 35: Representative picture of VSMC cultured from aortic explants of C57/Bl6 mice. Double 
stainings of explant derived VSMC for CaSR (red) and SM22α (green) shown as overlay. Nuclei 
appear in blue and were counterstained with Hoechst 34580). Scale bar = 500 µm. 
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Figure 36: Average percentage of VSMC in all analysed batches of VSMC grown from WT and KO 
aortae. N = 9 (WT), N= 6 (KO), mean + SEM, two-tailed T-test. 
 
Cellular distribution of the CaSR was mainly cytosolic and seemed to be denser in a diffuse 
pattern around the nucleus while SM22α immunostaining exhibited the filamentous structure 
of the cytoskeleton. Staining of acutely isolated control VSMC showed a very diffuse 
cytosolic pattern for the CaSR with an even density across the cells while SM22α exhibited a 
more granular appearance (Figure 37). 
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Figure 37: Immunolocalization of the CaSR in VSMC. Epifluorescence (A, C) and confocal images (B, 
D) of PFA fixed cultured (A and B) and acutely isolated (C and D) VSMC from control mice. Cells were 
stained using the Anaspec CaSR (red) and SM22α (green) antibodies, shown as overlay (A1, B1, C1, 
D1) including nuclear counterstaining with Hoechst 34580 (blue) and separately (A2, B2, C2 for CaSR 
and A3, B3, C3 for SM22α). In cultured VSMC from aortic explants, the CaSR is mainly distributed 
around the nucleus (A2, B2) and was present in SM22α positive and negative cells (A3, B3). In acutely 
isolated aortic VSMC, CaSR staining appeared much more granular and evenly distributed across the 
cytosol and nucleus of the cells (C2 and D2), which was similar to that seen for SM22α with the 
exception of the latter’s absence form the nucleus (C3 and D3). Negative controls, shown as overlay 
of all channels, showed no staining in cultured (E) and acutely isolated (H) VSMC. Cross-negative 
controls including rabbit anti CaSR primary antibody, with chicken anti goat secondary antibody (F) 
and goat anti SM22α antibody with goat anti rabbit secondary antibody (G) showed no significant 
immunoreactivity ascribed to primary antibodies. Scale bars = 100 µm in (A, B E–G), 10 µm in (C and 
D) and 50 µm in (H). 
 
When comparing VSMC derived from KO explants with those from WT mice, CaSR 
immunostaining in WT VSMC was the same as in VSMC derived from control mice, but 
staining intensity in KO VSMC was markedly reduced compared to WT control (Figure 38). 
Expression levels of CaSR in cultured WT vs. KO VSMC of passages 2-6 were measured 
using quantitative immunofluorescence analysis. Nine WT and 6 KO individual VSMC 
preparations, each containing VSMC grown from aortae of 2–3 mice, were analysed at 
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different passages and in multiple technical repeats with a total of 37,125 cells in 50 ROIs for 
WT and 54,414 cells in 27 ROIs for KO. For negative controls, 3,066 cells in19 ROIs from 6 
preparations were analysed for WT and 5,898 cells in 6 ROIs from 3 preparations for 
knockouts. Preparation, culture maintenance and stainings of VSMC preparations were 
performed in collaboration with Dr. Thomas Davies (Davies 2013), image acquisition, 
quantitative immunofluorescence and data analysis were performed by myself. 
Normalised to expression of SM22α and relative to the expression of CaSR in VSMC from 
WT control, CaSR expression levels in KO VSMC were reduced significantly by about 32 % 
when looking at all cells in the cell preparation. Background fluorescence, as determined by 
negative controls performed by omission of the primary antibodies, exhibited about 9–17 % 
of the fluorescence of the positively stained samples (Figure 39). When focusing only on 
VSMC (cell population staining positive for SM22α, c.f. Figure 36), CaSR staining intensity 
was significantly reduced by about 44 % (Figure 40). All numerical results are reported in 
Appendix A, Table 15.  
 
 
Figure 38: CaSR expression in cultured WT and KO VSMC. Epifluorescence overview images of PFA 
fixed cells showing large areas of cells. Immunostaining of VSMC derived from explants from WT and 
KO mice was performed using an Anaspec CaSR rabbit polyclonal antibody. KO cells show a large 
reduction in staining intensity compared to the WT control. Image contrast was enhanced for better 
visibility by the same amount in both images. Scale bars = 500 µm. 
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Figure 39: Quantitative immunofluorescence analysis of CaSR expression levels in all cells present in 
VSMC preparations of passages 2-6 cultured from WT and KO aortae. CaSR staining intensities were 
normalised to the SM22α intensity of the respective cell batch and weighed in respect to the cell 
number in the respective batch. Staining intensity of KO positive and all negative cells is expressed as 
fold change compared to WT positive. N = 9 (WT positive), 6 (KO positive), 6 (WT negative), 3 (KO 
negative), Mean + SEM, * p < 0.05, *** p < 0.001, two-way ANOVA with Bonferroni post-test. 
 
CaSR / SM22α  intensity
WT KO
0.0
0.5
1.0
1.5
**
fo
ld
 c
ha
ng
e
 
Figure 40: Quantitative immunofluorescence analysis of CaSR expression levels in the population of 
VSMC (staining positive for SM22α) in VSMC preparations of passages 2-6 cultured from WT and KO 
aortae. CaSR staining intensities were normalised to the SM22α intensity of the respective cell batch 
and weighed in respect to the VSMC number in the respective batch (. Staining intensity of KO cells is 
expressed as fold change compared to WT. N = 9 (WT), 6 (KO), Mean + SEM, ** p < 0.01, two-tailed 
T-test. 
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5.2.2 VSMC proliferation 
The conditions to test the effects of Ca2+ on VSMC in WT and KO cells were initially 
optimised by incubating VSMC explanted from C57/Bl6 mouse aortae in medium containing 
different extracellular Ca2+ concentrations. VSMC proliferation was measured at two different 
time points (day 5 and day 10) by cell counting using a haemocytometer. Normalization 
against the cell numbers obtained in the presence of medium containing 1.2 mM Ca2+ at day 5 
showed a highly significant difference in the increase in cell number after 10 days of 
incubation in the presence of medium containing 2.5 mM Ca2+ (p < 0.001) (Figure 41). When 
this protocol was employed to compare VSMC numbers from WT and KO mice kept in 
culture for 10 days (normalized against cell numbers of WT measured in the presence of 
medium containing 1.2 mM Ca2+), proliferation in the KO cells was not increased in the 
presence of medium containing 2.5 mM Ca2+ (Figure 42). All numerical results of the 
proliferation studies are reported in Appendix A, Table 16. 
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Figure 41: Number of VSMC from C57/BL6 control mice after 5 and 10 days of incubation in three 
different Ca2+ concentrations. 2.5 mM Ca2+ lead to a significant increase in control VSMC number 
compared to that measured in cells grown in the presence of medium containing 1.2 mM Ca2+. Data 
are normalized to cell number measured after 5 days incubation in medium containing 1.2 mM Ca2+ 
(line). *** p < 0.001 vs. 1.2 mM Ca2+ of the respective day. N = 5, n = 3, mean + SEM, two way 
ANOVA and Bonferroni post-test. 
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Figure 42: Number of VSMC from WT and KO mice after 10 days of incubation in the presence of 
medium containing different Ca2+ concentrations. The Ca2+ induced increase in proliferation observed 
in VSMC from WT mice is lost in VSMC from KO mice. Data are normalized to WT cell number at 1.2 
mM Ca2+. *** p < 0.001. N = 1, n = 3, mean + SEM, two way ANOVA and Bonferroni post-test. 
 
After my initial observations, these experiments were repeated by Thomas Davies in the 
course of his PhD thesis (Davies 2013). The observed results were very much comparable to 
the ones presented here. WT VSMC showed a Ca2+ dependent increase in cell proliferation 
while this response was not found in KO cells (Figure 43). 
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Figure 43: Replicate of the WT/KO VSMC proliferation experiment shown in Figure 42 by Dr. Thomas 
Davies. Number of VSMC from WT and KO mice after 10 days of incubation in the presence of 
medium containing different Ca2+ concentrations. Data are normalized to WT cell number at 1.2 mM 
Ca2+ (line). * p < 0.05, ** p < 0.01, *** p < 0.001. N = 5 (WT), N = 4 (KO), n = 2, mean + SEM, two way 
ANOVA and Bonferroni post-test. 
 
Because “cell proliferation” here is expressed as total cell counts, which includes live and 
dead cells, apoptosis of these cells has to be taken into consideration as well. Experiments on 
VSMC apoptosis were performed on VSMC prepared in collaboration with Dr. Thomas 
Davies. Generally, VSMC (SM22α+) exhibited a similar percentage of apoptosis, irrespective 
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of genotype or extracellular Ca2+ and Pi concentrations. However, while the TUNEL assay 
itself as well as the quantification by quantitative immunofluorescence produced consistent 
results, the available VSMC preparations showed exceedingly high phenotypic variability in 
staining intensity for SM22α as well as CaSR thereby making a reliable interpretation of these 
data difficult. If accepted to be correct, the equal levels of apoptosis would suggest that the 
observed Ca2+ dependent increase in cell number in WT VSMC is in fact driven by an 
increase in cell proliferation rather than decreased apoptosis. Results of these experiments are 
reported in Appendix B, 12.1. 
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5.3 Discussion 
5.3.1 CaSR expression in VSMC 
After optimization of an immunostaining protocol and selection of the most specific antibody 
(AnaSpec), it was confirmed that the CaSR is expressed in VSMC and that this expression is 
reduced in VSMC from KO mice.  
In this chapter, I have shown that the cell populations in the commonly used culture model for 
VSMC are rather heterogeneous with approximately 50 % of the cells present in the culture 
being VSMC, which is comparable to what others have found in passaged cultures of VSMC 
(Shanahan et al. 1993). The reason for this seemingly low purity of the culture can be found in 
the ready ability of cultured VSMC to undergo phenotypic transformation in vitro which goes 
along with the loss of VSMC markers (Shanahan et al. 1993). This heterogeneity of in vitro 
VSMC cultures has long been known and the expression patterns of VSMC markers depends 
on a variety of factors like animal age or species (Shanahan and Weissberg 1998). I 
hypothesise that the non SM22α-positive cells are either of fibroblastic origin – as CaSR 
expression has been demonstrated in fibroblasts of various, although not vascular origin 
(Ogata et al. 2006; Pacheco and Macleod 2008; Hattori et al. 2011) – or result from VSMC 
dedifferentiation which has been shown to occur in mineralizing VSMC (Shanahan et al. 
1994; Steitz et al. 2001). However, the heterogeneity and the percentage of VSMC were 
present and comparable in VSMC cultures from both genotypes while the culture and 
isolation was performed in exactly the same way for both genotypes. Since the classification 
into populations is based on the setting of an arbitrary (manually) set threshold for SM22α 
staining intensity, the population analyses are reflecting a subjective opinion of positive 
staining for SM22α. However, the introduced bias would have the same effect on both VSMC 
isolated from both WT and KO mice. Therefore, I suggest that it is possible to compare 
results from population and expression analyses as well as functional assays between WT and 
KO isolated cells. Ideally, a “pure” VSMC culture should be used for analysis of VSMC, 
which seemed not achievable with the explant derived VSMC cultures. For future 
experiments, we will consider digestion-based cell isolation methods, which might provide a 
purer and more stable VSMC culture (Prof. Cecilia Giachelli, University of Washington, 
USA, personal communication).  
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Immunoreactivity to CaSR in VSMC is present mainly in the cytosol and around the nucleus, 
which is in agreement with the fact that most of the CaSR present in the cell is stored in the 
endoplasmic reticulum and that trafficking from this pool to the membrane is a very important 
part of the regulation of CaSR signalling (White et al. 2009; Cavanaugh et al. 2010; Grant et 
al. 2011) A similar distribution pattern for the CaSR was observed in other cell types, e.g. 
human umbilical vein endothelial cells (HUVECs) (Bonomini et al. 2012), human oocytes 
(Dell'Aquila et al. 2006) or rat medullary thyroid carcinoma cells (Tharmalingam et al. 2011). 
Interestingly, while cultured VSMC showed the typical filamentous staining pattern (Ross et 
al. 2006) for SM22α, staining in acutely isolated VSMC had a very granular appearance. 
Since SM22α is localized to smooth muscle actin (Zhang et al. 2001a), these results suggest 
depolymerisation of filamentous F-actin to granular G-actin in response to the isolation 
procedure, which might also explain the granular appearance of CaSR staining in these cells, 
as the CaSR has been shown to bind to the actin-binding filamin A (Pi et al. 2002). 
CaSR expression was found in WT as well as KO VSMC (positive for SM22α) but expression 
levels were significantly lower in KO compared to WT VSMC. It was shown previously that 
the loss of the C-terminal exon 7 of the CaSR does not result in total loss of receptor 
expression: indeed, a truncated Δexon7 variant of the receptor is still expressed, but this 
truncated receptor is non-functional (Chang et al. 2008). Since the antigenic region of the 
used AnaSpec antibody is N-terminal and since the Δexon7 protein, which consists of the N-
terminal domain of the CaSR, can still be expressed by the KO cells, the reduction in staining 
in KO VSMC for CaSR indicates that total receptor expression is downregulated as a result of 
the genetic manipulation. In parathyroid gland specific CaSR knock-out mice mRNA 
abundance of the CaSR was increased but Δexon7 CaSR protein levels were decreased to 10 
% of full length protein in wild type controls. Furthermore, total knock out of the wild type 
receptor in the same mice has been shown to be ca. 95 %, suggesting that the tissue specific 
ablation is high but not complete (Chang et al. 2008). This, together with the presence of the 
truncated remains of the CaSR, can explain the remaining signal in KO VSMC (Figure 44). 
To determine the exact amount of knock-out of the receptor in the SM22α-Cre x CaSR-LoxP 
mouse, western blot and RT-qPCR analyses are currently being performed by other members 
of the laboratory. Nevertheless, even in the absence of these results, the observed reduction in 
CaSR staining, together with the observed tissue specific phenotypes described in the 
following chapters point towards successful partial deletion of the CaSR from VSMC. 
 
93 
 
 
Figure 44: Presumed cause for remaining CaSR immunostaining in VSMC from KO mice. The rabbit 
polyclonal antibody currently used for my studies binds the N-terminal (extracellular) domain of the 
CaSR. In the exon 7 KO model, transmembrane and carboxy-terminal domains of the CaSR are 
deleted while the extracellular domain, encoded by exon 1-6, can still be produced. When expressed 
in heterologous systems, this truncated form is unstable, non-functional and lacks plasma membrane 
retention motifs (Chang et al. 2008). The antigenic region of the Anaspec antibody, which resulted to 
be the most specific of those commercially and non-commercially available, is located in the putative 
amino terminus of the CaSR and therefore residual antigen-antibody binding in KO cells can still be 
visualised (red arrows). EC = extracellular space, PM = plasma membrane, IC = intracellular space. 
CaSR structure illustration modified after (Hofer and Brown 2003). 
 
5.3.2 Regulation of VSMC proliferation by the CaSR 
Previous studies have shown that in several cell types the activation of the CaSR influences 
cell proliferation. For instance, in colonic epithelial cells (Rey et al. 2010) CaSR activation 
reduces proliferation while in other cells, such as breast cancer-derived (El Hiani et al. 2009), 
osteoblast (Dvorak et al. 2004) or mesangial cells (Kwak et al. 2005), receptor activation 
promotes proliferation. For the vasculature, CaSR inhibition in human pulmonary artery 
smooth muscle cells reduced cell proliferation (Yamamura et al. 2012) and human aortic 
smooth muscle cells responded with increased proliferation in response to incubation with the 
orthosteric CaSR ligand, neomycin (Molostvov et al. 2008). In rat aortic VSMC, which are 
probably most comparable to the murine VSMC used in this study, elevated extracellular Ca2+ 
concentrations also induced an increase in cell proliferation, DNA synthesis and increased 
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ERK activation without significantly affecting Ca2+i signalling (Smajilovic et al. 2006). The 
authors suggested that the observed lack Ca2+i response to CaSR agonists in rat aortic VSMC 
could mean that these Ca2+ elicited effects on proliferation are not necessarily mediated 
exclusively by the CaSR but possible also by other calcium sensing receptors which might be 
present in VSMC (Farzaneh-Far et al. 2000; Smajilovic et al. 2006) namely GPRC6A (Harno 
et al. 2008). The definite role of GPRC6A in VSMC remains to be determined. 
I have shown in this study that incubation of wild-type VSMC in medium containing 2.5 mM 
Ca2+ led to an increase in VSMC cell numbers, when compared with medium mimicking 
normocalcaemic conditions (1.2 mM Ca2+), which is in agreement with previous observations. 
Most importantly, this effect was lost in VSMC from KO mice. For human aortic VSMC, 
silencing of the CaSR with siRNA yielded similar, but not quite as large results (Molostvov et 
al. 2008). Together, these observations suggest that the CaSR mediates Ca2+-dependent 
VSMC proliferation in murine VSMC. 
The significance of these results and their translatability from the in vitro to the in vivo 
situation remain has to be investigated further but the increased cell density in KO VSMC 
cells, together with the known effect of the CaSR on proliferation in cardiomyocytes (Sun et 
al. 2006) indicates that loss of CaSR in SM22α positive cells could play a role in the cardiac 
remodelling observed in KO hearts (see chapter 7.3.9). Furthermore, it substantiates the 
hypothesis that CaSR activation by extracellular Ca2+ could be involved in aortic remodelling 
as observed in atherosclerosis (Smajilovic et al. 2006). Future experiments aimed at 
determining the intracellular signalling mechanism by which Ca2+ exerts its influence on 
VSMC proliferation should be performed should clarify this issue further. 
 
5.4 Conclusions 
• Cultured VSMC express the CaSR, although cell populations in VSMC preparations 
were quite heterogeneous. 
• CaSR expression appears largely cytosolic in cultured VSMC. 
• CaSR was ablated from VSMC of the SM22α-Cre x LoxP-CaSR mouse. 
• Extracellular Ca2+ promotes VSMC proliferation via the CaSR in vitro. 
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6 Effect of CaSR deletion on vascular calcification 
6.1 Introduction 
Several in vivo and in vitro studies suggest that the CaSR plays a role in protection against 
vascular calcification, e.g. (Alam et al. 2009; Koleganova et al. 2009; Mendoza et al. 2011; 
Ciceri et al. 2012b; Ciceri et al. 2013; Henaut et al. 2014). As already outlined in the general 
introduction, vascular calcification is a major complication in CKD and is associated with 
highly increased cardiovascular morbidity and mortality (London et al. 2005). It has been 
shown that both extracellular Pi and Ca2+ levels are directly associated with the development 
of vascular calcification and the transdifferentiation of VSMC into osteoblast-like cells (Villa-
Bellosta et al. 2011). The CaSR directly controls Ca2+ levels via regulation of parathyroid 
hormone secretion, which account for the observed positive effects of calcimimetic on 
cardiovascular events, at least in animal models of CKD (Ogata et al. 2003; Koleganova et al. 
2009) and human studies even though the latter are contradictory or methodologically 
problematic (Block et al. 2010; Raggi et al. 2011; Carney 2013; Chow et al. 2014). However, 
as already discussed, the CaSR is also present in VSMC and therefore may have a direct 
protective effect against vascular calcification. This possibility was explored previously in our 
group where it was found that calcified human arteries had lost all expression of the CaSR 
compared to non-calcified control tissue. In the same study in vitro cultured bovine VSMC 
were transfected with a dominant negative form of the CaSR exhibited a large increase in 
calcification compared to empty vector control. Because stimulation of the CaSR with the 
calcimimetic R-568 prevented calcification in bovine VSMC (Alam et al. 2009), these results 
suggested that loss of CaSR expression exacerbates vascular calcification. However, these 
results in vitro do not conclusively prove that the VSMC CaSR protects against vascular 
calcification in vivo.  
For this reason, to elucidate the contribution of the vascular CaSR towards protection against 
vascular calcification, the impact of CaSR ablation from VSMC on calcification was 
investigated in vivo in whole animals, ex vivo using aortic explants and in vitro calcification 
using cultured aortic VSMC.  
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6.2 Results 
6.2.1 In vivo blood vessel calcification 
µCT analysis performed by Dr. Wenhan Chang (UCSF, USA) showed no aortic calcification 
in 12 month old WT or KO animals (W. Chang, personal communication). 
Staining of aorta sections from 12 month old male WT and KO mice with alizarin red S was 
performed under direction by an undergraduate student, Miss Amber Wheatley, and showed 
no mineral deposits in aortae from WT or KO mice (Figure 45). 
 
 
Figure 45: Alizarin Red S stainings of three thoracic aortae from 12 month old WT and KO animals. No 
calcification or calcified lesions could be detected. Contrast of all images was enhanced. Staining and 
pictures by Miss Amber Wheatley. 
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6.2.2 In vitro VSMC calcification 
The ability of aortic VSMC from WT and KO mice to mineralize in vitro was investigated by 
alizarin red S staining. No calcification was observed in WT VSMC cultured in presence of 2 
mM Pi over a range of 0.8 to 2.5 mM extracellular Ca2+. In the presence of 3 mM Pi 
calcification is visible in cells incubated in medium containing 1.6 mM Ca2+. In VSMC 
derived from KO cells however, visible calcification was found already in the presence of 
medium containing 2 mM Pi and 1.6 mM extracellular Ca2+ and already in the presence of 
medium containing physiological 1.2 mM extracellular Ca2+ and 3 mM Pi (Figure 46 and 
Figure 47). Densitometric quantification of Alizarin Red S stainings, performed by Dr. 
Thomas Davies after my initial observations (Davies 2013) showed comparable results 
(Figure 48). 
 
 
Figure 46: Photographs of WT and KO mouse derived VSMC cultured in 24-well plates stained with 
alizarin red S after 10 day incubation in medium containing different Ca2+ and Pi concentrations. 
Numbers indicate Ca2+ concentration in three horizontally adjacent wells. No calcification of WT cells 
was observed in the presence of medium containing 2 mM Pi regardless of Ca2+ concentration (upper 
left panel) while cell incubation in medium containing 3 mM Pi resulted in calcification starting at 1.6 
mM Ca2+ (lower left panel). In KO cells, Ca2+-deposition was found starting in cells incubated in 
medium containing 1.6 mM Ca2+ in the presence of 2 mM Pi (upper right panel) and at 1.2 mM Ca2+ in 
the presence of 3 mM Pi (lower right panel). 
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Figure 47: Representative phase-contrast microscopic images of WT and KO alizarin red S staining for 
VSMC incubated for 10 days with medium containing 2 mM Pi and 2 mM Ca2+. KO cells exhibit a 
marked increase in calcification compared to WT control. Scale bars = 500 µm (4x), 100 µm (20x). 
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Figure 48: Densitometric quantification of alizarin red S staining of VSMC incubated in the presence of 
medium containing different Ca2+ concentrations and 3 mM Pi (performed by Dr. Thomas Davies 
(Davies 2013)). Staining for calcium deposits is significantly greater in KO cells compared to WT 
control. *** p < 0.001, N = 2, n = 4, mean + SEM, two way ANOVA and Bonferroni post-test (Davies 
2013). 
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Quantification of Ca2+ incorporation via o-cresolphthalein complexone assay, performed by 
Dr. Thomas Davies (Davies 2013), showed a Ca2+ and Pi concentration dependent increase in 
calcification in WT as well as KO mice derived VSMC.  
In the presence of medium containing 1.4 mM Pi, calcium incorporation (normalized to 
amount of calcification measured in the presence of medium containing 1.2 mM Ca2+) was 
significantly increased in the presence of 2.5 mM Ca2+ vs. 1.2 mM Ca2+ in KO cells (1.52 ± 
0.15, vs. 1.00 ± 0.028, p < 0.001, N = 2, n = 8, Two-way ANOVA and Bonferroni post-test) 
but not in WT cells. In the presence of medium containing supraphysiological (3 mM) Pi, the 
increase in calcium incorporation in the presence of 1.8 as well as 2.5 mM Ca2+ was not 
different from that measured in the presence of 1.2 mM Ca2+ in WT and KO cells (Figure 49). 
Taken together, these results, as well as the alizarin red S staining experiments, suggest that 
CaSR ablation increases VSMC calcification in vitro in conditions mimicking 
hyperphosphataemia and hypercalcaemia. 
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Figure 49: Quantification of Ca2+ deposition using cresolphthalein complexone assay (performed by 
Dr. Thomas Davies (Davies 2013)). WT / KO data normalised to the WT / KO values at 1.2 mM Ca2+ 
(line). Compared to WT cells, mineral deposition in KO cells increased significantly in the presence of 
medium containing a Ca2+ concentration of 1.4 mM or above (upper panel) and 3 mM Pi (lower panel). 
* p < 0.05, ** p < 0.01, *** p < 0.001 vs. respective WT values, unless otherwise indicated by 
parenthesis, N = 2, (1.4 mM Pi), N = 5 (3 mM Pi), n = 4, two way ANOVA followed by Bonferroni post-
test. 
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6.3 Ex vivo calcification of aortic explants 
Aortic explants from 6 month old WT and KO male mice (N = 6) were subjected to the same 
conditions as in the in vitro experiment with cultured VSMC. To determine possible 
influences of the endothelium on the occurrence and magnitude of calcification, explants with 
intact endothelium were compared with explants which’s endothelial layer had been destroyed 
by air-bubbling. Either vehicle DMSO 1:1,000 or 10 nM of the calcimimetic R-568 were 
added to the incubation medium. After 10 days incubation in the presence of medium 
containing 3 mM Pi and 1.8 mM Ca2+, explants from KO mice showed no difference in 
incorporation of Ca2+, as determined by o-cresolpthalein complexone assay, compared to WT 
control, whether the endothelium was intact or destroyed and independently of the addition of 
10 nM R-568 (Figure 50). All numerical results are listed in Appendix A, Table 17. 
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Figure 50: Ex vivo calcification of aortic explants from 6 month old male WT and KO mice incubated 
for 10 days in the presence of 3 mM Pi and 1.8 mM Ca2+ and either presence or absence of 10 nM R-
568 with intact (left graph) or destroyed endothelium (right graph). N = 6, mean + SEM, two way 
ANOVA and Bonferroni post-test 
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6.4 Discussion 
6.4.1 In vitro calcification 
A main complication of CKD is vascular calcification (London et al. 2005) and previous 
observations in human and animal models suggested a protective role of the CaSR. 
Transfection with a dominant negative construct of the CaSR increased calcification of bovine 
aortic VSMC in vitro and CaSR expression is lost in calcified human arteries in vivo and in 
the presence of extracellular Ca2+ concentrations greater than 1.2 mM (Alam et al. 2009). To 
further explore the possible link between the CaSR and vascular calcification, we investigated 
the influence of different Ca2+ concentrations in the medium on mineralization of WT and KO 
VSMC in vitro. Experimental conditions for these studies had to be extensively optimized 
before any experiments could be carried out (see 3.2.2). 
Overall our results have consistently shown that CaSR ablation from VSMC leads to a 
significantly increased calcification in vitro, compared to that observed in VSMC isolated 
from WT mice. However, in these experiments, substantial variability in the absolute amounts 
of Ca2+ incorporation was observed between the different cell batches. A possible reason for 
this finding could be the heterogeneity of VSMC cultures (c.f. chapter 5.2) as the phenotype 
of these cells is very variable and depends on factors like animal age (Li et al. 1997), or cell 
passage (Shanahan and Weissberg 1998; Halayko and Solway 2001). In order to be able to 
quantify the results between the batches and experiments, the data had to be double 
normalized to protein content and to the amount of calcification achieved in the presence of 
1.2 mM Ca2+. This procedure led to loss of information as only the relative differences 
between Ca2+ concentration groups can be compared between WT and KO mice but not the 
absolute Ca2+ incorporation. However, the differences in Ca2+ deposition between 
physiological (1.2 mM) vs. supraphysiological (1.8 and 2.5 mM) extracellular Ca2+ 
concentrations was significantly higher in KO mice derived VSMC than in WT derived cells.  
Furthermore, Dr. Thomas Davies has demonstrated in the course of his PhD studies that the 
calcimimetic R-568 inhibits calcification of WT, but not KO VSMC. These findings are in 
agreement with previous studies (Alam et al. 2009) (Henaut et al. 2014) suggesting that the 
CaSR and its activation with calcimimetics can play a protective role against vascular 
calcification directly at the level of the cell, without a systemic influence.  
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Currently it is unclear how loss of CaSR expression from VSMC promotes this vascular 
calcification, and whether it directly drives osteogenic transdifferentiation of VSMC or leads 
to the loss of protective mineralization inhibitors, or a combination of both. Again, this is in 
agreement with the described putative effect of calcimimetics preventing transdifferentiation 
of VSMC into an osteoblastic phenotype (Koleganova et al. 2009; Ciceri et al. 2013) which is 
associated with the onset of vascular calcification (Jakoby and Semenkovich 2000; Tyson et 
al. 2003; Sage et al. 2010; Pai et al. 2011; Zhu et al. 2011). Such an experiment should be 
performed in the future, together with analyses for expression of other osteogenic and VSMC 
markers as well as the CaSR.  
Calcified plaques in blood vessels consist mainly of hydroxyapatite (Tomazic et al. 1987), 
which is the principal mineral component of bone (Johnsson and Nancollas 1992), and 
indeed, in vitro mineralization achieved in experiments with a similar experimental protocol 
consists of hydroxyapatite and its precursors (Sage et al. 2011; Villa-Bellosta et al. 2011). To 
confirm that the calcification we observed in our studies is cell-dependent mineralization and 
not precipitation of Ca3(PO4)2, X-ray diffraction analysis of the calcified deposits should be 
performed in the future. 
 
6.4.2 In vivo calcification 
In contrast to the in vitro findings, mice lacking the CaSR in VSMC did not show any 
vascular calcification in vivo even though blood Ca2+ levels have been shown to be increased 
in KO animals compared to WT control (see 8.2.2) and indeed no calcification in ex vivo 
experiments with isolated aortic rings. The absence of in vivo calcification can be explained 
by a number of possibilities, including in vivo – in vitro differences (1), changes in production 
of calcification inhibitors (2) and systemic effects (3). 
(1) Our immunostaining experiments, as well as work by others (Weston et al. 2005), showed 
a high abundance of the receptor in the vascular endothelium and its involvement in nitric 
oxide synthesis (Ziegelstein et al. 2006; Loot et al. 2013). This is especially important in the 
light of the findings NO synthesis might be controlled by the CaSR in the endothelium, as NO 
was shown to be a potent inhibitor of vascular calcification by preventing osteogenic 
differentiation of VSMC (Kanno et al. 2008). This hypothesis should be tested by generating 
an endothelium specific or endothelium-VSMC double CaSR knock-out mouse in the future.  
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Finally, the ex vivo studies on isolated aortic rings of WT and KO mice proved rather 
inconclusive, with very low overall calcium deposition in either WT or KO explants, 
independent of the absence or presence of the endothelial layer. Therefore, the protective 
mechanism of the CaSR against vascular calcification might also simply be a function of the 
native 3D cell structure with completely differentiated VSMC still present in the explants, 
which is lost when VSMC are cultured (Shanahan et al. 1993). On the other hand, studies 
have shown that calcification of isolated human blood vessels is highly dependent on the state 
of uraemia of the patient those blood vessels were derived from. Blood vessels from uraemic 
patients showed marked calcification when incubated in a high Pi and Ca2+ containing 
medium, while blood vessels from healthy patients did not (Shroff et al. 2008). The KO mice 
show a marked alteration in blood biochemistry with elevated blood Ca2+ levels. However, 
blood Pi levels were unchanged and the animals exhibited marked hyperphosphaturia, which 
is in contrast to the situation in CKD. Therefore, it is possible that KO blood vessels are 
simply not “preconditioned” towards calcification. 
(2) Fetuin A has been demonstrated to inhibit vascular calcification. Circulating fetuin A 
levels were shown to be unaltered between WT and KO mice (see 8.2.2), and while MGP 
remains to be assessed in the future, this suggest that at least the calcification inhibitor fetuin 
A is not responsible for the lack of observed in vivo calcification in the SM22α-Cre x LoxP-
CaSR mouse. However, fetuin A is enriched in sites of calcification (Reynolds et al. 2005) 
and circulating levels might not be directly correlated with risk for vascular calcification 
(Liabeuf et al. 2013). It therefore cannot be excluded, that fetuin A may play a local role in 
protection against vascular calcification in KO animals. 
(3) It is possible that the protective effect of the CaSR against vascular calcification only 
asserts itself in the artificial environment of the in vitro experiment because no systemic 
phenomena (mineral homeostasis), either in a CaSR dependant way or not, can exert a 
protective influence against calcification. This suggests that the CaSR in VSMC is not solely 
responsible for protection from vascular calcification, at least not in healthy animals. It is 
possible that KO mice, which are lacking the CaSR from conception, have adapted to the 
elevated Ca2+ concentrations and require more severe pathophysiological conditions for the 
development of vascular calcification. In vivo, the CaSR might be protective of vascular 
calcification in pathological states only, e.g. advanced CKD / end stage renal disease, where 
the Ca x Pi product is markedly elevated (London et al. 2005); indeed, Pi excretion is highly 
elevated in KO mice compared to WT control (see chapter 8.2.2). I speculate therefore that in 
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the SM22α-Cre x LoxP-CaSR mouse, vascular calcification does not occur despite the loss of 
the putative protective effect of the vascular CaSR and prevalence of hypercalcaemia because 
blood Pi levels are reduced below the threshold necessary for induction vascular calcification, 
as both Ca2+o and Pi are important determinants for VSMC transdifferentiation and 
calcification, as reviewed in (Shroff et al. 2013). In future experiments in collaboration with 
Dr. Ann Canfield (University of Manchester, UK) this hypothesis will be investigated by 
inducing CKD in our animals to increase the risk for vascular calcification by performing 5/6 
nephrectomy in combination with a high phosphate diet (Shobeiri et al. 2010; Lau et al. 
2013).  
It has to be noted that clinical trials showed no protective effect of activating the CaSR on 
vascular disease could be found (Raggi et al. 2011; Chertow et al. 2012). The technical 
shortcomings of these studies notwithstanding, these results raise the question if the observed 
protective effects of CaSR activation can be translated to the in vivo situation in patients and 
if the CaSR really is a valid target for therapy or prevention of vascular calcification or if the 
putative anti-calcifying effect of the vascular CaSR in only of academic interest.  
 
6.5 Conclusions 
• CaSR ablation from VSMC does not lead to in vivo calcification, despite elevated 
blood Ca2+ levels, possibly because of decreased increased urinary Pi removal 
from the blood. 
• The CaSR has a protective effect against in vitro VSMC calcification in a high Ca2+ 
and high Pi containing medium which can be enhanced by calcimimetics.  
• The protective effect of the CaSR might therefore only assert itself in a 
pathophysiological context, which should be investigated using a challenged 
mouse model of renal failure. 
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7 Effect of VSMC targeted CaSR deletion on 
cardiovascular function 
7.1 Introduction 
Previous studies have implicated the vascular CaSR in the regulation of vascular tone and of 
blood pressure in a variety of in vitro and in vivo studies, (see general introduction and 
(Smajilovic et al. 2011) for review). Special attention was therefore given to the investigation 
of the cardiovascular phenotype of the SM22α-Cre – LoxP-CaSR mice. In this chapter, the 
impact of CaSR deletion on blood pressure, vascular tone regulation and cardiac function and 
morphology was studied. Data on vascular tone regulation were primarily obtained by wire 
myography studies performed by Dr. Thomas Davies, Dr. Polina Yarova and Mrs Irene 
Lopez. Principal findings of these wire myography studies are shown and put in context with 
other results in the discussion of this chapter to allow for a more thorough interpretation of the 
mice’s cardiovascular phenotype.  
First, blood pressure measurements were performed by tail cuff measurements, which have 
been established as simple non-invasive method with acceptable reliability (Johns et al. 1996; 
Feng et al. 2008). Following the tail cuff experiments, radiotelemetry experiments (Boedtkjer 
et al. 2011), were performed to accurately assess and confirm blood pressure changes in our 
mice. To maximize output from these experiments, the influence of two different diets, 
namely a supplementation of the mice chow with 4 % NaCl, termed high salt diet, as well as 
supplementation of the mice’ drinking water with 0.5 mg / ml L-NAME (a pharmacological 
inhibitor of NO synthesis), on blood pressure and other cardiovascular parameters were 
investigated. Any differences observed between WT and KO mice in response to dietary 
changes would allow for a more thorough understanding of the mechanisms behind the CaSR 
influence on vascular tone regulation. 
High salt containing diets have been shown to induce salt-sensitive hypertension in mice (Yu 
et al. 2004), although the induction of measurable hypertension in healthy mice, especially 
with a mixed C57/BL6 background, is being reported to develop only over several weeks 
(Gros et al. 2002). However, short-term treatment with a high salt diet can be used to 
determine whether the blood pressure of a specific animal model is particularly sensitive to 
NaCl, by mechanisms which might involve the systemic RAAS as well as local factors like α2 
adrenoreceptors regulating NO production (Makaritsis et al. 1999; Duling et al. 2006). Short-
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time treatment with a high salt diet has been shown to rescue loss-of-ACE induced 
hypotension in mice (Carlson et al. 2002), thus allowing estimation if observed changes in 
blood pressure are salt sensitive or, by extent, related to changes in the RAAS. 
Administration of L-NAME is a common method for increasing blood pressure through an 
increase in peripheral resistance by downregulation of endothelial NO production and 
therefore loss of an important part of endothelium-derived dilatory capability (Mattson 2001; 
Newaz et al. 2005) thus allowing to determine the influence of NO, and by extent the 
endothelium, on blood pressure regulation in the SM22α-Cre x LoxP-CaSR mouse.  
In my telemetry / metabolic cage experiments, there were only about 3 weeks available for the 
protocols because of quarantine issues with the mice at our collaborator’s site at the 
University of Denmark. Thus, the time available for the different protocols (recovery from 
surgery, standard diet and altered diet phases) was limited to a few days each. 
Finally, cardiac cine MRI, the gold-standard for assessing heart function (Schneider et al. 
2006), was performed to assess the cardiac state of WT and KO mice. 
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7.2 Results 
7.2.1 Blood pressure measurements by tail cuff 
The blood pressure of 5 age groups, or batches, of male WT and KO mice was measured by 
use of the CODA tail cuff system. To begin with, it should be noted that the blood pressure of 
first two investigated groups, namely the groups of the 3–6 and 10–14 month old mice, were 
measured using a demonstration CODA unit. After the measurements were completed and the 
unit had been sent back to the company, I was informed by the company that the unit had a 
slight fault, which manifested itself in shifted values for both systolic and diastolic blood 
pressure. While the exact values for these age groups are therefore incorrect, all mice in these 
groups were measured using the same unit and channel and therefore it seems reasonable to 
assume that the relative differences observed between the genotypes are retained. However, in 
the final WT vs. KO comparison using normalised values (see below), two calculations were 
prepared, one containing the values from the “shifted” measurements and one where the 
values of the concerned age groups were omitted. The other three batches of mice (4 months, 
9 months and 17 months) were measured with newly bought and calibrated equipment. Since 
these measurements were not planned from the beginning and had to be performed because of 
the aforementioned fault affecting the measurements of the 3-6 and 10-14 month old mice, the 
number of available animals for blood pressure measurement was not as high as desirable for 
statistical purposes. Nevertheless, the observed reduction in blood pressure was confirmed in 
experiments using radiotelemetry. 
In the measurements with the loan unit, 3-6 month old male KO mice showed a significant (p 
< 0.01) reduction in systolic, diastolic and mean arterial pressure (MAP) compared to WT 
control (Figure 51), while there was no significant difference found in male mice of 10–14 
months of age (Figure 52). 
When measured with the new unit, 4 month old male KO mice showed a non-significant trend 
towards a slight reduction in diastolic, systolic and MAP compared to age matched WT 
control (Figure 53). A significant reduction (p < 0.05) in diastolic blood pressure was found in 
9 month old male KO mice compared to WT. Although systolic blood pressure and MAP 
were also reduced in these mice, the difference did not quite reach statistical significance 
(Figure 54). Finally, for the group of 17 month old animals, no significant differences were 
found between WT and KO mice, although the trend towards reduced blood pressure in the 
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KO mice compared to WT which was observed in the other age groups was visible in these 
mice as well (Figure 55). 
Blood pressure values obtained for WT and KO mice of all investigated age groups were 
normalised relative to the mean values for the WT mice of every age group. The so obtained 
average fold-changes in blood pressure between WT and KO mice showed a highly 
significant reduction in systolic blood pressure, diastolic blood pressure and MAP in KO mice 
compared to WT control of ~ 8–15 % (Figure 56). When excluding the measurements batches 
obtained with the faulty unit, diastolic blood pressure and MAP of KO mice remained 
significantly reduced by ~ 8–10 % compared to WT control, while systolic blood pressure 
showed a non-significant reduction by ~ 5 % (Figure 57). 
Measurements of heart rates obtained with the CODA tail cuff system exhibited a substantial 
amount of variability and very often measurement would not succeed. Therefore, results are 
not reported.  
Paw temperatures of the animals from the 3–6 and 10–14 month age groups were measured 
by Dr. Sarah Brennan by employing an infrared thermometer, since it is known that reduced 
blood pressure goes along with reduced temperature of the skin and limbs (Vazquez et al. 
2010; National Heart 2013). In good agreement with the blood pressure results, 3-6 month old 
KO animals showed a significant reduction in paw temperature by about 0.52 °C (p < 0.05) 
compared to WT control. In 10-14 month old animals, this reduction in paw temperature was 
measured was not significant (Figure 58). 
All numerical values of the blood pressure measurements and paw temperatures are listed in 
Appendix A, Table 18 and Table 19. 
Blood pressure and heart rate measurements were repeated using radiotelemetry to confirm 
the observed reductions in blood pressure in the KO mice compared to WT control using 
radiotelemetry (see next chapter). 
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Figure 51: Diastolic, systolic and mean arterial pressure of 3–6 month old male WT and KO mice, 
measured by tail cuff. Note that the parameters are above those reported for C57/B6 mice (Mattson 
2001). Following consultation with the company, a calibration error was detected, indicating an 
overestimation of these values (see text). *** p < 0.001, N = 8 (WT), 13 (KO), mean + SEM, two-tailed 
T-test. 
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Figure 52: Diastolic, systolic and mean arterial pressure of 10–14 month old male WT and KO mice as 
measured by tail cuff. Note that the parameters are above those reported for C57/B6 mice (Mattson 
2001). Following consultation with the company, a calibration error was detected, indicating an 
overestimation of these values (see text). N = 3 (WT), 7 (KO), mean + SEM, two-tailed T-test. 
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Figure 53: Diastolic, systolic and mean arterial pressure of 4 month old male WT and KO mice as 
measured by tail cuff. N = 3 (WT), 9 (KO), mean + SEM, two-tailed T-test. 
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Figure 54: Diastolic, systolic and mean arterial pressure of 9 month old male WT and KO mice as 
measured by tail cuff. N = 5 (WT), 11 (KO), mean + SEM, two-tailed T-test. 
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Figure 55: Diastolic, systolic and mean arterial pressure of 17 month old male WT and KO mice as 
measured by tail cuff. N = 3 (WT), 13 (KO), mean + SEM, two-tailed T-test. 
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Figure 56: Combined normalised diastolic, systolic and mean arterial pressure of all age groups 
including the overestimated values of the 3-6 and 10-14 month age group measurements (see text). 
Normalised values are averages of all WT and KO values normalised to their respective age group’s 
mean WT values (mean WT = 1, line). ** p < 0.01, *** p < 0.001 N = 22 (WT), 52 (KO), mean + SEM, 
two-tailed T-test. 
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Figure 57: Combined normalised diastolic, systolic and mean arterial pressure of all age groups 
excluding the overestimated values of the 3-6 and 10-14 month age group measurements (see text). 
Normalised values are averages of all WT and KO values normalised to their respective age group’s 
mean WT values (mean WT = 1, line). * p < 0.05, N = 11 (WT), 33 (KO), mean + SEM, two-tailed T-
test. 
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Figure 58: Average paw temperatures of 3–6 and 10–14 month old WT and KO mice used in the blood 
pressure study. N = 10 (WT, 3–6 months), 11 (KO, 3–6 months), 3 (WT, 10–14 months), 7 (KO, 10–14 
months), * p < 0.05, two-tailed T-test. These observations were made by Dr. Sarah Brennan. 
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7.2.2 Blood pressure measurements by radiotelemetry 
Tail cuff measurements strongly suggested that KO mice were mildly hypotensive. However, 
because tail cuff in mice is not widely accepted and the observed differences were small, to 
get greater information about the cardiovascular parameters of our genetically modified 
animals and because of the problems encountered with the loan unit, radiotelemetry 
experiments were planned and carried out on 3 month old WT and KO mice in collaboration 
with Prof. Robert Fenton and Dr. Vladimir Matchkov at the University of Aarhus, Denmark. 
Crucially, because the bacteriology tests of our animal facility did not allow our mice to be 
transferred into the Aarhus animal unit, all experiments were carried out while animals were 
kept in quarantine for the duration of the experiment. Initial experiments were performed in 
animals fed the same diet as in our animal facility in Cardiff to verify the reduced blood 
pressure of KO mice compared to WT control. In addition to the baseline recordings, mice 
were challenged by being fed a high salt diet (containing 4 % NaCl) and, after a “washout” 
period, they were treated with the NO synthase inhibitor L-NAME (0.5 mg / l in the drinking 
water). This treatment allowed us to determine if the previously observed reduction in blood 
pressure in KO mice is caused either by blood volume / kidney function (high salt diet) or 
TPR (L-NAME). Mice were housed in metabolic cages for the first part of the experiment 
(standard diet (1) vs. high salt diet), the results of which are described in chapter 8.2. For 
reasons of animal welfare, the mice were moved from metabolic cages into standard cages for 
the second part of the experiment (standard diet (2) vs. L-NAME). Because of this change in 
housing, the raw values from the two arms of the experiment cannot be directly compared. 
Read outs of the radiotelemetry probes which were analysed include diastolic blood pressure, 
systolic blood pressure, mean arterial pressure, pulse height (pulse pressure = difference 
between diastolic and systolic blood pressure), heart rate and the first derivative of the 
increase in the blood pressure curve (dp/dt) as a rough measure of left ventricular contractility 
(inotropy). The experimental plan and analysis methods are described in detail in the relevant 
methods section (2.7.2).  
When looking at the traces alone, immediate differences between WT and KO mice became 
apparent. KO mice showed a marked and consistent reduction of diastolic, systolic and mean 
arterial blood pressure compared to WT control. This difference was more pronounced in the 
diastolic pressure than in systolic blood pressure and appeared greater during the active period 
of the mice (night-time) than during their resting period (daytime). The reduction observable 
in blood pressure as well as the normalisation of their circadian rhythms over the course of the 
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first few days indicates that, despite the mice having had two days of recovery following the 
implantation of the radiotelemetry probes, their stress level and therefore blood pressure was 
still declining during that phase of the experiment. Possibly as a result of this situation, no 
difference was apparent in the blood pressure of WT and KO mice when they were switched 
onto the high salt diet, where blood pressure remained stable for WT as well as KO mice, with 
KO mice consistently showing a lower blood pressure than WT mice. The small peaks in 
blood pressure observable around 12:00 noon every day for mice of both genotypes were 
caused by the handling of the mice and metabolic cages necessary for sample collection and 
cage maintenance (Figure 59). Pulse height of KO animals appeared markedly elevated while 
heart rates were reduced compared to WT control, independent of the diet the animals were 
fed with. dp/dt remained stable and comparable between WT and KO mice while on standard 
diet but decreased in WT mice when they were switched on a high salt diet while it remained 
stable in KO animals fed the high salt diet (Figure 60).  
After 4 days on the high salt diet, mice were switched back on standard diet (standard diet (2)) 
and moved back in standard housing cages. In this phase, diastolic, systolic and mean arterial 
blood pressure of KO mice remained markedly lowered compared to WT, as already observed 
when the mice were fed standard diet (1). When drinking water was supplemented with 0.5 
mg / l L-NAME, blood pressure of mice of both genotypes rose immediately and the 
difference between WT and KO mice disappeared on the second day of L-NAME treatment 
(Figure 61). The already observed elevation of pulse height in KO animals compared to WT 
increased further under the influence of the NO synthase inhibitor L-NAME (Figure 62), 
indicating a larger increase in systolic than diastolic blood pressure in KO mice (a larger 
difference between diastolic and systolic blood pressure, which could indeed be observed in 
the respective traces, c.f. Figure 61). Heart rate in KO animals remained reduced in KO 
animals compared to WT and dropped slightly in both genotypes with a reduction in the 
circadian profile when the animals on 0.5 mg /l L-NAME (Figure 62). dp/dt of KO animals 
showed the same small increase compared to WT, which had developed during the previous 
experimental stage (Figure 60), and independently of L-NAME supplementation. This could 
be accounted for by the fact that the mice had not fully recovered during the first stage of the 
experiment and that the post-operative stress masked the natural (i.e. lower) dp/dt of the WT 
animals which continued to lower over time while KO animals returned to a higher baseline 
contractility. For reasons of time constraint at the quarantine facility in Aarhus, Denmark, the 
experiment had to be terminated at this point. 
116 
 
Systolic blood pressure
100
110
120
130
140
150
160 WT
KO
1 2 3 4 5 6 7 8 9
Standard diet (1) 4% NaCl diet
days
m
m
 H
g
Diastolic blood pressure
60
70
80
90
100
110
120 WT
KO
Standard diet (1) 4% NaCl diet
1 2 3 4 5 6 7 8 9
days
m
m
 H
g
Mean arterial pressure
80
90
100
110
120
130
140 WT
KO
Standard diet (1) 4% NaCl diet
1 2 3 4 5 6 7 8 9
days
m
m
 H
g
 
Figure 59: Systolic, diastolic and mean arterial pressure traces of WT and KO mice fed a standard diet 
or high salt diet as measured by radiotelemetry. X-axis indicates days of experiment; dotted lines 
indicate midnight; refer to Figure 16 for timeline. Mean ± SEM, N=5.  
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Figure 60: Pulse height, heart rate and dp/dt traces of WT and KO mice fed a standard diet or high salt 
diet as measured by radiotelemetry. X-axis indicates days of experiment; dotted lines indicate 
midnight; refer to Figure 16 for timeline. Mean ± SEM, N=5.  
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Figure 61: Systolic, diastolic and mean arterial pressure traces of WT and KO mice fed a standard diet 
or 0.5 mg / l L-NAME in the drinking water as measured by radiotelemetry. X-axis indicates days of 
experiment; dotted lines indicate midnight; refer to Figure 16 for timeline. Mean ± SEM, N=5.  
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Figure 62: Pulse height, heart rate and dp/dt traces of WT and KO mice fed a standard diet or 0.5 mg / 
l L-NAME in the drinking water as measured by radiotelemetry. X-axis indicates days of experiment; 
dotted lines indicate midnight; refer to Figure 16 for timeline. Mean ± SEM, N=5. 
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For statistical comparison of WT and KO mice and the effects of the different diets, averages 
of the read outs from fixed 3 hour intervals, 20:00-23:00 for active and 8:00-11:00 for resting 
phases, were selected across all mice on the last respective day of the four treatments.  
When comparing read outs at fixed time points for active and resting phases of the mice, two-
way ANOVA showed significant reductions in systolic (p < 0.05), diastolic ( p < 0.001) and 
mean arterial pressure (p < 0.01) between WT and KO mice during their active phase when 
fed either standard or 4% NaCl containing diet. This reduction in blood pressure was 
especially pronounced in diastolic blood pressure where Bonferroni post-test showed 
significant reductions for KO mice compared to WT in standard (p < 0.05) as well as high salt 
diet (p < 0.01). No significant differences were found during the resting phase of the mice 
(Figure 63). 
Pulse height showed a significant increase in KO mice compared to WT during the resting 
period of the animals (p < 0.05) but not for the individual diets. Heart rates of KO mice were 
highly significantly reduced during the active (p < 0.001) and resting phase (p < 0.01) of the 
mice. When the mice were active, the high salt diet did not influence heart rate in neither WT 
nor KO mice, while heart rate dropped significantly (p < 0.05) in KO, but not WT, mice 
compared to standard diet when the mice were resting. No differences were found in dp/dt 
between WT and KO mice and standard and high-salt diets (Figure 64). 
All results of the fixed time period analysis for standard diet vs. 4 % NaCl containing diet are 
listed in Appendix A, Table 20. 
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Figure 63: Systolic, diastolic and mean arterial pressure of WT and KO mice during their active and 
resting times of the day, fed on standard diet or high salt diet as measured by radiotelemetry. Active 
and resting time points calculated from average values at 20:00-22:00 (active) and 8:00-10:00 
(resting) of the last day of the diet. * p < 0.05, ** p < 0.01, *** p < 0.001. N = 5, mean + SEM, two way 
ANOVA (reported below graphs) and Bonferroni post-test (bars). 
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Figure 64: Pulse height, heart rate and dp/dt of WT and KO mice during their active and resting times 
of the day, fed on standard diet or high salt diet as measured by radiotelemetry. Active and resting 
time points calculated from average values at 20:00-22:00 (active) and 8:00-10:00 (resting) of the last 
day of the diet. * p < 0.05, ** p < 0.01, *** p < 0.001. N = 5, mean + SEM, two way ANOVA and 
Bonferroni post-test. 
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Supplementation of the drinking water of the mice with 0.5 mg / l L-NAME led to a profound 
effect on blood pressure of the mice. During their active phase, systolic blood pressure of KO 
mice showed a significant (p < 0.05) increase in blood pressure. For diastolic and mean 
arterial pressures Bonferroni post-test showed that the difference between WT and KO mice 
was only significant on standard diet but non-significant when the mice were treated with the 
NO synthase inhibitor. In the light of the blood pressure traces, it seems plausible that the 
remaining (non-significant) difference would have grown even smaller if it would have been 
possible to treat the mice with L-NAME for a longer period of time. During the resting phase 
of the mice, systolic (p < 0.001), diastolic (p < 0.01) and mean arterial blood pressure (p < 
0.001) of WT as well as KO mice increased significantly when the mice were treated with L-
NAME and did not show any differences between WT and KO mice (Figure 65). 
As in the experiments with the high salt diet, pulse height of KO mice was significantly 
increased compared to WT in active (p< 0.05) as well as resting phases of the mice (p < 0.01). 
During the resting phase, L-NAME treatment increased pulse height significantly (p < 0.05) 
in KO mice but not WT mice. Heart rates of KO mice were significantly reduced in KO mice 
compared to WT control (p < 0.001) during the active phase of the mice. Supplementation of 
the drinking water of the mice with 0.5 mg / l L-NAME resulted in a further significant drop 
of the mice’s heart rate in both WT (p < 0.01) and KO (p < 0.05) animals. In contrast, no 
differences in heart rate were observed during the mice’ resting phase, neither between 
genotypes nor standard diet or L-NAME treatment. Dp/dt was increased significantly in KO 
mice compared to WT (p < 0.05) in active and resting phases alike (Figure 66). 
All numerical results of the fixed time period analysis for standard diet vs. 0.5 mg / l L-
NAME are listed in Appendix A, Table 21. 
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Figure 65: Systolic, diastolic and mean arterial pressure of WT and KO mice during their active and 
resting times of the day, fed on standard diet or 0.5 mg / ml L-NAME as measured by radiotelemetry. 
Active and resting time points calculated from average values at 20:00-22:00 (active) and 8:00-10:00 
(resting) of the last day of the diet. * p < 0.05, ** p < 0.01, *** p < 0.001. N = 5, mean + SEM, two way 
ANOVA and Bonferroni post-test 
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Figure 66: Pulse height, heart rate and dp/dt of WT and KO mice during their active and resting times 
of the day, fed on standard diet or 0.5 mg / ml L-NAME as measured by radiotelemetry. Active and 
resting time points calculated from average values at 20:00-22:00 (active) and 8:00-10:00 (resting) of 
the last day of the diet. * p < 0.05, ** p < 0.01, *** p < 0.001. N = 5, mean + SEM, two way ANOVA and 
Bonferroni post-test 
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7.2.3 Cardiac cine-MRI 
Investigation of the impact of CaSR from VSMC on the heart function and morphology was 
carried out using cardiac cine-MRI. This method is the most accurate way of determining 
cardiac status in live mice and allows for measurements of all relevant cardiac parameters, 
such as left- and right-ventricular volumes, ejection fraction, and left ventricular flow rates 
(Schneider et al. 2006). 
Scans were performed on age-matched 12, 14 and 18 month old WT and KO mice. Values for 
CO are not presented since the animals were imaged under general anaesthesia, which leads to 
changes in heart rates of the animals (Berry et al. 2009). Peak fill rate (PFR) and peak ejection 
rate (PER) are similarly difficult to interpret since these values relate flow rates per second, 
which is dependent on the speed of the cardiac cycle (i.e. heart rates). For the analysis of these 
parameters, all cardiac cycles were normalized to a period of one second. 
 
7.2.3.1 12 month-old animals 
Visual observation of the long axis (Figure 67) or short axis scans (Figure 68) did not show 
any obvious differences between the hearts of 12 month-old WT and KO mice. In agreement 
with this observation, no differences were found in the measured heart parameters of the 12 
month cohort (Figure 69). Calculation of remodelling indices showed no difference for 
systole but a small but significant reduction in the diastolic remodelling index, (DRI, indicates 
reduced diastolic volume compared to total weight of the left ventricle) of KO hearts 
compared to WT (Figure 70). These results are somewhat surprising in light of the findings in 
the 14 month cohort (largely increased DRI in KO hearts, see below). However, the observed 
difference is much smaller than the one found in the 14 month old KO animals showing 
visible cardiac remodelling and might be attributed to chance. Long- axis cardiac dimension 
measurements showed a significant increase in left ventricular end-systolic length (LV-ESL) 
in KO compared to WT animals but no changes in end-systolic diameter or end-diastolic 
dimensions (Figure 71). When the measured cardiac parameters were normalised to total body 
weight (TBW), this difference in ESL disappeared. All other normalised values did not show 
a difference between heart of 12 month old WT and KO mice as well (Figure 72). 
All numerical results from cardiac cine MRI of 12 month old animals are listed in Appendix 
A, Table 22. 
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Figure 67: Long axis cardiac MRI scans of hearts from 12 month old WT and KO mice during diastole 
and systole. 
 
 
Figure 68: Short axis cardiac MRI scans of the third basal slice of hearts from 12 month old WT and 
KO mice showing diastole and systole. Green = epicardium, red = endocardium. 
 
5 mm 
Diastole Systole Diastole Systole 
WT KO 
5 mm 
Diastole Systole Diastole Systole 
WT KO 
128 
 
TBW
WT KO
0
10
20
30
40
50
g
LVM
WT KO
0
50
100
150
200
m
g
LV-EDV
WT KO
0
20
40
60
80
µl
LV-ESV
WT KO
0
10
20
30
40
µl
LV-SV
WT KO
0
10
20
30
40
50
µl
LV-EF
WT KO
0
20
40
60
80
µl
LV-PFR
WT KO
0
50
100
150
200
250
µl
 / 
s
LV-PER
WT KO
0
50
100
150
200
250
µl
 / 
s
 
Figure 69: Measured and calculated left-ventricular cardiac parameters from short-axis cardiac cine-
MRI scans of 12 month old WT and KO mice. LV = left ventricular, LVM = left ventricular mass, EDV = 
end diastolic volume, ESV = end systolic volume, SV = stroke volume, EF = ejection fraction, PFR = 
peak fill rate, PER = peak ejection rate. N = 3, mean + SEM. 
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Figure 70: Calculated cardiac remodelling indices of from short-axis cardiac cine-MRI scans of 12 
month old WT and KO mice. DRI = end-diastolic remodelling index, SRI = end-systolic remodelling 
index. ** p < 0.01, N = 3, mean + SEM, two-tailed T-test. 
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Figure 71: Measured heart dimensions from long-axis cardiac cine-MRI scans of 12 month old WT and 
KO mice. LV = left ventricular, ESL = end systolic length, ESD = end systolic diameter, EDL = end 
diastolic length, EDD = end diastolic diameter. ** p < 0.01, N = 3, mean + SEM, two-tailed T-test. 
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Figure 72: Parameters obtained from cardiac cine-MRI scans of 12 month old mice normalised to 
TBW. See Table 9 for abbreviations. N = 3 (WT), 3 (KO), mean + SEM, two-tailed T-test. 
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7.2.3.2 14 month old animals 
In contrast to the findings on the 12 month old mice, visual observation of the long axis of 5 
WT and 11 KO hearts of 14 month old animals showed no difference in end-diastole but a 
striking difference in end-systole in 5 out of the 11 hearts from KO animals. In these 5 hearts 
from KO mice, the left ventricle closed up the apical left ventricular cavity completely while 
the apical left ventricular cavity was still visible at the end-systole of the WT mice and the 
other 6 KO mice (Figure 73). Thus, the hearts of the KO mice were separated in two groups, 
those without obvious visual remodelling (termed “no rem” in figures and graphs) and those 
where remodelling was observed (termed “rem” in figures and graphs). This narrowing of the 
left ventricular cavity could be observed in the third basal short axis slices (representative 
images in Figure 74) of the remodelled KO hearts but was especially obvious in more apical 
sections (representative images in Figure 75), indicating a funnel-like shape of the end-
systolic left-ventricle in KO mice which could be seen in 3D reconstructions of the left 
ventricle after analysis was complete (representative images in Figure 76). These observations 
were reflected in numerous changes in cardiac parameters of 14 month old KO mice 
compared to WT. Left ventricular end-diastolic (EDV) as well as end-systolic volumes (ESV) 
were non-significantly decreased in KO mice compared to WT and non-remodelled KO hearts 
while ejection fraction (EF) was significantly increased in the remodelled hearts. No 
significant change was observed in stroke volume (SV), left ventricular mass (LVM), total 
body weight (TBW), peak ejection rate (PER) or peak flow rate (PFR) between all groups 
(Figure 77). 
End-diastolic (DRI) and end-systolic (SRI) remodelling indices, measures of the size of the 
ventricle vs. the end-diastolic and -systolic volumes, were significantly increased in 
remodelled hearts from KO mice compared to WT confirming the visually observed cardiac 
remodelling in this group of five 14 month old KO mice compared to WT and non-
remodelled KO (Figure 78). 
Because of the observed changes in the left ventricle, the right ventricle was also analysed. No 
changes in right ventricular EDV, ESV, SV and EF were found between hearts from WT and 
remodelled hearts from KO mice. However, right ventricular EDV was significantly increased 
in non-remodelled hearts from KO mice (Figure 79). This result can attributed to the presence 
of one “outlier heart” in the non-remodelled KO group, which exhibited an enormously sized 
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right ventricle (blue arrow in Figure 73). Since a similar enlarged right ventricle was not 
observed in any of the other hearts. 
Measurements of length and width of the hearts based on long central long axis scans showed 
no significant differences when comparing end-diastolic length (EDL), end-diastolic diameter 
(EDD), end-systolic length (ESL) and end-systolic diameter (ESL) between all the groups 
(Figure 80). 
The same results as described above were found when the measured volumes and size 
parameters (excluding already normalized parameters like EF, PFR, PER, DRI. SRI) were 
normalised to TBW, except that there was a significant difference in normalised SV in non-
remodelled KO hearts compared to WT (Figure 81). As mentioned above, this result can be 
attributed to the large right ventricle present in one of the KO hearts which can very probably 
be classified as an outlier. 
All numerical results from cardiac cine MRI of 14 month old animals are listed in Appendix 
A, Table 23 and Table 24. 
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Figure 73: Long axis cardiac MRI scans of hearts from 14 month old WT and KO mice showing 
diastole and systole. While 6 KO hearts appeared comparable to WT (KO no rem) 5 out of 11 
investigated KO hearts (KO rem) exhibited marked narrowing of the apical left ventricular cavity in 
systole with almost no lumen visible (red arrows) while the others. One of the KO hearts showed an 
excessively large right ventricle (blue arrow). Rem = remodelling.  
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Figure 74: Short axis cardiac MRI scans of the third basal slice of hearts from 3 representative hearts 
from 14 month old WT and KO mice with visible remodelling (KO rem) showing diastole and systole. 
Green = epicardium, red = endocardium. The left ventricular lumen is in systole is visibly narrower in 
hearts from KO mice compared to WT. 
 
 
Figure 75: Short axis cardiac MRI scans of the second apical slice of 3 representative hearts from 14 
month old WT and KO mice with visible remodelling (KO rem) showing diastole and systole. Green = 
epicardium, red = endocardium. The left ventricular lumen is in systole is considerably narrower in 
hearts from KO mice compared to WT. 
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Figure 76: 3D reconstruction of the manually segmented left ventricles of 3 representative hearts from 
14 month old WT and KO mice with visible remodelling (KO rem). Green = epicardium, red = 
endocardium. Apex and base were not segmented. In contrast to WT (and non-remodelled KO hearts, 
not shown), left ventricular cavities of hearts KO of mice with visible remodelling showed a funnel-like 
shape in systole indicating apical wall-thickening. 
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Figure 77: Measured and calculated left-ventricular cardiac parameters from short-axis cardiac cine-
MRI scans of 14 month old WT, KO mice without visible cardiac remodelling (KO (no rem)) and KO 
mice with visible remodelling (KO (rem)). See Table 9 for abbreviations. * p < 0.05, N = 5 (WT), 6 (KO 
(no rem)), 5 (KO (rem)), mean + SEM, ANOVA with Dunnet post-test vs WT. 
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Figure 78: Calculated cardiac remodelling indices of from short-axis cardiac cine-MRI scans of 14 
month old WT, KO mice without visible cardiac remodelling (KO (no rem)) and KO mice with visible 
remodelling (KO (rem)). See Table 9 for abbreviations. ** p < 0.01, *** p < 0.001 N = 5 (WT), 6 (KO 
(no rem)), 5 (KO (rem)), mean + SEM, ANOVA with Dunnet post-test. 
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Figure 79: Measured right ventricular cardiac parameters from short-axis cardiac cine-MRI scans of 14 
month old WT, KO mice without visible cardiac remodelling (KO (no rem)) and KO mice with visible 
remodelling (KO (rem)). See Table 9 for abbreviations. * p < 0.05, N = 5 (WT), 6 (KO (no rem)), 5 (KO 
(rem)), mean + SEM, ANOVA with Dunnet post-test vs WT. 
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Figure 80: Measured heart dimensions from long-axis cardiac cine-MRI scans of 14 month old WT, KO 
mice without visible cardiac remodelling (KO (no rem)) and KO mice with visible remodelling (KO 
(rem)). See Table 9 for abbreviations. N = 5 (WT), 6 (KO (no rem)), 5 (KO (rem)), mean + SEM, 
ANOVA with Dunnet post-test vs WT. 
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Figure 81: Parameters obtained from cardiac cine-MRI scans of 14 month old mice normalised to 
TBW. See Table 9 for abbreviations. N = 5 (WT), 6 (KO (no rem)), 5 (KO (rem)), mean + SEM, 
ANOVA with Dunnet post-test vs WT. 
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7.2.3.3 18 month old animals 
Measurements at 18 months of age proved difficult as 2 of the mice in the KO cohort and 1 of 
the mice in the WT cohort died under anaesthesia prior to completion of the short axis scans. 
The KO group at this age was therefore reduced to N = 2, which does not allow statistical 
analysis. For this reason, results of the cardiac cine-MRI analysis of 18 month old animals are 
reported in Appendix B, 12.3.  
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7.3 Discussion 
In the following sections, I will discuss the cardiovascular phenotype of the SM22α-Cre x 
LoxP-CaSR mouse, which was assessed by tail cuff and radiotelemetry analysis as well as 
cardiac cine-MRI. I will describe observed changes in baseline blood pressure and the 
possible mechanisms behind them, as well as the specific effects observed when the mice 
were challenged with high salt and L-NAME diets. Furthermore, I will compare and explain 
ex vivo wire myography data from experiments performed in our group by Dr. Thomas Davies 
(c.f. (Davies 2013)), Dr. Polina Yarova and Mrs. Irene Lopez to allow for better 
understanding of these mechanisms. Finally, I will discuss the cardiac phenotype of the mice. 
 
7.3.1 Blood pressure measured by tail cuff 
A systematic problem in the tail cuff experiments was the post-hoc detection of a defect in the 
first used tail cuff equipment, leading to reading being overestimated. For repeated 
measurements with new equipment, only a limited number of mice were available, thus 
resulting in low N numbers, especially for WT mice. However, because of the later performed 
radiotelemetry studies, tail cuff experiments were not followed up further. 
Tail cuff experiments demonstrated that mice lacking the CaSR in VSMC had decreased 
blood pressure, which was more pronounced in diastolic than systolic blood pressure. The 
combined result for all tail cuff measured mice, showed a significant reduction by about 8 % 
or 12 % (MAP) respectively, depending on the ex- or inclusion of the overestimated values 
(see below). Interestingly, the KO paw temperatures of 3–6 month old KO animals were 
significantly lower than the ones of WT control animals, in line with the observed 
hypotensive phenotype in KO mice. 
(Systolic) blood pressure of mice has been shown to increase with age in a linear fashion by 
about 20 mm Hg from 2 to 12 months of age (Gros et al. 2002). However, no such increase 
was found in WT mice of 4, 9 and 17 month of age, which all showed comparable blood 
pressure.  
Stress due to handling and unknown environments is generally known to cause elevated blood 
pressure in mice (Mattson 2001; Hoorn et al. 2011) and high variability between tail cuff vs. 
telemetry as well as inter-study inconsistency have been described (Mattson 2001). Moreover, 
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differences of 10 mm Hg and more are common in murine blood pressure on an hour to hour 
basis (Mattson 2001) which can seriously affect measurement accuracy and precision, 
especially if the “real” difference between two measured groups, as is the case in this study on 
WT and KO mice, is equal or lower than this natural scatter in murine blood pressure.  
To address these issues, radiotelemetry studies with continuous 24 h blood pressure recording 
were performed.  
 
7.3.2 Baseline blood pressure measured by radiotelemetry 
Telemetry analysis showed a very significant and immediately obvious reduction in blood 
pressure of KO mice compared to WT control that was greater in diastolic than systolic blood 
pressure. The general trend of the blood pressure curves followed a downward direction over 
the course of the first few days of the experiment (while the mice were on standard diet). 
Differences in blood pressure as well as other parameters such as dp/dt only asserted 
themselves shortly before the mice were changed to a high salt containing diet. This effect can 
be easily explained by the time constraints we had to adhere to when performing the 
experiments. Telemetry data was recorded beginning from day 2 post operation. It is therefore 
very probable that mice had not fully recovered from the post-operation stress in addition to 
being transferred to a new and uncomfortable environment (metabolic cages) on day 1 of the 
experiment (Mattson 2001; Hoorn et al. 2011). This hypothesis is confirmed by the evidence 
that, as the mice acclimatized and recovered, downwards trend in the blood pressure curves 
were observed. Interestingly, while the mice were assumedly under high levels of stress, i.e. 
on the first days of the experiment, circadian rhythms were shifted in KO mice compared to 
WT control. This suggests a different stress or light / dark cycle responses in the SM22α-Cre 
x LoxP-CaSR mouse, which could be the direct consequence of VSMC CaSR (blood vessels 
are everywhere, hence also in the CNS), or could be a secondary response to the reduced 
blood pressure or due to other metabolic changes observed in these mice (see chapter 8). 
Further investigation of the circadian rhythms of these animals might prove interesting for 
future studies. 
Once the mice had acclimatised and recovered, and circadian rhythms had synchronised 
between WT and KO mice, the magnitude of the difference between WT and KO mice 
showed a large dependence on the circadian rhythm: while the difference in BP between WT 
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and KO mice was small to non-existent during the resting phase of the mice at daytime, 
especially for systolic blood pressure, it peaked at their active period during the night. This 
indicates that the difference between WT and KO mice was highest when sympathetic drive 
(active phase) was highest, therefore suggesting either directly reduced sympathetic drive or a 
reduction in response to sympathetic drive in KO mice (see next section). 
Keeping with the basic physiology formula of blood pressure being the product of CO and 
TPR, the reduced blood pressure observed in the SM22α-Cre x LoxP-CaSR mouse could be 
caused by a reduction in CO, a reduction in TPR or a combination of both. Additionally, 
secondary mechanisms attributing to one or the other include changes in the RAAS or 
sympathetic drive. These possibilities are discussed in the course of the following sections. 
 
7.3.3 Role of the heart and arterial compliance 
7.3.3.1 Influence of the heart rate on blood pressure of KO mice 
Heart rate of animals lacking the VSMC CaSR was reduced, suggesting a reduction in CO as 
possible cause for the reduction in blood pressure. Heart rate dropped in response to L-NAME 
treatment, probably as a compensatory response to the increased TPR elicited by the 
compound. Salt loading further depressed heart rate in resting, but not active, KO animals. 
This result is somewhat difficult to interpret, as a reduction in heart rate would normally be 
accompanied with an increase in blood pressure when indeed, if anything the opposite was the 
case. When analysing the traces, a marked drop in heart rate compared to standard diet (and in 
fact WT animals) can only be identified on the last day of the high salt diet which was 
selected pre-analysis for statistical comparison of the different diets’ effects. One might 
speculate that unknown external circumstances could have contributed to this singular event, 
but it is possible of course that the effects of the high salt diet requires time to develop and 
only manifested on the last day, although this seems unlikely.  
Nevertheless, the lower blood pressure of KO animals does not seem to be caused solely by 
the reduced heart rate. A reduction in heart rate goes along with a reduction in CO (CO = 
heart rate x SV) if the stroke volume is constant which seems to be the case between WT and 
KO animals, even in the group of KO animals with remodelled hearts. On the assumption that 
SV is constant between WT and KO mice, reduced CO would primarily lead to lower systolic 
and not diastolic blood pressure. The opposite was found in KO mice where diastolic blood 
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pressure showed a much greater reduction than systolic blood pressure, which argues against 
a direct (exclusive) effect of CO on blood pressure of these mice. Of course the weakness of 
this assumption is that heart rates and SV were measured on mice of very different ages (3 
months for heart rate, 14 months for SV). The situation might very well be different in hearts 
of 3 months old animals where differences in SV could be present, with the heart in ageing 
mice having adapted over time. Since CO was not directly measured and SV and general 
cardiac analysis was performed only on older animals where the blood pressure profile or 
heart rates might have changed through adaptation, this question cannot be answered at this 
time. Further studies measuring CO directly and cardiac MRI studies of (younger) animals 
will be required to define the role of the heart in blood pressure regulation of these animals. 
As a matter for speculation dp/dt was elevated in KO mice independently of salt loading or L-
NAME treatment. This could be interpreted in such a way that increased inotropy of the heart 
was compensating for the reduction in chronotropy, again possibly arguing against CO as 
major component of the reduced blood pressure observed in the KO mice. 
 
7.3.3.2 Possible causes for reduced heart rates in KO mice 
The question remains why KO mice show such a pronounced reduction in heart rate. Systemic 
administration of cinacalcet was shown to have no influence on heart rate of normal and 
uremic rats (Fryer et al. 2007). While this may only be circumstantial, it indicates that 
globally, CaSR does not affect heart rate to a great extent. Reduction in blood pressure is 
normally compensated by an increase in heart rate or vice versa via the baroreflex response 
(Wang et al. 2004). The fact that hypotension is accompanied with bradycardia in the SM22α-
Cre x LoxP-CaSR mouse could be attributed to a reduction in baroreflex response, which 
occurs through increased arterial stiffness (Phillips et al. 2014). However, increased arterial 
stiffness generally goes along with elevated systolic pressure, which was not the case in KO 
mice. Further no vascular calcification was detected in aortae of KO mice (see chapter 6) and 
lastly, the administration of L-NAME in the drinking water led to a significant reduction in 
heart rate of KO (and WT) animals, which suggests intact baroreflex action in response to the 
increase in TPR through L-NAME. This probably baroreflex mediated reduction of heart rate 
through L-NAME administration has already been suggested previously (Sheriff et al. 2000; 
Fellet et al. 2003; Jones et al. 2004). Taken together, these findings make reduced arterial 
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compliance and therefore impaired baroreflex response as cause for the reduced heart rate in 
SM22α-Cre x LoxP-CaSR mice unlikely if sympathetic drive is not impaired.  
Indeed, a possible explanation could be seen in a reduction in sympathetic drive in these 
animals, suggesting that baroreflex, or more accurately baroreceptors, is in actual fact 
working but cannot exert its function due to reduced action of the sympathetic nervous system 
or reduced susceptibility of the heart towards adrenergic stimulation. The could be suggested 
by the fact that differences in heart rate between WT and KO animals were most developed 
during the active period of the mice (where sympathetic drive is highest). However, it is 
unclear by which way the vascular CaSR would elicit such a response. Systemically, it is 
feasible that undetermined changes in the microvasculature caused by the lack of the VSMC 
CaSR influence adrenalin production in the adrenal glands. Indeed such a phenomenon has 
been described for vascular changes in a model of diabetic rats, but in this case widening of 
adrenal capillaries was associated with increased adrenal function (Sricharoenvej et al. 2009) 
which is in contrast to what we would expect in the SM22α-Cre x LoxP-CaSR mice. The 
CaSR has also been found to be expressed in sympathetic neurons (Vizard et al. 2008) 
indicating a role in regulation of the sympathetic nervous system. Stimulation of the CaSR 
with poly-L-arginine in cirrhotic and normal rats, while decreasing portal vein but not 
systemic pressure, did not result in changes in plasma noradrenaline levels (Sansoe et al. 
2013), pointing again away from a possible direct effect of the CaSR on adrenergic 
stimulation. Finally, although only circumstantial, the already mentioned baroreflex elicited 
reduction in heart rate when the mice were treated with L-NAME also points away from an 
impaired autonomous drive. Possible systemic influences are discussed in chapter 7.3.5. 
Finally, a direct effect of CaSR knock-out on the heart is plausible, especially in relation to 
the sporadic cardiac remodelling observed in KO mice, and the documented transient 
embryonic expression of SM22α in mice (Lepore et al. 2005). The CaSR might directly 
potentiate adrenergic signalling in the heart as a mechanism for the potentiation of Ca2+ 
dependent contractions has been described, albeit for blood vessels (Loot et al. 2013). The 
possibilities and implications of direct CaSR mediated effects on the heart are discussed in 
chapter 7.3.9. 
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7.3.4 Role of TPR  
On standard diet, baseline diastolic blood pressure exhibited a greater reduction than systolic 
pressure in KO mice compared to WT control. As already mentioned above, diastolic blood 
pressure is generally recognised to be mainly influenced by TPR, while CO is more related to 
systolic pressure. This strongly points to reduced TPR as the main cause for reduced blood 
pressure in these mice. Pulse height was elevated in KO mice compared to WT control. 
Elevated pulse height can be a sign of reduced arterial compliance, though as already 
discussed, this is apparently not the case in the SM22α-Cre x LoxP-CaSR mouse; the 
increased pulse pressure, again as its major component is a reduction in diastolic and not an 
increase in systolic pressure (as would expected in case of reduced arterial compliance) can 
therefore be attributed to the loss of TPR.  
 
7.3.5 Systemic influences 
The observed hypercalcaemia in KO mice (see next chapter) is probably not associated with 
the observed hypotension. Even though elevated dietary intake of Ca2+ is generally recognised 
to lower blood pressure, pathological hypercalcaemia is associated with elevated blood 
pressure. Acute hypercalcaemia in animal models consistently leads to blood pressure 
increase (Iseki et al. 1986; Thorin et al. 1990) and total serum calcium levels were found to be 
associated with hypertension in a large cross sectional clinical study (Sabanayagam and 
Shankar 2011). Vitamin D supplementation was shown to have very mild blood pressure 
lowering effects (Forman et al. 2013; Kunutsor et al. 2013). Yet, high levels of 1,25-D3, as 
present in the KO mice, are more associated with the onset of vascular calcification, increased 
blood vessel stiffness (Bas et al. 2006) and subsequent hypertension.  
Furthermore, an effect of the systemic hypercalcaemia (as described in the next chapter) is 
thinkable, although evidence in the literature on this in conflicting. While classical physiology 
indicates that acute hypercalcaemia is associated with bradycardia, patients suffering from 
primary hyperparathyroidism, who are chronically hypercalcaemic, do not present changes in 
heart rate (Rosenqvist et al. 1992; Barletta et al. 2000; Farahnak et al. 2010; Birgander et al. 
2012). 
At this point it is not possible to determine whether increased 1,25-D3 levels or 
hypercalcaemia would have an influence or contribution to blood pressure and heart rate in 
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the SM22α-Cre x LoxP-CaSR mouse, especially because of the multitude of other possible 
influences. A potential way to determine the magnitude of a putative influence of the 1,25-D3 
levels as well as the elevated blood Ca2+ levels would be the generation of a SM22α-Cre x 
LoxP-CaSR x 1-α-Hydroxylase-/- mouse, thereby feasibly normalising the changes in blood 
Ca2+ and Pi levels making an estimation of the independent, direct actions of the CaSR in 
blood vessels on blood pressure possible. 
 
7.3.6 Effect of salt loading on blood pressure 
Salt loading with a 4 % NaCl containing diet did not have an increasing effect on blood 
pressure of WT as well as KO mice. If anything, blood pressure further decreased in WT as 
well as KO animals (not statistically significant), which can probably be attributed to the 
continuing acclimatisation process of the mice to their environment in the metabolic cages 
rather as a direct effect of salt loading. This conclusion is also supported by the marked drop 
in blood pressure once the mice were transferred into more comfortable standard cages and 
back onto standard diet after the high salt phase was concluded. Had the blood pressure 
decrease been caused by salt loading, blood pressure would have increased following 
unloading. On the other hand, such an effect cannot be entirely disregarded. Metabolic cage 
studies described in the next chapter showed that while urine production and water 
consumption was increased in animals on both genotypes, urine production in KO animals 
was further increased compared to WT control without a concomitant increase in water 
consumption on the high salt diet. This could suggest that blood pressure in KO mice could 
have dropped on the high salt diet as a result of reduced blood volume. 
The missing effect of salt loading on WT mice was expected as high salt diet induced 
hypertension takes weeks to assert itself in healthy mice, especially on a part-C57/Bl6 
background (Gros et al. 2002). Nevertheless, the missing effect of salt loading on KO mice 
suggests that the hypotonic phenotype of these animals is not salt sensitive, thus excluding 
Na+ imbalance as cause for the observed hypotension. Indeed, biochemical studies described 
in the next chapter demonstrated that Na+ and Cl- serum as well as urinary excretion levels are 
unchanged between WT and KO mice.  
Finally, the absence of increased blood pressure in KO animals in response to salt loading 
points away from an involvement of the RAAS in the hypotension observed in these animals. 
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Transgenic animals lacking ACE (ACE-/-) have a phenotype of extensive hypotension, in all 
likelihood caused by impaired angiotensin II production and bradykinin breakdown. Salt 
loading leads to an immediate increase and normalisation of the blood pressure of these mice 
which is thought to be caused by a failure of the RAAS to detect high plasma Na+ levels 
(Carlson et al. 2002). The hypertension prevalent in chronic renal failure, which is associated 
with low renin levels and increased arterial stiffening, was also shown to be salt sensitive in 
rats after only 5 days of a 4 % NaCl containing diet (Nguy et al. 2013). The fact that SM22α-
Cre x LoxP-CaSR mice did not react with blood pressure normalisation to the high salt diet 
therefore provides some evidence that the RAAS, or at least ACE activity, in these mice is not 
impaired which is substantiated by the unchanged renin and aldosterone plasma levels 
observed in KO mice compared to WT as described in the next chapter. At first, this may 
seem surprising as the natural response to a drop in blood pressure would be the activation of 
the RAAS to combat the hypotension. However, it has to be kept in mind that the SM22α-Cre 
x LoxP-CaSR mouse is not an acute, but rather a chronic model. Consequently, the set-point 
for blood pressure maintenance and therefore action of the RAAS might be altered compared 
to mice being born with a functional vascular CaSR. Taken together these results indicate that 
kidney function and the RAAS are probably not causative in the hypotensive phenotype of 
these mice.  
 
7.3.7 Effect of NO synthesis inhibition on blood pressure 
As expected, blood pressure of both WT and KO mice increased when being given 0.5 mg / l 
of the NO synthase inhibitor L-NAME in their drinking water (Mattson 2001). Importantly, 
this increase was much larger in KO animals, particularly in systolic blood pressure, but also 
in diastolic pressure to the point that the difference between WT and KO animals was lost. 
This rectifying outcome of NO synthesis inhibition, together with the larger reduction in 
diastolic blood pressure again strongly points towards compromised TPR in mice lacking the 
VSMC CaSR and that this reduction in TPR might be caused by excessive NO synthesis / 
production in KO mice. 
Heart rate dropped significantly in both genotypes when the mice were awake, probably as a 
baroreflex mediated result compensating for increased TPR induced by L-NAME. The 
increase in pulse height, resulting from a greater increase in systolic than diastolic blood 
pressure, could indicate elevated CO in response to L-NAME. This is somewhat surprising as 
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heart rate was decreased. Dp/dt however showed a slight but significant increase in KO 
animals, suggesting a (further) elevated inotropy in KO hearts which could account for the 
greater increase in systolic than diastolic blood pressure. In light of the large(er) increase in 
contraction of KO blood vessels than WT control when treated with L-NAME (see below), it 
is also possible that systolic blood pressure increased because of increased stiffening of 
conductance arteries such as the aorta (Ruiz et al. 2008). 
 
7.3.8 Direct influence of the vascular CaSR on vascular tone 
The telemetry studies strongly pointed towards a reduction in TPR as cause for the 
hypotensive phenotype of the SM22α-Cre x LoxP-CaSR mouse.  
Direct interaction of the VSMC CaSR with contraction and / or dilation of VSMC and 
therefore changes in TPR seems to be the most probable explanation for the reduced blood 
pressure. One, or a combination of the following ways of interaction at the level of the blood 
vessels to achieve a lower TPR by CaSR deletion seems possible: direct contracting action of 
the CaSR on VSMC, direct inhibition relaxation of VSMC, indirect inhibition of relaxation of 
VSMC by decreasing NO sensitivity in VSMC and indirect promotion of contraction by 
increasing adrenergic stimuli (Figure 82).  
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Figure 82: Possible mechanisms of direct interaction of the VSMC CaSR with contraction and dilation 
of VSMC. Actions of the CaSR on VSMC to promote an increase in TPR, explaining the reduced blood 
pressure in KO mice. The CaSR could interact with adrenergic sensitivity, have a direct effect on 
contraction, inhibit NO sensitivity or inhibit VSMC dilation. Green arrows: stimulation, Red broken 
arrows: inhibition. 
 
To investigate these assumptions and a possible NO related mechanism (implied by the 
reduced difference in blood pressure elicited with L-NAME treatment), in collaboration with 
Dr David Edwards (Heart Centre, Cardiff University), Dr. Thomas Davies, Dr. Polina Iarova 
and Mrs. Irene Lopez of our group performed ex vivo wire myography studies on isolated 
blood vessels. In their experiments, rings of aortae of KO 3-6 month old KO animals showed 
a marked reduction of maximum contractility in response to phenylephrine compared to WT 
control (Figure 83A). Of note, potency of phenylephrine to evoke contraction was the same in 
WT and KO aortae (not shown), thereby excluding an effect of the VSMC CaSR on 
adrenergic sensitivity of VSMC. This observation is especially revealing in the light of the 
observation that the hypotension of KO mice compared to WT was most pronounced during 
the animals’ active phase, i.e. when sympathetic drive was greatest. This occurrence can 
therefore be explained by the reduced contractile activity elicited by phenylephrine and – by 
extension – adrenergic activity in vivo, on the microvasculature and therefore TPR and blood 
pressure. In addition to this loss of contractility in response to adrenergic stimuli, aortic 
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explants contracted less in response to high extracellular K+, which causes depolarisation and 
subsequent Ca2+i rise and contraction, which indicates that not only adrenergic contraction 
(Figure 83B), but the contractile ability of the blood vessels in general is impaired by loss of 
VSMC CaSR. 
In agreement with the observed effect of L-NAME on blood pressure in vivo, inhibition of 
NO synthesis with L-NAME increased general contractility and abolished the difference 
between WT and KO aortae (Figure 83C). Additional experiments with the NO donor S-
Nitroso-N-acetylpenicillamine (SNAP) (Dahboul et al. 2014) on endothelium denuded 
mesenteric arteries performed by Dr. Vladimir Matchkov (Aarhus University, Denmark) 
showed that there was no difference in NO potency between blood vessels of WT and KO 
mice (not shown). 
These results suggest that the VSMC CaSR contributes to blood vessel contraction by 
counterbalancing NO mediated dilation via a direct contractile effect. Such a contractile effect 
was already suggested by Ohanian and colleagues who observed a biphasic effect of Ca2+ on 
rat subcutaneous small arteries, causing contraction at lower and dilation in higher 
concentrations of Ca2+, although the authors believed that the contractile effect was probably 
not CaSR-mediated (Ohanian et al. 2005). However, we have found the same biphasic effect 
in WT aortae, while the contracting component was lost in KO aortae which only exhibited 
dilation in response to increases in extracellular Ca2+ (Figure 83D). This result clearly 
suggests that the VSMC CaSR is responsible for the Ca2+ induced contractions in these blood 
vessels.  
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Figure 83: Wire myography experiments performed by Dr. Polina Yarova and Dr. Thomas Davies 
(Davies 2013). A: Phenylephrine (PE) concentration response curves of WT and KO aortae. Mean ± 
SEM, N = 5, * p < 0.01, ** p < 0.01, two-way ANOVA with Bonferroni post-test. B: Contraction 
response of aortae to 45 mM KCl. Mean ± SEM, *** p < 0.001, N = 11, two-tailed T-test. C: 
Phenylephrine (PE) concentration-response curves of WT and KO aortae in the presence of 100 µM 
L-NAME. Mean ± SEM, N = 6 (WT), 7 (KO), two-way ANOVA with Bonferroni post-test. D: Ca2+ 
concentration-response curves of WT and KO aortae following preconstruction with 0.3 µM 
phenylephrine. Mean ± SEM, * p < 0.01, N = 4-8 (WT), 7-9 (KO), two-way ANOVA with Bonferroni 
post-test. 
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The intracellular signalling mechanisms involved which could be responsible for contraction 
of VSMC have recently been uncovered for human aortic smooth muscle cells, where CaSR 
activation leads to an increase in cytosolic Ca2+i via PLC/PKC pathway, releasing Ca2+ from 
intracellular stores via IP3 and activating TRPC receptor-operated Ca2+-channels (Chow et al. 
2011). My findings showing abundant CaSR expression in the vascular endothelium as well 
as studies by others (Ziegelstein et al. 2006; Loot et al. 2013) indicate that the CaSR also 
stimulates endothelial NO production (Awumey et al. 2013), thus suggesting a dual role for 
the vascular CaSR: contracting in VSMC and dilating in the endothelium (Figure 84). 
 
 
Figure 84: Simplified model of balanced CaSR action on VSMC and the endothelium. Green arrows 
indicate activation and black arrows indicate Ca2+ pathways. The VSMC CaSR directly elicits 
contraction in VSMC while the endothelial CaSR activates NO oxide production leading to dilation. 
Loss of VSMC CaSR in SM22α-Cre x LoxP-CaSR mice leads to an increase in NO dependant dilation 
and thus reduced blood pressure. 
 
However, this model is likely to be an oversimplification. While it can explain the effects I 
have described here to a certain extent, CaSR interaction with vascular contraction and 
dilation is very probably exceedingly more complex, as demonstrated by the numerous, partly 
contradictory effects of the CaSR on isolated blood vessels and blood pressure, as detailed in 
the introduction and reviewed by (Smajilovic et al. 2011). Loot and colleagues have recently 
found that murine blood vessels, in which the CaSR was inhibited via calcilytics, showed 
attenuated contraction is response phenylephrine as well as high K+ induced blood vessel 
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contractions. This is in agreement with our findings. In addition, Loot and colleagues also 
reported that blood vessels from animals fed a high fat diet showed also attenuated responses 
to phenylephrine which they attributed to increased cleavage of the VSMC CaSR by calpain 
during metabolic stress (Loot et al. 2013).  
Importantly, phenylephrine and K+ evoked contractions are driven by influx of extracellular 
Ca2+. This extracellular Ca2+ is then transported out of the VSMC and into the interstitium 
where it can again activate the CaSR (Hofer and Brown 2003; Loot et al. 2013). This 
autocrine self-amplifying pathway of VSMC contraction via the CaSR is then lost when mice 
blood vessels are treated with calcilytics (Loot et al. 2013). Indeed, loss of this mechanism in 
VSMC, together with increased or even unchanged NO production could explain the reduced, 
NO dependent, VSMC contractility in the SM22α-Cre x LoxP-CaSR mouse. Furthermore, 
Ca2+i transported out of the cell could activate CaSR present on endothelial projections in the 
myo-endothelial space (Dora et al. 2008), thus acting as in a negative feedback loop against 
VSMC contraction, providing a possible explanation for assumed increased NO levels in KO 
mice as cause for reduced vascular tone, which could explain the restored contractility of KO 
aortas and blood pressure when subjected to L-NAME. In KO animals, adrenergic stimulation 
would still lead to increased levels of Ca2+i which would be removed from the VSMC. 
However, because of the lack of a VSMC CaSR, no potentiation of the contraction would 
occur while the still functional endothelial CaSR would react with increasing NO production 
to the elevated Ca2+i levels in the myo-endothelial space. Figure 85 shows this proposed 
signalling mechanism. Extensive molecular biological work combined with mice with 
targeted CaSR deletion from the endothelium will be needed to investigate this hypothesised 
signalling mechanism. 
The contribution of NO mediated reductions in dilation warrants further investigation on the 
role of the endothelium in the SM22α-Cre x LoxP-CaSR mice by measuring circulating NO 
levels, eNOS expression and activity, as well as a thorough investigation in the role of the 
endothelial CaSR, potentially via a mouse model of targeted gene deletion, e.g. using the 
angiopoietin receptor Tie-2 promoter for driving Cre recombinase (Kisanuki et al. 2010), 
which would also allow the generation of a VSMC – endothelium double knock out mouse.  
In conclusion, I propose that the CaSR in VSMC counteracts NO-mediated reductions in 
blood vessel tone, possibly via a direct contribution to VSMC contraction via auto- / paracrine 
potentiation of Ca2+ dependent contractions. The loss of this potentiating mechanism is 
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responsible, or at least contributes, to the observed hypotension in the SM22α-Cre x LoxP-
CaSR mouse. 
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Figure 85: Proposed mechanism of the CaSR in VSMC and endothelial cells. Green arrows indicate 
activations; black arrows indicate Ca2+ pathways. (1) Ca2+ activates the endothelial CaSR, leading to 
increased Ca2+i levels through release from the endoplasmic reticulum (ER) which in turn activates NO 
production via eNOS which diffuses into VSMC promoting dilation (Ziegelstein et al. 2006). (2) 
Adrenergic stimulation via α1-adrenoreceptors (α1-AR) leads to increased Ca2+i levels via Ca2+ 
release from the sarcoplasmic reticulum (SR) leading to depolarisation and activation of voltage gated 
Ca2+ channels (Cav) and subsequent contraction. Ca2+i is then removed from the cell via various 
mechanisms (CaX), including the Na-Ca-exchanger and Ca2+-ATPase, into the interstitium (3) where it 
can act on CaSR which in turn activates TRPC receptor activated Ca2+ channels (ROC) (Chow et al. 
2011) and releases Ca2+ from the SR leading to potentiated contraction (Loot et al. 2013). Ca2+i is also 
removed into the myoendothelial space where it can activate CaSR on endothelial projections (Dora et 
al. 2008) again promoting NO production. Note that this schematic does not include alternative 
proposed signalling mechanisms of EDH, i.e. K+ clouds or hyperpolarisation transfer via gap junctions 
(Weston et al. 2005) nor the influence of perivascular nerves. This signalling mechanism was devised 
with the help of Dr. Polina Yarova and is based on ideas proposed in (Loot et al. 2013).  
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7.3.9 Cardiac remodelling 
No cardiac remodelling was visible in hearts from12 month old animals irrespective of 
genotype. However, at 14 months of age, cardiac remodelling was observed in five out of 
eleven investigated hearts of KO mice, while no remodelling was found in hearts of WT mice. 
As an age difference of only 2 months is probably not likely to elicit such a marked increase 
in remodelling, and seeing that only less than half of the 14 month old animals presented with 
cardiac remodelling, it is possible that the effect was just missed in the 12 month old animals 
because only 3 mice of each genotype were investigated.  
The remodelled hearts were immediately apparent in the long axis scans, where the apical left 
ventricular cavity was closing up completely during systole, while appearing normal during 
diastole. In 3D reconstructions, this was seen as a marked change in the shape of the left 
ventricular cavity exhibiting a funnel-like appearance. Based on this visual observation, the 
hearts were divided into three groups, hearts from WT mice, non-remodelled KO hearts and 
remodelled KO hearts. In the cardiac parameters, the remodelling presented itself with 
(borderline non-significantly) decreased LV-EDV and LV-ESV, in combination with 
significantly increased LV-EF, while LVM, SV, PFR and PER were unchanged between all 
three groups. The remodelling index is a relatively new parameter to assess changes in heart 
geometry in relation to function (De Castro et al. 2007). DRI and SRI were both significantly 
increased in remodelled KO animals compared to WT control, expressing the striking visual 
change into comparable numbers. Compared with published values in the literature on 12 
month old C57/Bl10 mice, LV-EDV and LV-ESV of WT mice were lower (by about 10-13 
µl) while EF was elevated by about 5 % (Stuckey et al. 2012). However, these differences can 
probably be attributed to differences in mouse strain, age and detection method.  
Importantly, when re-analysing for wall thickness in the WT and KO hearts from the 14 
month age group, Mr Peter Edwards, an undergraduate student working in our laboratory, 
found that wall thickness appears to be generally increased in hearts from KO mice compared 
to WT control, even in the non-visibly remodelled KO group (Peter Edwards, personal 
communication). This indicates beginning remodelling in all KO mice with some presenting 
an exacerbated phenotype pointing to individual differences in the susceptibility for 
development of cardiac remodelling or of the mice which at the moment cannot be explained. 
Probably the most unexpected feature of the visibly remodelled KO hearts was the increased 
EF, resulting from the respectively greater reduction in systolic than diastolic volume 
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compared to WT mice. Classical cardiac remodelling as a marker of heart failure is generally 
associated with reductions in EF caused by reduced inotropy (Klabunde 2005), while 
increased EF is associated with cardiac health. At the same time, SV was equal across all 
genotypes. In the telemetry studies on 3 month old animals, KO mice were shown to have 
markedly reduced heart rate. If this difference in heart rate persists in 14 month old animals, 
this could be indicative of lower CO in KO animals compared to WT. The fact that EF is 
increased in the KO could thus be interpreted as a compensating increase in inotropy, which is 
also suggested by the increased dp/dt values in the telemetry experiments (although again on 
different age groups) possibly in response to lower blood pressure. However, tail cuff 
measurements of 14 and 17 month old animals failed to detect a significantly reduced blood 
pressure in these mice.  
 
7.3.9.1 Possible change in inotropic response 
The underlying cause for the cardiac remodelling could be a compensatory response in form 
of increased inotropy (but not chronotropy) of the hearts in KO mice to the reduced blood 
pressure which develops over time and possibly in an individual specific manner. Supporting 
the notion of an acquired cardiac phenotype, Dr. Thomas Davies has shown that while heart 
weights of 6 month old animals did not differ, hearts of 18 month old animals were 
significantly heavier than hearts from age matched WT control (Davies 2013). A higher 
inotropy in hearts from KO mice is supported by the general increase in dp/dt observed in KO 
mice compared to WT control. This increase in inotropic contraction in the KO hearts could 
also be a function of the hypercalcaemia present in these mice, as elevated Ca2+o causes 
increased contractile force of the heart. This relationship has been shown for hypercalcaemic 
hyperparathyroidism patients before and it subsided after parathyroidectomy (Otto et al. 
2003). 
 
7.3.9.2 Possible deletion of the CaSR from the heart 
Hypotension, presented together with cardiac remodelling, is uncommon but has been 
reported previously (Wang et al. 2010; Schreier et al. 2013). Interestingly, in one of the 
studies the observed cardiac hypertrophy was caused by knocking out the epidermal growth 
factor receptor EGFR (a receptor tyrosine kinase) from VSMC and cardiomyocytes using the 
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SM22α-Cre mouse for target specific ablation. EGFR KO mice also showed a phenotype of 
reduced diastolic and mean arterial blood pressure through reduced TPR, although those 
SM22α-Cre x LoxP-EGFR mice, in contrast to the SM22α-Cre x LoxP-CaSR mouse, had a 
much higher mortality than WT control and more severe cardiac remodelling (Schreier et al. 
2013). These results act as a reminder that the SM22α-Cre promoter is not fully target specific 
for VSMC. SM22α is also expressed transiently in the heart (and other cells of myogenic 
lineage) of mouse embryos (Li et al. 1996a), and possibly the adult heart (Lepore et al. 2005), 
which suggests deletion of the CaSR from cardiac tissue.  
The CaSR is expressed in various cell types in the heart (Wang et al. 2003; Klein et al. 2008), 
though like in VSMC cells, its roles there are not yet fully understood. However, several 
studies strongly point towards a protective role for the cardiac CaSR against cardiac 
remodelling which would be in-line with the increased prevalence in cardiac remodelling 
observed in the hearts of SM22α-Cre x LoxP-CaSR mice. 
In vitro, expression of the receptor has been demonstrated in cultured neonatal rat 
cardiomyocytes (Tfelt-Hansen et al. 2006) where it has been suggested to promote apoptosis 
(Sun et al. 2006; Qi et al. 2013) and in a recent study, the cardiac CaSR has been found to be 
associated with the promotion of proliferation of cardiac fibroblasts (Zhang et al. 2014). 
Indeed, in this study, although performed on cells grown from aortic explants, cells derived 
from KO aortae showed increased cell density and reduced levels of apoptosis, the latter not 
being the case when adjusted for VSMC only (see chapter 12.1). In vivo, the cardiac CaSR 
has been implicated in protecting the cardiac tissue from ischemic preconditioning (Sun and 
Murphy 2010) and diabetic cardiomyopathy (Bai et al. 2012; Qi et al. 2013). Importantly, in a 
model of uremic rats, treatment with the calcimimetic R-568 attenuated cardiac fibrosis and 
the expression of hypertrophy and fibrosis marker proteins although left ventricular mass 
remained unchanged (Mizobuchi et al. 2011). These results show that complete ablation of the 
CaSR from the heart could have a profound influence on cardiac function and structure. 
I also speculate that, if the VSMC CaSR directly contributes to VSMC contractility, possibly 
via autocrine potentiation of Ca2+ dependant contractions (see above and (Loot et al. 2013)), a 
similar mechanism might exist in the heart and the observed reduction in heart rate could be a 
direct result of CaSR deletion in the cardiomyocytes, which might be independent of the 
discovered role of the CaSR in vascular tone regulation. On the other hand, this would 
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probably associate with reduced inotropic responses as well, which argues against that 
hypothesis. 
 
7.3.9.3 Systemic influences 
Apart from a direct effect of CaSR deletion on heart tissue and cardiomyocytes, it is 
conceivable that cardiac remodelling could even be a direct effect of CaSR deletion from 
coronary blood vessels, e.g. by reduced tone and therefore blood supply. Alternatively cardiac 
remodelling could also be caused by the chronic exposure of the mice’s hearts to elevated 
FGF23 levels that were observed in 3 and 18 month old mice. FGF23 was shown to induce 
left ventricular hypertrophy independently of its renal co-factor klotho in isolated rat 
cardiomyocytes, in mice intracardially injected with FGF23 as well as in klotho-deficient 
mice which have upregulated systemic levels of FGF23 (Faul et al. 2011). 
Furthermore, the striking changes in the mineral ion metabolism of the mice could play a role 
in the development of the cardiac remodelling. As argued in the following chapter, the mice 
present a phenotype resembling primary hyperparathyroidism. Primary hyperparathyroidism 
can be, but does not have to be associated with cardiac hypertrophy (Stefenelli et al. 1993; 
Farahnak et al. 2010; Walker et al. 2010). However, hypertrophy is commonly attributed to 
the increased blood pressure and calcifications (Stefenelli et al. 1993) while the KO mice are, 
due to decreased vascular contractility, hypotensive and show no ectopic calcifications. Other 
studies have inferred that PTH itself could be the cause for left ventricular remodelling 
(Schiffl and Lang 2011) although in the light of the results by Faul and colleagues, it is 
possible that indeed FGF23 is the main factor in cardiac hypertrophy in primary 
hyperparathyroidism. 
 
7.3.9.4 Future prospects 
To determine if the observed changes in remodelled KO hearts are indeed caused by 
ventricular remodelling, we will have to perform histological examination of mouse hearts 
specifically aimed at detecting markers of fibrosis and hyperplasia. 
Irrespective of all these possibilities, it should be emphasised that the results obtained from 
the cine-MRI studies produced somewhat ambiguous results (no remodelling of KO hearts at 
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12 months, remodelling in 5 out of 11 investigated hearts at 14 months). On the other hand, 
heart rate was consistently reduced in younger animals, suggesting that the reduction in heart 
rate takes precedence over a possibly long-term acquired cardiac remodelling.  
Further studies with additional methods to assess cardiac function are therefore necessary in 
the future. Indeed, at the time of the submission of this thesis, talks on collaboration to 
achieve these ends are already in progress. In all likelihood, ex vivo Langendorff experiments 
on isolated hearts from WT and KO animals will be performed in collaboration with Prof. 
Kenneth Broadley (Cardiff University) for precise measurement of innate heart contractility 
and frequency of WT and KO mice, thus allowing us to answer the question if the hearts from 
the SM22α-Cre x LoxP-CaSR mice are intrinsically different from their WT counterparts. In 
addition, we are discussing the possibility of performing high frequency echocardiography in 
collaboration with Dr. Rene Botnar, (Kings College, London, UK) which will allow 
determination of CO in vivo and thus the contribution of their cardiac phenotype to the 
hypotension observed in KO mice. Finally, electrophysiological experiments on isolated 
cardiomyocytes should be performed to allow the assessment of contractility and ion channel 
expression in these cells. 
As already mentioned, to dissect the direct influences of the VSMC CaSR on the heart as well 
as the vasculature and blood pressure from putative systemic influences, generation of a 
SM22α-Cre x LoxP-CaSR – 1-α-Hydroxylase-/- mice, which could rescue the phenotype of 
extensive changes in mineral ion metabolism (see next chapter) could be revealing. 
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7.4 Conclusions 
• The VSMC CaSR is involved in blood pressure regulation; SM22α-Cre x LoxP-CaSR 
KO mice show reduced blood pressure which can be attributed to impaired 
arterial contractility (reduced TPR) and possibly reduced heart rate, but not the 
RAAS. 
• Inhibition of NO synthesis restores blood pressure in KO mice and contractility in 
isolated aortic rings. The VSMC CaSR therefore has a direct contractile effect on 
blood vessels which counterbalances NO induced dilation. 
• Sporadic cardiac remodelling and reduced heart rate in KO animals could be 
caused by a compensatory effect to the hypotension, direct CaSR deletion from 
cardiac tissue, influence of chronic exposure to high FGF23 levels or changes in 
the cardiac vasculature. Further studies are required to elucidate the cardiac 
function of the SM22a-Cre x LoxP-CaSR mouse. 
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8 Effect of VSMC specific CaSR deletion on 
metabolism and mineral ion homeostasis 
8.1 Introduction 
In this chapter, I describe metabolism and mineral ion homeostasis in the SM22α-Cre x LoxP-
CaSR mouse. 
Metabolism of the mice was assessed using metabolic cage studies when the mice either fed a 
standard or a high salt (containing 4 % (w/w) NaCl) diet. The mice of these experiments were 
subsequently used for telemetry analysis of their blood pressure, allowing measuring the 
influence of the high salt diet on metabolism together with blood pressure. As already 
described in the previous chapter, high salt diets are generally recognised to induce 
hypertension and, although this effect can take weeks to manifest itself in mice (Gros et al. 
2002), it can be useful short-term to determine a NaCl-sensitive phenotype (Carlson et al. 
2002). The high salt diet in the context of the analysis of food and water metabolism can also 
be seen as a test for renal function. 
The CaSR has been shown to be expressed all along the gastrointestinal tract where it acts as 
nutrient sensor (Brennan et al. 2014), and is also expressed in the small and large intestines 
(Chattopadhyay et al. 1998) where it is involved in the inhibition of fluid and Cl- secretion 
(Cheng et al. 2002) induced by natural secretagogues as well as bacterial enterotoxins (Geibel 
et al. 2006). This anti-secretory effect seems to be elicited through a combination of direct 
action on epithelial cells as well as through an influence on the intestinal nervous system 
(Cheng 2012). A knock-out study using the same LoxP-CaSR mouse as in this study, revealed 
a role for the colonic epithelial CaSR in controlling cell proliferation and maintenance of 
crypt structure possibly via wnt/β-catenin signalling (Rey et al. 2012). Furthermore, CaSR 
localised in colonic myofibroblasts regulates epithelial differentiation (Pacheco and Macleod 
2008). Since SM22α is expressed in colonic myofibroblasts, investigation of possible 
gastrointestinal changes in the SM22α-Cre x LoxP-CaSR mouse could provide further insight 
in CaSR mediated action of myofibroblasts. Since this study focuses mainly on the vascular 
roles of the CaSR, investigation of the gastrointestinal phenotype of the mice exceeding 
metabolic cage studies will be investigated in collaboration with Dr. Enikö Kallay and Mr. 
Abhishek Aggarwal (University of Vienna, Austria).  
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Similarly to the gastrointestinal tract, the renal / urogenital tract of the mice is of particular 
interest in connection with the CaSR. The CaSR has been shown to play a major role in the 
kidney where it is expressed in all nephron segments (Riccardi et al. 1998). The main function 
of the renal CaSR is by directly promoting urinary Ca2+ excretion by the thick ascending limb 
upon it sensing elevated blood Ca2+ levels, in concert with its role as suppressor of PTH 
production by the parathyroid glands, indirectly resulting in decrease urinary Ca2+ 
reabsorption. In addition, the CaSR suppresses renin release (Maillard et al. 2009), regulates 
PTH-inhibited phosphate reabsorption in the proximal tubule, inhibits Na+, Ca2+ and Mg2+ 
reabsorption in the thick ascending limb and Ca2+ reabsorption in the distal tubule and 
promotes urine acidification and polyuria in the collecting duct, as reviewed in (Riccardi and 
Brown 2010). Although these effects are elicited by CaSR expressed in renal cells, the kidney 
is an extremely highly vascularised organ, which makes an influence of the VSMC CaSR on 
renal function plausible. While an investigation of the renal phenotype of the SM22α-Cre x 
LoxP-CaSR mouse is planned as part of the general characterisation of this mouse model, it 
was not a primary aim of this thesis. The changes in blood pressure of these mice (see chapter 
7.2) implied an involvement of the kidney in this process, by controlling diuresis, TPR or 
both. To assess kidney function, urine production and ionic composition were assessed when 
the mice were fed either standard diet, or a high salt diet (containing 4 % (w/w) NaCl).  
Blood and urine clinical chemistry was of particular interest in the characterisation of the 
SM22α-Cre x LoxP-CaSR mouse. Blood chemical analysis included measurements of 
electrolytes, creatinine, blood urea nitrogen and total protein as an estimate for the animal’s 
renal health. Furthermore, CaSR-regulated hormones involved in mineral ion homeostasis, 
namely PTH and 1,25-(OH)2-Vitamin D3 (1,25-D3) were measured. In addition, because of its 
role as phosphaturic hormone and in its ability to induce cardiac remodelling (Faul et al. 
2011) of KO mice (see chapter 7.2.3), serum FGF23 levels were also measured. 
Renin and aldosterone plasma levels were measured to investigate a potential involvement of 
the renin angiotensin aldosterone system (RAAS) in the observed changes in blood pressure 
in the SM22α-Cre x LoxP-CaSR mice. Finally, plasma concentration of the calcification 
inhibitor fetuin A was measured. 
Because of the involvement of the kidney and the renal CaSR in mineral ion metabolism, 
especially Ca2+ excretion, urine composition of WT and KO mice was investigated. 
Creatinine acts as a general marker of kidney function, as its excretion rate is exclusively tied 
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to glomerular filtration and can therefore be used to normalise electrolyte excretion to kidney 
function. Urea, total protein and uric acid levels in urine were measured as markers of kidney 
function and health. 
Finally, the bone status of the SM22α-Cre x LoxP-CaSR mice was assessed. As already 
outlined, the bone plays a major role in mineral ion metabolism as it acts as the major 
reservoir for Ca2+. The CaSR plays a major role in bone biology (Chang et al. 1999), 
especially in promotion of osteoblastic activation and incorporation of Ca2+ in the bone 
(Chang et al. 2008). 
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8.2 Results 
8.2.1 Metabolic cage studies 
The metabolism of 12-18 month old male WT and KO mice was investigated using metabolic 
cages. Monitoring over 24 hours showed an increased amount of faeces excreted by KO mice 
compared to WT control while there were no differences in food, water consumption and 
urine excretion over a 24 h period (Figure 86). By observation, faeces of KO mice had a 
damper appearance than faeces from WT mice. The metabolic cages used in this experiment 
are optimized for rat. The obtained results should therefore be interpreted with caution. 
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Figure 86: Metabolic cage studies of WT and KO mice. Data were normalised to daily collection 
periods and animal body weight. * p < 0.05, N = 6 (food consumption, faeces excretion and water 
consumption), 5 (urine excretion), mean + SEM, two-tailed T-test. 
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Additional metabolic cage studies were performed on 3 month old animals in collaboration 
with Prof. Robert Fenton and Dr. Vladimir Matchkov (Aarhus University, Denmark) in 
metabolic cages specifically designed for mice and over a period of 9 days. After 4 days, the 
diet of the investigated mice was changed from standard diet to a high salt (containing 4 % 
NaCl) diet to investigate the capabilities of the KO mice to handle high salt load in terms of 
blood pressure (see chapter 7.2.1) and metabolism. 
Like the 12-18 month old animals, no difference in food and water consumption, nor faeces 
and urine excretion was observed between WT and KO animals while they were fed a 
standard diet. Levels of food consumption rose during the first two days but remained stable 
afterwards which can be attributed to the mice not adjusting to their new environment in the 
metabolic cages. When the diet was changed to a high-salt (containing 4% NaCl) diet, food 
consumption and faces excretion remained unchanged compared to the standard diet in both 
WT and KO animals. As expected, the high-salt diet resulted in large increase in both water 
consumption and urine excretion in mice of both genotypes. On the high salt diet, KO mice 
showed a significantly higher urine excretion than WT mice. See Figure 87 for traces and 
Figure 88 for direct comparisons between diets and genotypes.  
All numerical results of the metabolic cage studies are listed in Appendix A, Table 25. 
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Figure 87: Metabolic cage studies of 3 month old male WT and KO mice. The traces show food 
consumption, faeces excretion, water consumption and urine excretion over a course of 9 days. 
Standard diet was changed to a high salt (containing 4% NaCl) diet (yellow area). Data were 
normalised to daily collection periods and animal body weight. 
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Figure 88: Metabolic cage studies of 3 month old male WT and KO mice. Comparisons between 
averages of data for standard diet vs. 4 % NaCl diet are shown (see Figure 87). Data were normalised 
to daily collection periods and animal body weight. ** p < 0.01, *** p < 0.001, N = 6 per genotype, 
mean + SEM, two-way ANOVA with Bonferroni post-test 
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8.2.2 Clinical chemistry 
8.2.2.1 Blood 
Serum of 3 (Figure 89) as well as 18 month (Figure 90) old KO mice showed a significant 
increase in Ca2+ levels control (p < 0.01 and p < 0.05 respectively). As the samples showed 
some haemolysis, K+ levels are not reported. Mg2+, Na+ and Cl- levels did not differ between 
the genotypes. FGF23 levels were significantly increased in 3 (Figure 91) as well as 18 month 
old KO animals (Figure 92) compared to WT control (p < 0.01 and p < 0.05 respectively). 
Plasma from a further batch of 3 month old mice was analysed for the concentrations of 
biomarkers for calcium metabolism, kidney function and protection from calcification. PTH 
(intact PTH) levels showed a slight increase in KO mice compared to WT control, although 
this difference was not significant and the mice showed a high variability in PTH levels 
independent of genotype. 1,25-D3 levels were significantly elevated (p < 0.01) in KO mice 
compared to WT control, showing an about two-fold increase. No differences were found in 
renin and aldosterone level, as well as pyrophosphate and fetuin A levels between WT and 
KO mice (Figure 93). 
Clinical chemistry results from plasma of the 3 month old male mice used for telemetry and 
metabolic cage analysis in collaboration with Prof. Robert Fenton and Dr. Vladimir Matchkov 
(University of Aarhus, Denmark) are reported separately, as it was obtained following 2 days 
of the mice being fed 0.5 mg / ml L-NAME in their drinking water. Na+ and creatinine levels 
showed a significant (p < 0.05) reduction in KO mice compared to WT. In good agreement 
with the previously obtained results, Ca2+ levels were highly significantly (p < 0.001) elevated 
in these mice. Plasma Pi concentration showed a non-significant trend towards reduction in 
the KO mice compared to WT (p = 0.0679), which is in agreement with hypophosphataemia 
in the same mice reported to us from our collaborator Prof. Wenhan Chang (personal 
communication). K+, Cl-, Mg2+, blood urea nitrogen and total protein levels were unchanged 
between WT and KO mice (Figure 94). 
Numerical values for all clinical chemistry blood analyses are listed in Appendix A, Table 26. 
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Figure 89: Electrolyte analysis of sera collected from 3 month old WT and KO mice. ** p < 0.01, N = 11 
(WT), 4-6 (KO), mean + SEM, two-tailed T-test. 
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Figure 90: Electrolyte analysis of sera collected from 18 month old WT and KO mice. * p < 0.05, N = 3, 
mean + SEM, two-tailed T-test. 
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Figure 91: FGF23 levels of sera collected from 3 month old WT and KO mice. ** p < 0.01, N = 11 
(WT), N = 6 (KO), mean + SEM, two-tailed T-test. 
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Figure 92: FGF23 levels of sera collected from 18 month old mice. ** p < 0.01, N = 3, mean + SEM, 
two-tailed T-test. 
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Figure 93: PTH, 1,25-D3, renin, aldosterone and fetuin A levels of plasma collected from 3 month old 
male WT and KO mice. ** p < 0.01, N = 12 (WT), N = 12 (KO), mean + SEM, two-tailed T-test. 
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Figure 94: Electrolyte, creatinine, blood urea nitrogen and total protein levels of sera collected from 
male WT and KO mice following metabolic cage studies and 2 days of 0.5 mg / ml L-NAME (drinking 
water) administration. * p < 0.05, *** p < 0.001, N = 6, mean + SEM, two-tailed T-test. 
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8.2.2.2 Urine 
Urine of the 3 month old male mice used for telemetry and metabolic cage studies (see 8.2.1) 
was analysed. 24 h urine collections were performed while the animals were fed standard diet 
or a high salt diet containing (4 % (w/w) NaCl. Electrolyte concentrations are reported as 
ion:creatinine ratio (abbreviated as ion:Cr), other clinical urine biomarkers (creatinine, total 
protein, urea and uric acid) are reported as excreted amount per day and total body weight 
(TBW). 
When fed standard diet, urine of WT and KO animals showed no differences in Na+:Cr, 
K+:Cr, Cl-:Cr and Mg2+:Cr. Ca2+:Cr and Pi:Cr were both highly significantly (p < 0.001) 
elevated in KO animals compared to WT. On the high salt diet, electrolyte excretion generally 
increased in animals of both genotypes compared to the standard diet, with Na+:Cr, Cl-:Cr, 
K+:Cr, and Pi:Cr showing a highly significant (p < 0.001) and Ca2+:Cr and Mg2+:Cr a 
significant increase (p < 0.05). On the high salt diet, in addition to the persisting large 
elevation in KO mice of Ca2+:Cr and Pi:Cr compared to WT control which was already seen 
on the standard diet (p < 0.001), K+:Cr as well as Mg2+:Cr of KO mice were highly 
significantly increased (p < 0.01) compared to WT animals (Figure 95). 
No significant differences were found in creatinine, total protein and urea excretion 
irrespective of genotype or standard vs high salt diet. Uric acid excretion was significantly 
elevated on the high salt diet (p < 0.01) vs standard diet in both genotypes (Figure 96).  
Numerical values for all clinical chemistry urine analyses are listed in Appendix A, Table 27. 
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Figure 95: Electrolyte concentrations of urine from 24 h collections using metabolic cages from 3 
month old WT and KO mice on standard or high salt (containing 4 % (w/w) NaCl) diet. Concentrations 
shown as ion:creatinine (Cr) ratio. * p < 0.05, ** p < 0.01, *** p < 0.001, N = 5-6, 4 (Mg2+ WT), 3 (Mg2+ 
KO), mean + SEM, two-way ANOVA with Bonferroni post-test. 
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Figure 96: Clinical chemistry of urine from 24 h collections using metabolic cages from 3 month old 
WT and KO mice on standard or high salt (containing 4 % (w/w) NaCl) diet. Concentrations shown as 
excreted amount per day and TBW. * p < 0.05, ** p < 0.01, *** p < 0.001, N = 5-6, mean + SEM, two-
way ANOVA with Bonferroni post-test. 
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8.2.3 Bone 
Hind-leg bones (femur, tibia and fibia) of 3 month old WT and KO animals were analysed by 
µCT by Dr. Wenhan Chang, UCSF, USA. Trabeculae of the distal femur as well as cortical 
bone of the tibio-femural junction were analysed. Reductions in bone quality were indicated 
by significant changes in all measured femoral trabecular bone parameters (Figure 97), i.e. 
total volume (Tb.TV), bone volume (Tb.BV), bone volume fracture (Tb.BV/TV), connectivity 
density (Tb.CD), structure model index (Tb.SMI.), trabecular number (Tb.N), trabecular 
spacing (Tb.Sp) and trabecular bone mineral density (Tb.BMD). In cortical bone, only bone 
mineral density (Ct.BMD) was significantly reduced (Figure 98). Results and statistical 
analysis of all investigated bone parameters are reported in Appendix A, Table 28. 
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Figure 97: Bone parameters of the trabecular bone of the distal femur of 3 month old WT and KO mice 
as determined by µCT. Tb = trabecular bone of distal femur, TV = total bone volume, BV = bone 
volume, BV/TV = bone volume ratio, CD = connectivity density, SMI = structure model index, N = 
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number of trabeculae, Th = trabecular thickness, Sp = trabecular spacing, BMD = bone mineral 
density (arbitrary units). * p < 0.05, ** p < 0.01, two-tailed T-test. 
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Figure 98: Bone parameters of the cortical bone of tibio-fibular junction of the distal femur of 3 month 
old WT and KO mice as determined by µCT. Ct = Cortical bone of tibio-fibular junction, TV = total bone 
volume, BV = bone volume, BV/TV = bone volume ratio, BMD = bone mineral density (arbitrary units), 
Th = thickness. ** p < 0.01, two-tailed T-test. 
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8.3 Discussion 
From the initial hypothesis for deletion of the CaSR in VSMC, namely the role of the VSMC 
CaSR in vascular calcification, we were surprised to see the large differences in mineral ion 
homeostasis in KO mice. The SM22α-Cre x LoxP-CaSR presented striking differences in 
Ca2+ and Pi handling, namely a phenotype of hypercalcaemia, hypercalciuria and 
hyperphosphaturia, going along with changes in calciotropic and phosphaturic hormones. 
These changes are discussed in the following sections. 
 
8.3.1 Food and water metabolism 
Visual observation of the faecal output of SM22α-Cre x LoxP-CaSR KO mice pointed to an 
increase in faecal water content, as faeces of KO mice appeared stickier by cursory 
observation. The metabolic cage studies on 3 month old animals showed no difference 
between food intake and faeces excretion between WT and KO mice, irrespective of a high 
salt diet suggesting that food metabolism is not influenced by VSMC specific CaSR deletion. 
Again, faeces of KO animals had a damper appearance than those of WT control. The CaSR 
is believed to modulate intestinal motility (Geibel et al. 2006). SM22α-Cre expression in 
visceral smooth muscle cells of the intestine has been reported (Lepore et al. 2005). It is 
therefore possible that deletion of the CaSR from intestinal visceral smooth muscle cells 
could attribute to a potentially imbalanced water homeostasis in the gastrointestinal tract. The 
intestinal phenotype of these mice is currently being investigated by our collaborators Dr. 
Enikö Kallay and Mr Abhishek Aggarwal (Medical University of Vienna, Austria). 
It has to be noted that the metabolic cages available in Cardiff University and used in the 
earlier study were designed for housing rats. The much smaller size of the mice resulted in the 
animals being able to defecate and urinate in the food container. The faeces were carefully 
separated from residual food but there is a very high probability that at least the gravimetric 
urine measurement was influenced by this systematic problem. Differences between the two 
age groups can therefore be attributed to the different metabolic cages these two groups of 
experiments were carried out in. The technical issues in the experiment with the 12-18 month 
old animals notwithstanding, no differences between WT and KO mice was detected in older 
mice which is in agreement with the results obtained in the study performed on the 3 month 
old animals in Denmark while on a low salt diet. 
181 
 
The high-salt diet (4 % NaCl) did not induce any changes in faecal output or food 
consumption. As expected, the high salt diet induced polyuria in WT as well as KO mice and 
increased water consumption in both genotypes. However, urine output was significantly 
more elevated in KO animals compared to WT. This can probably be attributed to the high 
urinary Ca2+ (and Pi) excretion levels of KO animals (see below). High salt induces polyuria 
because of the large increase in urine osmolarity, sensed by the macula dense and 
juxtaglomerular apparatus in the kidney, which supresses the RAAS (Kobori et al. 2007). 
Because of the high concentration of ions already excreted in the KO animals, the high salt 
diet would increase the polyuria even more in the KO than WT animals. In light of a recent 
discovery by Renkema and colleagues, the observed polyuria could therefore be a protective 
mechanism against the formation of kidney stones, which, together with increased urinary 
acidification, was recently shown to be mediated by the CaSR in the collecting duct 
(Renkema et al. 2009).  
 
8.3.2 Effect of L-NAME on plasma chemistry 
Before discussing the results of the blood plasma analyses, it is necessary to make a point 
about the samples used for analysis in the second batch of plasma. This batch was collected 
on the last day of the telemetry experiments (see previous chapter), where animals had 
received the nitric oxide synthase inhibitor L-NAME for 2 days in their drinking water. L-
NAME increases blood pressure through inhibition of nitric oxide production (Mattson 2001) 
and it is known that L-NAME induced hypertension goes along with changes in plasma and 
urine biochemistry due to pressure diuresis by the kidney. It was shown that blood pressure 
elevating concentrations of L-NAME induce increased Na+ excretion (Lahera et al. 1991). In 
pregnant rats, chronic L-NAME treatment reduced blood plasma Ca2+ levels by about 0.1 
mmol / l (Ebose et al. 2007). Urea and plasma creatinine were shown to be elevated as a 
consequence of L-NAME treatment (Hropot et al. 1994; Cardoso et al. 2013), although this 
happened after 6 weeks of treatment. Taken together, it seems likely that the short-term L-
NAME treatment in my experiments did not have a profound effect on the observed plasma 
levels of Ca2+ and Mg2+, while a small effect on Na+ and plasma creatinine and blood urea 
nitrogen is to be expected. Because the obtained values from this analysis might therefore not 
be completely comparable with blood samples from untreated animals, they were not used to 
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calculate creatinine clearance. However, comparisons between genotypes should be 
unaffected. 
 
8.3.3 KO mice are hypercalcaemic, hypercalciuric and 
hyperphosphaturic 
Plasma Na+ levels exhibited a small but significant reduction in L-NAME treated KO animals 
while there was no such difference in the other experimental groups. It is possible that L-
NAME induced increased Na+ excretion, as detailed above, leading to a decrease in Na+ levels 
in the blood in this particular experiment. Mg2+, Cl- and K+ were unchanged.  
However, compared to WT control, KO mice showed robust and unexpected changes in their 
Ca2+ and Pi metabolism. KO mice were distinctively hypercalcaemic, had elevated serum 
FGF23 and 1,25-D3 levels. Again surprisingly, PTH levels were not significantly different 
between KO mice compared to WT control. At the same time, the KO animals showed 
dramatically increased urinary Ca2+ and Pi excretion when fed a standard diet. 
The high salt diet protocol was mainly devised for to assess the influence of salt loading on 
blood pressure, but urines were collected on high NaCl diet as well. Compared to standard 
diet, electrolyte excretion was elevated for all ions in both WT and KO animals, as expected 
(Luft et al. 1979; Goulding and Campbell 1983; Yatabe et al. 2012). On the high salt diet, KO 
animals exhibited a greater increase of K+ and Mg2+ excretion then the WT controls, while 
there was no difference in the excretion of those ions when animals were kept on a normal 
diet. The increased K+ and Mg2+ excretions of the KO animals can probably be related to the 
increased urine volume observed in KO mice on a high salt diet compared to WT. As 
suggested in the previous section, this is probably a normal response to the increased filtrate 
osmolarity due to the excretion of already high levels of Ca2+ and Pi in these mice to prevent 
the formation of urolithiasis. The increase in Mg2+ and K+ excretion of KO mice on high salt 
diet suggested an effect on the distal nephron and should be investigated further by collecting 
information concerning plasma values for high salt intake (which currently are not available). 
In the following chapters I will attempt to discuss the possible mechanisms that could lead to 
the striking changes in mineral ion metabolism between WT and KO mice. 
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8.3.3.1 Influence of the kidney on Ca2+ homeostasis 
The kidney is highly involved in Ca2+ homeostasis via a PTH independent regulation of Ca2+ 
and Mg2+ excretion mediated by the CaSR. In essence, CaSR activation by high plasma Ca2+ 
levels reduces Ca2+ reabsorption, as reviewed in (Riccardi and Brown 2010).  
Therefore, the increased blood Ca2+ levels could be the result of reduced CaSR activity in the 
kidney. However, expression of a functional CaSR in the kidney appears not be affected in 
KO mice as this would at the same time lead to markedly reduced Ca2+ excretion, as shown 
for a kidney specific CaSR KO mouse (Toka et al. 2012). However, the opposite effect, 
increased urinary Ca2+ excretion, was found in the SM22α-Cre x LoxP-CaSR mouse.  
Furthermore, blood urea nitrogen, urea and uric acid excretion were comparable in WT and 
KO mice, suggesting normal kidney function. Importantly, serum creatinine levels were not 
elevated and urine creatinine excretion was not reduced in KO animals compared to WT. 
Indeed, while urinary creatinine excretion was equal between WT and KO mice, plasma 
creatinine levels were slightly reduced in KO animals. The reduction in plasma creatinine in 
KO mice compared to WT could possibly be explained by the hypotensive phenotype. 
Currently, the state of the renal microvasculature is unknown in these animals, but I would 
predict that, owing to the gene deletion from VSMC, both afferent and or efferent arterioles 
would be affected. Since these two arterioles are known to react differently to various 
contractile and dilatory stimuli (Ito et al. 1993; Liu et al. 2012), it is possible that the afferent 
arteriole would be dilated more than the efferent one, therefore potentially leading to an 
increase in GFR. Nevertheless, even though GFR could not be calculated because of the 
limitations of the experimental protocol (influence of L-NAME), these data still suggest that 
kidney function in KO animals was equal, if not better than in WT animals. However, 
dedicated studies to measure GFR in these animals should be performed in the future. 
In addition to measurements of GFR, the high excretion of Ca2+ and Pi would point towards 
formation of nephrolithiasis, which was, at least by cursory observation and considering the 
long life span of these mice, not the case or not a major problem. Histological investigation of 
the kidneys of WT and KO mice is currently underway. 
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8.3.3.2 KO mice exhibit a phenotype similar to models of primary 
hyperparathyroidism 
As reviewed in (Hu et al. 2013), Ca2+, Pi, PTH, 1,25-D3 and FGF23 are controlled by a highly 
regulated mechanisms consisting of multiple positive and negative feedback loops (c.f. Figure 
4). PTH controls 1,25-D3 production in the kidney and promotes bone resorption and FGF23 
production. 1,25-D3 promotes Ca2+ and Pi reabsorption from kidney and Ca2+ absorption 
from the intestine and also stimulates FGF23 production in bone. Conversely, 1,25-D3 and 
Ca2+ inhibit PTH release via negative feedback. FGF23 promotes Pi excretion and also 
inhibits PTH secretion. 
1,25-D3, Ca2+ and FGF23 are all markedly elevated in our KO mice. Because of the negative 
feedback mechanisms by 1,25-D3, Ca2+ and FGF23 on PTH production one would assume 
that PTH levels were markedly reduced in SM22α-Cre x LoxP-CaSR mice. However, PTH 
levels of these mice are not only non-decreased compared to WT control animals – they even 
show a trend towards elevation, albeit non-significant. Therefore, PTH levels might be 
slightly elevated, but are at least surprisingly unchanged, in the face of the elevations of Ca2+, 
FGF23 and 1,25-D3. This leads to the conclusion that might in fact be PTH which drives the 
elevations of the elevations of Ca2+, FGF23 and 1,25-D3.  
Indeed, the phenotype of the KO mice seems similar to what is seen in mice that are 
heterozygous for the CaSR in the parathyroid gland (Chang et al. 2008). These mice are 
hypercalcaemic, hypercalciuric and have reduced bone density. However, the PTH-Cre x 
LoxP-CaSR HET mice have about 2-fold elevated PTH levels compared to controls which 
was not observed in our animals. Furthermore, the total phenotype of the SM22α-Cre x LoxP-
CaSR mouse shows a resemblance to what was described for a mouse model of primary 
hyperparathyroidism induced by parathyroid-specific cyclin D1 overexpression (Imanishi et 
al. 2001). Cyclin D1 is a potent oncogene that is involved in the development of parathyroid 
adenomas (Motokura et al. 1991). Like the SM22α-Cre x LoxP-CaSR mouse, the PT-cyclin 
D1 mice lived up to two years and older, and were comparable to WT controls in body 
weight, serum albumin, blood urea nitrogen and creatinine levels. Furthermore, like the 
SM22α-Cre x LoxP-CaSR mouse, the PTH-cyclin D1 mice were hypercalcaemic, normo-
hypophosphataemic and showed elevated FGF23 and 1,25-D3 levels and non to moderately 
increased PTH levels depending on age, together with impaired bone structure. The principal 
component of all these changes were the cyclin D1 induced hyperplasia of the parathyroid 
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gland, and a concomitant reduction of parathyroid CaSR expression (Imanishi et al. 2001; 
Kawata et al. 2007).  
Indeed, these changes are indicative of primary hyperparathyroidism (Ward et al. 2012), with 
the noticeable exception of 1,25-D3. The 1,25-D3 levels in the PT-cyclin D1 mice were 
elevated compared to WT control, although this elevation appeared only in later stages of 
their life (Kawata et al. 2007). The two-fold elevated 1,25-D3 levels present in the SM22α-
Cre x LoxP-CaSR mice might therefore not be explainable by a PTH driven phenotype alone. 
Indeed, the absence of elevated PTH levels in KO mice could suggest that other factors are 
contributing to the phenotype of the mice as well and that 1,25-D3 supresses abnormally 
elevated PTH production (Ritter et al. 2006) Still, the marked absence of a reduction in PTH 
levels points to PTH production being at least involved in the observed phenotype. 
Importantly, the PT-cyclin-D1 mice only develop their phenotype over a matter of months, 
with increased plasma Ca2+ levels appearing before an increase in plasma PTH (Kawata et al. 
2007). I have shown increased Ca2+ and FGF23 levels at 3 as well as 18 months of age, 
suggesting the onset of the phenotypical changes is occurring more rapidly than in PT-cyclin 
D1 mice. For further studies, it might be interesting to investigate the SM22α-Cre x LoxP-
CaSR mice at a younger age as well. 
 
8.3.3.3 Other possible influences 
The proposed form of mild primary hyperparathyroidism seems like the best-fitting 
explanation for the observed changes in the mineral ion metabolism of the SM22α-Cre x 
LoxP-CaSR, however other explanations can be put forward. This is especially relevant as, 
even though PTH levels in these mice showed a trend towards elevation, a significant change 
in plasma PTH was not detected in KO mice. Yet, the absence of a significant reduction in 
PTH levels suggests PTH is involved in the observed phenotype, because an elevation in 
Ca2+, 1,25-D3 and FGF23 would be expected to supress PTH secretion (Brown 2013). 
In addition to the primary hyperparathyroidism-like hypothesis, a possible explanation for the 
observed changes in our KO mice could be an increase in 1,25-D3 levels. Primary elevated 
1,25-D3 levels would increase FGF23 levels (hence phosphaturia) and promote Ca2+ and Pi 
absorption from the intestine while the phosphaturia induced by FGF23 would induce bone 
loss. Increased 1,25-D3 plasma levels (Ritter et al. 2006) and the resulting hypercalcaemia 
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would however suppress PTH release in the presence of a functional CaSR in the parathyroid 
gland, while PTH levels were equal to slightly increased in KO animals compared to WT. 
These findings would suggest that, for 1,25-D3 to be a principal component of the phenotype, 
CaSR function would have to be impaired in the parathyroid gland in addition to a putative 
hypervitaminosis D.  
1-alpha hydroxylase, the rate limiting enzyme for 1,25-D3 synthesis was shown to be 
expressed in VSMC (Somjen et al. 2005). Ca2+ was shown to supress 1-alpha hydroxylase 
activity directly, possibly via the CaSR (Bland et al. 1999). Therefore, it seems at least 
possible that deletion of the CaSR from VSMC resulted in upregulation of 1,25-D3 through 
increased 1-alpha-hydroxylase activity. If such a hypothetical elevation could be responsible 
for a large increase in 1,25-D3 levels as observed in the SM22α-Cre x LoxP-CaSR mouse is 
unknown. On the other hand, if such a mechanism would be present in addition to changes in 
the parathyroid gland, as detailed in the next section, this could explain the blunted PTH 
response (i.e. unexpectedly equal or slightly elevated PTH levels despite characteristics of 
primary hyperparathyroidism) as well as the elevated 1,25-D3 levels.  
Similarly, it could be speculated that FGF23 is the principal component in the phenotype of 
the KO animals. However, FGF23 production is believed not to be regulated by the CaSR 
directly (Quinn et al. 2013b) and principally elevated FGF23 levels would inhibit 1,25-D3 as 
well as PTH production which was not observed in the KO mice. On the other hand, it was 
recently shown that FGF23 is not able to supress PTH secretion in a uremic state (Canalejo et 
al. 2010), which could indicate that in KO mice, which are hypercalcaemic, PTH would not 
be suppressed by FGF23. However, FGF23 was recently shown not be expressed human 
blood vessels (Donate-Correa et al. 2013), and VSMC targeted deletion of Klotho, the co-
factor for FGF23, did not result in changes in mineral ion metabolism or vascular calcification 
(Lindberg et al. 2013) therefore making a putative mechanism of increased FGF23 production 
by VSMC CaSR deletion difficult to explain. 
Klotho, has not been studied here but could play a role in the phenotype of these mice. 
Klotho-/- mice exhibit hypervitaminosis D (Kuro-o et al. 1997; Yoshida et al. 2002). Klotho 
reduces 1,25-D3 levels and inhibits PTH secretion (Hu et al. 2013). However, Klotho-/- 
deficient mice are extremely hyperphosphataemic and show enhanced ageing process (Kuro-o 
et al. 1997) which was not the case in SM22α-Cre x LoxP-CaSR mice. 
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Because of the similarity of the mouse models of PT-cyclin D1 and the phenotype present in 
the SM22α-Cre x LoxP-CaSR mouse, I hypothesize that indeed a form of primary 
hyperparathyroidism, possibly in combination with other additional factors like changes in 
1,25-D3 synthesis could be the driving force behind the observed change in mineral ion 
metabolism in these mice. Figure 99 shows a schematic of these hypothetical complex 
interrelations. 
Primary hyperparathyroidism is often associated with hypertension which can be reversed by 
parathyroidectomy (Broulik et al. 2011). In a small human study, the hypertension observed 
in primary hyperparathyroidism was shown to go along with only very small increases in 
plasma renin activity and aldosterone levels, while smooth muscle contractility in response to 
noradrenalin was shown to be enhanced (Schiffl and Lang 2011). By extension these findings 
suggest that in the SM22α-Cre x LoxP-CaSR mice, blood pressure was not elevated because 
of the lost contractility of their blood vessels. In addition, as already detailed in chapter 7.3.9, 
the cardiac remodelling observed in some of the KO hearts could be, amongst other factors, a 
direct consequence of the mineral ion metabolism phenotype, possibly because of the elevated 
FGF23 levels (Faul et al. 2011). Furthermore, as already explained in chapter 6, the absence 
of in vivo calcification in the SM22α-Cre x LoxP-CaSR mice can be explained by the 
hyperphosphaturia and therefore normal blood Pi levels despite elevated 1,25-D3 levels, as Pi 
was shown to be highly associated with the onset of vascular calcification and the underlying 
phenotypic transdifferentiation of VSMC (Jono et al. 2000). 
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Figure 99: Possible mechanism of mineral ion homeostasis and related phenotypic phenomena in the 
SM22α-Cre x LoxP-CaSR mouse. Green arrows indicate activation (or increased resorption), red 
arrows indicate inhibition. Solid arrows are established, dashed arrows are hypothetical. Upward 
pointing black arrows indicate increase, downward pointing black arrows indicate decrease, levelled 
black bi-headed arrows indicate no change (1) PTH promotes (2) 1,25-D3 production and (3) bone 
resorption which leads to (4) hypercalcaemia. Blood Ca2+ is excreted via the kidney, leading to 
hypercalciuria, and limits further PTH production via the parathyroid CaSR. (5) PTH and 1,25 D3 also 
increase FGF23 production in bone, leading to phosphaturia, (6) which in turn might be responsible for 
the prevention of vascular calcification. (7) Hypothetical undetermined influences could be responsible 
for increased 1,25-D3 and FGF23 levels as well, which in turn would counteract an increase in PTH, 
such as increased 1α-Hydrolase activity, providing a possible explanation for the elevated 1,25-D3 
and FGF23 levels with unchanged PTH. (8) The reduced blood vessel contractility prevents 
development of hypertension. (9) Elevated FGF23 levels could account for, or at least contribute to the 
observed sporadic cardiac remodelling. 
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8.3.4 Link between VSMC CaSR and changes in mineral ion 
metabolism 
The possible interrelations between the different factors involved in the mineral ion 
metabolism in the SM22α-Cre x LoxP-CaSR mice notwithstanding, the question remains how 
deletion of the VSMC CaSR can elicit these changes. 
In Cre-LoxP systems of targeted gene deletion, the occurrence of off-target expression of the 
promoter and therefore deletion of the target gene in undesired tissues is known to happen. A 
small leak of the SM22α-Cre allele was reported to have happened for renal epithelium 
(Malhowski et al. 2011). However, deletion of the CaSR from the kidney in KO mice can 
probably be excluded as Ca2+ excretion function appeared to be unaffected and a kidney 
deletion of the CaSR leads to hypocalciuria (Toka et al. 2012), which is the opposite of the 
phenotype present in KO mice. Similarly, a constitutive knock-down of the CaSR would lead 
to an FHH or NSHPT like phenotype, which would again characterised by hypocalciuria (Ho 
et al. 1995). If only some parathyroid cells were to have impaired CaSR expression, this could 
mean that those impaired cells would exhibit increased PTH production while the non-
affected cells would have downregulated PTH production. We have tested for Ca2+ and 
FGF23 levels in advanced age of the mice (18 months) and the differences were comparable 
to what was seen in 3 month old animals. These observations point toward a non-progressing 
form of the phenotype observed in the KO mice. Furthermore, deletion of the CaSR 
specifically in parathyroid chief cells leads to only mild hypercalcaemia of about 14 % 
increase vs. control in case of heterozygous deletion (Chang et al. 2008), while our mice 
exhibited an increase of ~ 25-50 %, which would be more in line with homozygous deletion 
of the parathyroid CaSR (40 %) but these mice have a very severe phenotype of growth 
retardation (Chang et al. 2008). Finally, an expression of SM22α or SM22 (the human 
isoform) or a leakage of SM22α-Cre in the parathyroid or thyroid has not been reported 
previously. Nevertheless, a reduction of CaSR activity in the parathyroid chief cells seems a 
valid hypothesis to explain the biochemical changes in this mouse, making studies on 
parathyroid CaSR functionality (see below) imperative. 
If specificity of the KO for smooth muscle and possibly heart cells (Li et al. 1996a; Lepore et 
al. 2005) is assumed, then the CaSR is still functionally expressed in the parathyroid gland. 
Again, this assumption is substantiated by the much more severe phenotype of parathyroid 
loss of the CaSR (Chang et al. 2008), which is clearly not the case in the SM22α-Cre x LoxP-
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CaSR mouse. The question arises how the vascular CaSR could influence mineral ion 
homeostasis in such a profound matter.  
It seems possible that the CaSR in VSMC of blood vessels supporting the parathyroid gland 
contributes to the parathyroid gland’s function as blood Ca2+ regulator so that deletion of the 
CaSR could lead to mild form of hyperparathyroidism via yet unknown paracrine actions. 
It could be speculated that, since blood vessels permeate every organ in the body, not only the 
blood vessels themselves but all organs in the body would be affected by a vasculature 
specific KO of the CaSR. Similar effects of targeted gene deletion from the vasculature on 
other organ systems has been described e.g. for bone morphogenic protein receptor 1A, where 
VSMC specific deletion led to impaired brain development through impaired vascularization 
(El-Bizri et al. 2008).  
One of the most striking features of the SM22α-Cre x LoxP-CaSR mouse is the prevalent 
hypotension which seems to be caused by a reduction in TPR. This feature would indicate that 
blood flow in various organs should also be altered. The parathyroid gland certainly is highly 
vascularized (Murakami et al. 1995) and indeed, a relationship between blood flow and 
parathyroid hormone secretion has been described in humans where a higher vascular 
resistance was inversely correlated with blood PTH levels (Mohammadi et al. 2013). A 
similar influence of blood vessel diameter on gland function has also been described for the 
adrenal gland in diabetic rats (Sricharoenvej et al. 2009). 
From this point of view, it is therefore possible that CaSR deletion from blood vessels could 
have multiple effects in different organs of the body. E.g. the CaSR has been found to be 
expressed in osteoclasts (Kameda et al. 1998), osteoblasts (Dvorak et al. 2004) and osteocytes 
(Chang et al. 1999) and has been shown to play a profound role in bone physiology as mice 
lacking the CaSR in osteoblasts show severe growth and skeletal impairment compared to 
control littermates (Chang et al. 2008). As with the parathyroid gland, the bone is a highly 
vascularized organ (Johnson et al. 2004) and vascular CaSR in bone blood vessels might 
contribute the aforementioned functions. By a similar mechanism, the vascular CaSR could 
play a role in supressing 1-α-hydroxylase in the kidney (Bland et al. 1999), therefore loss of 
CaSR could increase 1,25-D3 production explaining the high levels of 1,25-D3 in our mice. 
Again, these hypotheses have to be investigated by investigations on parathyroid gland and 
the influence of 1,25-D3 and FGF23 by other methods (see below).  
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8.3.5 Bone 
The results of the bone analysis by Dr. Wenhan Chang showed that KO animals had 
significant trabecular and cortical cone loss. Indeed, the impaired bone structure is probably 
linked to the profound changes in mineral ion metabolism, namely the increased Ca2+ and Pi 
urinary excretion. Indeed, in primary hyperparathyroidism, which the SM22α-Cre x LoxP-
CaSR mouse is similar to, bone turnover is generally increased and bone structure impaired 
(Christiansen et al. 1997; Chang et al. 2008). 
 
8.3.6 Future directions 
Taken together, it is clear that there are too many variables to draw any definitive conclusions 
from the biochemical changes alone. Substantial future investigations into the cause for the 
observed changes in mineral ion homeostasis are therefore clearly necessary to understand the 
primary driving force or possibly forces behind these changes. 
For the described PT-cyclin-D1 mouse, which has a phenotype similar, albeit milder or 
slower progressing, phenotype to the SM22α-Cre x LoxP-CaSR mouse, it was described that 
proliferation of parathyroid cells occurs before the onset of the symptomatic primary 
hyperparathyroidism (Mallya et al. 2005). To substantiate the hypothesis of a possible form of 
primary hyperparathyroidism, experiments to assess the status of the parathyroid glands in the 
SM22α-Cre x LoxP-CaSR are clearly necessary and should encompass trials to investigate 
histology (i.e. presence of hyperplasia), expression levels of CaSR and functionality of the 
CaSR. Furthermore, the possible additional influences on 1,25-D3 and PTH could be 
investigated by breeding the SM22α-Cre x LoxP-CaSR mouse with a 1-α-Hydroxylase or 
PTH deficient mouse.  
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8.4 Conclusions 
• KO mice show (Chertow et al. 2012) elevated blood Ca2+, FGF23, 1,25-D3 levels 
and trends towards elevated PTH and reduced Pi levels. 
• Urinary Ca2+ and Pi excretion was elevated in KO mice compared to WT control. 
• These changes in mineral ion metabolism are associated with impaired bone 
structure and probably increased bone turnover. 
• This phenotype is similar to a mild form of primary hyperparathyroidism. 
• Kidney function appears to be unaffected in KO mice. 
• The underlying cause for these differences in mineral ion metabolism remains to 
be determined but may be found in partial deletion of the CaSR from the 
parathyroid gland through “leaky” expression of the Cre enzyme, changes in 
parathyroid vascularisation or blood flow. 
• Experiments assessing parathyroid gland histology, CaSR expression and CaSR 
functionality, as well as possible other influences (directly affected 1,25-D3 
synthesis) are required in the future. 
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9 Thesis conclusions and future directions  
In the course of my thesis, I investigated these roles for the VSMC CaSR in a mouse model of 
VSMC targeted CaSR deletion. In the following section, I want to briefly recapitulate the 
three principal discoveries I have in the course of the phenotypic characterisation of this 
mouse model. All key results of the phenotypic characterisation are furthermore listed in 
Table 27. Key future experiments are listed in Table 13. 
 
9.1 Protective effect of the VSMC CaSR against 
calcification 
It has been shown before that loss of the VSMC CaSR increases in vitro VSMC susceptibility 
to mineralise by transfection with a dominant negative construct (Alam et al. 2009) or siRNA 
(Henaut et al. 2014). I was able to prove this protective effect of the VSMC CaSR against 
VSMC calcification in VSMC cultured from WT and KO mice. However, and very 
importantly, even though the KO mice exhibited increased blood Ca2+ levels, they did not 
show any ectopic calcification in vivo. It is therefore possible that this protective effect of the 
vascular CASR only asserts itself in the synthetic in vitro environment or only protects 
against vascular calcification in pathophysiological disease states of hyperphosphataemia as 
seen in CKD. Indeed, KO mice did not present any hyperphosphataemia but were in fact 
hyperphosphaturic. To investigate these possibilities, the KO animals should be challenged 
with hyperphosphataemia, for example by performing 5/6 nephrectomy followed by a high 
Pi-containing diet (Shobeiri et al. 2010; Lau et al. 2013). I anticipate that, if the CaSR protects 
against vascular calcification in vivo is correct, higher levels of vascular calcification should 
be observed in KO animals, compared to WT control. 
 
9.2 The VSMC CaSR is involved in blood pressure 
regulation 
I was able to demonstrate that loss of the vascular CaSR is associated with hypotension and 
that this reduction blood pressure is most likely due to reduced TPR. Other members of our 
group were able to demonstrate that CaSR deletion results in loss of arterial contractility in 
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response to high K+ and phenylephrine which indicates a potentiating effect of the VSMC 
CaSR on blood vessel contraction. These results prove, for the first time, a role for the VSMC 
CaSR in blood vessel tone regulation and blood pressure regulation in vivo. 
Since the CaSR is also highly expressed in the endothelium and inhibition of NO synthases 
abrogates the hypotension in KO animals, as well as the putative influence of the endothelial 
CaSR on NO production in vitro (Ziegelstein et al. 2006) the specific role of the endothelium 
CaSR should be investigated in vivo, for example by use of transgenic mice expressing Cre 
specifically in the endothelium (Kisanuki et al. 2010). 
Furthermore, some hearts of KO animals showed signs of functional changes and remodelling 
as identified via cardiac cine-MRI and KO mice were bradycardic compared to WT animals. 
To elucidate a possible primary functional change in the hearts of these mice, potentially via 
deletion of the CaSR from cardiomyocytes, functional studies on isolated hearts of WT and 
KO mice should be performed in the future. 
 
9.3 The VSMC CaSR is involved in mineral ion homeostasis 
KO mice exhibited a rather unexpected phenotype of hypercalcaemia, hypercalciuria, 
hyperphosphaturia and elevated FGF23 and 1,25-D3 levels as well as impaired bone, while 
PTH levels were surprisingly unchanged compared to WT control. In addition, I have shown 
that kidney function is not impaired in KO animals. Since a primary elevation in 1,25-D3 or 
FGF23 should lead to depressed PTH levels, the best fitting explanation can be found in a 
form of mild primary hyperparathyroidism in these mice and their phenotype is indeed quite 
similar to such animals (Imanishi et al. 2001; Kawata et al. 2007). However, it seems 
plausible that other regulatory loops could be affected in these mice as well, e.g. the 1,25-D3 
axis, providing possible angles for explaining the unchanged PTH levels. The underlying 
cause(s) for this phenotype will have to be identified in future studies, with one possibility 
being breeding the SM22α-Cre x LoxP-CaSR mice with PTH-/- or 1-α-hydroxylase-/- mice 
which should allow identification of the primary cause of the mineral ion metabolism 
phenotype of KO mice. Nevertheless, this phenotype suggests that the vascular CaSR plays a 
role in regulation of mineral ion metabolism via a yet unknown mechanism. 
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Table 12: Summary of the observed phenotype of the SM22α-Cre x LoxP-CaSR mouse in the course 
of this thesis. 
CaSR involvement in Phenotype Interpretation 
Cardiovascular system Hypotension, Blood vessel 
contractility↓ 
Reduced TPR, CaSR acts on 
VSMC to potentiate 
contractions and on 
endothelium to promote NO 
production 
 Bradycardia Possible result of CaSR 
deletion from the heart, 
systemic influences 
 Sporadic cardiac remodelling Possible result of CaSR 
deletion from the heart, 
compensation to hypotension, 
systemic influences (FGF23) 
Mineral ion metabolism Blood Ca2+↑, Ca2+:Cr↑, Pi:Cr↑, 
FGF23↑, 1,25-D3↑, Pi→, PTH 
→, bone structure↓ 
Phenotypic resemblance to 
primary hyperparathyroidism 
 Plasma creatinine↓, urine 
creatinine→, BUN→, urine uric 
acid→, Na+:Cr→, K+:Cr→, Cl-
:Cr→, renin→, aldosterone→ 
No renal involvement 
Protection from calcification  Fetuin A→ 
no calcification in vivo, 
increased VSMC calcification in 
vitro 
Protective mechanism possibly 
only in disease state of high Pi, 
or restricted to artificial 
conditions 
Other In vitro proliferation of VSMC is 
controlled by the CaSR 
undetermined 
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Table 13: Future experiments to further the understanding of the VSMC CaSR and the phenotype of 
the SM22α-Cre x LoxP-CaSR mouse. Note that only “large scale” experiments are listed. 
Rationale Experiment Expected outcome 
Functional involvement of the 
heart in phenotype unknown, 
possible deletion of CaSR from 
the heart 
Langendorff preparation of 
isolated hearts, high frequency 
echocardiography 
Measurement of heart 
contractility, pacemaker 
function, sensitivity against 
external stimuli independent of 
systemic phenotype 
Phenotype similar to primary 
hyperparathyroidism 
Histology, Ca2+ imaging, 
immunostaining, western blot, 
RT-qPCR 
Involvement of the parathyroid 
gland (hyperplasia, expression 
of functional CaSR) 
No vascular calcification in KO 
mice 
5/6 nephrectomy + high Pi diet Determination if VSMC CaSR 
protects from vascular 
calcification in disease state of 
hyperphosphataemia 
Moist appearance of faeces 
from KO mice, hypercalcaemia 
and hypercalciuria indicate 
elevated intestinal Ca2+ 
absorption 
Faeces composition, histology, 
etc. 
Characterisation of gastro-
intestinal phenotype 
Hypercalcaemia and 
hypervitaminosis D could 
contribute to cardiovascular 
phenotype 
SM22α-Cre x LoxP-CaSR x 1-
α-hydroxylase-/- mice 
Contribution of systemic 
changes in mineral ion 
metabolism to cardiovascular 
phenotype of bradycardia and 
hypotension 
L-NAME reversible hypotension Endothelium-VSMC double KO 
mouse 
Involvement of the CaSR in NO 
production and contribution to 
hypotensive phenotype 
 
 
 
  
197 
 
10 References 
Alam, M. U. et al. 2009. Calcification is associated with loss of functional calcium-sensing 
receptor in vascular smooth muscle cells. Cardiovascular research 81(2), pp. 260-268. 
 
Amann, K. and Ritz, E. 1998. Cardiovascular abnormalities in ageing and in uraemia--only 
analogy or shared pathomechanisms? Nephrology, dialysis, transplantation : official 
publication of the European Dialysis and Transplant Association - European Renal 
Association 13 Suppl 7, pp. 6-11. 
 
Amann, K. and Tyralla, K. 2002. Cardiovascular changes in chronic renal failure--
pathogenesis and therapy. Clinical nephrology 58 Suppl 1, pp. S62-72. 
 
Armato, U. et al. 2013. Calcium-sensing receptor antagonist (calcilytic) NPS 2143 
specifically blocks the increased secretion of endogenous Abeta42 prompted by exogenous 
fibrillary or soluble Abeta25-35 in human cortical astrocytes and neurons-therapeutic 
relevance to Alzheimer's disease. Biochimica et biophysica acta 1832(10), pp. 1634-1652. 
 
Assinder, S. J. et al. 2009. Transgelin: an actin-binding protein and tumour suppressor. The 
international journal of biochemistry & cell biology 41(3), pp. 482-486. 
 
Atchison, D. K. et al. 2010. Acute activation of the calcium-sensing receptor inhibits plasma 
renin activity in vivo. American journal of physiology. Regulatory, integrative and 
comparative physiology 299(4), pp. R1020-1026. 
 
Austin, C. P. et al. 2004. The knockout mouse project. Nature genetics 36(9), pp. 921-924. 
 
Awumey, E. M. et al. 2013. Nitric-oxide synthase knockout modulates Ca(2)(+)-sensing 
receptor expression and signaling in mouse mesenteric arteries. The Journal of pharmacology 
and experimental therapeutics 346(1), pp. 38-47. 
 
Ayachi, S. 1979. Increased dietary calcium lowers blood pressure in the spontaneously 
hypertensive rat. Metabolism: clinical and experimental 28(12), pp. 1234-1238. 
 
Ba, J. et al. 2003. Calcium-sensing receptor regulation of PTH-inhibitable proximal tubule 
phosphate transport. American journal of physiology. Renal physiology 285(6), pp. F1233-
1243. 
 
Bai, M. et al. 1998. Dimerization of the extracellular calcium-sensing receptor (CaR) on the 
cell surface of CaR-transfected HEK293 cells. The Journal of biological chemistry 273(36), 
pp. 23605-23610. 
 
198 
 
Bai, S. Z. et al. 2012. Decrease in calcium-sensing receptor in the progress of diabetic 
cardiomyopathy. Diabetes research and clinical practice 95(3), pp. 378-385. 
 
Barletta, G. et al. 2000. Cardiovascular effects of parathyroid hormone: a study in healthy 
subjects and normotensive patients with mild primary hyperparathyroidism. The Journal of 
clinical endocrinology and metabolism 85(5), pp. 1815-1821. 
 
Bas, A. et al. 2006. Reversibility of calcitriol-induced medial artery calcification in rats with 
intact renal function. Journal of bone and mineral research : the official journal of the 
American Society for Bone and Mineral Research 21(3), pp. 484-490. 
 
Belz, G. G. 1995. Elastic properties and Windkessel function of the human aorta. 
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular 
Pharmacotherapy 9(1), pp. 73-83. 
 
Berry, C. J. et al. 2009. Effects of deep sedation or general anesthesia on cardiac function in 
mice undergoing cardiovascular magnetic resonance. Journal of cardiovascular magnetic 
resonance : official journal of the Society for Cardiovascular Magnetic Resonance 11, p. 16. 
 
Birgander, M. et al. 2012. Adrenergic and cardiac dysfunction in primary 
hyperparathyroidism. Clinical endocrinology 76(2), pp. 189-195. 
 
Blacher, J. et al. 2001. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-
stage renal disease. Hypertension 38(4), pp. 938-942. 
 
Blacher, J. et al. 1999. Impact of aortic stiffness on survival in end-stage renal disease. 
Circulation 99(18), pp. 2434-2439. 
 
Bland, R. et al. 1999. Constitutive expression of 25-hydroxyvitamin D3-1alpha-hydroxylase 
in a transformed human proximal tubule cell line: evidence for direct regulation of vitamin D 
metabolism by calcium. Endocrinology 140(5), pp. 2027-2034. 
 
Block, G. A. et al. 1998. Association of serum phosphorus and calcium x phosphate product 
with mortality risk in chronic hemodialysis patients: a national study. American journal of 
kidney diseases : the official journal of the National Kidney Foundation 31(4), pp. 607-617. 
 
Block, G. A. et al. 2010. Cinacalcet hydrochloride treatment significantly improves all-cause 
and cardiovascular survival in a large cohort of hemodialysis patients. Kidney international 
78(6), pp. 578-589. 
 
199 
 
Boedtkjer, E. et al. 2011. Disruption of Na+,HCO(3)(-) cotransporter NBCn1 (slc4a7) inhibits 
NO-mediated vasorelaxation, smooth muscle Ca(2)(+) sensitivity, and hypertension 
development in mice. Circulation 124(17), pp. 1819-1829. 
 
Bogusz, A. M. et al. 2012. Quantitative immunofluorescence reveals the signature of active 
B-cell receptor signaling in diffuse large B-cell lymphoma. Clinical cancer research : an 
official journal of the American Association for Cancer Research 18(22), pp. 6122-6135. 
 
Bonomini, M. et al. 2012. Calcimimetic R-568 and its enantiomer S-568 increase nitric oxide 
release in human endothelial cells. PloS one 7(1), p. e30682. 
 
Bradbury, R. A. et al. 1998. Expression of the parathyroid Ca(2+)-sensing receptor in 
cytotrophoblasts from human term placenta. The Journal of endocrinology 156(3), pp. 425-
430. 
 
Brennan, S. C. et al. 2014. Emerging roles of the extracellular calcium-sensing receptor in 
nutrient sensing: control of taste modulation and intestinal hormone secretion. The British 
journal of nutrition, pp. 1-7. 
 
Broulik, P. D. et al. 2011. Improvement of hypertension after parathyroidectomy of patients 
suffering from primary hyperparathyroidism. International journal of endocrinology 2011, p. 
309068. 
 
Brown, E. M. 2010. Clinical utility of calcimimetics targeting the extracellular calcium-
sensing receptor (CaSR). Biochemical pharmacology 80(3), pp. 297-307. 
 
Brown, E. M. 2013. Role of the calcium-sensing receptor in extracellular calcium 
homeostasis. Best practice & research. Clinical endocrinology & metabolism 27(3), pp. 333-
343. 
 
Brown, E. M. et al. 1993. Cloning and characterization of an extracellular Ca(2+)-sensing 
receptor from bovine parathyroid. Nature 366(6455), pp. 575-580. 
 
Brown, E. M. and MacLeod, R. J. 2001. Extracellular calcium sensing and extracellular 
calcium signaling. Physiological reviews 81(1), pp. 239-297. 
 
Bruce, J. I. et al. 1999. Molecular and functional identification of a Ca2+ (polyvalent cation)-
sensing receptor in rat pancreas. The Journal of biological chemistry 274(29), pp. 20561-
20568. 
 
Bukoski, R. D. 2001. Dietary Ca(2+) and blood pressure: evidence that Ca(2+)-sensing 
receptor activated, sensory nerve dilator activity couples changes in interstitial Ca(2+) with 
200 
 
vascular tone. Nephrology, dialysis, transplantation : official publication of the European 
Dialysis and Transplant Association - European Renal Association 16(2), pp. 218-221. 
 
Bukoski, R. D. et al. 1997. Perivascular sensory nerve Ca2+ receptor and Ca2+-induced 
relaxation of isolated arteries. Hypertension 30(6), pp. 1431-1439. 
 
Caltabiano, S. et al. 2013. Characterization of the effect of chronic administration of a 
calcium-sensing receptor antagonist, ronacaleret, on renal calcium excretion and serum 
calcium in postmenopausal women. Bone 56(1), pp. 154-162. 
 
Canaff, L. et al. 2001. Extracellular calcium-sensing receptor is expressed in rat hepatocytes. 
coupling to intracellular calcium mobilization and stimulation of bile flow. The Journal of 
biological chemistry 276(6), pp. 4070-4079. 
 
Canalejo, R. et al. 2010. FGF23 fails to inhibit uremic parathyroid glands. Journal of the 
American Society of Nephrology : JASN 21(7), pp. 1125-1135. 
 
Cardoso, A. M. et al. 2013. Physical training prevents oxidative stress in L-NAME-induced 
hypertension rats. Cell biochemistry and function 31(2), pp. 136-151. 
 
Carlson, S. H. et al. 2002. Blood pressure and NaCl-sensitive hypertension are influenced by 
angiotensin-converting enzyme gene expression in transgenic mice. Hypertension 39(2), pp. 
214-218. 
 
Carney, E. F. 2013. Chronic kidney disease: No significant effect of cinacalcet on 
cardiovascular outcomes in patients undergoing dialysis--EVOLVE results. Nature reviews. 
Nephrology 9(1), p. 4. 
 
Cavanaugh, A. et al. 2010. Calcium-sensing receptor biosynthesis includes a cotranslational 
conformational checkpoint and endoplasmic reticulum retention. The Journal of biological 
chemistry 285(26), pp. 19854-19864. 
 
Chang, W. et al. 2008. The extracellular calcium-sensing receptor (CaSR) is a critical 
modulator of skeletal development. Science signaling 1(35), p. ra1. 
 
Chang, W. et al. 1999. Expression and signal transduction of calcium-sensing receptors in 
cartilage and bone. Endocrinology 140(12), pp. 5883-5893. 
 
Chattopadhyay, N. et al. 1998. Identification and localization of extracellular Ca(2+)-sensing 
receptor in rat intestine. The American journal of physiology 274(1 Pt 1), pp. G122-130. 
 
201 
 
Cheng, S. X. 2012. Calcium-sensing receptor inhibits secretagogue-induced electrolyte 
secretion by intestine via the enteric nervous system. American journal of physiology. 
Gastrointestinal and liver physiology 303(1), pp. G60-70. 
 
Cheng, S. X. et al. 2002. Expression of calcium-sensing receptor in rat colonic epithelium: 
evidence for modulation of fluid secretion. American journal of physiology. Gastrointestinal 
and liver physiology 283(1), pp. G240-250. 
 
Cheng, Z. et al. 2013. Sex and age modify biochemical and skeletal manifestations of chronic 
hyperparathyroidism by altering target organ responses to Ca2+ and parathyroid hormone in 
mice. Journal of bone and mineral research : the official journal of the American Society for 
Bone and Mineral Research 28(5), pp. 1087-1100. 
 
Chertow, G. M. et al. 2012. Effect of cinacalcet on cardiovascular disease in patients 
undergoing dialysis. The New England journal of medicine 367(26), pp. 2482-2494. 
 
Chertow, G. M. et al. 2007. Evaluation of Cinacalcet Therapy to Lower Cardiovascular 
Events (EVOLVE): rationale and design overview. Clinical journal of the American Society 
of Nephrology : CJASN 2(5), pp. 898-905. 
 
Chow, J. Y. et al. 2011. Calcium-sensing receptor modulates extracellular Ca(2+) entry via 
TRPC-encoded receptor-operated channels in human aortic smooth muscle cells. American 
journal of physiology. Cell physiology 301(2), pp. C461-468. 
 
Chow, K. M. et al. 2014. Effect of Cinacalcet Treatment on Vascular Arterial Stiffness among 
Peritoneal Dialysis Patients with Secondary Hyperparathyroidism. Nephrology. 
 
Christensen, S. E. et al. 2011. Familial hypocalciuric hypercalcaemia: a review. Current 
opinion in endocrinology, diabetes, and obesity 18(6), pp. 359-370. 
 
Christiansen, P. et al. 1997. Primary hyperparathyroidism: biochemical markers and bone 
mineral density at multiple skeletal sites in Danish patients. Bone 21(1), pp. 93-99. 
 
Ciceri, P. et al. 2013. The Calcimimetic Calindol Prevents High Phosphate-Induced Vascular 
Calcification by Upregulating Matrix GLA Protein. Nephron. Experimental nephrology 
122(3-4), pp. 75-82. 
 
Ciceri, P. et al. 2012a. Combined effects of ascorbic acid and phosphate on rat VSMC 
osteoblastic differentiation. Nephrology, dialysis, transplantation : official publication of the 
European Dialysis and Transplant Association - European Renal Association 27(1), pp. 122-
127. 
 
202 
 
Ciceri, P. et al. 2012b. The combination of lanthanum chloride and the calcimimetic calindol 
delays the progression of vascular smooth muscle cells calcification. Biochemical and 
biophysical research communications 418(4), pp. 770-773. 
 
Clemmensen, C. et al. 2014. The GPCR, class C, group 6, subtype A (GPRC6A) receptor: 
from cloning to physiological function. British journal of pharmacology 171(5), pp. 1129-
1141. 
 
Conigrave, A. D. et al. 2007. Aromatic L-amino acids activate the calcium-sensing receptor. 
The Journal of nutrition 137(6 Suppl 1), pp. 1524S-1527S; discussion 1548S. 
 
Cunningham, J. et al. 2011. Secondary hyperparathyroidism: pathogenesis, disease 
progression, and therapeutic options. Clinical journal of the American Society of Nephrology : 
CJASN 6(4), pp. 913-921. 
 
Dahboul, F. et al. 2014. S,S'-dinitrosobucillamine, a new nitric oxide donor, induces a better 
vasorelaxation than other S-nitrosothiols. European journal of pharmacology. 
 
Dao, H. H. et al. 2005. Evolution and modulation of age-related medial elastocalcinosis: 
impact on large artery stiffness and isolated systolic hypertension. Cardiovascular research 
66(2), pp. 307-317. 
 
Davey, A. E. et al. 2012. Positive and negative allosteric modulators promote biased signaling 
at the calcium-sensing receptor. Endocrinology 153(3), pp. 1232-1241. 
 
Davies, S. L. et al. 2006. Ca2+-sensing receptor induces Rho kinase-mediated actin stress 
fiber assembly and altered cell morphology, but not in response to aromatic amino acids. 
American journal of physiology. Cell physiology 290(6), pp. C1543-1551. 
 
Davies, T. 2013. Investigating the role of the extracellular calcium-sensing receptor (CaSR) 
in vascular pathophysiology using a novel mouse model of selective ablation of CaSR from 
mouse vascular smooth muscle cells. PhD Thesis, Cardiff University.  
 
De Castro, S. et al. 2007. Left ventricular remodelling index (LVRI) in various 
pathophysiological conditions: a real-time three-dimensional echocardiographic study. Heart 
93(2), pp. 205-209. 
 
de Francisco, A. L. et al. 2006. Impact of treatment with calcimimetics on 
hyperparathyroidism and vascular mineralization. Journal of the American Society of 
Nephrology : JASN 17(12 Suppl 3), pp. S281-285. 
 
203 
 
Dell'Aquila, M. E. et al. 2006. Localization and quantitative expression of the calcium-
sensing receptor protein in human oocytes. Fertility and sterility 85 Suppl 1, pp. 1240-1247. 
 
Donate-Correa, J. et al. 2013. Expression of FGF23/KLOTHO system in human vascular 
tissue. International journal of cardiology 165(1), pp. 179-183. 
 
Dora, K. A. et al. 2008. Modulation of endothelial cell KCa3.1 channels during endothelium-
derived hyperpolarizing factor signaling in mesenteric resistance arteries. Circulation 
research 102(10), pp. 1247-1255. 
 
Duer, M. J. et al. 2008. Mineral surface in calcified plaque is like that of bone: further 
evidence for regulated mineralization. Arteriosclerosis, thrombosis, and vascular biology 
28(11), pp. 2030-2034. 
 
Duling, L. C. et al. 2006. Loss of alpha2B-adrenoceptors increases magnitude of hypertension 
following nitric oxide synthase inhibition. American journal of physiology. Heart and 
circulatory physiology 291(5), pp. H2403-2408. 
 
Dvorak-Ewell, M. M. et al. 2011. Osteoblast extracellular Ca2+ -sensing receptor regulates 
bone development, mineralization, and turnover. Journal of bone and mineral research : the 
official journal of the American Society for Bone and Mineral Research 26(12), pp. 2935-
2947. 
 
Dvorak, M. M. et al. 2004. Physiological changes in extracellular calcium concentration 
directly control osteoblast function in the absence of calciotropic hormones. Proceedings of 
the National Academy of Sciences of the United States of America 101(14), pp. 5140-5145. 
 
Ebose, E. J. et al. 2007. Electrolytes and pH changes in pre-eclamptic rats. Clinica chimica 
acta; international journal of clinical chemistry 384(1-2), pp. 135-140. 
 
Edwards, G. et al. 2010. Endothelium-derived hyperpolarising factors and associated 
pathways: a synopsis. Pflugers Archiv : European journal of physiology 459(6), pp. 863-879. 
 
Egbuna, O. et al. 2009. The full-length calcium-sensing receptor dampens the calcemic 
response to 1alpha,25(OH)2 vitamin D3 in vivo independently of parathyroid hormone. 
American journal of physiology. Renal physiology 297(3), pp. F720-728. 
 
Egbuna, O. I. and Brown, E. M. 2008. Hypercalcaemic and hypocalcaemic conditions due to 
calcium-sensing receptor mutations. Best practice & research. Clinical rheumatology 22(1), 
pp. 129-148. 
 
204 
 
El-Bizri, N. et al. 2008. SM22alpha-targeted deletion of bone morphogenetic protein receptor 
1A in mice impairs cardiac and vascular development, and influences organogenesis. 
Development 135(17), pp. 2981-2991. 
 
El Hiani, Y. et al. 2009. Activation of the calcium-sensing receptor by high calcium induced 
breast cancer cell proliferation and TRPC1 cation channel over-expression potentially through 
EGFR pathways. Archives of biochemistry and biophysics 486(1), pp. 58-63. 
 
Farahnak, P. et al. 2010. Cardiac function in mild primary hyperparathyroidism and the 
outcome after parathyroidectomy. European journal of endocrinology / European Federation 
of Endocrine Societies 163(3), pp. 461-467. 
 
Farzaneh-Far, A. et al. 2000. Matrix gla protein is regulated by a mechanism functionally 
related to the calcium-sensing receptor. Biochemical and biophysical research 
communications 277(3), pp. 736-740. 
 
Faul, C. et al. 2011. FGF23 induces left ventricular hypertrophy. The Journal of clinical 
investigation 121(11), pp. 4393-4408. 
 
Felder, C. B. et al. 1999. The Venus flytrap of periplasmic binding proteins: an ancient 
protein module present in multiple drug receptors. AAPS pharmSci 1(2), p. E2. 
 
Fellet, A. L. et al. 2003. Effect of acute nitric oxide synthase inhibition in the modulation of 
heart rate in rats. Brazilian journal of medical and biological research = Revista brasileira de 
pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.] 36(5), pp. 669-
676. 
 
Feng, J. et al. 2010. Calcium-sensing receptor is a physiologic multimodal chemosensor 
regulating gastric G-cell growth and gastrin secretion. Proceedings of the National Academy 
of Sciences of the United States of America 107(41), pp. 17791-17796. 
 
Feng, M. et al. 2008. Validation of volume-pressure recording tail-cuff blood pressure 
measurements. American journal of hypertension 21(12), pp. 1288-1291. 
 
Finney, B. et al. 2011. An exon 5-less splice variant of the extracellular calcium-sensing 
receptor rescues absence of the full-length receptor in the developing mouse lung. 
Experimental lung research 37(5), pp. 269-278. 
 
Forman, J. P. et al. 2013. Effect of vitamin D supplementation on blood pressure in blacks. 
Hypertension 61(4), pp. 779-785. 
 
205 
 
Fryer, R. M. et al. 2007. Systemic activation of the calcium sensing receptor produces acute 
effects on vascular tone and circulatory function in uremic and normal rats: focus on central 
versus peripheral control of vascular tone and blood pressure by cinacalcet. The Journal of 
pharmacology and experimental therapeutics 323(1), pp. 217-226. 
 
Gattineni, J. et al. 2009. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces 
hypophosphatemia in vivo predominantly via FGF receptor 1. American journal of 
physiology. Renal physiology 297(2), pp. F282-291. 
 
Gauthier-Bastien, A. et al. 2013. Vascular remodeling and media calcification increases 
arterial stiffness in chronic kidney disease. Clinical and experimental hypertension. 
 
Geibel, J. et al. 2006. Calcium-sensing receptor abrogates secretagogue- induced increases in 
intestinal net fluid secretion by enhancing cyclic nucleotide destruction. Proceedings of the 
National Academy of Sciences of the United States of America 103(25), pp. 9390-9397. 
 
Goulding, A. and Campbell, D. 1983. Dietary NaCl loads promote calciuria and bone loss in 
adult oophorectomized rats consuming a low calcium diet. The Journal of nutrition 113(7), 
pp. 1409-1414. 
 
Grant, M. P. et al. 2011. Agonist-driven maturation and plasma membrane insertion of 
calcium-sensing receptors dynamically control signal amplitude. Science signaling 4(200), p. 
ra78. 
 
Gros, R. et al. 2002. Effects of age, gender, and blood pressure on myogenic responses of 
mesenteric arteries from C57BL/6 mice. American journal of physiology. Heart and 
circulatory physiology 282(1), pp. H380-388. 
 
Guyton, A. C. and Hall, J. E. 2006. Textbook of medical physiology. 11th ed. Philadelphia: 
Elsevier Saunders, pp. xxxv, 1116 p. 
 
Habib, Z. and Camacho, P. 2010. Primary hyperparathyroidism: an update. Current opinion in 
endocrinology, diabetes, and obesity 17(6), pp. 554-560. 
 
Halayko, A. J. and Solway, J. 2001. Molecular mechanisms of phenotypic plasticity in 
smooth muscle cells. Journal of applied physiology 90(1), pp. 358-368. 
 
Harno, E. et al. 2008. Evidence for the presence of GPRC6A receptors in rat mesenteric 
arteries. Cell calcium 44(2), pp. 210-219. 
 
206 
 
Hattori, T. et al. 2011. Pharmacological evidences for the stimulation of calcium-sensing 
receptors by nifedipine in gingival fibroblasts. Journal of pharmacology & 
pharmacotherapeutics 2(1), pp. 30-35. 
 
Hebert, S. C. 2003. Bartter syndrome. Current opinion in nephrology and hypertension 12(5), 
pp. 527-532. 
 
Henaut, L. et al. 2014. Calcimimetics increase CaSR expression and reduce mineralization in 
vascular smooth muscle cells: mechanisms of action. Cardiovascular research 101(2), pp. 
256-265. 
 
Herberger, A. L. and Loretz, C. A. 2013. Vertebrate extracellular calcium-sensing receptor 
evolution: selection in relation to life history and habitat. Comparative biochemistry and 
physiology. Part D, Genomics & proteomics 8(1), pp. 86-94. 
 
Ho, C. et al. 1995. A mouse model of human familial hypocalciuric hypercalcemia and 
neonatal severe hyperparathyroidism. Nature genetics 11(4), pp. 389-394. 
 
Hofer, A. M. and Brown, E. M. 2003. Extracellular calcium sensing and signalling. Nature 
reviews. Molecular cell biology 4(7), pp. 530-538. 
 
Holtwick, R. et al. 2002. Smooth muscle-selective deletion of guanylyl cyclase-A prevents the 
acute but not chronic effects of ANP on blood pressure. Proceedings of the National Academy 
of Sciences of the United States of America 99(10), pp. 7142-7147. 
 
Hoorn, E. J. et al. 2011. High tail-cuff blood pressure in mice 1 week after shipping: the need 
for longer acclimation. American journal of hypertension 24(5), pp. 534-536. 
 
Hropot, M. et al. 1994. Ramipril prevents the detrimental sequels of chronic NO synthase 
inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency. Naunyn-
Schmiedeberg's archives of pharmacology 350(6), pp. 646-652. 
 
Hu, M. C. et al. 2013. Fibroblast growth factor 23 and Klotho: physiology and 
pathophysiology of an endocrine network of mineral metabolism. Annual review of 
physiology 75, pp. 503-533. 
 
Imanishi, Y. et al. 2001. Primary hyperparathyroidism caused by parathyroid-targeted 
overexpression of cyclin D1 in transgenic mice. The Journal of clinical investigation 107(9), 
pp. 1093-1102. 
 
Iseki, K. et al. 1986. Effects of hypercalcemia and parathyroid hormone on blood pressure in 
normal and renal-failure rats. The American journal of physiology 250(5 Pt 2), pp. F924-929. 
207 
 
 
Ito, S. et al. 1993. Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II 
action in the isolated microperfused rabbit afferent but not efferent arteriole. The Journal of 
clinical investigation 91(5), pp. 2012-2019. 
 
Jakoby, M. G. t. and Semenkovich, C. F. 2000. The role of osteoprogenitors in vascular 
calcification. Current opinion in nephrology and hypertension 9(1), pp. 11-15. 
 
John, M. R. et al. 2011. ATF936, a novel oral calcilytic, increases bone mineral density in rats 
and transiently releases parathyroid hormone in humans. Bone 49(2), pp. 233-241. 
 
Johns, C. et al. 1996. Models of experimental hypertension in mice. Hypertension 28(6), pp. 
1064-1069. 
 
Johnson, E. O. et al. 2004. Vascular anatomy and microcirculation of skeletal zones 
vulnerable to osteonecrosis: vascularization of the femoral head. The Orthopedic clinics of 
North America 35(3), pp. 285-291, viii. 
 
Johnson, K. 2008. Introduction to rodent cardiac imaging. ILAR journal / National Research 
Council, Institute of Laboratory Animal Resources 49(1), pp. 27-34. 
 
Johnsson, M. S. and Nancollas, G. H. 1992. The role of brushite and octacalcium phosphate in 
apatite formation. Critical reviews in oral biology and medicine : an official publication of 
the American Association of Oral Biologists 3(1-2), pp. 61-82. 
 
Jones, A. M. et al. 2004. Nitric oxide synthase inhibition with L-NAME reduces maximal 
oxygen uptake but not gas exchange threshold during incremental cycle exercise in man. The 
Journal of physiology 560(Pt 1), pp. 329-338. 
 
Jono, S. et al. 2000. Phosphate regulation of vascular smooth muscle cell calcification. 
Circulation research 87(7), pp. E10-17. 
 
Jono, S. et al. 1997. Parathyroid hormone-related peptide as a local regulator of vascular 
calcification. Its inhibitory action on in vitro calcification by bovine vascular smooth muscle 
cells. Arteriosclerosis, thrombosis, and vascular biology 17(6), pp. 1135-1142. 
 
Kalogerou, M. et al. 2011. T2 weighted MRI for assessing renal lesions in transgenic mouse 
models of tuberous sclerosis. European journal of radiology. 
 
Kameda, T. et al. 1998. Calcium-sensing receptor in mature osteoclasts, which are bone 
resorbing cells. Biochemical and biophysical research communications 245(2), pp. 419-422. 
 
208 
 
Kanno, Y. et al. 2008. Nitric oxide regulates vascular calcification by interfering with TGF- 
signalling. Cardiovascular research 77(1), pp. 221-230. 
 
Kantham, L. et al. 2009. The calcium-sensing receptor (CaSR) defends against hypercalcemia 
independently of its regulation of parathyroid hormone secretion. American journal of 
physiology. Endocrinology and metabolism 297(4), pp. E915-923. 
 
Karwowski, W. et al. 2012. The mechanism of vascular calcification - a systematic review. 
Medical science monitor : international medical journal of experimental and clinical 
research 18(1), pp. RA1-11. 
 
Kawata, T. et al. 2007. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse 
model of primary hyperparathyroidism. Journal of the American Society of Nephrology : 
JASN 18(10), pp. 2683-2688. 
 
Kawata, T. et al. 2008. Cinacalcet suppresses calcification of the aorta and heart in uremic 
rats. Kidney international 74(10), pp. 1270-1277. 
 
Kisanuki, Y. Y. et al. 2010. Low blood pressure in endothelial cell-specific endothelin 1 
knockout mice. Hypertension 56(1), pp. 121-128. 
 
Klabunde, R. E. 2005. Cardiovascular physiology concepts. Philadelphia ; London: 
Lippincott Williams & Wilkins, pp. ix, 235 p. 
 
Klein, G. L. et al. 2008. Cardiovascular distribution of the calcium sensing receptor before 
and after burns. Burns : journal of the International Society for Burn Injuries 34(3), pp. 370-
375. 
 
Kobori, H. et al. 2007. The intrarenal renin-angiotensin system: from physiology to the 
pathobiology of hypertension and kidney disease. Pharmacological reviews 59(3), pp. 251-
287. 
 
Koleganova, N. et al. 2009. A calcimimetic (R-568), but not calcitriol, prevents vascular 
remodeling in uremia. Kidney international 75(1), pp. 60-71. 
 
Komuves, L. et al. 2002. Epidermal expression of the full-length extracellular calcium-
sensing receptor is required for normal keratinocyte differentiation. Journal of cellular 
physiology 192(1), pp. 45-54. 
 
Kos, C. H. et al. 2003. The calcium-sensing receptor is required for normal calcium 
homeostasis independent of parathyroid hormone. The Journal of clinical investigation 
111(7), pp. 1021-1028. 
209 
 
 
Krajisnik, T. et al. 2007. Fibroblast growth factor-23 regulates parathyroid hormone and 
1alpha-hydroxylase expression in cultured bovine parathyroid cells. The Journal of 
endocrinology 195(1), pp. 125-131. 
 
Kunutsor, S. K. et al. 2013. Vitamin D and risk of future hypertension: meta-analysis of 
283,537 participants. European journal of epidemiology 28(3), pp. 205-221. 
 
Kuro-o, M. et al. 1997. Mutation of the mouse klotho gene leads to a syndrome resembling 
ageing. Nature 390(6655), pp. 45-51. 
 
Kwak, J. O. et al. 2005. The extracellular calcium sensing receptor is expressed in mouse 
mesangial cells and modulates cell proliferation. Experimental & molecular medicine 37(5), 
pp. 457-465. 
 
Lahera, V. et al. 1991. Effects of NG-nitro-L-arginine methyl ester on renal function and 
blood pressure. The American journal of physiology 261(6 Pt 2), pp. F1033-1037. 
 
Lau, W. L. et al. 2013. High phosphate feeding promotes mineral and bone abnormalities in 
mice with chronic kidney disease. Nephrology, dialysis, transplantation : official publication 
of the European Dialysis and Transplant Association - European Renal Association 28(1), pp. 
62-69. 
 
Lee, H. J. et al. 2013. Calcium-sensing receptor and apoptosis in parathyroid hyperplasia of 
patients with secondary hyperparathyroidism. The Journal of international medical research 
41(1), pp. 97-105. 
 
Lees-Miller, J. P. et al. 1987. Isolation and characterization of an abundant and novel 22-kDa 
protein (SM22) from chicken gizzard smooth muscle. The Journal of biological chemistry 
262(7), pp. 2988-2993. 
 
Lepore, J. J. et al. 2005. High-efficiency somatic mutagenesis in smooth muscle cells and 
cardiac myocytes in SM22alpha-Cre transgenic mice. Genesis 41(4), pp. 179-184. 
 
Leroux-Berger, M. et al. 2011. Pathologic calcification of adult vascular smooth muscle cells 
differs on their crest or mesodermal embryonic origin. Journal of bone and mineral research : 
the official journal of the American Society for Bone and Mineral Research 26(7), pp. 1543-
1553. 
 
Li, L. et al. 1996a. SM22 alpha, a marker of adult smooth muscle, is expressed in multiple 
myogenic lineages during embryogenesis. Circulation research 78(2), pp. 188-195. 
 
210 
 
Li, L. et al. 1996b. Expression of the SM22alpha promoter in transgenic mice provides 
evidence for distinct transcriptional regulatory programs in vascular and visceral smooth 
muscle cells. The Journal of cell biology 132(5), pp. 849-859. 
 
Li, P. et al. 1999. Circadian blood pressure and heart rate rhythms in mice. The American 
journal of physiology 276(2 Pt 2), pp. R500-504. 
 
Li, Z. et al. 1997. Enhanced proliferation and migration and altered cytoskeletal proteins in 
early passage smooth muscle cells from young and old rat aortic explants. Experimental and 
molecular pathology 64(1), pp. 1-11. 
 
Liabeuf, S. et al. 2013. Vascular calcification in chronic kidney disease: are biomarkers useful 
for probing the pathobiology and the health risks of this process in the clinical scenario? 
Nephrology, dialysis, transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association. 
 
Lindberg, K. et al. 2013. Arterial Klotho Expression and FGF23 Effects on Vascular 
Calcification and Function. PloS one 8(4), p. e60658. 
 
Liu, J. et al. 2011. The abnormal phenotypes of cartilage and bone in calcium-sensing 
receptor deficient mice are dependent on the actions of calcium, phosphorus, and PTH. PLoS 
genetics 7(9), p. e1002294. 
 
Liu, Z. Z. et al. 2012. Iodinated contrast media differentially affect afferent and efferent 
arteriolar tone and reactivity in mice: a possible explanation for reduced glomerular filtration 
rate. Radiology 265(3), pp. 762-771. 
 
London, G. M. et al. 2008. Association of bone activity, calcium load, aortic stiffness, and 
calcifications in ESRD. Journal of the American Society of Nephrology : JASN 19(9), pp. 
1827-1835. 
 
London, G. M. et al. 2005. Arteriosclerosis, vascular calcifications and cardiovascular disease 
in uremia. Current opinion in nephrology and hypertension 14(6), pp. 525-531. 
 
London, G. M. et al. 2013. Vascular calcifications, arterial aging and arterial remodeling in 
ESRD. Blood purification 35(1-3), pp. 16-21. 
 
Loot, A. E. et al. 2013. Ca2+ sensing receptor cleavage by calpain partially accounts for 
altered vascular reactivity in mice fed a high fat diet. Journal of cardiovascular 
pharmacology. 
 
211 
 
Luft, F. C. et al. 1979. Cardiovascular and humoral responses to extremes of sodium intake in 
normal black and white men. Circulation 60(3), pp. 697-706. 
 
Luo, G. et al. 1997. Spontaneous calcification of arteries and cartilage in mice lacking matrix 
GLA protein. Nature 386(6620), pp. 78-81. 
 
MacLeod, R. J. 2013. Extracellular calcium-sensing receptor/PTH knockout mice colons have 
increased Wnt/beta-catenin signaling, reduced non-canonical Wnt signaling, and increased 
susceptibility to azoxymethane-induced aberrant crypt foci. Laboratory investigation; a 
journal of technical methods and pathology 93(5), pp. 520-527. 
 
Magno, A. L. et al. 2011. The calcium-sensing receptor: a molecular perspective. Endocrine 
reviews 32(1), pp. 3-30. 
 
Maillard, M. P. et al. 2009. Calcium-sensing receptors modulate renin release in vivo and in 
vitro in the rat. Journal of hypertension 27(10), pp. 1980-1987. 
 
Makaritsis, K. P. et al. 1999. Role of the alpha2B-adrenergic receptor in the development of 
salt-induced hypertension. Hypertension 33(1), pp. 14-17. 
 
Maldonado-Perez, D. et al. 2003. Human calcium-sensing receptor can be suppressed by 
antisense sequences. Biochemical and biophysical research communications 311(3), pp. 610-
617. 
 
Malhowski, A. J. et al. 2011. Smooth muscle protein-22-mediated deletion of Tsc1 results in 
cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin. Human molecular 
genetics 20(7), pp. 1290-1305. 
 
Mallya, S. M. et al. 2005. Abnormal parathyroid cell proliferation precedes biochemical 
abnormalities in a mouse model of primary hyperparathyroidism. Molecular endocrinology 
19(10), pp. 2603-2609. 
 
Martinez-Miguel, P. et al. 2013. Regulation of endothelin-converting enzyme-1 (ECE-1) by 
the calcimimetic R-568. Pharmacological research : the official journal of the Italian 
Pharmacological Society 76, pp. 106-118. 
 
Mattson, D. L. 2001. Comparison of arterial blood pressure in different strains of mice. 
American journal of hypertension 14(5 Pt 1), pp. 405-408. 
 
McCarron, D. A. et al. 1982. Dietary calcium in human hypertension. Science 217(4556), pp. 
267-269. 
 
212 
 
McLarnon, S. et al. 2002. Aminoglycoside antibiotics induce pH-sensitive activation of the 
calcium-sensing receptor. Biochemical and biophysical research communications 297(1), pp. 
71-77. 
 
Mendoza, F. J. et al. 2009. Direct upregulation of parathyroid calcium-sensing receptor and 
vitamin D receptor by calcimimetics in uremic rats. American journal of physiology. Renal 
physiology 296(3), pp. F605-613. 
 
Mendoza, F. J. et al. 2011. Effect of calcium and the calcimimetic AMG 641 on matrix-Gla 
protein in vascular smooth muscle cells. Calcified tissue international 88(3), pp. 169-178. 
 
Mizobuchi, M. et al. 2011. Effects of calcimimetic combined with an angiotensin-converting 
enzyme inhibitor on uremic cardiomyopathy progression. American journal of nephrology 
34(3), pp. 256-267. 
 
Moessler, H. et al. 1996. The SM 22 promoter directs tissue-specific expression in arterial but 
not in venous or visceral smooth muscle cells in transgenic mice. Development 122(8), pp. 
2415-2425. 
 
Mohammadi, A. et al. 2013. Spectral Doppler analysis of parathyroid adenoma: correlation 
between resistive index and serum parathyroid hormone concentration. AJR. American 
journal of roentgenology 201(2), pp. W318-321. 
 
Molostvov, G. et al. 2008. Extracellular calcium-sensing receptor mediated signalling is 
involved in human vascular smooth muscle cell proliferation and apoptosis. Cellular 
physiology and biochemistry : international journal of experimental cellular physiology, 
biochemistry, and pharmacology 22(5-6), pp. 413-422. 
 
Molostvov, G. et al. 2007. Extracellular calcium-sensing receptor is functionally expressed in 
human artery. American journal of physiology. Renal physiology 293(3), pp. F946-955. 
 
Moorehead, W. R. and Biggs, H. G. 1974. 2-Amino-2-methyl-1-propanol as the alkalizing 
agent in an improved continuous-flow cresolphthalein complexone procedure for calcium in 
serum. Clinical chemistry 20(11), pp. 1458-1460. 
 
Moskalenko, A. V. et al. 2010. Single protein molecule mapping with magnetic atomic force 
microscopy. Biophysical journal 98(3), pp. 478-487. 
 
Motokura, T. et al. 1991. A novel cyclin encoded by a bcl1-linked candidate oncogene. 
Nature 350(6318), pp. 512-515. 
 
213 
 
Motoyama, H. I. and Friedman, P. A. 2002. Calcium-sensing receptor regulation of PTH-
dependent calcium absorption by mouse cortical ascending limbs. American journal of 
physiology. Renal physiology 283(3), pp. F399-406. 
 
Murakami, T. et al. 1995. Blood vascular bed and pericapillary space in rat parathyroid 
glands. Microscopy research and technique 32(2), pp. 112-119. 
 
Nagao, T. et al. 1992. Heterogeneous distribution of endothelium-dependent relaxations 
resistant to NG-nitro-L-arginine in rats. The American journal of physiology 263(4 Pt 2), pp. 
H1090-1094. 
 
Nakagawa, K. et al. 2009. Acute cardiovascular effects of the calcimimetic R-568 and its 
enantiomer S-568 in rats. Pediatric nephrology 24(7), pp. 1385-1389. 
 
National Heart, Lung, and Blood Institute. 2013. What is Hypotension? [Online].  Available 
at: http://www.nhlbi.nih.gov/health/health-topics/topics/hyp/ [Accessed: 20.04.2013].  
 
Naveh-Many, T. et al. 1995. Parathyroid cell proliferation in normal and chronic renal failure 
rats. The effects of calcium, phosphate, and vitamin D. The Journal of clinical investigation 
96(4), pp. 1786-1793. 
 
Nemeth, E. F. et al. 1998. Calcimimetics with potent and selective activity on the parathyroid 
calcium receptor. Proceedings of the National Academy of Sciences of the United States of 
America 95(7), pp. 4040-4045. 
 
Newaz, M. et al. 2005. NAD(P)H oxidase/nitric oxide interactions in peroxisome proliferator 
activated receptor (PPAR)alpha-mediated cardiovascular effects. Mutation research 579(1-2), 
pp. 163-171. 
 
Nguy, L. et al. 2013. Rats with adenine-induced chronic renal failure develop low-renin, salt-
sensitive hypertension and increased aortic stiffness. American journal of physiology. 
Regulatory, integrative and comparative physiology 304(9), pp. R744-752. 
 
Oda, Y. et al. 2000. The calcium sensing receptor and its alternatively spliced form in murine 
epidermal differentiation. The Journal of biological chemistry 275(2), pp. 1183-1190. 
 
Odenwald, T. et al. 2006. Acute blood pressure effects and chronic hypotensive action of 
calcimimetics in uremic rats. Journal of the American Society of Nephrology : JASN 17(3), 
pp. 655-662. 
 
214 
 
Ogata, H. et al. 2003. Beneficial effects of calcimimetics on progression of renal failure and 
cardiovascular risk factors. Journal of the American Society of Nephrology : JASN 14(4), pp. 
959-967. 
 
Ogata, S. et al. 2006. Ca2+ stimulates COX-2 expression through calcium-sensing receptor in 
fibroblasts. Biochemical and biophysical research communications 351(4), pp. 808-814. 
 
Ohanian, J. et al. 2005. Evidence for a functional calcium-sensing receptor that modulates 
myogenic tone in rat subcutaneous small arteries. American journal of physiology. Heart and 
circulatory physiology 288(4), pp. H1756-1762. 
 
Orban, P. C. et al. 1992. Tissue- and site-specific DNA recombination in transgenic mice. 
Proceedings of the National Academy of Sciences of the United States of America 89(15), pp. 
6861-6865. 
 
Ortiz-Capisano, M. C. et al. 2007. Expression and function of the calcium-sensing receptor in 
juxtaglomerular cells. Hypertension 50(4), pp. 737-743. 
 
Otto, A. C. et al. 2003. Enhanced myocardial contractility associated with hypercalcaemia of 
hyperparathyroidism - a case study in six patients. Cardiovascular journal of South Africa : 
official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac 
Practitioners 14(3), pp. 141-143. 
 
Pacheco, II and Macleod, R. J. 2008. CaSR stimulates secretion of Wnt5a from colonic 
myofibroblasts to stimulate CDX2 and sucrase-isomaltase using Ror2 on intestinal epithelia. 
American journal of physiology. Gastrointestinal and liver physiology 295(4), pp. G748-759. 
 
Pai, A. et al. 2011. Elastin degradation and vascular smooth muscle cell phenotype change 
precede cell loss and arterial medial calcification in a uremic mouse model of chronic kidney 
disease. The American journal of pathology 178(2), pp. 764-773. 
 
Panizo, S. et al. 2009. RANKL increases vascular smooth muscle cell calcification through a 
RANK-BMP4-dependent pathway. Circulation research 104(9), pp. 1041-1048. 
 
Peuler, J. D. et al. 1987. High calcium diet reduces blood pressure in Dahl salt-sensitive rats 
by neural mechanisms. Hypertension 9(6 Pt 2), pp. III159-165. 
 
Phillips, A. A. et al. 2014. Increased central arterial stiffness explains baroreflex dysfunction 
in spinal cord injury. Journal of neurotrauma. 
 
215 
 
Pi, M. et al. 2000. Sensing of extracellular cations in CasR-deficient osteoblasts. Evidence for 
a novel cation-sensing mechanism. The Journal of biological chemistry 275(5), pp. 3256-
3263. 
 
Pi, M. et al. 2002. Calcium-sensing receptor activation of rho involves filamin and rho-
guanine nucleotide exchange factor. Endocrinology 143(10), pp. 3830-3838. 
 
Pollak, M. R. et al. 1994. Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing 
receptor gene mutation. Nature genetics 8(3), pp. 303-307. 
 
Pollak, M. R. et al. 1996. Three inherited disorders of calcium sensing. Medicine 75(3), pp. 
115-123. 
 
Prosdocimo, D. A. et al. 2010. Regulation of vascular smooth muscle cell calcification by 
extracellular pyrophosphate homeostasis: synergistic modulation by cyclic AMP and 
hyperphosphatemia. American journal of physiology. Cell physiology 298(3), pp. C702-713. 
 
Proudfoot, D. and Shanahan, C. M. 2006. Molecular mechanisms mediating vascular 
calcification: role of matrix Gla protein. Nephrology 11(5), pp. 455-461. 
 
Puchtler, H. et al. 1969. On the history and mechanism of alizarin and alizarin red S stains for 
calcium. The journal of histochemistry and cytochemistry : official journal of the 
Histochemistry Society 17(2), pp. 110-124. 
 
Qi, H. et al. 2013. Crucial role of calcium-sensing receptor activation in cardiac injury of 
diabetic rats. PloS one 8(5), p. e65147. 
 
Quinn, S. J. et al. 2004. pH Sensing by the calcium-sensing receptor. The Journal of 
biological chemistry 279(36), pp. 37241-37249. 
 
Quinn, S. J. et al. 2013a. CaSR-mediated interactions between calcium and magnesium 
homeostasis in mice. American journal of physiology. Endocrinology and metabolism 304(7), 
pp. E724-733. 
 
Quinn, S. J. et al. 2013b. Interactions between calcium and phosphorus in the regulation of the 
production of fibroblast growth factor 23 in vivo. American journal of physiology. 
Endocrinology and metabolism 304(3), pp. E310-320. 
 
Quinn, S. J. et al. 1997. The Ca2+-sensing receptor: a target for polyamines. The American 
journal of physiology 273(4 Pt 1), pp. C1315-1323. 
 
216 
 
Raggi, P. et al. 2011. The ADVANCE study: a randomized study to evaluate the effects of 
cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. 
Nephrology, dialysis, transplantation : official publication of the European Dialysis and 
Transplant Association - European Renal Association 26(4), pp. 1327-1339. 
 
Rasschaert, J. and Malaisse, W. J. 1999. Expression of the calcium-sensing receptor in 
pancreatic islet B-cells. Biochemical and biophysical research communications 264(3), pp. 
615-618. 
 
Ray, K. et al. 1999. Identification of the cysteine residues in the amino-terminal extracellular 
domain of the human Ca(2+) receptor critical for dimerization. Implications for function of 
monomeric Ca(2+) receptor. The Journal of biological chemistry 274(39), pp. 27642-27650. 
 
Razzaque, M. S. 2009. The FGF23-Klotho axis: endocrine regulation of phosphate 
homeostasis. Nature reviews. Endocrinology 5(11), pp. 611-619. 
 
Renkema, K. Y. et al. 2009. The calcium-sensing receptor promotes urinary acidification to 
prevent nephrolithiasis. Journal of the American Society of Nephrology : JASN 20(8), pp. 
1705-1713. 
 
Rey, O. et al. 2012. Negative cross-talk between calcium-sensing receptor and beta-catenin 
signaling systems in colonic epithelium. The Journal of biological chemistry 287(2), pp. 
1158-1167. 
 
Rey, O. et al. 2010. Extracellular calcium sensing receptor stimulation in human colonic 
epithelial cells induces intracellular calcium oscillations and proliferation inhibition. Journal 
of cellular physiology 225(1), pp. 73-83. 
 
Reynolds, J. L. et al. 2004. Human vascular smooth muscle cells undergo vesicle-mediated 
calcification in response to changes in extracellular calcium and phosphate concentrations: a 
potential mechanism for accelerated vascular calcification in ESRD. Journal of the American 
Society of Nephrology : JASN 15(11), pp. 2857-2867. 
 
Reynolds, J. L. et al. 2005. Multifunctional roles for serum protein fetuin-a in inhibition of 
human vascular smooth muscle cell calcification. Journal of the American Society of 
Nephrology : JASN 16(10), pp. 2920-2930. 
 
Riccardi, D. and Brown, E. M. 2010. Physiology and pathophysiology of the calcium-sensing 
receptor in the kidney. American journal of physiology. Renal physiology 298(3), pp. F485-
499. 
 
Riccardi, D. et al. 1998. Localization of the extracellular Ca2+/polyvalent cation-sensing 
protein in rat kidney. The American journal of physiology 274(3 Pt 2), pp. F611-622. 
217 
 
 
Riccardi, D. et al. 1995. Cloning and functional expression of a rat kidney extracellular 
calcium/polyvalent cation-sensing receptor. Proceedings of the National Academy of Sciences 
of the United States of America 92(1), pp. 131-135. 
 
Richard, C. et al. 2010. The calcium-sensing receptor and 25-hydroxyvitamin D-1alpha-
hydroxylase interact to modulate skeletal growth and bone turnover. Journal of bone and 
mineral research : the official journal of the American Society for Bone and Mineral 
Research 25(7), pp. 1627-1636. 
 
Ritter, C. S. et al. 2006. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by 
bovine parathyroid cells. Kidney international 70(4), pp. 654-659. 
 
Rodriguez, L. et al. 2005. Expression and functional assessment of an alternatively spliced 
extracellular Ca2+-sensing receptor in growth plate chondrocytes. Endocrinology 146(12), pp. 
5294-5303. 
 
Rodriguez, M. E. et al. 2007. The calcimimetic R-568 increases vitamin D receptor 
expression in rat parathyroid glands. American journal of physiology. Renal physiology 
292(5), pp. F1390-1395. 
 
Romero, J. R. et al. 2013. Parathyroid hormone ablation alters erythrocyte parameters that are 
rescued by calcium-sensing receptor gene deletion. European journal of haematology 91(1), 
pp. 37-45. 
 
Rosenqvist, M. et al. 1992. Cardiac conduction in patients with hypercalcaemia due to 
primary hyperparathyroidism. Clinical endocrinology 37(1), pp. 29-33. 
 
Ross, J. J. et al. 2006. Cytokine-induced differentiation of multipotent adult progenitor cells 
into functional smooth muscle cells. The Journal of clinical investigation 116(12), pp. 3139-
3149. 
 
Rostaing, L. et al. 1997. Changes in blood pressure and renal function following subtotal 
parathyroidectomy in renal transplant patients presenting with persistent hypercalcemic 
hyperparathyroidism. Clinical nephrology 47(4), pp. 248-255. 
 
Ruat, M. et al. 1995. Calcium sensing receptor: molecular cloning in rat and localization to 
nerve terminals. Proceedings of the National Academy of Sciences of the United States of 
America 92(8), pp. 3161-3165. 
 
Ruiz, A. et al. 2008. The effects of NG-nitro-L-arginine methyl ester on systolic pressure, 
diastolic pressure and pulse pressure according to the initial level of blood pressure. 
Fundamental & clinical pharmacology 22(1), pp. 45-52. 
218 
 
 
Rybczynska, A. et al. 2010. Blockade of calcium channels and AT1 receptor prevents the 
hypertensive effect of calcilytic NPS 2143 in rats. Journal of physiology and pharmacology : 
an official journal of the Polish Physiological Society 61(2), pp. 163-170. 
 
Sabanayagam, C. and Shankar, A. 2011. Serum calcium levels and hypertension among U.S. 
adults. Journal of clinical hypertension 13(10), pp. 716-721. 
 
Sadler, A. M. and Bailey, S. J. 2013. Validation of a refined technique for taking repeated 
blood samples from juvenile and adult mice. Laboratory animals 47(4), pp. 316-319. 
 
Sage, A. P. et al. 2011. Hyperphosphatemia-induced nanocrystals upregulate the expression of 
bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. 
Kidney international 79(4), pp. 414-422. 
 
Sage, A. P. et al. 2010. Regulatory mechanisms in vascular calcification. Nature reviews. 
Cardiology 7(9), pp. 528-536. 
 
Saidak, Z. et al. 2009. Agonists and allosteric modulators of the calcium-sensing receptor and 
their therapeutic applications. Molecular pharmacology 76(6), pp. 1131-1144. 
 
Sandow, S. L. et al. 2002. Involvement of myoendothelial gap junctions in the actions of 
endothelium-derived hyperpolarizing factor. Circulation research 90(10), pp. 1108-1113. 
 
Sansoe, G. et al. 2013. Calcium receptors located in fibrotic septa: a new target to reduce 
portal pressure in liver cirrhosis. Clinical science 125(2), pp. 67-75. 
 
Schiffl, H. and Lang, S. M. 2011. Hypertension Secondary to PHPT: Cause or Coincidence? 
International journal of endocrinology 2011, p. 974647. 
 
Schneider, J. E. et al. 2006. How to perform an accurate assessment of cardiac function in 
mice using high-resolution magnetic resonance imaging. Journal of cardiovascular magnetic 
resonance : official journal of the Society for Cardiovascular Magnetic Resonance 8(5), pp. 
693-701. 
 
Schreier, B. et al. 2013. Loss of epidermal growth factor receptor in vascular smooth muscle 
cells and cardiomyocytes causes arterial hypotension and cardiac hypertrophy. Hypertension 
61(2), pp. 333-340. 
 
Shanahan, C. M. et al. 1994. High expression of genes for calcification-regulating proteins in 
human atherosclerotic plaques. The Journal of clinical investigation 93(6), pp. 2393-2402. 
 
219 
 
Shanahan, C. M. et al. 1999. Medial localization of mineralization-regulating proteins in 
association with Monckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular 
calcification. Circulation 100(21), pp. 2168-2176. 
 
Shanahan, C. M. et al. 2011. Arterial calcification in chronic kidney disease: key roles for 
calcium and phosphate. Circulation research 109(6), pp. 697-711. 
 
Shanahan, C. M. and Weissberg, P. L. 1998. Smooth muscle cell heterogeneity: patterns of 
gene expression in vascular smooth muscle cells in vitro and in vivo. Arteriosclerosis, 
thrombosis, and vascular biology 18(3), pp. 333-338. 
 
Shanahan, C. M. et al. 1993. Isolation of gene markers of differentiated and proliferating 
vascular smooth muscle cells. Circulation research 73(1), pp. 193-204. 
 
Shen, Z. et al. 2012. Smooth muscle protein 22 alpha-Cre is expressed in myeloid cells in 
mice. Biochemical and biophysical research communications 422(4), pp. 639-642. 
 
Sheriff, D. D. et al. 2000. Does autonomic blockade reveal a potent contribution of nitric 
oxide to locomotion-induced vasodilation? American journal of physiology. Heart and 
circulatory physiology 279(2), pp. H726-732. 
 
Shimokawa, H. et al. 1996. The importance of the hyperpolarizing mechanism increases as 
the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. 
Journal of cardiovascular pharmacology 28(5), pp. 703-711. 
 
Shoback, D. M. et al. 2003. The calcimimetic cinacalcet normalizes serum calcium in subjects 
with primary hyperparathyroidism. The Journal of clinical endocrinology and metabolism 
88(12), pp. 5644-5649. 
 
Shobeiri, N. et al. 2010. Vascular calcification in animal models of CKD: A review. American 
journal of nephrology 31(6), pp. 471-481. 
 
Shroff, R. et al. 2013. Mechanistic insights into vascular calcification in CKD. Journal of the 
American Society of Nephrology : JASN 24(2), pp. 179-189. 
 
Shroff, R. C. et al. 2008. Dialysis accelerates medial vascular calcification in part by 
triggering smooth muscle cell apoptosis. Circulation 118(17), pp. 1748-1757. 
 
Shu, L. et al. 2011. The calcium-sensing receptor mediates bone turnover induced by dietary 
calcium and parathyroid hormone in neonates. Journal of bone and mineral research : the 
official journal of the American Society for Bone and Mineral Research 26(5), pp. 1057-1071. 
 
220 
 
Silve, C. et al. 2005. Delineating a Ca2+ binding pocket within the venus flytrap module of 
the human calcium-sensing receptor. The Journal of biological chemistry 280(45), pp. 37917-
37923. 
 
Silverberg, S. J. 2000. Editorial: cardiovascular disease in primary hyperparathyroidism. The 
Journal of clinical endocrinology and metabolism 85(10), pp. 3513-3514. 
 
Smajilovic, S. et al. 2006. Extracellular calcium sensing in rat aortic vascular smooth muscle 
cells. Biochemical and biophysical research communications 348(4), pp. 1215-1223. 
 
Smajilovic, S. et al. 2007. Calcimimetic, AMG 073, induces relaxation on isolated rat aorta. 
Vascular pharmacology 47(4), pp. 222-228. 
 
Smajilovic, S. and Tfelt-Hansen, J. 2007. Calcium acts as a first messenger through the 
calcium-sensing receptor in the cardiovascular system. Cardiovascular research 75(3), pp. 
457-467. 
 
Smajilovic, S. et al. 2011. The calcium-sensing receptor and calcimimetics in blood pressure 
modulation. British journal of pharmacology 164(3), pp. 884-893. 
 
Somjen, D. et al. 2005. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human 
vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic 
compounds. Circulation 111(13), pp. 1666-1671. 
 
Son, B. K. et al. 2006. Statins protect human aortic smooth muscle cells from inorganic 
phosphate-induced calcification by restoring Gas6-Axl survival pathway. Circulation 
research 98(8), pp. 1024-1031. 
 
Sricharoenvej, S. et al. 2009. Morphological and microvascular changes of the adrenal glands 
in streptozotocin-induced long-term diabetic rats. Italian journal of anatomy and embryology 
= Archivio italiano di anatomia ed embriologia 114(1), pp. 1-10. 
 
Stefenelli, T. et al. 1993. Primary hyperparathyroidism: incidence of cardiac abnormalities 
and partial reversibility after successful parathyroidectomy. The American journal of medicine 
95(2), pp. 197-202. 
 
Steitz, S. A. et al. 2001. Smooth muscle cell phenotypic transition associated with 
calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. 
Circulation research 89(12), pp. 1147-1154. 
 
Sternberg, N. and Hamilton, D. 1981. Bacteriophage P1 site-specific recombination. I. 
Recombination between loxP sites. Journal of molecular biology 150(4), pp. 467-486. 
221 
 
 
Stuckey, D. J. et al. 2012. In vivo MRI characterization of progressive cardiac dysfunction in 
the mdx mouse model of muscular dystrophy. PloS one 7(1), p. e28569. 
 
Sun, J. and Murphy, E. 2010. Calcium-sensing receptor: a sensor and mediator of ischemic 
preconditioning in the heart. American journal of physiology. Heart and circulatory 
physiology 299(5), pp. H1309-1317. 
 
Sun, W. et al. 2010. Alterations in phosphorus, calcium and PTHrP contribute to defects in 
dental and dental alveolar bone formation in calcium-sensing receptor-deficient mice. 
Development 137(6), pp. 985-992. 
 
Sun, Y. et al. 2012. Smooth muscle cell-specific runx2 deficiency inhibits vascular 
calcification. Circulation research 111(5), pp. 543-552. 
 
Sun, Y. et al. 2011. Sudan black B reduces autofluorescence in murine renal tissue. Archives 
of pathology & laboratory medicine 135(10), pp. 1335-1342. 
 
Sun, Y. H. et al. 2006. Calcium-sensing receptor induces rat neonatal ventricular 
cardiomyocyte apoptosis. Biochemical and biophysical research communications 350(4), pp. 
942-948. 
 
Tfelt-Hansen, J. et al. 2006. Calcium receptor is functionally expressed in rat neonatal 
ventricular cardiomyocytes. American journal of physiology. Heart and circulatory 
physiology 290(3), pp. H1165-1171. 
 
Thakore, P. and Ho, W. S. 2011. Vascular actions of calcimimetics: role of Ca(2)(+) -sensing 
receptors versus Ca(2)(+) influx through L-type Ca(2)(+) channels. British journal of 
pharmacology 162(3), pp. 749-762. 
 
Tharmalingam, S. et al. 2011. Calcium-sensing receptor modulates cell adhesion and 
migration via integrins. The Journal of biological chemistry 286(47), pp. 40922-40933. 
 
Thomsen, A. R. et al. 2012. Biased agonism of the calcium-sensing receptor. Cell calcium 
51(2), pp. 107-116. 
 
Thorin, E. et al. 1990. Vascular calcium overload produced by administration of vitamin D3 
and nicotine in rats. Changes in tissue calcium levels, blood pressure, and pressor responses to 
electrical stimulation or norepinephrine in vivo. Journal of cardiovascular pharmacology 
16(2), pp. 257-266. 
 
222 
 
Toka, H. R. et al. 2012. Deficiency of the calcium-sensing receptor in the kidney causes 
parathyroid hormone-independent hypocalciuria. Journal of the American Society of 
Nephrology : JASN 23(11), pp. 1879-1890. 
 
Tomazic, B. B. et al. 1987. Nature and properties of cardiovascular deposits. Scanning 
microscopy 1(1), pp. 95-105. 
 
Topala, C. N. et al. 2009. Activation of the Ca2+-sensing receptor stimulates the activity of 
the epithelial Ca2+ channel TRPV5. Cell calcium 45(4), pp. 331-339. 
 
Tu, Q. et al. 2003. Rescue of the skeletal phenotype in CasR-deficient mice by transfer onto 
the Gcm2 null background. The Journal of clinical investigation 111(7), pp. 1029-1037. 
 
Tyson, K. L. et al. 2003. Osteo/chondrocytic transcription factors and their target genes 
exhibit distinct patterns of expression in human arterial calcification. Arteriosclerosis, 
thrombosis, and vascular biology 23(3), pp. 489-494. 
 
Urena-Torres, P. A. et al. 2013. Protocol adherence and the progression of cardiovascular 
calcification in the ADVANCE study. Nephrology, dialysis, transplantation : official 
publication of the European Dialysis and Transplant Association - European Renal 
Association 28(1), pp. 146-152. 
 
Vargas-Poussou, R. et al. 2002. Functional characterization of a calcium-sensing receptor 
mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. Journal 
of the American Society of Nephrology : JASN 13(9), pp. 2259-2266. 
 
Vazquez, R. et al. 2010. Accuracy of bedside physical examination in distinguishing 
categories of shock: a pilot study. Journal of hospital medicine : an official publication of the 
Society of Hospital Medicine 5(8), pp. 471-474. 
 
Viegas, M. S. et al. 2007. An improved and cost-effective methodology for the reduction of 
autofluorescence in direct immunofluorescence studies on formalin-fixed paraffin-embedded 
tissues. European journal of histochemistry : EJH 51(1), pp. 59-66. 
 
Villa-Bellosta, R. et al. 2011. Role of calcium-phosphate deposition in vascular smooth 
muscle cell calcification. American journal of physiology. Cell physiology 300(1), pp. C210-
220. 
 
Villa-Bellosta, R. and Sorribas, V. 2011. Calcium phosphate deposition with normal 
phosphate concentration. -Role of pyrophosphate. Circulation journal : official journal of the 
Japanese Circulation Society 75(11), pp. 2705-2710. 
 
223 
 
Vizard, T. N. et al. 2008. Regulation of axonal and dendritic growth by the extracellular 
calcium-sensing receptor. Nature neuroscience 11(3), pp. 285-291. 
 
Walker, M. D. et al. 2010. Cardiac structure and diastolic function in mild primary 
hyperparathyroidism. The Journal of clinical endocrinology and metabolism 95(5), pp. 2172-
2179. 
 
Wang, C. C. et al. 2007. Insulin attenuates vascular smooth muscle calcification but increases 
vascular smooth muscle cell phosphate transport. Atherosclerosis 195(1), pp. e65-75. 
 
Wang, Q. et al. 2010. Cardiac hypertrophy, low blood pressure, and low aldosterone levels in 
mice devoid of the three circadian PAR bZip transcription factors DBP, HLF, and TEF. 
American journal of physiology. Regulatory, integrative and comparative physiology 299(4), 
pp. R1013-1019. 
 
Wang, R. et al. 2003. Calcium and polyamine regulated calcium-sensing receptors in cardiac 
tissues. European journal of biochemistry / FEBS 270(12), pp. 2680-2688. 
 
Wang, W. et al. 2004. Baroreceptor reflex in heart failure. Sheng li xue bao : [Acta 
physiologica Sinica] 56(3), pp. 269-281. 
 
Ward, B. K. et al. 2012. The role of the calcium-sensing receptor in human disease. Clinical 
biochemistry 45(12), pp. 943-953. 
 
Ward, D. T. et al. 1998. Disulfide bonds in the extracellular calcium-polyvalent cation-
sensing receptor correlate with dimer formation and its response to divalent cations in vitro. 
The Journal of biological chemistry 273(23), pp. 14476-14483. 
 
Weston, A. H. et al. 2005. Evidence in favor of a calcium-sensing receptor in arterial 
endothelial cells: studies with calindol and Calhex 231. Circulation research 97(4), pp. 391-
398. 
 
White, E. et al. 2009. Pharmacochaperone-mediated rescue of calcium-sensing receptor loss-
of-function mutants. Molecular endocrinology 23(7), pp. 1115-1123. 
 
Wonneberger, K. et al. 2000. Evidence for a calcium-sensing receptor in the vascular smooth 
muscle cells of the spiral modiolar artery. The Journal of membrane biology 175(3), pp. 203-
212. 
 
Xu, R. et al. 2003. Human SM22 alpha BAC encompasses regulatory sequences for 
expression in vascular and visceral smooth muscles at fetal and adult stages. American 
journal of physiology. Heart and circulatory physiology 284(4), pp. H1398-1407. 
224 
 
 
Xue, Y. et al. 2012. The calcium-sensing receptor complements parathyroid hormone-induced 
bone turnover in discrete skeletal compartments in mice. American journal of physiology. 
Endocrinology and metabolism 302(7), pp. E841-851. 
 
Yamamura, A. et al. 2012. Enhanced Ca(2+)-sensing receptor function in idiopathic 
pulmonary arterial hypertension. Circulation research 111(4), pp. 469-481. 
 
Yamashita, T. et al. 2000. Identification of a novel fibroblast growth factor, FGF-23, 
preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochemical and 
biophysical research communications 277(2), pp. 494-498. 
 
Yano, S. et al. 2000. Association of decreased calcium-sensing receptor expression with 
proliferation of parathyroid cells in secondary hyperparathyroidism. Kidney international 
58(5), pp. 1980-1986. 
 
Yano, S. et al. 2003. Decrease in vitamin D receptor and calcium-sensing receptor in highly 
proliferative parathyroid adenomas. European journal of endocrinology / European 
Federation of Endocrine Societies 148(4), pp. 403-411. 
 
Yatabe, M. S. et al. 2012. Effects of a high-sodium diet on renal tubule Ca2+ transporter and 
claudin expression in Wistar-Kyoto rats. BMC nephrology 13, p. 160. 
 
Yoshida, T. et al. 2002. Mediation of unusually high concentrations of 1,25-dihydroxyvitamin 
D in homozygous klotho mutant mice by increased expression of renal 1alpha-hydroxylase 
gene. Endocrinology 143(2), pp. 683-689. 
 
Yu, Q. et al. 2004. Characterization of high-salt and high-fat diets on cardiac and vascular 
function in mice. Cardiovascular toxicology 4(1), pp. 37-46. 
 
Zhang, J. C. et al. 2001a. Analysis of SM22alpha-deficient mice reveals unanticipated 
insights into smooth muscle cell differentiation and function. Molecular and cellular biology 
21(4), pp. 1336-1344. 
 
Zhang, X. et al. 2014. Calcium Sensing Receptor Promotes Cardiac Fibroblast Proliferation 
and Extracellular Matrix Secretion. Cellular physiology and biochemistry : international 
journal of experimental cellular physiology, biochemistry, and pharmacology 33(3), pp. 557-
568. 
 
Zhang, Z. et al. 2001b. The extracellular calcium-sensing receptor dimerizes through multiple 
types of intermolecular interactions. The Journal of biological chemistry 276(7), pp. 5316-
5322. 
225 
 
 
Zhu, D. et al. 2011. The appearance and modulation of osteocyte marker expression during 
calcification of vascular smooth muscle cells. PloS one 6(5), p. e19595. 
 
Ziegelstein, R. C. et al. 2006. Expression of a functional extracellular calcium-sensing 
receptor in human aortic endothelial cells. Biochemical and biophysical research 
communications 342(1), pp. 153-163. 
 
Zitt, E. et al. 2011. Effect of cinacalcet on renal electrolyte handling and systemic arterial 
blood pressure in kidney transplant patients with persistent hyperparathyroidism. 
Transplantation 92(8), pp. 883-889. 
 
 
 
  
226 
 
11 Appendix A 
In this appendix, the raw data values of the experiments are given in tabularised format. 
 
Table 14: Weights of WT, HET and KO mice. N = number of weighed animals. Mean ± SEM. 1–6 
month data by Thomas Davies (Davies 2013), 12 and 18 month data by MS. 
Age WT N HET N KO N 
Male             
1 15.65 ± 0.56 41 15.27 ± 1.35 9 14.79 ± 0.76 21 
2 25.18 ± 0.38 37 26.70 ± 0.70 10 25.72 ± 0.50 21 
3 28.12 ± 0.35 65 29.52 ± 0.61 17 27.64 ± 0.41 27 
4 29.78 ± 0.41 27 29.68 ± 0.36 7 28.81 ± 0.38 21 
5 31.76 ± 0.39 42 32.70 ± 0.97 10 29.96 ± 0.53 19 
6 33.69 ± 0.56 25 36.45 ± 1.29 6 32.93 ± 1.22 8 
12 39.57 ± 1.98 3     37.52 ± 2.17 3 
18 36.30 ± 2.20 3     35.78 ± 1.52 3 
    
Female   
1 14.87 ± 0.40 35 11.34 ± 1.07 4 12.27 ± 0.75 21 
2 20.99 ± 0.34 33 21.57 ± 0.40 5 20.19 ± 0.54 19 
3 23.53 ± 0.38 36 22.85 ± 0.50 7 22.37 ± 0.54 17 
4 25.46 ± 0.61 19 24.65 ± 0.69 4 23.01 ± 0.66 13 
5 26.90 ± 0.48 25 25.38 ± 0.51 7 25.06 ± 1.04 15 
6 30.20 ± 1.25 8 25.70 ± 0.35 3 28.70 ± 2.11 6 
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Table 15: Results of quantitative immunofluorescence analysis of CaSR expression levels in VSMC 
preparations of passages 2-6 cultured from WT and KO aortae. CaSR staining intensities were 
normalised to the SM22α intensity of the respective cell batch and weighed in respect to the cell 
number in the respective batch. Staining intensity of KO cells is expressed as fold change compared 
to WT. Results are shown for all cells present in the preparation (all cells) for either positively stained 
samples (Positive) or negative controls (Negative) or for the population of VSMC only (VSMC only). All 
cell group: N = 9 (WT positive), 6 (KO positive), 6 (WT negative), 3 (KO negative), Mean + SEM, * p < 
0.05, two-way ANOVA with Bonferroni post-test WT vs KO (p values), VSMC cell only group: N = 9 
(WT), 6 (KO), Mean + SEM, ** p < 0.01, two-tailed T-test. 
Group Unit WT KO P  
All cells          
Positive fold 1.000 ± 0.090 0.683 ± 0.075 < 0.05 * 
Negative fold 0.177 ± 0.039 0.091 ± 0.048 > 0.05  
          
VSMC only fold 1.000 ± 0.081 0.559 ± 0.094 0.0038 ** 
 
 
Table 16: Results of VSMC proliferation studies. Day = days in culture. All data presented as fold-
change vs. the data at 1.2 mM Ca2+ of the respective first group (Day 5, WT). N = 5 (control VSMC), 1 
(WT, KO VSMC), n = 3. All cell batches contained VSMC isolated from 2-3 mice. Mean ± SEM. Two-
way ANOVA with Bonferroni post-test (p-values) for Day 10 1.2 mm Ca2+ (Day 10) and vs. WT 1.2 mM 
Ca2+ (WT). 
 
Group Unit Day 5 Day 10 p 
Control cells         
1.2 mM Ca2+ fold 1.00 ± 0.09 3.96 ± 0.72 - 
1.8 mM Ca2+ fold 1.21 ± 0.16 6.51 ± 1.27 > 0.05 
2.5 mM Ca2+ fold 1.12 ± 0.07 11.95 ± 2.47 < 0.001 
         
Group Unit WT KO  
WT vs KO VSMC        
1.2 mM Ca2+ fold 1.00 ± 0.07 0.97 ± 0.05 > 0.05 
1.8 mM Ca2+ fold 0.98 ± 0.08 0.99 ± 0.09 > 0.05 
2.5 mM Ca2+ fold 1.70 ± 0.03 1.11 ± 0.03 < 0.001 
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Table 17: Results of ex vivo aortic ring calcification experiments. All aortic rings were incubated in the 
presence of 1.8 mM Ca2+ and 3 mM Pi. Values in µg Ca2+ normalised to explant weight (mg) for 10 
days. Mean (± SEM when N > 2), Two-way ANOVA with Bonferroni post-test (for 6 month male group; 
p-values). 
Group Unit WT KO P  
6 month old male mice, N =6 
Endothelium intact  
Vehicle fold 1.66 ± 0.23 2.81 ± 0.77 > 0.05  
10 nM R-568 fold 2.59 ± 0.31 2.19 ± 0.08 > 0.05  
          
Endothelium removed  
Vehicle  fold 2.20 ± 0.34 1.90 ± 0.17 > 0.05  
10 nM R-568 fold 2.95 ± 0.62 5.18 ± 1.79 > 0.05  
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Table 18: Blood pressure measurements via tail cuff. The values for the 3-6 and 10-14 month old 
animals were obtained with a loan unit (subsequently proven to overestimate its readings, marked 
“loan” in the table). Since this overestimation applies to the measurements of both WT and KO mice, it 
was deemed that the values between the two genotypes were still useable for the relative 
comparisons. Normalised values are averages of all WT and KO values normalised to their respective 
age group’s mean WT values (mean WT = 1), either including or excluding the overestimated values 
of the 3-6 and 10-14 month age group measured with the loan unit. Diastolic = diastolic blood 
pressure, systolic = systolic blood pressure, MAP = mean arterial pressure. Mean ± SEM, * p < 0.05, 
** p < 0.01, *** p < 0.001, two-tailed T-test. 
Parameter Unit WT KO P  
3-6 month old animals, N = 8 (WT), 13 (KO) – loan 
Diastolic mm Hg 145.75 ± 4.17 103.92 ± 5.08 < 0.0001 *** 
Systolic mm Hg 187.31 ± 3.36 157.76 ± 4.60 0.0002 *** 
MAP mm Hg 159.19 ± 3.73 121.53 ± 4.64 < 0.0001 *** 
 
10-14 month old animals, N = 3 (WT), 6 (KO) – loan 
Diastolic mm Hg 103.06 ± 4.94 90.65 ± 6.70 0.2684  
Systolic mm Hg 133.22 ± 4.41 130.26 ± 7.60 0.8041  
MAP mm Hg 112.74 ± 4.76 103.50 ± 6.52 0.3879  
 
4 month old animals, N = 3 (WT), 9 (KO) 
Diastolic mm Hg 76.73 ± 1.23 72.13 ± 2.54 0.3402  
Systolic mm Hg 108.60 ± 4.15 104.65 ± 3.12 0.5242  
MAP mm Hg 86.97 ± 2.12 82.67 ± 2.68 0.4028  
 
9 month old animals, N = 7 (WT), 11 (KO) 
Diastolic mm Hg 80.41 ± 3.72 70.40 ± 2.60 0.0475 * 
Systolic mm Hg 109.97 ± 4.35 101.75 ± 3.36 0.1781  
MAP mm Hg 89.95 ± 3.87 80.49 ± 2.75 0.0717  
 
17 month old animals, N = 3 (WT), 13 (KO) 
Diastolic mm Hg 78.25 ± 2.94 70.94 ± 2.96 0.2765  
Systolic mm Hg 108.18 ± 1.88 104.07 ± 3.29 0.5715  
MAP mm Hg 87.88 ± 2.46 81.61 ± 3.04 0.3563  
 
Normalised combined values, N = 22 (WT), 52 (KO) – including loan 
Diastolic fold 1.000 ± 0.016 0.854 ± 0.020 < 0.0001 *** 
Systolic fold 1.000 ± 0.012 0.926 ± 0.015 0.0045 ** 
MAP fold 1.000 ± 0.014 0.883 ± 0.018 0.0001 *** 
          
Normalised combined values, N = 11 (WT), 33 (KO) – excluding loan 
Diastolic fold 1.000 ± 0.022 0.905 ± 0.020 0.0159 * 
Systolic fold 1.000 ± 0.020 0.950 ± 0.017 0.1293  
MAP fold 1.000 ± 0.020 0.923 ± 0.019 0.0331 * 
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Table 19: Paw temperatures of 3-6 and 10-14 month old male mice. Paw T. = Paw temperature, mean 
± SEM, * p < 0.05, two-tailed T-test. 
Parameter Unit WT KO p  
3-6 month old animals, N = 10 (WT), 11 (KO) 
Paw T. °C 17.75 ± 0.13 17.23 ± 0.13 0.0106 * 
 
10-14 month old animals, N =3 (WT), 7 (KO) 
Paw T. °C 17.48 ± 0.19 17.29 ± 0.13 0.4625  
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Table 20: Results of radiotelemetry experiments carried out on 3 month old WT and KO mice, 
standard diet (1) vs. high salt diet (4 % NaCl diet). Active and resting intervals were globally selected 
for all mice (active: 20:00-22:00, resting: 8:00-10:00). See Figure 12 for experimental timeline, Figure 
18 for selected active and resting time intervals and Table 8 for parameter explanations and 
abbreviations. * p < 0.05, ** p < 0.01, *** p < 0.001. N = 5, mean ± SEM, two way ANOVA and 
Bonferroni post-test. Pa = Bonferroni post-test (WT vs KO), Pb = ANOVA (WT vs KO) within active or 
resting groups, Pc = ANOVA (diets) within active or resting groups. 
Parameter Unit WT KO Pa Pb Pc 
Standard diet (1) – Active   
Systolic mm Hg 133.46 ± 1.79 126.61 ± 4.40    
Diastolic mm Hg 104.05 ± 1.55 92.37 ± 3.81 *   
MAP mm Hg 118.95 ± 1.34 109.67 ± 4.18    
PH mm Hg 29.41 ± 1.96 34.24 ± 1.64    
HR bpm 638.90 ± 2.34 545.35 ± 22.82 **   
dp/dt mm Hg / ms 2412.13 ± 109.40 2628.54 ± 300.31    
           
4 % NaCl diet – Active   
Systolic mm Hg 133.10 ± 4.48 123.45 ± 3.26  *  
Diastolic mm Hg 103.77 ± 0.99 90.49 ± 3.29 ** ***  
MAP mm Hg 118.14 ± 2.13 107.05 ± 3.22 * **  
PH mm Hg 29.33 ± 3.94 32.96 ± 1.05    
HR bpm 610.53 ± 19.83 515.24 ± 24.56 ** ***  
dp/dt mm Hg / ms 2041.84 ± 104.63 2307.40 ± 231.43    
           
Standard diet (1) – Resting   
Systolic mm Hg 116.04 ± 3.17 119.39 ± 3.91    
Diastolic mm Hg 87.15 ± 1.60 84.74 ± 4.09    
MAP mm Hg 101.65 ± 2.39 102.02 ± 4.11    
PH mm Hg 28.88 ± 1.75 34.65 ± 2.34    
HR bpm 488.98 ± 13.60 457.74 ± 32.83    
dp/dt mm Hg / ms 2181.70 ± 96.08 2451.37 ± 245.78    
           
4 % NaCl diet – Resting   
Systolic mm Hg 114.04 ± 2.57 113.59 ± 1.87    
Diastolic mm Hg 85.57 ± 1.39 78.63 ± 2.28    
MAP mm Hg 99.68 ± 1.49 95.78 ± 1.92    
PH mm Hg 28.46 ± 2.54 34.97 ± 1.92  *  
HR bpm 469.78 ± 13.98 382.86 ± 9.06 * ** * 
dp/dt mm Hg / ms 2197.51 ± 127.27 2293.60 ± 186.32    
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Table 21: Results of radiotelemetry experiments carried out on 3 month old WT and KO mice, 
standard diet (2) vs. 0.5 mg / l L-NAME in drinking water. Active and resting intervals were globally 
selected for all mice (active: 20:00-22:00, resting: 8:00-10:00). See Figure 12 for experimental 
timeline, Figure 18 for selected active and resting time intervals and Table 8 for parameter 
explanations and abbreviations. * p < 0.05, ** p < 0.01, *** p < 0.001. N = 5, mean ± SEM, two way 
ANOVA and Bonferroni post-test. Pa = Bonferroni post-test (WT vs KO), Pb = ANOVA (WT vs KO) 
within active or resting groups, Pc = ANOVA (diets) within active or resting groups. 
Parameter Unit WT KO Pa Pb Pc 
Standard diet (2) – Active   
Systolic mm Hg 127.25 ± 4.86 112.06 ± 2.61    
Diastolic mm Hg 101.42 ± 4.93 81.31 ± 2.15 **   
MAP mm Hg 114.61 ± 4.66 97.27 ± 2.39 **   
PH mm Hg 25.83 ± 2.46 30.75 ± 1.48    
HR bpm 621.09 ± 19.69 515.71 ± 16.07 **   
dp/dt mm Hg / ms 1934.87 ± 162.26 2437.19 ± 244.26    
           
0.5 mg / l L-NAME – Active   
Systolic mm Hg 130.00 ± 4.85 127.89 ± 4.65   * 
Diastolic mm Hg 101.79 ± 3.59 89.89 ± 4.11  ***  
MAP mm Hg 115.77 ± 3.40 108.62 ± 4.19  **  
PH mm Hg 28.22 ± 4.57 38.00 ± 2.07  *  
HR bpm 537.37 ± 20.03 447.58 ± 13.02 ** *** *** 
dp/dt mm Hg / ms 1945.58 ± 293.48 2639.18 ± 241.91  *  
           
Standard diet (2) – Resting   
Systolic mm Hg 108.63 ± 2.32 106.62 ± 2.31    
Diastolic mm Hg 82.67 ± 1.48 76.75 ± 3.36    
MAP mm Hg 95.98 ± 1.60 92.01 ± 2.80    
PH mm Hg 25.97 ± 2.04 29.87 ± 1.94    
HR bpm 482.77 ± 23.93 459.67 ± 19.98    
dp/dt mm Hg / ms 2008.36 ± 95.08 2399.02 ± 259.70    
           
0.5 mg / l L-NAME – Resting   
Systolic mm Hg 122.83 ± 3.69 131.43 ± 5.31   *** 
Diastolic mm Hg 95.11 ± 5.74 91.78 ± 5.27   ** 
MAP mm Hg 108.84 ± 4.37 111.20 ± 5.23   *** 
PH mm Hg 27.72 ± 4.32 39.65 ± 1.44 * ** * 
HR bpm 472.45 ± 20.85 433.42 ± 18.17    
dp/dt mm Hg / ms 1943.23 ± 276.62 2722.47 ± 201.67 * *  
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Table 22: Results of cardiac MRI analysis of 12 month old animals. TBW = Total body weight, See 
Table 9 for abbreviations. LV-EF 3b = left ventricular ejection fraction approximated from third basal 
MRI slice only. # PFR and PER: one cardiac cycle normalised to 1 second. N = 3, Mean ± SEM, ** p < 
0.01, two-tailed T-test. 
Parameter Unit WT KO P  
Raw values 
TBW g 38.0 ± 4.2 32.9 ± 0.2 0.2997  
LVM mg 141.0 ± 13.5 135.3 ± 11.4 0.7646  
LV-EDV µl 60.0 ± 7.5 68.7 ± 6.6 0.4360  
LV-ESV µl 22.0 ± 4.0 28.3 ± 8.4 0.5339  
LV-SV µl 38.0 ± 3.5 41.0 ± 4.2 0.6111  
LV-EF % 63.7 ± 1.9 60.0 ± 8.5 0.6952  
LV-PFR µl / s# 174.7 ± 23.9 173.0 ± 15.5 0.9562  
LV-PER µl / s# 165.3 ± 12.7 195.7 ± 38.3 0.4937  
DRI g / µl 2.4 ± 0.1 2.0 ± 0.0 0.0059 ** 
SRI g / µl 6.6 ± 0.5 5.4 ± 1.0 0.3207  
EDL mm 8.3 ± 0.2 9.1 ± 0.2 0.0503  
EDD mm 6.5 ± 0.2 6.5 ± 0.2 0.8203  
ESL mm 7.8 ± 0.1 8.7 ± 0.2 0.0093 ** 
ESD mm 6.0 ± 0.2 6.1 ± 0.1 0.9001  
 
Normalised to TBW 
LVM mg / g 3.765 ± 0.343 4.111 ± 0.349 0.5190  
LV-EDV µl / g 1.598 ± 0.166 2.086 ± 0.201 0.1345  
LV-ESV µl / g 0.580 ± 0.075 0.859 ± 0.253 0.3491  
LV-SV µl / g 1.017 ± 0.103 1.247 ± 0.134 0.2459  
EDL mm / g 0.224 ± 0.025 0.276 ± 0.006 0.1096  
EDD mm / g 0.176 ± 0.017 0.196 ± 0.006 0.3128  
ESL mm / g 0.210 ± 0.024 0.265 ± 0.005 0.0843  
ESD mm / g 0.162 ± 0.015 0.184 ± 0.002 0.2249  
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Table 23: Results of cardiac MRI analysis of 14 month old animals. TBW = Total body weight, See 
Table 9 for abbreviations, KO (no vis remod): hearts of KO mice which did not show any apparent 
difference compared to WT control by visual observation, KO (vis remod): hearts of KO mice which 
showed apparent remodelling compared to WT control by visual observation. # PFR and PER: one 
cardiac cycle normalised to 1 second. N = 5 (WT), 6 (KO (no rem)), 5 (KO (rem), Mean ± SEM, 
ANOVA with Dunnett post-test vs. WT (p-values). 
Parameter Unit WT KO (no vis. remod.) P  
TBW g 34.6 ± 3.0 31.6 ± 1.8 > 0.05  
LVM mg 124.1 ± 10.5 119.5 ± 9.9 > 0.05  
LV-EDV µl 62.0 ± 9.2 60.3 ± 6.6 > 0.05  
LV-ESV µl 22.8 ± 5.9 20.0 ± 3.6 > 0.05  
LV-SV µl 38.8 ± 3.2 40.3 ± 3.3 > 0.05  
LV-EF µl 65.4 ± 4.2 68.7 ± 3.8 > 0.05  
LV-PFR µl / s# 178.4 ± 31.3 220.0 ± 29.7 > 0.05  
LV-PER µl / s# 215.6 ± 47.1 200.0 ± 19.9 > 0.05  
DRI g / µl 2.1 ± 0.1 2.0 ± 0.1 > 0.05  
SRI g / µl 6.7 ± 1.3 7.6 ± 2.0 > 0.05  
EDL mm 8.8 ± 0.4 8.8 ± 0.2 > 0.05  
EDD mm 6.1 ± 0.2 5.9 ± 0.2 > 0.05  
ESL mm 7.8 ± 0.3 7.3 ± 0.3 > 0.05  
ESD mm 5.5 ± 0.2 5.6 ± 0.3 > 0.05  
RV-EDV µl 22.8 ± 2.9 43.3 ± 7.6 > 0.05  
RV-ESV µl 9.0 ± 2.8 13.0 ± 3.8 > 0.05  
RV-SV µl 14.0 ± 0.6 30.2 ± 5.1 > 0.05  
RV-EF % 64.6 ± 7.9 72.0 ± 6.0 > 0.05  
          
     KO (vis. remod.)   
TBW g    36.7 ± 1.5 > 0.05  
LVM mg    124.7 ± 6.3 > 0.05  
LV-EDV µl    45.6 ± 2.9 > 0.05  
LV-ESV µl    9.4 ± 2.4 > 0.05  
LV-SV µl    36.4 ± 1.1 > 0.05  
LV-EF µl    80.6 ± 4.4 < 0.05 * 
LV-PFR µl / s#    137.0 ± 14.9 > 0.05  
LV-PER µl / s#    206.6 ± 20.3 > 0.05  
DRI g / µl    2.8 ± 0.1 < 0.001 *** 
SRI g / µl    21.7 ± 9.5 < 0.01 ** 
EDL mm    8.7 ± 0.2 > 0.05  
EDD mm    5.9 ± 0.1 > 0.05  
ESL mm    7.4 ± 0.3 > 0.05  
ESD mm    5.4 ± 0.1 > 0.05  
RV-EDV µl    29.8 ± 8.3 > 0.05  
RV-ESV µl    15.0 ± 6.2 > 0.05  
RV-SV µl    14.8 ± 3.1 < 0.05 * 
RV-EF %    54.4 ± 10.8 > 0.05  
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Table 24: Results of cardiac MRI analysis of 14 month old animals normalised to total body weight. 
See Table 9 for abbreviations, KO (no vis remod): hearts of KO mice which did not show any apparent 
difference compared to WT control by visual observation, KO (vis remod): hearts of KO mice which 
showed apparent remodelling compared to WT control by visual observation. N = 5 (WT), 6 (KO (no 
rem)), 5 (KO (rem), Mean ± SEM, ANOVA with Dunnett post-test vs. WT (p-values). 
Parameter Unit WT KO (no vis. remod.) P  
LVM mg / g 3.607 ± 0.191 3.765 ± 0.183 > 0.05  
LV-EDV µl / g 1.781 ± 0.206 1.895 ± 0.176 > 0.05  
LV-ESV µl / g 0.639 ± 0.147 0.617 ± 0.105 > 0.05  
LV-SV µl / g 1.131 ± 0.071 1.278 ± 0.093 > 0.05  
EDL mm / g 0.260 ± 0.018 0.284 ± 0.019 > 0.05  
EDD mm / g 0.179 ± 0.012 0.189 ± 0.009 > 0.05  
ESL mm / g 0.232 ± 0.022 0.236 ± 0.018 > 0.05  
ESD mm / g 0.163 ± 0.015 0.179 ± 0.007 > 0.05  
RV-EDV µl / g 0.661 ± 0.062 1.367 ± 0.257 > 0.05  
RV-ESV µl / g 0.252 ± 0.069 0.415 ± 0.129 > 0.05  
RV-SV µl / g 0.414 ± 0.032 0.946 ± 0.160 > 0.05  
          
     KO (vis. remod.)   
LVM mg / g    3.399 ± 0.112 > 0.05  
LV-EDV µl / g    1.243 ± 0.067 > 0.05  
LV-ESV µl / g    0.253 ± 0.064 > 0.05  
LV-SV µl / g    0.995 ± 0.031 > 0.05  
EDL mm / g    0.239 ± 0.014 > 0.05  
EDD mm / g    0.161 ± 0.005 > 0.05  
ESL mm / g    0.202 ± 0.010 > 0.05  
ESD mm / g    0.147 ± 0.004 > 0.05  
RV-EDV µl / g    0.817 ± 0.216 > 0.05  
RV-ESV µl / g    0.406 ± 0.162 > 0.05  
RV-SV µl / g    0.411 ± 0.091 < 0.05 * 
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Table 25: Results of metabolic cage studies of 12-18 month old WT and KO animals and 3 month old 
WT and KO animals on standard or high salt (containing 4 % NaCl) diet. Values are normalised 
against collection period and body weight of the individual animals. ** p < 0.01, mean + SEM, exact p 
values of two-tail t-tests (12-18 month animal group) and approximations for the Bonferroni post-test of 
two-way ANOVAs (3 month animal group, WT vs KO) are reported. C. = consumption, e. = excretion 
Parameter Unit WT KO p  
12 – 18 month old animals, N = 5-6 
Food c. (mg / h) / g 1.54 ± 0.30 1.25 ± 0.34 0.6810  
Faeces e. (mg / h) / g 1.84 ± 0.23 2.86 ± 0.30 0.0235 * 
Water c. (mg / h) / g 4.75 ± 0.70 5.71 ± 0.47 0.2794  
Urine e. (mg / h) / g 8.95 ± 1.54 8.97 ± 0.86 0.9927  
          
3 month old animals, N = 5-6 
Standard diet 
Food c. (mg / h) / g 6.28 ± 0.32 6.36 ± 0.12 > 0.05  
Faeces e. (mg / h) / g 2.65 ± 0.15 2.78 ± 0.14 > 0.05  
Water c. (mg / h) / g 7.91 ± 0.92 9.57 ± 1.64 > 0.05  
Urine e. (mg / h) / g 2.50 ± 0.23 3.24 ± 0.89 > 0.05  
          
4% NaCl diet 
Food c. (mg / h) / g 6.50 ± 0.12 6.69 ± 0.57 > 0.05  
Faeces e. (mg / h) / g 2.77 ± 0.14 3.13 ± 0.45 > 0.05  
Water c. (mg / h) / g 14.08 ± 1.50 17.15 ± 1.05 > 0.05  
Urine e. (mg / h) / g 5.97 ± 0.89 9.26 ± 0.52 < 0.01 ** 
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Table 26: Clinical chemistry of WT and KO mouse serum and plasma. K+ levels of 3 and 18 month old 
mice were non interpretable due to haemolysis in the samples. * p < 0.05, ** p < 0.01 WT vs. KO, 
mean ± SEM, two-tailed T-test.  
Parameter Unit WT KO P  
3 month old mice, N = 11 (WT), 4-6 (KO) 
Na+ mmol / l 146.4 ± 0.8 147.3 ± 1.1 0.5806  
Cl- mmol / l 110.6 ± 1.0 111.5 ± 3.2 0.7293  
Ca2+ mmol / l 2.3 ± 0.1 3.0 ± 0.3 0.0047 ** 
Mg2+ mmol / l 1.06 ± 0.03 1.14 ± 0.09 0.3107  
FGF23 pg / ml 145.0 ± 11.0 384.4 ± 83.5 0.0015 ** 
          
3 month old mice, N = 12, 19 (PTH), 11 (WT: 1,25-D3), 9 (KO: 1,25-D3) 
PTH pg / ml 161.42 ± 32.65 240.05 ± 57.03 0.2636  
1,25-D3 pmol / l 188.85 ± 28.87 391.89 ± 65.53 0.0072 ** 
Aldosterone pg / ml 508.07 ± 57.45 421.81 ± 59.24 0.3072  
Renin ng / ml 123.82 ± 16.74 115.44 ± 11.65 0.6849  
Fetuin A µg / ml 201.43 ± 11.80 192.98 ± 11.79 0.6171  
          
3 month old mice, metabolic cage studies, N=4-6 
Na+ mmol / l 143.5 6 0.63 140.6 4 0.94 0.0295 * 
K+ mmol / l 5.2 3 0.23 5.6 3 0.10 0.2092  
Cl- mmol / l 106.5 6 0.55 106.9 4 1.13 0.7469  
Ca2+ mmol / l 2.3 6 0.07 3.5 5 0.24 0.0003 *** 
Mg2+ mmol / l 1.2 6 0.04 1.3 5 0.07 0.1263  
Pi mmol / l 2.6 6 0.10 1.9 5 0.33 0.0679  
Creatinine µmol / l 15.4 6 0.66 13.0 5 0.57 0.0265 * 
Urea mmol / l 10.1 6 0.52 10.4 5 0.15 0.6474  
Total Protein mg /ml 54.4 6 1.21 51.2 4 1.32 0.1196  
          
18 month old mice, N = 3 
Na+ mmol / l 149.0 ± 2.1 146.3 ± 1.8 0.3837  
Cl- mmol / l 114.3 ± 0.7 111.0 ± 2.1 0.2020  
Ca2+ mmol / l 2.3 ± 0.1 3.0 ± 0.2 0.0401 * 
Mg2+ mmol / l 1.65 ± 0.10 2.04 ± 0.19 0.1369  
FGF23 pg / ml 131.1 ± 26.3 330.0 ± 28.7 0.0069 ** 
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Table 27: Clinical chemistry of WT and KO mouse urine. ** p < 0.01 WT, *** p < 0.001, mean ± SEM, 
two-way ANOVA with Bonferroni post-test (3 month old mice, p-values = WT vs KO post-test).  
Parameter Unit WT KO P  
Standard diet, N = 5-6, 4 (Mg2+ WT), 3 (Mg2+ KO) 
Na+:Cr fold 38.81 ± 2.90 32.87 ± 3.85 > 0.05  
K+:Cr fold 50.51 ± 2.95 57.53 ± 2.76 > 0.05  
Cl-:Cr fold 71.68 ± 3.69 67.62 ± 6.03 > 0.05  
Ca2+:Cr fold 0.94 ± 0.17 5.52 ± 1.23 < 0.001 *** 
Mg2+:Cr fold 6.54 ± 0.71 7.87 ± 1.42 > 0.05  
Pi:Cr fold 7.73 ± 0.98 21.43 ± 1.97 < 0.001 *** 
Creatinine µmol / d / g 0.23 ± 0.01 0.22 ± 0.03 > 0.05  
Total protein µg / dl / d / g 1.97 ± 0.33 1.60 ± 0.31 > 0.05  
Urea µmol / d / g 80.23 ± 6.37 80.84 ± 9.91 > 0.05  
Uric acid nmol / d / g 37.33 ± 2.93 32.96 ± 7.29 > 0.05  
          
4 % NaCl diet, N=6 
Na+:Cr fold 296.58 ± 20.24 333.04 ± 18.41 > 0.05  
K+:Cr fold 91.90 ± 3.23 107.57 ± 4.40 < 0.01 ** 
Cl-:Cr fold 358.59 ± 21.97 407.98 ± 23.00 > 0.05  
Ca2+:Cr fold 1.83 ± 0.15 7.81 ± 0.74 < 0.001 *** 
Mg2+:Cr fold 7.59 ± 7.59 10.42 ± 10.42 < 0.01 ** 
Pi:Cr fold 12.50 ± 1.08 27.05 ± 1.00 < 0.001 *** 
Creatinine µmol / d / g 0.25 ± 0.04 0.21 ± 0.01 > 0.05  
Total protein µg / dl / d / g 1.74 ± 0.19 1.38 ± 0.23 > 0.05  
Urea µmol / d / g 101.80 ± 14.24 91.89 ± 4.73 > 0.05  
Uric acid nmol / d / g 57.95 ± 9.24 50.17 ± 4.01 > 0.05  
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Table 28: Results of µCT analysis of 3 month old WT and KO mice. See Table 10 for list of parameter 
abbreviations. AU = arbitrary units. Mean ± SEM, * p < 0.05, ** p < 0.01, two-tailed T-test. 
Parameter Unit WT (N = 8) KO (N = 9) p  
Tb.TV mm³ 2.13 ± 0.09 1.88 ± 0.05 0.0236 * 
Tb.BV mm³ 0.33 ± 0.02 0.24 ± 0.01 0.0013 ** 
Tb.BV/TV fold 0.16 ± 0.01 0.13 ± 0.01 0.0134 * 
Tb.CD mm 369.6 ± 14.1 285.2 ± 16.5 0.0016 ** 
Tb.SMI AU 2.07 ± 0.10 2.37 ± 0.05 0.0123 * 
Tb.N 1/mm 5.91 ± 0.15 5.08 ± 0.27 0.0189 * 
Tb.Th µm 39.3 ± 2.1 37.4 ± 1.5 0.4827  
Tb.Sp mm 0.17 ± 0.00 0.19 ± 0.01 0.0140 * 
Tb.BMD AU 1165 ± 3 1139 ± 8 0.0098 ** 
          
Ct.TV mm³ 0.40 ± 0.01 0.39 ± 0.01 0.3707  
Ct.BV mm³ 0.27 ± 0.01 0.25 ± 0.01 0.2036  
Ct.BV/TV fold 0.66 ± 0.01 0.66 ± 0.01 0.5443  
Ct.BMD AU 1433 ± 12 1394 ± 6 0.0069 ** 
Ct.Th mm 0.24 ± 0.01 0.23 ± 0.00 0.2344  
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12 Appendix B 
Results and experiments listed here were performed correctly but were either redundant with 
other results or could not be interpreted due to methodical or other underlying reasons.  
 
12.1 VSMC apoptosis 
Apoptosis of cultured VSMC from WT and KO mice was measured by TUNEL staining 
followed by quantitative immunofluorescence analysis. Prior to the staining, VSMC were 
cultured in culture medium containing 1.2, 1.8 or 2.5 mM Ca2+ and 1 or 3 mM Pi for 48 h to 
investigate possible effects of extracellular Ca2+ and Pi concentration on prevalence of 
apoptosis in these cells, analogous to the proliferation experiments described before. 3 (WT) 
and 4 (KO) individual VSMC preparations, each containing VSMC grown from aortae of 2–3 
mice, were analysed at different passages and in multiple technical repeats with a total of 
91,690 cells in 36 ROIs for WT and 293,651 cells in 48 ROIs for KO. 
Analysed VSMC preparations showed a very high degree of heterogeneity in themselves as 
well as in between each other. Even though VSMC (SM22α+) could be selected via gating, 
these differences make a final interpretation impossible. 
Apoptotic and non-apoptotic cells were clearly identifiable by the TUNEL staining, as 
apoptotic nuclei showed strong and immediately recognizable staining (c.f. Figure 12). Cells 
from all different culture conditions combined showed a clear difference in TUNEL staining 
between apoptotic and non-apoptotic cells, with no differences between cell isolated from WT 
or KO mice. Apoptotic nuclei were significantly smaller than their non-apoptotic 
counterparts, again with no differences between genotypes (Figure 100). 
The percentage of apoptotic cells of all cells present in the VSMC cultures was about 4-fold 
higher in cells isolated from WT mice than cells isolated from KO mice, although batch to 
batch variability was high. No influence of extracellular Ca2+ or Pi concentration on apoptosis 
rate was found (Figure 101). When looking at VSMC (SM22α+ populations only, see above), 
both VSMC from WT as well as KO mice showed the same rate of about 1% apoptotic cells 
(Figure 102), independent of extracellular Ca2+ and Pi concentrations. The increased apoptotic 
rate in observed in WT cells compared to KO when looking at all cells can therefore be 
limited to non-VSMC. Total cell density (cells / mm2) showed an about 2-fold increase in KO 
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cells compared to WT control, independent of extracellular Ca2+ or Pi concentration (Figure 
103) which is in agreement with the lower rates of apoptosis in KO cells compared to WT 
when looking at all cells. 
All numerical results are listed in Table 29. 
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Figure 100: Quantitative fluorescence microscopy of TUNEL stained VSMC preparations showing 
TUNEL staining intensity and nuclei size of apoptotic (TUNEL+) and non-apoptotic (TUNEL-) cells. 
Cells from VSMC preparations cultured for 48 h in the presence of 1.2, 1.8 or 2.5 mM Ca2+ and 1 or 3 
mM Pi were pooled for these analysis. * p < 0.05, *** p < 0.001. N = 3 (WT), N = 4 (KO), mean + SEM, 
two way ANOVA with Bonferroni post-test. Preparation, culture maintenance and stainings of VSMC 
preparations were performed in collaboration with Dr Thomas Davies, quantitative 
immunofluorescence analysis by MS. 
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Figure 101: Quantitative fluorescence microscopy of TUNEL stained VSMC preparations showing 
percentage of apoptotic cells (TUNEL+) in VSMC preparations cultured for 48 h in the presence of 1.2, 
1.8 or 2.5 mM Ca2+ and 1 or 3 mM Pi. * p < 0.05, *** p < 0.001. N = 3 (WT), N = 4 (KO), mean + SEM, 
two way ANOVA with Bonferroni post-test. Preparation, culture maintenance and stainings of VSMC 
preparations were performed in collaboration with Dr Thomas Davies, quantitative 
immunofluorescence analysis by MS. 
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Figure 102: Quantitative fluorescence microscopy of TUNEL stained VSMC preparations showing 
percentage of apoptotic cells (TUNEL+) of VSMC (SM22α+) in VSMC preparations cultured for 48 h in 
the presence of 1.2, 1.8 or 2.5 mM Ca2+ and 1 or 3 mM Pi. * p < 0.05, *** p < 0.001. N = 3 (WT), N = 4 
(KO), mean + SEM, two way ANOVA with Bonferroni post-test. Preparation, culture maintenance and 
stainings of VSMC preparations were performed in collaboration with Dr Thomas Davies, quantitative 
immunofluorescence analysis by MS. 
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Figure 103: Quantitative fluorescence microscopy of TUNEL stained VSMC preparations showing total 
cell density in VSMC preparations cultured for 48 h in the presence of 1.2, 1.8 or 2.5 mM Ca2+ and 1 
or 3 mM Pi. * p < 0.05. N = 3 (WT), N = 4 (KO), mean + SEM, two way ANOVA with Bonferroni post-
test. Preparation, culture maintenance and stainings of VSMC preparations were performed in 
collaboration with Dr Thomas Davies, quantitative immunofluorescence analysis by MS. 
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Table 29: Results of quantitative fluorescence microscopy of TUNEL stained VSMC preparations. 
VSMC preparations cultured for 47 h in the presence of 1.2, 1.8 or 2.5 mM Ca2+ and 1 or 3 mM Pi. * p 
< 0.05. N = 3 (WT), N = 4 (KO), mean + SEM, two way ANOVA with Bonferroni post-test. Mgv = men 
grey value, c = cells. Preparation, culture maintenance and stainings of VSMC preparations were 
performed in collaboration with Dr Thomas Davies, quantitative immunofluorescence analysis by MS. 
Group Unit WT   KO   p  
TUNEL intensity       < 0.001 *** 
TUNEL+ mgv 51.46 ± 10.25 54.46 ± 7.06 > 0.05  
TUNEL- mgv 3.55 ± 0.38 3.57 ± 0.20 > 0.05  
          
Nuclei size        < 0.001 *** 
TUNEL+ µm2 187.39 ± 18.43 231.14 ± 24.31 > 0.05  
TUNEL- µm2 364.29 ± 21.96 330.89 ± 20.18 > 0.05  
          
Apoptotic cells – all cells        
1 mM Pi        < 0.001 *** 
1.2 mM Ca2+ % 4.53 ± 2.10 0.89 ± 0.13 > 0.05  
1.8 mM Ca2+ % 4.54 ± 1.66 0.91 ± 0.18 > 0.05  
2.5 mM Ca2+ % 5.90 ± 2.12 0.94 ± 0.17 < 0.05 * 
          
3 mM Pi        < 0.05 * 
1.2 mM Ca2+ % 4.53 ± 2.10 1.04 ± 0.22 > 0.05  
1.8 mM Ca2+ % 3.22 ± 1.26 1.71 ± 0.74 > 0.05  
2.5 mM Ca2+ % 3.44 ± 1.17 1.52 ± 0.23 > 0.05  
          
Apoptotic cells – VSMC        
1 mM Pi        > 0.05  
1.2 mM Ca2+ % 0.82 ± 0.34 0.93 ± 0.18 > 0.05  
1.8 mM Ca2+ % 1.10 ± 0.67 0.97 ± 0.18 > 0.05  
2.5 mM Ca2+ % 1.14 ± 0.80 1.29 ± 0.34  > 0.05  
          
3 mM Pi        > 0.05  
1.2 mM Ca2+ % 0.82 ± 0.34 1.21 ± 0.27 > 0.05  
1.8 mM Ca2+ % 1.07 ± 0.73 2.52 ± 1.61 > 0.05  
2.5 mM Ca2+ % 0.53 ± 0.30 1.29 ± 0.41 > 0.05  
          
Cell density          
1 mM Pi        < 0.05 * 
1.2 mM Ca2+ c / mm2 113.15 ± 29.62 249.74 ± 77.90 > 0.05  
1.8 mM Ca2+ c / mm2 103.62 ± 28.06 250.39 ± 70.64 > 0.05  
2.5 mM Ca2+ c / mm2 98.53 ± 26.04 296.39 ± 120.16 > 0.05  
          
3 mM Pi        < 0.05 * 
1.2 mM Ca2+ c / mm2 113.15 ± 29.62 248.75 ± 72.56 > 0.05  
1.8 mM Ca2+ c / mm2 94.15 ± 19.69 226.39 ± 80.35 > 0.05  
2.5 mM Ca2+ c / mm2 81.05 ± 17.58 209.26 ± 78.47 > 0.05  
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12.2 Radiotelemetry experiments - Variable time point 
comparisons based on rolling minimum and maximum 
detection 
Since the circadian rhythms of the individual mice are not perfectly in sync (illustrated in 
Figure 104), minima and maxima (resting and active period of the mice) in all the individual 
smoothed curves for MAP of all investigated mice were detected by either a) detecting the 
minimum and maximum per day (24 h period from 0:00 to 24:00) or b) by using a local 
minimum and maximum detection approach spanning 17 hours (target hour ± 8 hours; Figure 
105). The time points of the last minima and maximum of the MAP of a given diet regimen 
was used to select the values of all other parameters from their respective averaged curves. 
This approach allowed correcting for variations in the mice circadian rhythm, therefore 
comparing the parameters of the individual mice during their distinct period of highest 
(maximum MAP) and lowest activity (minimum MAP) as well as incorporating the general 
trend of the curves due to the use of the averaged values. Data analysis was performed using 
Microsoft Excel 2010 (Microsoft, Redmond, CA, USA). 
Two-way ANOVA showed no significant differences between WT and KO mice in systolic 
blood pressure, neither during their active nor resting phases, independent of the diet the mice. 
Mean arterial pressure (p <0.05) and diastolic blood pressure (p < 0.01) showed a statistically 
significant reduction in KO mice compared to WT during the active phase of the mice. During 
the mice’s resting phase, diastolic blood pressure of KO mice was significantly reduced (p < 
0.05) compared to WT. The diet (standard vs. high salt) had no significant impact on blood 
pressure (Figure 106).  
Pulse height of KO animals was significantly (p < 0.05) elevated compared to WT during the 
active phase of the mice. Heart rate of KO animals was highly significantly (p < 0.001) 
reduced compared to WT during the active phase of the mice when fed standard diet or high 
salt diet. A highly significant reduction of the heart rate of KO animals was found during 
active (p < 0.001) and resting (p < 0.01) phases of the mice; a significant reduction of the 
heart rate was also seen between diets, where the heart rate of the animals was significantly 
lower on the high salt diet compared to standard. This reduction was particularly pronounced 
in KO mice, where post-test showed a significant reduction (p < 0.05). Whether this effect is 
caused by the high salt diet alone or results from the aforementioned incomplete recovery 
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from surgery is unclear. No difference was found in dp/dt between WT and KO mice (Figure 
107).  
All numerical results of the variable time point analysis for standard diet vs. 4 % NaCl 
containing diet are listed in Table 30. 
 
Mouse 1
Mouse 2
 
Figure 104: Illustration of small differences in the circadian rhythms of the single mice on a segment of 
MAP curves from two different mice. Arrows indicate local minima (upward pointing arrows) and 
maxima (downward pointing arrows).  
 
MAP
local minima
local maxima
 
Figure 105: Illustration of local minimum / maximum detection on a segment of a MAP curve 
(smoothed by rolling average over 4 hours) of a single mouse. Every hour is checked for being the 
local minimum or maximum value in an interval of ±8 hours, resulting in detection of daily minima (blue 
symbols) and maxima (orange symbols) of the MAP of every single mouse. The values of the 
telemetry parameters pertaining to these detected hours for every mouse were used for comparison of 
active vs. resting state of the mice and to account for variations in circadian rhythm between the 
individual mice. 
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Figure 106: Systolic, diastolic and mean arterial pressure of WT and KO mice during their active and 
resting times of the day, fed on standard diet or high salt diet as measured by radiotelemetry. 
Individual active and resting time points were averaged and were detected by rolling maximum (active) 
and minimum (resting) detection based on MAP curve of each individual mouse. * p < 0.05, ** p < 
0.01, *** p < 0.001. N = 5, mean + SEM, two way ANOVA and Bonferroni post-test. 
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Figure 107: Pulse height, heart rate and dp/dt of WT and KO mice during their active and resting times 
of the day, fed on standard diet or high salt diet as measured by radiotelemetry. Individual active and 
resting time points were averaged and were detected by rolling maximum (active) and minimum 
(resting) detection based on MAP curve of each individual mouse. * p < 0.05, ** p < 0.01, *** p < 
0.001. N = 5, mean + SEM, two way ANOVA and Bonferroni post-test. 
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When the mice had been transferred to standard housing cages, diastolic and mean arterial 
blood pressure showed a significant (p < 0.01, 0.05) reduction in KO mice during their active 
and resting phases compared to WT. this difference was abolished when the drinking water of 
the mice was supplemented with 0.5 mg / ml L-NAME. Systolic blood pressure did not show 
a significant difference between WT and KO mice but increased significantly under the 
influence of the NO synthase inhibitor, especially during the resting phase of the mice (p < 
0.05), as shown by Bonferroni post-test (Figure 108).  
Pulse height was significantly elevated in KO mice compared to WT during the active and 
resting phases of the mice (p < 0.05). As determined by post-test, this elevation was especially 
pronounced when the mice were administered 0.5 mg/l L-NAME in their drinking water (p < 
0.05). Heart rates of KO mice during their active phase were highly significantly reduced (p < 
0.001) compared to WT and dropped significantly further during their active phase as 
determined by Bonferroni post-test (p < 0.01 for WT, p < 0.05 for KO) when the mice were 
given L-NAME. Reduction in heart rate of KO mice compared to WT was smaller when the 
mice were resting but still significant (p < 0.05). dp/dt of KO mice was significantly elevated 
compared to WT (p < 0.05) during active and resting phases, independently of the 
administration of L-NAME (Figure 109).  
All numerical results from the variable time point analysis for standard diet vs. 0.5 mg / ml L-
NAME are listen in Table 31.  
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Figure 108: Systolic, diastolic and mean arterial pressure of WT and KO mice during their active and 
resting times of the day, fed on standard diet or 0.5 mg / ml L-NAME as measured by radiotelemetry. 
Individual active and resting time points were averaged and were detected by rolling maximum (active) 
and minimum (resting) detection based on MAP curve of each individual mouse. * p < 0.05, ** p < 
0.01, *** p < 0.001. N = 5, mean + SEM, two way ANOVA and Bonferroni post-test. 
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Figure 109: Pulse height, heart rate and dp/dt of WT and KO mice during their active and resting times 
of the day, fed on standard diet or 0.5 mg / ml L-NAME as measured by radiotelemetry. Individual 
active and resting time points were averaged and were detected by rolling maximum (active) and 
minimum (resting) detection based on MAP curve of each individual mouse. * p < 0.05, ** p < 0.01, *** 
p < 0.001. N = 5, mean + SEM, two way ANOVA and Bonferroni post-test.  
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Table 30: Results of radiotelemetry experiments carried out on 3 month old WT and KO mice, 
standard diet (1) vs. high salt diet (4 % NaCl diet). Individual active and resting time points were 
averaged and were detected by rolling maximum (active) and minimum (resting) detection based on 
MAP curve of each individual mouse. See Figure 16 for experimental timeline and Table 8 for 
parameter explanations and abbreviations. * p < 0.05, ** p < 0.01, *** p < 0.001. N = 5, mean ± SEM, 
two way ANOVA and Bonferroni post-test. Pa = Bonferroni post-test (WT vs KO), Pb = ANOVA (WT vs 
KO) within active or resting groups, Pc = ANOVA (diets) within active or resting groups. 
Parameter Unit WT KO Pa Pb Pc 
Standard diet (1) – Active   
Systolic mm Hg 135.74 ± 0.90 131.55 ± 4.56    
Diastolic mm Hg 105.79 ± 1.31 97.22 ± 4.32    
MAP mm Hg 120.91 ± 0.79 114.58 ± 4.41    
PH mm Hg 29.95 ± 1.80 34.33 ± 1.42    
HR bpm 641.96 ± ±.46 571.63 ± 15.64 ***   
dp/dt mm Hg / ms 2432.37 ± 113.97 2692.86 ± 262.68    
           
4 % NaCl diet – Active   
Systolic mm Hg 133.98 ± 4.08 126.70 ± 2.41    
Diastolic mm Hg 104.47 ± 0.92 93.01 ± 2.74 * **  
MAP mm Hg 119.17 ± 2.04 110.05 ± 2.59  *  
PH mm Hg 29.51 ± 3.72 33.70 ± 0.81    
HR bpm 613.29 ± 11.86 544.61 ± 6.58 *** *** * 
dp/dt mm Hg / ms 2089.16 ± 104.38 2441.37 ± 233.39    
           
Standard diet (1) – Resting   
Systolic mm Hg 114.22 ± 2.61 115.47 ± 3.11    
Diastolic mm Hg 85.67 ± 1.30 81.55 ± 3.13    
MAP mm Hg 99.94 ± 1.90 98.44 ± 3.14    
PH mm Hg 28.55 ± 1.92 33.92 ± 2.16    
HR bpm 475.61 ± 11.93 427.34 ± 22.62    
dp/dt mm Hg / ms 2094.89 ± 110.49 2324.58 ± 189.20    
           
4 % NaCl diet – Resting   
Systolic mm Hg 110.28 ± 3.00 109.85 ± 1.39    
Diastolic mm Hg 82.35 ± 0.92 76.38 ± 2.32  *  
MAP mm Hg 96.08 ± 1.81 92.68 ± 1.61   * 
PH mm Hg 27.94 ± 2.72 33.47 ± 2.03  *  
HR bpm 449.90 ± 18.79 357.23 ± 17.00 ** ** * 
dp/dt mm Hg / ms 2112.77 ± 161.26 2090.38 ± 212.17    
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Table 31: Results of radiotelemetry experiments carried out on 3 month old WT and KO mice, 
standard diet (2) vs.0.5 mg / l L-NAME in drinking water. Individual active and resting time points were 
averaged and were detected by rolling maximum (active) and minimum (resting) detection based on 
MAP curve of each individual mouse. See Figure 16 for experimental timeline and Table 8 for 
parameter explanations and abbreviations. * p < 0.05, ** p < 0.01, *** p < 0.001. N = 5, mean ± SEM, 
two way ANOVA and Bonferroni post-test. Pa = Bonferroni post-test (WT vs KO), Pb = ANOVA (WT vs 
KO) within active or resting groups, Pc = ANOVA (diets) within active or resting groups. 
Parameter Unit WT KO Pa Pb Pc 
Standard diet (2) – Active   
Systolic mm Hg 128.78 ± 4.29 116.95 ± 2.21    
Diastolic mm Hg 102.10 ± 4.60 84.76 ± 2.04 *   
MAP mm Hg 115.69 ± 4.21 101.42 ± 2.14 *   
PH mm Hg 26.68 ± 2.32 32.18 ± 1.51    
HR bpm 610.37 ± 16.28 522.80 ± 16.70 **   
dp/dt mm Hg / ms 1972.15 ± 141.65 2593.42 ± 287.34    
           
0.5 mg / l L-NAME – Active   
Systolic mm Hg 132.74 ± 4.72 135.35 ± 4.93   * 
Diastolic mm Hg 104.54 ± 3.95 94.51 ± 4.97  **  
MAP mm Hg 117.66 ± 3.98 114.53 ± 4.90  *  
PH mm Hg 28.20 ± 4.74 40.84 ± 1.48 * **  
HR bpm 550.92 ± 11.68 445.42 ± 18.46 *** *** *** 
dp/dt mm Hg / ms 1971.58 ± 280.66 2796.01 ± 252.67  *  
           
Standard diet (2) – Resting   
Systolic mm Hg 107.61 ± 1.84 105.03 ± 2.40    
Diastolic mm Hg 81.64 ± 1.09 74.63 ± 2.79    
MAP mm Hg 94.89 ± 1.15 89.79 ± 2.49    
PH mm Hg 25.97 ± 1.79 30.41 ± 2.15    
HR bpm 467.92 ± 23.89 416.83 ± 20.63    
dp/dt mm Hg / ms 1944.97 ± 84.79 2194.13 ± 190.33    
           
0.5 mg / l L-NAME – Resting   
Systolic mm Hg 117.58 ± 2.33 116.29 ± 2.70   *** 
Diastolic mm Hg 89.54 ± 4.74 78.21 ± 3.57  *  
MAP mm Hg 103.34 ± 2.99 96.89 ± 3.03  * ** 
PH mm Hg 28.04 ± 4.54 38.08 ± 2.65  *  
HR bpm 450.67 ± 20.97 383.15 ± 19.08  *  
dp/dt mm Hg / ms 1913.98 ± 298.08 2680.19 ± 247.53  *  
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12.3 Cardiac cine MRI - 18 month old animals 
3 of the investigated animals died mid-scan under general anaesthesia (1 WT, 2 KO) reducing 
the number of available completed scans for KO animals to 2. One of the dies KO animals 
was scanned up to the third basal short axis slice, allowing an approximation of the ejection 
fraction (see below). 
Visual analysis of the long axis (Figure 110) scans as well as the third basal short axis scans 
(Figure 111; this was the last completed scan for the mice that died during the procedure) did 
not show any obvious differences between WT and KO hearts. Mean values for the measured 
parameters (Figure 112), as well as cardiac remodelling indices (Figure 113) from the three 
completed WT and two completed KO scans did not show any specific trends between 18 
month old WT and KO animals.  
To allow for some degree of comparison of cardiac parameters, the third basal slice only 
(instead of the whole heart) was used to approximate the ejection fraction. This method is 
normally used for ultrasonic observations where heart parameters are extrapolated from the 
centre of the left ventricle (using the papillary muscle as point of reference) only (Johnson 
2008). This analysis was performed on all available WT and KO hearts (N = 3 for both 
genotypes). No difference between WT and KO hearts was found (Figure 114).  
Measurement of heart dimensions from the long axis scans (which were completed on all 
mice) did not show significant differences between 18 month old WT and KO hearts (Figure 
115). 
Heart parameters normalised to TBW showed a trend toward increased left ventricular stroke 
volume, although a statistical comparison was not possible due to the lack of a TBW record 
for one of the mice (Figure 116).  
All numerical results from cardiac cine MRI of 18 month old animals are listed in Table 32. 
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Figure 110: Long axis cardiac MRI scans of hearts from 18 month old WT and KO mice showing 
diastole and systole. 
 
 
Figure 111: Short axis cardiac MRI scans of the third basal slice of hearts from 18 month old WT and 
KO mice showing diastole and systole. Green = epicardium, red = endocardium. 
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Figure 112: Measured and calculated left-ventricular cardiac parameters from short-axis cardiac cine-
MRI scans of 18 month old WT and KO mice. LV = left ventricular, LVM = left ventricular mass, EDV = 
end diastolic volume, ESV = end systolic volume, SV = stroke volume, EF = ejection fraction, PFR = 
peak fill rate, PER = peak ejection rate. N = 3 (WT), 2 (KO), mean + SEM (WT), mean (KO). 
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Figure 113: Calculated cardiac remodelling indices of from short-axis cardiac cine-MRI scans of 18 
month old WT and KO mice. DRI = end-diastolic remodelling index, SRI = end-systolic remodelling 
index. N = 3 (WT), 2 (KO), mean + SEM (WT), mean (KO). 
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Figure 114: Approximated left ventricular EF from the third basal slice of short axis cine-MRI scans of 
18 month old WT and KO mice. LV=EF = left ventricular ejection fraction. N = 3, mean + SEM. 
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Figure 115: Measured heart dimensions from long-axis cardiac cine-MRI scans of 18 month old WT 
and KO mice. LV = left ventricular, ESL = end systolic length, ESD = end systolic diameter, EDL = end 
diastolic length, EDD = end diastolic diameter. N = 3, mean + SEM 
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Figure 116: Parameters obtained from cardiac cine-MRI scans of 18 month old mice normalised to 
TBW. See Table 9 for abbreviations. N = 2 (WT), 2 (KO), mean. 
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Table 32: Results of cardiac MRI analysis of 18 month old animals. TBW = Total body weight, See 
Table 9 for abbreviations. LV-EF 3b = left ventricular ejection fraction approximated from third basal 
MRI slice only. # PFR and PER: one cardiac cycle normalised to 1 second, N = 3 (WT), 2 (KO), 3 (KO: 
EDL, EDD, ESL, ESD) Mean ± SEM, two-tailed T-test (where N = 3). 
Parameter Unit WT KO P  
Raw values 
TBW g 38.5 ± 0.2 37.3 ± 0.5   
LVM mg 150.0 ± 11.9 172.5 ± 1.5   
LV-EDV µl 76.7 ± 4.8 85.0 ± 6.0   
LV-ESV µl 34.0 ± 4.6 36.0 ± 2.0   
LV-SV µl 42.3 ± 7.4 49.0 ± 5.0   
LV-EF % 54.7 ± 7.1 57.5 ± 1.5   
LV-PFR µl / s# 209.7 ± 47.9 188.0 ± 33.0   
LV-PER µl / s# 173.3 ± 22.4 158.0 ± 16.0   
DRI g / µl 2.0 ± 0.1 2.0 ± 0.2   
SRI g / µl 4.6 ± 0.9 4.8 ± 0.3   
EDL mm 9.6 ± 0.2 9.5 ± 0.2 0.7096  
EDD mm 6.6 ± 0.0 6.5 ± 0.2 0.8944  
ESL mm 8.6 ± 0.2 8.7 ± 0.4 0.9435  
ESD mm 6.2 ± 0.2 6.2 ± 0.3 0.8766  
LV-EF 3b % 59.7 ± 5.9 66.7 ± 2.3 0.3334  
          
Normalised to TBW 
LVM mg / g 3.648 ± 0.306 3.084 ± 1.543   
LV-EDV µl / g 1.870 ± 0.042 1.518 ± 0.763   
LV-ESV µl / g 0.986 ± 0.099 0.643 ± 0.322   
LV-SV µl / g 0.909 ± 0.057 0.875 ± 0.443   
EDL mm / g 0.255 ± 0.009 0.260 ± 0.009   
EDD mm / g 0.171 ± 0.001 0.178 ± 0.007   
ESL mm / g 0.229 ± 0.006 0.243 ± 0.007   
ESD mm / g 0.160 ± 0.010 0.176 ± 0.004   
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13 Curriculum vitae 
Personal details  
  
Full name Martin Wolfgang Schepelmann 
Academic degree Master of Pharmacy (Magister der Pharmazie) 
Date and place of birth November 10th, 1983; Vienna 
Nationality Austria 
Current occupation Marie Curie Early Stage Researcher / PhD student, Cardiff University, UK 
  
Education and Career  
  
1990–1994 Elementary school (Maria Regina, Vienna, Austria) 
1994–2002 Secondary school (Döblinger Gymnasium, Vienna, Austria) 
06/2002 School leaving examination (Matura) 
2003–2004 Training as paramedic (examination passed with honors) in the context of the 
Austrian compulsory community service (Zivildienst) 
2004–2010 Study of Pharmacy at the University of Vienna, Austria 
11/2009–05/2010 Diploma thesis in pharmacy under supervision of Dr. Walter Jäger, Department of 
Clinical Pharmacy, University of Vienna, Austria and Dr. Isabella Ellinger, 
Department of Pathophysiology and Allergy Research, Medical University of 
Vienna, Austria; Title: "Potential mechanisms behind blood pressure modulation 
by melatonin – Expression analysis of melatonin receptors MT1 and MT2 in the 
rat aorta" 
07/2010 Graduation in pharmacy with first class honors, granted academic degree: Master 
of Pharmacy (Magister der Pharmazie) 
07/2010–06/2011 Research associate in the groups of Dr. Isabella Ellinger and Dr. Theresia 
Thalhammer at the Department of Pathophysiology and Allergy Research, 
Medical University of Vienna, Austria; Main focus: in vitro osteoclast cultivation 
for quantification of influences on osteoclast growth as part of an industry-
university spanning research project (FFG Bridge) 
07/2011–05/2014 PhD studies in physiology under supervision of Dr. Daniela Riccardi and Dr. Paul 
Kemp in the course of a Marie Curie Fellowship (employment as a Marie Curie 
Early Stage Researcher) at Cardiff University, United Kingdom 
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Supervision- and Teaching-Experience 
 
06/2007 Workshop on plant anatomy in two tenth and one ninth grade biology classes at a 
secondary school (Billrothgymnasium, Vienna, Austria) 
07/2010–08/2010 Supervision of a student summer intern (Medical University Vienna) 
09/2010–06/2011 Assistance in supervision of one bachelor and two diploma students (Medical 
University of Vienna) 
2011 Assistance in teaching “statistical seminar for students of medicine”, SSM2 (held 
by Dr. Isabella Ellinger, Medical University Vienna) 
2011 - ongoing Assistance in supervision of final year project students of medicine and biology 
(Cardiff University) 
2012 Demonstrating: Statistics for 1st years, Solutions and Molarity (Cardiff 
University) 
  
Awards  
  
04/1998 1st place at the Austrian finals of CyberSchool98  
(students develop IT-projects; www.cyberschool.at) 
05/2001 1st place at the Austrian finals of Business@School  
(students develop business plans; initiated by the Boston Consulting Group; 
www.business-at-school.de) 
06/2001 3rd place at the Austrian-German finals of Business@School (see above) in 
Munich, Germany 
01/2008 Merit scholarship of the University of Vienna (StudFG WS2008) for excellent 
academic achievements in the year 2007 
04/2011 Science2business Award (Team award, 3rd place) at the LifeScienceScuccess 
2011, Techgate, Vienna 
06/2011 Travel grant of the Austrian Society for Bone and Mineral Research to attend the 
ECTS 2011, Athens, Greece 
09/2012 Poster prize of the third Retreat of the Center for Pathophysiology, Infectiology 
and Immunology, Medical University Vienna 
12/2012 Travel grant of the Austrian Society for Bone and Mineral Research to attend the 
International conference on Progress in Bone and Mineral Research 2012, Vienna, 
Austria 
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Professional memberships 
 
 Member of the Austrian society for Bone and Mineral Research 
(http://www.knochenundmineralstoffwechsel.at/) 
 Member of the European Calcified Tissue Society (http://www.ectsoc.org/) 
 Member of the Physiological Society (http://www.physoc.org/) 
  
Attended workshops Conference Organization 
E-moderation 
Flow Cytometry 
Genotyping, predictive testing reporting and genetic counselling 
Management Systems and Internal Auditing 
Microarrays 
Practical Teaching 
Pre-/clinical trials 
Quality and risk management in the routine diagnostic laboratory 
Scientific ethics 
Systems biology 
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General skills  
  
Languages German (native language), English (fluent) 
IT Microsoft Office (Word, Excel, PowerPoint) 
Adobe Photoshop, Adobe Illustrator, Adobe Premiere 
Statistical software (GraphPad Prism, Minitab)  
Operating systems (DOS, Windows (3.11 – 7) 
System assembling and maintenance, computer administration 
Invitation of offers for IT infrastructure from major companies 
ECDL (European Computer Driving License) 
Driving license B 
  
Hobbies Movies, reading, hiking, IT, classical music, microscopy, history 
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M. Schepelmann, L. Molcan, H. Uhrova, M. Zeman, I. Ellinger: The Presence and Localization of Melatonin Receptors in the Rat Aorta. 
Cell Mol Neurobiol. 2011 Nov;31(8):1257-65 
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Vienna, November 2010, Austria 
Journal für Mineralstoffwechsel (17) 2010, Sonderheft 2, p.7 
M. Schepelmann, A. Heindl, A. Seewald, A. Nussbaumer, G. Bises, R. Rogojanu, P. Pietschmann, I. Ellinger, T. Thalhammer: Influence 
of melatonin on murine osteoclast formation in culture – automated detection and quantification by a novel image analysis system. 3rd 
Joint Meeting of ECTS & IBMS, Athens, May 2011, Greece 
Bone, 48 (2011), S133-S134, PP0112-S 
M. Schepelmann, A. Heindl., H. Uhrova, V. Pohl, R. Rogojanu, A. Seewald, H. Helmer, I. Ellinger: The neonatal IgG Fc-receptor (FcRn) 
is expressed in the syncytiotrophoblast, fetal endothelial cells and Hofbauer cells of human term placental chorionic villi. 14th IFPA 
meeting, Geilo, September 2011, Norway 
Placenta, 32 (9): A54, 2011 
M. Schepelmann, A. Heindl, A. Seewald, A. Nussbaumer, G. Bises, R. Rogojanu, R. Ecker, P. Pietschmann, I. Ellinger, T. Thalhammer: 
Automated detection and quantification of multinucleated osteoclasts by a novel image analysis system. Abstract and 2 minute talk. 2nd 
Retreat of the Center for Pathophysiology, Immunology and Infectiology, Vienna, September 2011, Austria 
M. Schepelmann, T. Davies, S. Brennan, P. Yarova, W. Chang, D. Bikle, M. Krssak, T. Wells, A. Stewart, B. van der Kolk, B. Monk, D. 
Ward, A. Canfield, D. Edwards, P. Kemp, D. Riccardi: Phenotypic characterisation of a mouse model of targeted gene deletion of the 
calcium-sensing receptor (CaSR) from vascular smooth muscle cells (SM22α-Cre x LoxP-CaSR). 6th Mammalian Genes, Development and 
Disease, Bath, UK, July 2012 
M. Schepelmann, T. Davies, S. Brennan, P. Yarova, W. Chang, D. Bikle, M. Krssak, T. Wells, A. Stewart, D. Ward, A. Canfield, E. 
Kallay, D. Edwards, P. Kemp, D. Riccardi: A vascular smooth muscle cell (VSMC) specific calcium sensing receptor knock out mouse 
implicates the CaSR in blood pressure regulation and protection from calcification. Abstract and 2 minute talk. 3rd Retreat of the Center for 
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Riccardi: Targeted gene deletion of the calcium-sensing receptor (CaSR) from vascular smooth muscle cells shows involvement of the 
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M. Schepelmann, T. Davies, P. Yarova, S. Brennan, W. Chang, D. Bikle, M. Krssak, T. Wells, A. Stewart, B. van der Kolk, B. Monk, D. 
Ward, A. Canfield, D. Edwards, P. Kemp, D. Riccardi: A mouse model of targeted deletion of the calcium sensing receptor (CaSR) from 
vascular smooth muscle cells implicates the CaSR in vascular pathophysiology. Oral communication at the Symposium on the Calcium 
Sensing Receptor at the International Conference on Progress in Bone and Mineral Research, Vienna, Austria 2012. 
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receptor knock-out mouse. Oral communication at the 7th Mammalian Genes, Development and Disease, Bath, UK, June 2013 
M. Schepelmann, T. Davies, P. Yarova, S. Brennan, J. Graca, W. Chang, D. Bikle, P. Edwards, M. Krssak, A. Stewart, D. Ward, A. 
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Birmingham, UK, July 2013 
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Book chapter 
 
A. Heindl, M. Schepelmann, R. Ecker, P. Pietschmann, I. Ellinger, A. Seewald, T. Thalhammer: Towards the automated detection and 
characterization of osteoclasts in microscopic images 
In: Principles of Osteoimmunology. Molecular Mechanisms and Clinical Applications; Ed. P. Pietschmann, Wien: Springer-Verlag 
 
Invited talks 
 
26.9.2011 Invited talk at the institute of Pathophysiology and Allergy Research, Medical University Vienna, 
Austria: “Perspectives on investigating the Calcium sensing receptor’s role in vascular calcification”. 
Invitation by Dr. Isabella Ellinger 
11.5.2012 Invited talk at the institute of Pathophysiology and Allergy Research, Medical University Vienna, 
Austria: “Investigating the role of the CaSR in the vasculature using targeted gene deletion”. Invitation 
by Dr. Enikö Kallay 
 
 
 
 
 
 
